



# 10TH

## INTERNATIONAL CONGRESS ON **AUTOIMMUNITY**

APRIL 6-10, 2016, LEIPZIG, GERMANY



# PROGRAM BOOK

## CONGRESS ORGANIZERS




Rue François-Versonnex 7,  
CH-1207 Geneva, SWITZERLAND

Tel: +41 22 908 0488

Fax: +41 22 906 9140

Email: [autoimmunity@kenes.com](mailto:autoimmunity@kenes.com)

Website: [autoimmunity.kenes.com](http://autoimmunity.kenes.com)



# TABLE OF CONTENTS

Welcome Message.....	3
Committees.....	4
Timetable.....	6
General Information.....	10
CME/CPD Accreditation.....	12
Information for Presenters.....	15
E-Poster Discussion Sessions.....	16
Venue Maps.....	18
About Leipzig.....	20
Awards.....	21
Networking Events.....	26
Congress App.....	27
4th International Symposium on Vaccines.....	28
Basic Immunology Course.....	29
Patient Forum.....	30

## SCIENTIFIC PROGRAM & E-POSTER DISCUSSIONS

Wednesday, April 6.....	33
Thursday, April 7.....	39
Friday, April 8.....	81
Saturday, April 9.....	129
Sunday, April 10.....	177
Index.....	187

## ACKNOWLEDGEMENTS & INDUSTRY SUPPORT

Acknowledgements.....	211
Industry Symposia.....	214
Exhibition Map.....	218
List of Exhibitors.....	219
Supporter & Exhibitor Profiles.....	223

# WELCOME MESSAGE

Dear Friends,

The International Congress on Autoimmunity has reached a historical moment: in April 2016 more than 2000 of the world's autoimmunologists have gathered for the 10th time to exchange knowledge about the more than 80 autoimmune diseases.

The meeting point this time is the artistic city of Leipzig, Germany, known for its long tradition in trade fairs and its compelling selection of museums, musical events and other cultural offerings.

Our loyal participants are already familiar with the high level of medical science that awaits them at the International Congresses on Autoimmunity and our newcomers will be impressed by the diversity of excellent sessions offered on a variety of topics, ranging from basic research to novel diagnostic and treatment methods of autoimmune diseases. This year's Congress introduces a variety of hot subjects for the first time: from spicy food and cannabis to obesity, smoking, the microbiome, novel peptides and revolutionary therapies.

The International Congress on Autoimmunity is the biggest multidisciplinary congress that discusses all aspects of the related diseases under one roof, offering courses and lectures by some of the world's most distinguished experts. At the same time, the Congress prides itself on providing a stage for young upcoming talents to present their research to a first-rate audience.

Join us and enjoy the inspiring atmosphere of medical science among old and new colleagues; share, learn and network to build the future of autoimmunology at the 10th International Congress on Autoimmunity!



Sincerely,

A handwritten signature in black ink that reads "Y. Shoenfeld". The signature is fluid and cursive.

**Yehuda Shoenfeld, MD, FRCP, MaACR**  
Congress President

# COMMITTEES

## **CONGRESS PRESIDENT & SCIENTIFIC PROGRAM CHAIRMAN**

Yehuda Shoenfeld, Israel

## **CONGRESS CO-CHAIRPERSONS & LOCAL SCIENTIFIC COMMITTEE**

Karsten Conrad, Dresden, Germany

Arno Kromminga, Hamburg, Germany

Annegret Kuhn, Mainz, Germany

Enno Schmidt, Lübeck, Germany

Torsten Witte, Hannover, Germany

## **LOCAL CONGRESS SUPPORT GROUP**

Thomas Dörner, Berlin, Germany

Rüdiger Eming, Marburg, Germany

Falk Hiepe, Berlin, Germany

Yoachim Kalden, Erlangen, Germany

Jürgen Kratzsch, Leipzig, Germany

Min Ae Lee-Kirsch, Dresden, Germany

Ulrich Sack, Leipzig, Germany

Reinhold Ernst Schmidt, Hannover, Germany

Günter Steiner, Vienna, Austria

Michael Sticherling, Erlangen, Germany

Georg Wick, Innsbruck, Austria



## INTERNATIONAL CONGRESS SUPPORT GROUP

- Abul K. Abbas, USA  
 Steven B. Abramson, USA  
 Razzaque Ahmed, USA  
 Juan Manuel Anaya, Colombia  
 Luis E. Coelho Andrade, Brazil  
 Tatsuya Atsumi, Japan  
 Tadej Avcin, Slovenia  
 Cristina Belizna, France  
 Sonia Berrih-Aknin, France  
 Nicola Bizzaro, Italy  
 Miri Blank, Israel  
 Dimitrios Bogdanos, Greece  
 Dimitrios Boumpas, Greece  
 Ricard Cervera, Spain  
 Edward Chan, USA  
 Christopher Chang, USA  
 Joab Chapman, Israel  
 Shunle Chen, China  
 Douglas Cines, USA  
 Jan Willem Cohen Tervaert, The Netherlands  
 Maurizio Cutolo, Italy  
 Terry Davies, USA  
 David D'Cruz, UK  
 Caterina De Carolis, Italy  
 Carlos Dias, Portugal  
 Andrea Doria, Italy  
 Christopher Edwards, UK  
 Kok-Yong Fong, Singapore  
 João Eurico Fonseca, Portugal  
 Johan Frostegard, Sweden  
 Mauro Galeazzi, Italy  
 Roberto Gerli, Italy  
 M. Eric Gershwin, USA  
 Ahmet Gul, Turkey  
 Michael Hayden, Canada  
 Chunyu Huang, China  
 Graham Hughes, UK  
 Luis Javier Jara, Mexico  
 Cees Kallenberg, The Netherlands  
 Munther Khamashta, UK  
 Takao Koike, Japan  
 Ivica Lazurova, Slovak Republic  
 Roger Levy, Brazil  
 ZhanGuo Li, China  
 Claudio Lunardi, Italy  
 Trevor Marshall, USA  
 Eiji Matsuura, Japan  
 Marco Matucci-Cerinic, Italy  
 David McLain, USA  
 Pier Luigi Meroni, Italy  
 Tsuneyo Mimori, Japan  
 Pierre Miossec, France  
 Eric Morand, Australia  
 Marta Mosca, Italy  
 Luc Mouthon, France  
 David Naor, Israel  
 Yaakov Naparstek, Israel  
 Sandra Navarra, Philippines  
 Ferdinando Nicoletti, Italy  
 David Norris, USA  
 Roberto Perricone, Italy  
 Alexander B. Poletaev, Russia  
 Bernardo Pons-Estel, Argentina  
 Chaim Putterman, USA  
 Noel R. Rose, USA  
 Eric Rosenthal, France  
 Piercarlo Sarzi-Puttini, Italy  
 Guy Serre, France  
 Veerte Somers, Belgium  
 Zoltán Szekanecz, Hungary  
 Zera Tellier, France  
 Angela Tincani, Italy  
 Yaron Tomer, USA  
 Elias Toubi, Israel  
 George C. Tsokos, USA  
 Athanasios Tzioufas, Greece  
 Guido Valesini, Italy  
 Carlos Vasconcelos, Portugal  
 Matthias G. von Herrath, USA  
 Allan Wiik, Denmark  
 Kazuhiko Yamamoto, Japan  
 Pierre Youinou, France  
 Gisele Zandman-Goddard, Israel  
 Xiaofeng Zeng, China

# TIMETABLE




## WEDNESDAY, APRIL 6

	Hall 1	Hall MP3&4	Hall 2	Hall 3	Hall 4
12:00 – 12:30			4th INT'L SYMPOSIUM ON VACCINES in collaboration with CMSRI	BASIC IMMUNOLOGY COURSE Abul K. Abbas, USA	
12:30 – 13:00			Coffee Break	Coffee Break	
13:00 – 13:30			4th INT'L SYMPOSIUM ON VACCINES in collaboration with CMSRI	BASIC IMMUNOLOGY COURSE Abul K. Abbas, USA	
13:30 – 14:00		Industry Session not included in main event CME/CPD credit	Coffee Break		
14:00 – 14:30			4th INT'L SYMPOSIUM ON VACCINES in collaboration with CMSRI		
14:30 – 14:50			Coffee Break		
14:50 – 15:00					
15:00 – 15:30					
15:30 – 16:10					
16:10 – 16:30					Industry Session not included in main event CME/CPD credit
16:00 – 17:00					
17:00 – 17:30					
17:30 – 18:00					
18:00 – 19:45	Opening Ceremony followed by Welcome Reception (in the Exhibition Area)				

**THURSDAY, APRIL 7**

	Hall 1	Hall MP3&4	Hall 2	Hall 3	Hall 4	Hall 5
08:00 – 10:00	<b>PL01</b> PLENARY SESSION					
10:00 – 10:30	Coffee break, Exhibition and E-Poster sessions					
10:30 – 12:30	<b>PS01</b> Etiology and pathogenesis of autoimmunity	<b>PS02</b> Celiac disease: novelties in 2016	<b>PS03</b> IVIg: the best biologic?	<b>PS04</b> Standardization and harmonization in autoantibody testing	<b>PS05</b> The integument and oral mucosa	<b>PS06</b> Citrullination (CCP)
12:30 – 14:00		Industry Session not included in main event CME/CPD credit	Lunch break, Exhibition and E-Poster viewing			
14:00 – 16:00	<b>PS07</b> Hygiene theory, microbiome, probiotics	<b>PS08</b> Novel biologics and biosimilars	<b>PS09</b> B cells: pathogenesis and suppression	<b>PS10</b> Immunomodulation by vitamin D and IVIg	<b>PS11</b> Systemic sclerosis: new approaches	<b>PS12</b> Novel autoantigens: DFS70, 14-3-3 $\eta$
16:00 – 16:30	Coffee break, Exhibition and E-Poster sessions					
16:30 – 18:30	<b>PS13</b> Vasculitides	<b>PS14</b> Vaccines and autoimmunity	<b>PS15</b> Autoimmune pathways in multiple sclerosis, myasthenia gravis and the central nervous system	<b>PS16</b> Induction, determination and the pathogenic role of autoantibodies	<b>PS17</b> The autoimmune basis of reproductive failure	<b>PS18</b> Autoimmune hematological diseases



# FRIDAY, APRIL 8

	Hall 1	Hall MP3&4	Hall 2	Hall 3	Hall 4	Hall 5	Hall MP1
08:00 – 10:00	<b>PL02</b> PLENARY SESSION						
10:00 – 10:30	Coffee break, Exhibition and E-Poster sessions						
10:30 – 12:30	<b>PS19</b> T cells in autoimmunity	<b>PS20</b> Diagnostics: pathogenesis and autoantibody standardization	<b>PS21</b> SLE: is it the classical autoimmune disease?	<b>PS22</b> Kidney involvement in autoimmunity	<b>PS23</b> Autoimmunity in dermatology	<b>PS24</b> Experimental animal models of autoimmune diseases	
12:30 – 14:00	Lunch break, Exhibition and E-Poster viewing						
14:00 – 16:00	<b>PS25</b> Prediction, monitoring and personalized medicine	<b>PS26</b> EASI session: ANCA and ANCA-associated vasculitis	<b>PS27</b> Autoimmune aspects of neurological diseases	<b>PS28</b> Peptides and new molecules in therapeutics	<b>PS29</b> Autoimmune liver diseases	<b>PS30</b> Type 1 diabetes mellitus	<b>PS30B</b> New horizons in autoimmune therapy
16:00 – 16:30	Coffee break, Exhibition and E-Poster sessions						
16:30 – 18:30	<b>PS31</b> Environmental factors and sex hormones in autoimmunity	<b>PS32</b> Rheumatoid arthritis: challenges in the new era	<b>PS33</b> Genetics and epigenetics of autoimmune diseases	<b>PS34</b> European Forum on antiphospholipid antibodies	<b>PS35</b> Big data analysis, registries and epidemiological studies in autoimmunity	<b>PS36</b> Systemic onset juvenile idiopathic arthritis and hereditary periodic fever syndromes	

**SATURDAY, APRIL 9**

	Hall 1	Hall MP3&4	Hall 2	Hall 3	Hall 4	Hall 5
08:00 – 10:00	<b>PL03 PLENARY SESSION</b>					
10:00 – 10:30	Coffee break, Exhibition and E-Poster sessions					
10:30 – 12:30	<b>PS37</b> Systemic lupus erythematosus: the challenge	<b>PS38</b> Infection and autoimmunity: two edges of the sword	<b>PS39</b> High-lights in diagnostics	<b>PS40</b> Innate immunity and natural autoantibodies (IVIg)	<b>PS41</b> UCTD, MCTD and other connective tissue diseases	<b>PS42</b> Pregnancy and autoimmunity
12:30 – 14:00		Industry Session not included in main event CME/CPD credit	Lunch break, Exhibition and E-Poster viewing			
14:00 – 16:00	<b>PS43</b> ANA diagnostics and immunofluorescence	<b>PS44</b> T-reg, B-reg, tolerance and autoimmunity	<b>PS45</b> Autoimmunity and endocrinology	<b>PS46</b> Novel studies in autoimmune diseases	<b>PS47</b> Epstein-Barr virus driven inflammatory diseases: from primary immunodeficiencies to autoimmune diseases (NEDAL session)	<b>PS48</b> Pearls in autoimmunity: top candidates for the MAI Award 2016
16:00 – 16:30	Coffee break, Exhibition and E-Poster sessions					
16:30 – 18:30	<b>PS 49</b> New therapeutic avenues in autoimmune diseases	<b>PS50</b> APS: Diagnostics and challenges for the future	<b>PS51</b> Autoimmune syndrome induced by adjuvants (ASIA syndrome)	<b>PS52</b> The autoimmune aspects of psoriasis, myositis and atherosclerosis	<b>PS53</b> The autoimmune side of inflammatory arthritis and autoinflammation	<b>PS54</b> Cytokines and autoimmunity

**SUNDAY, APRIL 10**

	Hall MP3&4	Hall 2	Hall 3	Hall 4	Hall 5
08:00 – 10:00	<b>PL04 PLENARY SESSION</b>				
10:00 – 10:30	Coffee Break				
10:30 – 12:30	<b>PS55</b> Sjogren's syndrome	<b>PS56</b> Immunomanipulation	<b>PS57</b> The autoimmune origin of celiac and gastrointestinal diseases	<b>PS58</b> New autoimmune diseases, cancer and autoimmunity	<b>PS59</b> IL-6 and JAK inhibition: new achievements

# GENERAL INFORMATION

## CONGRESS VENUE

Congress Center Leipzig  
Messe-Allee 1, 04356 Leipzig, Germany  
Tel.: +49 (0) 341 / 6 78 84 40 Fax: +49 (0) 341 / 6 78 84 42

## OPENING HOURS

	Registration	Exhibition	Tourist Information
Wednesday, April 6	10:30 – 20:00	18:00 – 20:00	16:00 – 18:00
Thursday, April 7	07:00 – 18:30	09:30 – 17:00	09:00 – 17:00
Friday, April 8	07:30 – 18:30	09:30 – 17:00	09:00 – 17:00
Saturday, April 9	07:30 – 18:30	09:30 – 16:30	09:00 – 17:00
Sunday, April 10	07:30 – 12:30		

## LANGUAGE

The official language of the Congress is English.

## CONGRESS ABSTRACTS

The Congress abstracts are available on USB cards, in the Congress app, on the Congress website, as well as on the Autoimmunity Network. Please collect your abstract USB card from booth No. 4.

## INTERNET STATIONS

Internet stations are available for participants' use in the Exhibition area. Please be considerate of fellow participants when using these facilities.

## WI-FI

Free Wi-Fi is available to all participants in the public areas and in the Exhibition area.

Network name: **auto2016** | Username: **auto2016** | Password: **auto2016**



## AUTOIMMUNITY 2016 APP

Install the Autoimmunity 2016 interactive mobile App to your smartphone and portable devices to access all the Congress information you could need during the Congress:

- See the overview of sessions, speakers and exhibitors.
- Create your personal schedule for the event, including bookmarking the sessions you wish to attend.
- Receive real-time updates.

**Download the Autoimmunity 2016 App now to enhance your congress experience! (available on the App Store or Google Play)**



## **BADGE**

You are kindly requested to wear your name badge during all Congress sessions and events.

## **LUNCH AND COFFEE BREAKS**

Lunch and coffee will be offered as per the lunch and coffee breaks indicated in the timetable. Catering areas are located in the Exhibition area.

## **CLOAK ROOM**

Cloak room facilities are available on level -1 at a price of €1/item.

## **PHOTOGRAPHY & RECORDING PRIVILEGES**

No photographs, video recording or audio recording will be permitted in the scientific sessions at the Congress, unless authorized by the organizers.

## **MOBILE PHONES**

Participants are kindly requested to keep their mobile phones on silent in the session halls.



## **SMOKING POLICY**

Smoking is prohibited at all times in the session halls, Exhibition and restrooms. Your compliance is appreciated.

## **LIABILITY AND INSURANCE**

The Congress Secretariat and organizers cannot accept liability for personal accidents or loss of or damage to private property of participants, either during or indirectly arising from the Autoimmunity Congress. We recommend that all participants take out personal travel and health insurance for the trip.

## **ACKNOWLEDGMENTS AND INDUSTRY SUPPORT**

In accordance with compliance and regulations, acknowledgment of industry supporting the Congress appears separately from the scientific program. Industry information is available from page 209 onwards, under the section ACKNOWLEDGMENTS AND INDUSTRY SUPPORT. Industry symposia details are available on pages 214–217.

## **CONGRESS SECRETARIAT**



Rue François-Versonnex 7, CH-1207 Geneva, Switzerland

Tel: +41 22 908 0488 | Fax: +41 22 906 9140

Email: [autoimmunity@kenes.com](mailto:autoimmunity@kenes.com) | Website: [autoimmunity.kenes.com](http://autoimmunity.kenes.com)

# CME/CPD ACCREDITATION

## EDUCATIONAL OBJECTIVES

After attending this event, participants should be able to:

- Address individual needs in compliance with their Continuous Professional Development (CPD) plan.
- Evaluate best practices in Autoimmune Diseases -Discuss new scientific knowledge and recent research findings about Autoimmune Diseases.
- Recognize opportunities for scientific collaborations around the world.
- Integrate the most up to date information in their clinical and research activities.
- Employ novel multidisciplinary treatment strategies for patients with rheumatologic and Autoimmune Diseases.
- Evaluate the most important aspects of diagnosis and treatment of autoimmune diseases.

## TARGET AUDIENCE

The 10th International Congress on Autoimmunity is the global meeting place for experts in immunology, rheumatology and related fields to discuss under one roof the genetic, etiology, diagnostic, clinical aspects and novel therapies of 80 autoimmune diseases. Because of the diverse, clinically focused educational offering, participants are able to tailor the curriculum to meet the needs of international clinicians of all levels of experience.

## ACCREDITATION STATEMENT AND CREDIT DESIGNATION

### EUROPEAN ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION (UEMS/EACCME)

The 10th International Congress on Autoimmunity (Autoimmunity 2016) is accredited by European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): [www.uems.net](http://www.uems.net)

The 10th International Congress on Autoimmunity is designated for a maximum of, or up to, 24 European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

### AMERICAN MEDICAL ASSOCIATION (AMA)

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

### ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit: [www.royalcollege.ca](http://www.royalcollege.ca).



**SÄCHSISCHE LANDESÄRZTEKAMMER**

The 10th International Congress on Autoimmunity (Autoimmunity 2016) is accredited by the Sächsischen Landesärztekammer to provide the following CPD activity for medical specialists. The Sächsischen Landesärztekammer is the professional representation of all doctors in the Free State of Saxony (Freistaat Sachsen). For more information please visit <http://www.slaek.de/de/01/fortbildung.php>

The 10th International Congress on Autoimmunity (Autoimmunity 2016) is designated for a maximum of, or up to 27 Category B CME credits. Each physician should claim only those hours of credit that he/she actually spent in the educational activity:

- 06/04/2016 (12:00- 14:30), VNR 276160 201602510 0002, Passwort 8914, Vormittags, 3 credits Category B
- 06/04/2016 (12:00- 14:30), VNR 276160 201602510 0010, Passwort 8914, Nachmittags, 3 credits Category B
- 07/04/2016 (08:00- 12:30), VNR 276160 201602510 0028, Passwort 8914, Vormittags, 3 credits Category B
- 07/04/2016 (14:00- 18:30), VNR 276160 201602510 0036, Passwort 8914, Nachmittags, 3 credits Category B
- 08/04/2016 (08:00- 12:30), VNR 276160 201602510 0044, Passwort 8914, Vormittags, 3 credits Category B
- 08/04/2016 (14:00- 18:30), VNR 276160 201602510 0051, Passwort 8914, Nachmittags, 3 credits Category B
- 09/04/2016 (08:00- 12:30), VNR 276160 201602510 0069, Passwort 8914, Vormittags, 3 credits Category B
- 09/04/2016 (14:00- 18:30), VNR 276160 201602510 0077, Passwort 8914, Nachmittags, 3 credits Category B
- 10/04/2016 (08:00- 12:30), VNR 276160 201602510 0085, Passwort 8914, Vormittags, 3 credits Category B

**CREDIT BREAKDOWN**

Each participant should claim only those hours of credit that he/she actually spent in the educational activity.

<b>DAY</b>	<b>MAXIMUM CREDITS</b>
Wednesday, April 6	3
Thursday, April 7	6
Friday, April 8	6
Saturday, April 9	6
Sunday, April 10	3
<b>Total Credits:</b>	<b>24</b>

## **TO RECEIVE YOUR CME/CPD CERTIFICATE**

The CME/CPD certificate will be available after completing the online evaluation and credit claiming procedure. The process takes about 5 minutes. We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings.

### **Before May 8, 2016:**

1. Access the online system via any of the following:
  - Visit the CME-CPD Accreditation page on the Congress website.
  - Follow the link in the email sent at the end of the Congress.
2. Complete the anonymous online evaluation.
3. Complete the credit claim form and submit.
4. The CME/CPD certificate will be available for download; fill-in and retain for your personal records.

## **DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF INTEREST**

In accordance with CME/CPD accreditation criteria and standards for commercial support to ensure balance, independence, objectivity, and scientific rigor, those in control of the educational content must disclose potential or actual conflicts of interest. Disclosure information is evaluated and conflicts of interest resolved. Disclosure is made to participants prior to the activity. Participants will be asked on the evaluation to assess the objectivity and independence of the event.

- Disclosure information is available on the event website and also posted on the notice board in the registration area.

## **INDUSTRY SUPPORT DISCLOSURE**

This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support. Appropriate acknowledgement of all supporting organizations is made in the program guide, on the event website, and with signage during the event.

- A list of all industry supporters is available in the Acknowledgements & Industry Support section at the back of the program book.
- Detailed program for all Industry Sessions are available on page 214–217.

# INFORMATION FOR PRESENTERS

## ORAL PRESENTATIONS

Please check the program book and the app to stay updated with any last minute scheduling changes.

**Speakers presenting in oral sessions are requested to submit their presentations to the speakers' ready room at least 1 hour before the start of their session.** The Speakers' Ready Room can be found on level 2 and will be open at the following times:

Wednesday, April 6	10:30 - 20:00
Thursday, April 7	07:00 - 18:30
Friday, April 8	07:30 - 18:30
Saturday, April 9	07:30 - 18:30
Sunday, April 10	07:30 - 12:30

## UPLOADING YOUR PRESENTATION:

If using a PowerPoint (or any other) presentation, please note you need to bring it on a CD, a DVD or on a memory stick and load it on one of the conference' computers in the Speakers' Ready Room, at least 1 hour before the start of the session.

Please note that the conference computers in the session halls are being supplied with Office 2013.

If combining video films with PowerPoint, please make sure to check it in the session hall where your lecture is taking place during a coffee or lunch break, at least 30 minutes before the start of the session - **even after checking it in the Speakers' Ready Room.**

**Speakers are requested not to use own computers for presentation. Please note that the time used for connecting own computer will be deducted from the total presentation time.**

## PRESENTATION DURATION:

The duration of your presentation is indicated in the program book and in the congress app. Please note that your presentation time includes time for questions and answers. Therefore, you are asked to plan your presentation accordingly and leave 1-2 minutes for questions at the end of your presentation. It is possible that there will not be sufficient time for questions after your presentation. Please follow the instructions of the session Chairpersons.

## CME COMPLIANCE:

Oral presenters are required to use a Disclosure Slide as the second slide of their presentation. The template can be downloaded from the congress website or obtained at the Speakers' Ready Room.

## IMPORTANT NOTE FOR MACINTOSH USERS:

In order to use MAC presentations on a PC compatible computer, please note that you need to prepare it according to the instructions below, before bringing it to the Speakers' Ready Room:

1. Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a default font on a PowerPoint based PC).
2. Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on a PowerPoint based PC).

Alternatively, you may use your own Macintosh laptop computer. In such a case please ensure you provide a **VGA adaptor** for external signal and come to check it first in the Speakers' Ready Room as soon as you arrive and later on in the session hall where your lecture is taking place during the coffee or lunch break, at least 30 minutes before the start of the session.

## E-POSTER PRESENTATIONS

Electronic or E-Posters are similar to traditional paper posters but displayed on-site on large LCD screens. E-Posters will be available at the E-Poster stations in the Exhibition area, during the Exhibition opening hours.

Using a simple search engine, you can easily and quickly access the E-Posters you want, searching by author, topic, poster title or keywords. High resolution touch screens provide excellent quality viewing experience of the posters and allow seamless switching from full view to section view.

## E-POSTER DISCUSSION SESSIONS (SHORT ORAL PRESENTATIONS)

Discussion sessions will take place at the E-Poster stations during the morning and afternoon coffee breaks on Thursday, Friday and Saturday (April 7-8-9). During the sessions an E-Poster chairperson will be present to discuss E-Posters selected by the Scientific Committee.


Please be sure to arrive 5 minutes prior to the start of your E-Poster discussion session.

# E-POSTER DISCUSSION SESSIONS (SHORT ORAL PRESENTATIONS)


	Station 1	Station 2	Station 3	Station 4	Station 5	Station 6	Station 7	Station 8
<b>THURSDAY, APRIL 7, 2016</b>								
10:00-10:30	<b>EPD01</b> APS: revelations	<b>EPD02</b> New cytokines: the flame and the inflamed	<b>EPD03</b> SLE: the disease of a thousand faces	<b>EPD04</b> Modern avenues in autoimmune diagnostics	<b>EPD05</b> Atherosclerosis and autoimmunity	<b>EPD06</b> Multiplex diagnostic and chip technique	<b>EPD07</b> Autoimmunity and hematology	<b>EPD08</b> How can we immunomodulate autoimmune conditions?
16:00-16:30	<b>EPD09</b> The mother and the child: autoimmune relationship	<b>EPD10</b> Etiology and mechanism of autoimmunity	<b>EPD11</b> SLE: more systemic than systemic	<b>EPD12</b> Steps in autoimmune diagnostics	<b>EPD13</b> Cancer and autoimmunity	<b>EPD14</b> Vasculitis: the inflammation of the vessels	<b>EPD15</b> Novel therapies in autoimmunity	<b>EPD16</b> The bugs and us: inter-relationship of autoimmunity
<b>FRIDAY, APRIL 8, 2016</b>								
10:00-10:30	<b>EPD17</b> APS diagnostics	<b>EPD18</b> Pathogenetic avenues in autoimmune diseases	<b>EPD19</b> SLE: what can we learn about autoimmunity?	<b>EPD20</b> What's new in autoimmune diagnostics?	<b>EPD21</b> CNS involvement in autoimmunity	<b>EPD22</b> Systemic sclerosis: how can we overcome an unknown etiology?	<b>EPD23</b> Are there breakthroughs in the therapy of autoimmune diseases?	<b>EPD24</b> Immunomodulation: better than immunosuppression
16:00-16:30	<b>EPD25</b> Type 1 diabetes mellitus: the sweet and the autoimmune	<b>EPD26</b> Experimental models: from mice to men	<b>EPD27</b> SLE: novel aspects	<b>EPD28</b> Methods in autoimmune diagnostics	<b>EPD29</b> Celiac: don't miss the diagnosis	<b>EPD30</b> Sjogren's syndrome: the ultimate B cell stimulation	<b>EPD31</b> Myasthenia gravis & multiple sclerosis	<b>EPD32</b> IVIg, innate immunity: how to restore the immune system to normal
<b>SATURDAY, APRIL 9, 2016</b>								
10:00-10:30	<b>EPD33</b> APS: novelties	<b>EPD34</b> Gene, families, RNA	<b>EPD35</b> SLE: the leading autoimmune condition	<b>EPD36</b> Diagnostics: from the lab to the clinic	<b>EPD37</b> CNS: brain, autoimmunity and beyond	<b>EPD38</b> Vasculitis: a systemic autoimmune condition	<b>EPD39</b> IL-17: why Miossec is right?	<b>EPD40</b> IVIg: the biologic of preference
16:00-16:30	<b>EPD41</b> Thyroid: avenues in disease diagnostics	<b>EPD42</b> Citrullination: an important factor in autoimmune conditions	<b>EPD43</b> Liver: a piece of the mosaic of autoimmunity	<b>EPD44</b> ANA diagnostics: the ultimate procedure	<b>EPD45</b> Additional aspects of gastrointestinal autoimmunity	<b>EPD46</b> Vasculitis: the great imitator	<b>EPD47</b> Personalized and precision trends in autoimmunity	<b>EPD48</b> The skin as the mirror of autoimmunity

# VENUE MAPS


## LEVEL -1




## LEVEL 0



## LEVEL 1



## LEVEL 2



# ABOUT LEIPZIG

## LEIPZIG IS A COSMOPOLITAN CITY THAT IS ALIVE AND WAITING TO BE EXPLORED

Constantly reinventing itself, Leipzig still preserves the city's influential and historical aspects. The soul of this city has always been characterized by its energy, creative will and the pride of its citizens. Hospitality and openness to new ideas are centuries-old traditions in the city of Leipzig.

Leipzig is not only famous because of its long trade fair tradition but also because of its multifaceted music and cultural scene. Owing to its unique system of passageways, the historic city centre exudes a distinctive flair. Stylish boutiques and top department stores invite visitors to shop and stroll.

Most of the city's sights are located within walking distance, e. g. the Old Town Hall, St. Thomas Church, St. Nicholas Church, diverse museums and galleries. Cultural enjoyment is among others provided by the Gewandhaus, the Leipzig Opera or the world-famous St. Thomas Boys Choir.





# AWARDS

## LIFETIME CONTRIBUTION TO AUTOIMMUNITY AWARD, 2016

We are pleased to announce that following the tradition, three distinguished personalities have been chosen to receive the "Lifetime Contribution to Autoimmunity Award" in 2016. This award is presented every two years at the Autoimmunity Congress as a recognition to individuals who have contributed in a significant way to the field of autoimmunology.

The prize will be presented during the Opening Ceremony of the Congress.

This award is sponsored by industry. Please see page 211 for the details.


## THIS YEAR'S RECIPIENTS



### DR. ROBERT MORRIS, USA

Dr. Robert Morris was born in 1940 in New Jersey. After graduating at Rutgers University, he attended Hahneman Medical School and he was accepted to the renowned UCLA Rheumatology Fellowship. Dr. Morris has taught through the UCLA medical school and other institutions for over 25 years.

In 1974 he began private practice, and was troubled by the paucity of quality autoimmune testing for his patients. After much effort Dr. Morris opened RDL in 1977, with the goal of providing the most reliable and cost effective laboratory testing for Rheumatologists throughout the USA. Since its inception, RDL has been a leader in scientific research, always at the forefront of new assay development, including introducing anti-CCP testing in the USA. In 1999 Dr. Morris retired from private practice in order to devote his full energies to RDL. In late 2003, Dr. Morris was diagnosed with a rare form of hydrocephalus resistant to conventional treatments. After two years of hospitalization and rehabilitation, Dr. Morris returned to work full-time at RDL. From the time of his Fellowship until the present, Dr. Morris' vision has not been limited to his Practice and RDL. He was the primary investigator in the studies which demonstrated the link between HLA-B27, Ankylosing Spondylitis and Reactive Arthritis. This discovery was published in the New England Journal of Medicine in 1974. Dr. Morris was the first clinician to make a finding of legionella infection in synovial fluid. In addition to many other contributions, Dr. Morris has been instrumental in the development of the helminth compound as a potential treatment and/or vaccine for auto-immune disease. In 2014 Dr. Morris was made Master of the ACR.



## PROF. **ANGELA TINCANI**, ITALY

Angela Tincani is Professor of Rheumatology, University of Brescia and Head of Rheumatology and Clinical Immunology, Brescia General Hospital, Italy. After receiving her MD from the University of Milan in 1974, Prof. Tincani continued postgraduate studies in Allergology and Clinical Immunology, Hematology and Rheumatology, before taking up several senior positions at the University of Brescia. Since 2010 she is Head of Rheumatology and

Clinical Immunology Unit of Spedali Civili, Brescia.

Her main clinical and research areas include: pathogenesis, diagnosis and treatment of systemic autoimmune diseases in particular SLE and APS; management of pregnancy in patients with inflammatory arthritis and systemic autoimmune diseases: biomarkers of outcome and use of anti-rheumatic drugs in pregnant patients; evolution of autoantibodies determinations and reliability and clinical significance of emerging new technology. Professor Tincani has been included in the organization of many national and international congresses including the International Congress on Autoimmunity series since 1999 (Tel Aviv). She has served on many international committees for research and education in lupus, most recently the EULAR committee "Points to consider for use of antirheumatic drugs before pregnancy and during pregnancy and lactation" (2013–14) and, as co-chair, "Recommendations for the management of family planning, assisted reproduction, gestation, delivery and menopause in patients with Systemic Lupus Erythematosus.

Professor Tincani is a widely published author (300 publications indexed by PubMed with nearly 11000 citations and H-index 50 (by WOS). She is regional Editor (Europe) of the journal *Autoimmunity* and sits on the Editorial Boards of *Clinical and Experimental Rheumatology* and *Autoimmunity Reviews*.



**MR. POJU ZABLUDOWICZ, UK**

Poju Zabłudowicz is a global investor, entrepreneur and philanthropist. Poju is Chairman of Tamares which he has led since 1990. Tamares makes long-term investments in real estate, technology and primary sector and is a long-standing contributor to medical facilities. Over the years Poju has had an increased interest in the field of autoimmunity. He created the Zabłudowicz Center for Autoimmune Diseases, one of the world's most advanced centers

for research into autoimmune diseases. Poju has contributed to research on subjects like IVIg applications in autoimmunity, immunomodulating drugs and basic research on the etiology and pathogenesis of autoimmune models.

In 1994, together with his wife, Anita Zabłudowicz, Poju established The Zabłudowicz Collection, a dynamic collection of contemporary art works. The Zabłudowicz Collection has supported hundreds of new artists many of which have achieved significant success.

Poju Zabłudowicz was born in Finland and remains a passionate supporter of his home country. Alongside Tamares' investment in Outotec, a leading Finnish mining technology company, Poju serves on its board of directors as well as on the board of the Kiasma Museum of Contemporary Art in Helsinki. He is also a key supporter in the initiative to establish Guggenheim Finland.



## MOSAIC OF AUTOIMMUNITY AWARD (MAI) 2016

This annual award was established to encourage progress in autoimmunity research.

This is a prize awarded to a young scientist who has enriched the field of autoimmunity through outstanding, creative and independent research. The MAI Award will be delivered during the morning Plenary Session on April 8th, 2016.

This award is sponsored by industry. Please see page 211 for the details.

### WINNER IN 2016



#### DR. CARLO PERRICONE, ITALY

Carlo Perricone is a specialist in Rheumatology, PhD in Immunological, Hematologic and Rheumatological Sciences at Sapienza University of Rome. He received his Master Degree with honors in Medicine and Surgery in July 2007 at the University of Rome Tor Vergata, the title of Specialist in Rheumatology at the Sapienza University of Rome in April 2012 and the PhD in Immunological, Hematologic and Rheumatological Sciences at Sapienza University of Rome on February 2016.

His scientific work has been devoted to the study of autoimmune diseases with particular emphasis of systemic lupus erythematosus and antiphospholipid antibody syndrome. His studies focused on the role of NK cells and the complement system in the pathogenesis of autoimmune diseases and the interactions between genetic and multifactorial diseases. In addition, part of his scientific work has been focused on the study of imaging ultrasound in rheumatic diseases and on the autoimmune phenomena associated with vaccines. Teacher of musculoskeletal ultrasound for the European League Against Rheumatism and the Italian Society of Rheumatology. Founder of ReumaCamp for the Italian Society of Rheumatology.

The research activity is documented by more than 100 publications in extenso in prestigious national and international journals. He has authored and co-authored, as well as chapters in books and treatises. Referee for 50 peer-reviewed journals including Arthritis and Rheumatism and Rheumatology (Oxford). Member of the Editorial Board of the World Journal of Immunology. He has participated as investigator in clinical trials of phase III, randomized, controlled, double-blind, multicenter studies. In addition, he has participated as a speaker/chairman at numerous courses, seminars and conferences at national and international level.

The main topic of his research concerns the detection of novel genetic variants associated with the susceptibility to autoimmune diseases, particularly SLE, and capable of influencing disease phenotype. He has already found a locus (TRAF3IP2) potentially involved in SLE pathogenesis, especially in the development of pericarditis. In a further analysis, he has discovered another genetic variant (in HCP5 gene) associated with the presence of antibodies anti-Ro/SSA. His efforts are now dedicated to the unveiling of the pathogenic mechanisms by which an abnormal function of HCP5 may alter the immune response leading to the development of such antibodies, crucial in determining specific disease phenotypes as cutaneous involvement. This may allow to find a novel potential therapeutic target in SLE.

## HONORABLE MENTIONS



### DR. **JOOST SMOLDERS**, NETHERLANDS

As a PhD-student at Maastricht University Medical Center (Maastricht,NL) and post-doctoral researcher at the Netherlands Institute for Neuroscience (Amsterdam,NL), Dr. Smolders investigated the association of vitamin D status with clinical and immunological disease outcomes of MS. This work resulted in intervention-studies on the disease and immune modulating effects of vitamin D supplementation in MS. Currently, he works as a neurologist in training and research fellow at the neurology department of a large general hospital. He is also part of the research group of Prof. Dr. Raymond Hupperts at the Academic MS Center Limburg (Sittard, NL). His current research is mainly focused on the interaction between environmental factors and the pathophysiology of MS. Dr. Smolders co-authored over 40 scientific publications.

Current position and Institute:

CWZ MS Center, Department of Neurology, Canisius Wilhelmina Ziekenhuis, Nijmegen (NL)  
Academic MS Center Limburg, Department of Neurology, Zuyderland Medical Center, Sittard (NL)



### DR. **MAURIZIO FAREZ**, ARGENTINA

Mauricio Farez is the Director of the Center For Research on Neuroimmunological Diseases (CIEN) and an Associate Researcher in Neurology at the Institute for Neurological Research Dr. Raúl Carrea (FLENI) in Buenos Aires, Argentina. Mauricio received his M.D. degree with honors in 2006 and continued his training as a Research Fellow in Dr. Howard Weiner's laboratory at Harvard Medical School followed by a Master of Public Health at Harvard School of Public Health.

He has received several awards including the Bruce S. Schoenberg International Award in Neuroepidemiology of the American Academy of Neurology, the Investigator Award by the Allende Foundation the Young Investigation award of the Argentinean Multiple Sclerosis Society and the Du Pre award from the Multiple Sclerosis International Federation. He is coauthor of 36 papers in international peer reviewed journals and has contributed to several book chapters.

# NETWORKING EVENTS



## OPENING CEREMONY

WEDNESDAY, APRIL 6

18:00-19:00

### HALL 1

This year's Opening Ceremony will take us on a journey back in history, to relive the foundation and the thriving of the Autoimmunity Congress series. The Family of Autoimmunity will reunite for the 10th time on an evening full of music and surprises.




## WELCOME RECEPTION

WEDNESDAY, APRIL 6

19:00-20:00

### EXHIBITION AREA

Open the 10th International Congress with refreshments and lively discussion among old colleagues and new faces.



## BOOK SIGNING

SATURDAY, APRIL 9

12:30-13:00

### AUTOIMMUNITY NETWORK BOOTH

Prof. Shoenfeld will be signing his recent book *Vaccines and Autoimmunity*, available free of charge to Congress participants on a first-come first-served basis. Please exchange your voucher for a copy at the Autoimmunity Network Booth (Booth No.38) during Exhibition opening hours.



## NETWORKING DINNER

SATURDAY, APRIL 9

19:30-23:15

### PORSCHE CUSTOMER CENTRE LEIPZIG


Porsche Leipzig GmbH  
Porschestraße 1, 04158 Leipzig

Join your colleagues for an exciting evening of networking at the famous Porsche Customer Centre in Leipzig where culinary delight meets innovative technology. The centre houses an exhibition of rare and valuable vehicles and offers a unique setting for an informal conversation with old and new friends. Join us for a celebration and let us send off the 10th International Congress on Autoimmunity together. To purchase tickets, please approach the registration desk



# AUTOIMMUNITY 2016 AT YOUR FINGERTIPS

Search "Autoimmunity 2016" and Download  
the App for the Full Congress Experience



# New Research Links Autoimmune Diseases and Vaccines in Prone Individuals


The Children's Medical Safety Research Institute invites you to the

## 4th International Symposium on Vaccines Wednesday, April 6 12:00-17:30 Hall 2

Meet the experts and discuss the findings of recent studies on:

- Aluminum-induced macrophagic myofasciitis
- Aluminum and long-term neurotoxicity in mouse studies
- Cellular uptake of aluminum adjuvants
- Ovine ASIA syndrome
- Molecular mechanisms in vaccine-induced autoimmunity
- Primary ovarian failure & chronic fatigue syndrome related to HPV vaccine

Attendees will receive a complimentary copy of "**Vaccines & Autoimmunity**," a compilation of studies conducted worldwide, edited by Yehuda Schoenfeld, Lucija Tomljenovic and Nancy Agmon-Levin *while supplies last*.





## BASIC IMMUNOLOGY COURSE

WEDNESDAY, APRIL 6

12:30 – 17:30, HALL 3

The purpose of the course is to review major topics in basic immunology, with emphasis on recent advances and issues that are relevant to the pathogenesis and treatment of immune-mediated diseases. The course is designed for practicing clinicians, trainees, and scientists in biotech.

At the conclusion of this course, attendees will be able to:

- Describe the major advances in basic immunology that are relevant to human diseases, and the unresolved issues and future challenges.
- Recognize the fundamental mechanisms underlying immunologic diseases.
- Identify the basic principles underlying therapeutic modulation of the immune system, and the mechanisms of action of some of the major classes of immune modulators.

Course Director: **Abul K. Abbas**, MD, University of California San Francisco, USA



Abul K. Abbas received his medical degree in India, completed training in Pathology at Harvard and joined the faculty at Harvard Medical School and the Brigham and Women's Hospital, where he rose to become Professor of Pathology and Head of the Immunology Research Division. In 1999, after twenty years on the Harvard faculty, he moved to the University of California San Francisco as Professor and Chairman of the Department of Pathology. Dr. Abbas has received several honors, including election to the Institute of Medicine of the National Academy of

Sciences, election as a Fellow of the American Academy of Arts and Sciences, and the Rous-Whipple Award and Robbins Educator Award of the American Society of Investigative Pathology. He has served as one of the founding Editors and Associate Editor of *Immunity*, Associate Editor and Section Editor for *The Journal of Immunology*, Associate Editor of *Cell*, Consulting Editor of *The Journal of Clinical Investigation*, and founding Editor of the *Annual Review of Pathology: Mechanisms of Disease*. From 2011-2013, he was the President of the Federation of Clinical Immunology Societies (FOCIS). Dr. Abbas' research interests are in Immunology, with a focus on the control of immune responses and the causes of autoimmunity. His laboratory has used experimental models to analyze the generation and maintenance of regulatory T cells. He has published over 190 peer-reviewed papers and invited reviews, and is the author of four widely read textbooks, two in Immunology and two in Pathology. He has taught Immunology at Harvard Medical School and UCSF, and has organized and conducted Immunology courses worldwide.

# THE ZABLUDOWICZ & MORRIS PATIENT FORUM ON AUTOIMMUNE DISEASES

SATURDAY, APRIL 9

8:00 – 15:30, HALL MP1

Chairs: **Annegret Kuhn** (Germany), **Yehuda Shoenfeld** (Israel)

---

## SESSION 1: **AUTOIMMUNITY, PEMPHIGUS AND SCLERODERMA**

8:00	<b>Ulrich Sack</b>	Immunodeficiency or autoimmunity?
8:30	<b>Enno Schmidt</b>	Mucous membrane pemphigoid
9:00	<b>Gabriela Riemekasten</b>	Systemic sclerosis
9:30	<b>Q&amp;A</b>	
10:00	<b>Coffee Break</b>	

---

## SESSION 2: **CELIAC, SJOGREN'S, THYROID DISEASE & PSORIASIS**

10:25	<b>A. Kuhn &amp; Y. Shoenfeld</b>	Welcome words
10:30	<b>Georg Wick</b>	Celiac disease - pathogenic mechanisms, diagnosis and treatment
10:50	<b>Torsten Witte</b>	Sjogren's syndrome
11:10	<b>George Kahaly</b>	Autoimmune thyroid diseases
11:30	<b>Michael Sticherling</b>	The autoimmune aspects of psoriasis
11:50	<b>Q&amp;A</b>	
12:20	<b>Lunch Break</b>	

---

## SESSION 3: **LUPUS AND BULLOUS SKIN DISEASES**


13:15	<b>Annegret Kuhn</b>	Cutaneous lupus erythematosus
13:45	<b>Falk Hiepe</b>	Systemic lupus erythematosus
14:15	<b>Ralf Ludwig</b>	Epidermolysis bullosa acquisita and bullous pemphigoid
14:45	<b>O&amp;A</b>	

**Lectures will be given in German. Participation is free of charge.**



# SCIENTIFIC PROGRAM

## WEDNESDAY, APRIL 6, 2016



# 10<sup>TH</sup>

INTERNATIONAL CONGRESS  
ON **AUTOIMMUNITY**

APRIL 6-10, 2016, LEIPZIG, GERMANY



Autoimmunity Network Member



JOIN US IN **BOLOGNA**

4<sup>TH</sup> INTERNATIONAL CONGRESS ON

**CONTROVERSIES  
IN RHEUMATOLOGY  
& AUTOIMMUNITY**



BOLOGNA, ITALY, 9-11 MARCH 2017

[cora2017.kenes.com](http://cora2017.kenes.com)



# WEDNESDAY, APRIL 6, 2016

**12:00 - 17:30**

**Hall 2**

**Course: 4th INTERNATIONAL SYMPOSIUM ON VACCINES AND AUTOIMMUNITY in collaboration with CMSRI**

**Chair: C. Dwo skin** (USA)

**Chair: C. Exley** (United Kingdom)

12:00	THE TOXICITY OF ALUMINIUM ADJUVANTS <b>C. Exley</b> (United Kingdom)	1
12:20	PHYSICO-CHEMICAL PROPERTIES OF ALUMINIUM ADJUVANTS <b>E. Shardlow</b> (United Kingdom)	2
12:40	CELLULAR UPTAKE OF ALUMINIUM ADJUVANTS <b>M. Mold</b> (United Kingdom)	3
13:00	LOW CONCENTRATIONS OF ALUMINIUM (AL) HYDROXIDE ADJUVANT FORMING LIMITED SIZE AGGREGATES SELECTIVELY INDUCE LONG TERM NEUROTOXICITY AND INCREASE CEREBRAL AL CONTENT IN MOUSE <b>J. Cadasseau</b> (France)	4
13:20	POSITRON EMISSION TOMOGRAPHY OF THE BRAIN IN PATIENTS WITH ALUM-INDUCED MACROPHAGIC MYOFASCIITIS <b>J. Authier</b> (France)	5
13:40	PANEL DISCUSSION: WHY DO YOU THINK THAT THE AUTHORITIES ARE TRYING TO HIDE THE TRUTH? WHAT IS THE OBJECTIVE EVIDENCE THAT HPV VACCINATION IS NOT JUSTIFIED? WHAT DO YOU THINK, ARE THE MECHANISMS BY WHICH VACCINE CAN INDUCE AUTOIMMUNITY? <b>L. Tomljenovic</b> (Canada) <b>C. Exley</b> (United Kingdom) <b>J. Cadasseau</b> (France) <b>W. Kyle</b> (USA)	6 7 8 9

**14:30 COFFEE BREAK**



## SCIENTIFIC PROGRAMME

14:50	NEW INSIGHTS IN OVINE ASIA SYNDROME: CLINICOPATHOLOGICAL CHANGES IN EXPERIMENTALLY INDUCED ANIMALS	10
	<b>L. Luján</b> (Spain)	
15:10	MOLECULAR MECHANISMS IN VACCINE INDUCED AUTOIMMUNITY	11
	<b>D. Kanduc</b> (Italy)	
15:30	QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE AND AUTOIMMUNE ADVERSE EVENTS: A CASE-CONTROL ASSESSMENT OF THE VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS) DATABASE	12
	<b>M. Geier</b> , D. Geier (USA)	
15:50	PRIMARY OVARIAN FAILURE AND HPV VACCINE	13
	<b>O. Hamiel</b> (Israel)	

## 16:10 COFFEE BREAK



16:30	CHRONIC FATIGUE SYNDROME FOLLOWING HUMAN PAPILLOMA VIRUS VACCINATION: IS LATENT EPIPHARYNGITIS TO BLAME?	14
	<b>O. Hotta</b> (Japan)	
16:50	SEVERE CASES OF ASIA SYNDROME	15
	<b>L.J. Jara Quezada</b> (Mexico)	
17:10	VACCINES, ADJUVANTS AND AUTOIMMUNITY	16
	<b>L. Eça Guimarães</b> (Portugal)	

## 12:30 - 14:30

## Hall 3

Course: **BASIC IMMUNOLOGY COURSE Part 1**

12:30	INTRODUCTION TO THE IMMUNE SYSTEM	17
	<b>A.K. Abbas</b> (USA)	
13:00	INNATE IMMUNITY	18
	<b>A.K. Abbas</b> (USA)	
13:45	ANTIGEN PRESENTATION AND T CELL ACTIVATION	19
	<b>A.K. Abbas</b> (USA)	

## 14:30 COFFEE BREAK



---

**13:30 - 15:30****MP3 & 4****Industry Supported Session:**NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT

---

**15:00 - 17:00****Hall 3****Course: BASIC IMMUNOLOGY COURSE Part 2**

15:00	T CELL SUBSETS, CYTOKINES <b>A.K. Abbas</b> (USA)	20
15:40	B CELLS AND ANTIBODIES <b>A.K. Abbas</b> (USA)	21
16:20	IMMUNE REGULATION, TOLERANCE AND AUTOIMMUNITY <b>A.K. Abbas</b> (USA)	22

---

**15:30 - 17:00****Hall 4****Industry Supported Session:**NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT

---

**18:00 - 19:45****Hall 1****OPENING CEREMONY FOLLOWED BY WELCOME RECEPTION (IN THE EXHIBITION AREA)**





WEDNESDAY

THURSDAY

FRIDAY

SATURDAY

SUNDAY


INDEX

ACKNOWLEDGEMENTS



# SCIENTIFIC PROGRAM

## THURSDAY, APRIL 7, 2016



# 10<sup>TH</sup>

INTERNATIONAL CONGRESS  
ON **AUTOIMMUNITY**

APRIL 6-10, 2016, LEIPZIG, GERMANY

LACA 2017



Join Us in Cancun

6<sup>th</sup> Latin American  
Congress on

Auto   
immunity 

Cancun, Mexico, 26-29 November 2017



[laca2017.kenes.com](http://laca2017.kenes.com)

# THURSDAY, APRIL 7, 2016

8:00 - 10:00

Hall 1

## PLENARY SESSION 1

	<b>Chair: G. Hughes</b> (United Kingdom)	23
	<b>Chair: N.R. Rose</b> (USA)	24
	<b>Chair: P. Youinou</b> (France)	25
8:00	THE MANY FACES OF TRANSGLUTAMINASE AND CELIAC DISEASE <b>A. Lerner</b> (Germany)	26
8:30	SLE AND APS: TWO SYSTEMIC AUTOIMMUNE DISEASES CLOSE BUT STILL DIFFERENT <b>P.L. Meroni</b> (Italy)	27
9:00	IL-17: FROM DISCOVERY TO TARGETING <b>P. Miossec</b> (France)	28
9:30	RHEUMATOID ARTHRITIS: BEYOND ANTI-TNF - CAN WE DO BETTER? <b>R. van Vollenhoven</b> (Sweden)	29

THURSDAY

10:00-10:30

Exhibition

COFFEE BREAK &amp; EXHIBITION



10:00 - 10:30

Station 1

## EPD01: APS: REVELATIONS

- Chair: R. Willis** (USA) 30
- 10:00 THE PLASMATIC PLATELET-ACTIVATING FACTOR ACETYLDHROLASE ACTIVITY: A POSSIBLE RISK BIOMARKER IN PATIENTS WITH ANTI-PHOSPHOLIPID SYNDROME 31  
**A. Cifu'**, M. Fabris, R. Giacomello, C. Pistis, E. Tonutti, F. Curcio (Italy)
- 10:05 NK CELLS EXPANSION ASSOCIATED WITH ANTI-PHOSPHOLIPID SYNDROME IN PATIENTS WITH RECURRENT REPRODUCTIVE FAILURE 32  
**A. Comins-Boo**, J. Ochoa-Grullón, M. Núñez-Beltrán, A. García-Segovia, S. Sánchez-Ramón (Spain)
- 10:10 A MONOCLONAL ANTIBODY THAT DISRUPTS ANTIPHOSPHOLIPID ANTIBODY (APL)-ACTIVATED COMPLEX FORMATION BETWEEN B2-GPI AND APOER2PREVENTS APL-INDUCED FETAL LOSS AND THROMBOSIS IN MICE 33  
**C. Mineo**, A. Sacharidou, J. Salmon, R. Brekken, X. Huang, P. Shaul (USA)
- 10:15 A NEW DIAGNOSTIC PROFILE FOR ANTIPHOSPHOLIPID SYNDROME IN GENDER PERSPECTIVE 34  
**P. Sabatini**, P. Amato, A.M. D'ursi, A. Vitagliano (Italy)
- 10:20 ANTIPHOSPHOLIPID AUTOANTIBODY VARIATION IN A PRIMARY ANTIPHOSPHOLIPID ANTIBODY PATIENT - CLINICAL INSIGHTS 35  
Z. Shums, **R. Willis**, C. Gleason, E.B. Gonzalez, M. Mahler, G.L. Norman (USA)
- 10:25 PERFORMANCE OF A FULLY AUTOMATED CHEMILUMINESCENCE ASSAY FOR ANTIPHOSPHOLIPID ANTIBODIES DETECTION 36  
**V. Cunill Monjo**, E. Villegas, M. Montes, V. Avila, M.R. Fuster, A. Molina Fuentes, M.R. Jimenez, A. Urruticoechea, C. Moll, M. Ibañez, E. González, L. Pallares, M.R. Julià (Italy)

10:00 - 10:30

Station 2

EPD02: **NEW CYTOKINES: THE FLAME AND THE INFLAMED**

- Chair: D. Thiyagarajan** (Norway) 37
- 10:00 IL-33 IS PROCESSED INTO PRO-INFLAMMATORY ISOFORMS BY DYING NEUTROPHILS IN GRANULOMATOSIS WITH POLYANGIITIS 38  
**A. Kerstein**, A. Erschig, K. Holl-Ulrich, G. Marschner, S. Pitann, A. Mueller, G. Riemekasten, P. Lamprecht (Germany)
- 10:05 TOXICITY, TOXICOKINETICS AND IMMUNOGENICITY OF NOVEL IL-1 TRAP HETERODIMERIC FUSION PROTEIN 39  
A. Krotkova, **E. Shipaeva**, C.M. Luetjens, F.T. Ludwig, T. Hardwick, Y. Lavrovsky, M. Samsonov (Russia)
- 10:10 CLINICALLY INACTIVE DISEASE STATUS WITH TOCILIZUMAB EVERY 4 WEEKS IN REFRACTORY SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS 40  
**H. Xiao**, H. Song, H. Wang, W. Wang, Y.H. Yanyan He, M. Wei (China)
- 10:15 ADIPONECTIN-ADIPOR1-STAT3 DEPENDENT PATHWAY IS A CRITICAL REGULATOR OF TH17 CELL DIFFERENTIATION IN COLLAGEN-INDUCED ARTHRITIS 41  
X. Sun, W. Tan, Y. Wang, **M. Zhang** (China)
- 10:20 ENDOGENOUS IL-1BETA PROMOTES NUCLEAR TRANSLOCATION AND A DE NOVO FUNCTION OF DNASE1 AS TRANSCRIPTION FACTOR FOR THE FAS RECEPTOR GENE 42  
**D. Thiyagarajan**, H.L. Pedersen, K.D. Horvei, N. Seredkina, O.P. Rekvig (Norway)

10:00 - 10:30

Station 3

## EPD03: SLE: THE DISEASE OF A THOUSAND FACES

- Chair: S. Hirohata** (Japan) 43
- 10:00 ETHOSUXIMIDE-INDUCED LUPUS-LIKE SYNDROME: A CASE REPORT 44  
G. Zani, D. Vairo, **M. Cattalini**, S. Giliani, R. Ferraro, L. Giordano (Italy)
- 10:05 ROLE OF SERUM AUTOANTIBODIES IN BLOOD BRAIN BARRIER 45  
DAMAGES IN NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS  
**S. Hirohata**, Y. Sakuma, T. Yanagida, T. Yoshio (Japan)
- 10:10 DIAGNOSIS AND TREATMENT DIFFICULTIES OF SLE AND LUNG 46  
TUBERCULOSIS COINFECTION  
**N. Indriyaningrum**, H. Kalim, B.P.P. Suryana, C.S. Wahono (Indonesia)
- 10:15 INCIDENCE AND RISK FACTORS FOR FREQUENT HOSPITALIZATIONS 47  
IN SYSTEMIC LUPUS ERYTHEMATOSUS  
**S.S. Lee**, J.W. Lee, D.J. Park, Y.R. Yim, J.E. Kim, L. Wen, K.E. Lee  
(Republic of Korea)
- 10:20 MUCOSAL-ASSOCIATED INVARIANT T CELL DEFICIENCY IN SYSTEMIC 48  
LUPUS ERYTHEMATOSUS  
**Y.W. Park**, S.J. Kee, Y.N. Cho, H.M. Jin (Republic of Korea)
- 10:25 FINDING POSSIBLE SURROGATE MARKERS OF RENAL BIOPSY IN 49  
PATIENTS OF LUPUS NEPHRITIS  
**I. Thakur**, A. Karmakar, S.K. Chatterjee (India)

10:00 - 10:30

Station 4

## EPD04: MODERN AVENUES IN AUTOIMMUNE DIAGNOSTICS

- Chair: F. Struck** (Germany) 50
- 10:00 A NOVEL, AUTOMATED AND RANDOM-ACCESSED CHEMILUMINESCENCE IMMUNOASSAY ON TESTING TO ANTI-NUCLEAR ANTIBODIES IN HEALTHY INDIVIDUALS 51  
X. Chen, Z. Chen, X. Zhang, Q. Li, Q. Wei, S. Cao, **J. Gu**, C. Lee, J. Li, L. Liu (China)
- 10:05 SHOULD DENSE FINE SPECKLED 70 (DFS70) PATTERN BE REPORTED? BIOMNIS REFERENCE LAB EXPERIENCE ON 12619 ANA SCREENING CONSECUTIVE SERA 52  
**L. Guis**, A. Ebel, J. Leroy, S.A. Michaud, A. Pomaredes, C. Marcenaro, L. Chalouas (France)
- 10:10 UTILITY ANTI-SINTHETASE ANTIBODIES FOR EVOLUTION IDIOPATHIC INTERSTITIAL LUNG DISEASE (ILD) TO SYSTEMIC AUTOIMMUNE DISEASE: PRELIMINARY STUDY 53  
F. Marques-Garcia, **M.B. Aparicio-Hernandez**, I. De Los Santos, J.M. Gonzalez-Ruiz, M.D. Ludeña-Cruz (Spain)
- 10:15 THE STUDY OF ASTHMA AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA) DISEASES 54  
**H.A. Khazaei**, N.A. Moulaei, A. Khazaei, F. Hejazenia, B. Khazaei (Iran)
- 10:20 DEVELOPMENT AND EVALUATION OF 4G AUTOIMMUNE ANA PANEL ON THE AUTOMATED IMMUNOASSAY LUMIRAY® 1260 ANALYZER 55  
C. Lee, **L. Liu**, F. Qin, Z. Ma, Y. Xie, J. Wang, J. Wang, L. Cui, Z. Zhao (China)
- 10:25 PERFORMANCE OF THE IMPROVED MIKROGEN LINE IMMUNOASSAY DETECTING CIRCULATING AUTOANTIBODIES TO NUCLEAR AND CYTOPLASMIC PROTEINS WITH SPECIAL CONSIDERATION OF SLE AUTOANTIGENS 56  
**F. Struck**, T. Lüttich, I. Albrecht-Walz, O. Böcher, E. Soutschek (Germany)

10:00 - 10:30

Station 5

EPD05: **ATHEROSCLEROSIS AND AUTOIMMUNITY**

- Chair: J. Schofield** (USA) 57
- 10:00 CORRELATION BETWEEN CARDIOVASCULAR PARAMETERS AND DISEASE ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS 58  
**L. Gianturco**, F. Atzeni, S. Bongiovanni, L. Boccassini, P. Sarzi-Puttini, M. Turiel (Italy)
- 10:05 EVALUATION OF GLUCOSE METABOLISM IN RHEUMATIC PATIENTS: A CASE CONTROL STUDY 59  
M. Bellan, S. Bor, A. Gibbin, G. Guaschino, D. Sola, R. Pedrazzoli, **A. Rossini**, R. Bonometti, G.P. Carnavale Schianca, M. Pirisi, P.P. Sainaghi (Italy)
- 10:10 ANTI-CALRETICULIN AUTOANTIBODIES AND CALRETICULIN IN SERA OF PATIENTS DIAGNOSED WITH DILATED CARDIOMYOPATHY AND PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 60  
**D. Sánchez**, P. Gregor, K. Curila, I. Hoffmanová, V. Hábová, L. Tučková, H. Tlaskalová-Hogenová (Czech Republic)
- 10:15 AUTONOMIC NEUROPATHY – IN ITS MANY GUISES – AS THE INITIAL MANIFESTATION OF THE ANTIPHOSPHOLIPID SYNDROME 61  
**J. Schofield** (USA)



10:00 - 10:30

Station 6

## EPD06: MULTIPLEX DIAGNOSTIC AND CHIP TECHNIQUE

	<b>Chair: M.E. Crisostomo</b> (USA)	62
10:00	THE BIOPLEX® 2200 ANTIPHOSPHOLIPID SYNDROME (APLS) MULTIPLEX IMMUNOASSAYS DEMONSTRATE HIGHER ANALYTICAL SENSITIVITY <b>M. Crisostomo</b> , S. Zhou, H. Scholz, R. Walker, E. Barrett (USA)	63
10:05	25-HYDROXY-VITAMIN D ON THE BIO-RAD BIOPLEX 2200 - COMPARISON WITH BECKMAN DXI AND MASS SPECTROMETRY D. Spradbery, R. Wilmot, <b>S. Holding</b> (United Kingdom)	64
10:10	NEXT GENERATION MULTIPLEX CHIP-BASED DETECTION OF AUTOANTIBODIES FOR THE DIAGNOSIS OF SYSTEMIC AUTOIMMUNE DISEASES: EXPERIENCE IN A TERTIARY CARE CENTER LABORATORY <b>M. Miyara</b> , J.L. Charuel, P. Ghillani-Dalbin, R.L. Romero, C.A. Cherwien, A. Wang, L. Musset, R.W. Burlingame (France)	65
10:15	SCREENING FOR NOVEL AUTOANTIBODIES ON 42K PROTEIN MICROARRAYS <b>R. Sjöberg</b> , C. Hellström, E. Andersson, C. Mattsson, P. Nilsson (Sweden)	66
10:20	APLS AND CELIAC ANALYTICAL SENSITIVITY ON THE BIOPLEX 2200 <b>W. Vandam</b> , M. Crisostomo, H. Scholz, R. Walker (USA)	67
10:25	COMPARISON OF FOUR AUTOMATED INDIRECT IMMUNOFLUORESCENCE SYSTEMS IN THE DETECTION OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES <b>S. Degandt</b> , M. Hutsebaut, P. Vogeleere, H. Devos (Belgium)	68

10:00 - 10:30

Station 7

## EPD07: AUTOIMMUNITY AND HEMATOLOGY

	<b>Chair: D. Škorić</b> (Serbia)	69
10:00	CLINICAL MANIFESTATIONS OF IGG4-RELATED DISEASE IN COLOMBIA E.P. Navarro, J.P. Suso, M. Chamorro, A. Hormaza, A. Echeverri, F. Bonilla-Abadía, J. Escobar, C.A. Cañas, J.C. Bravo, <b>G.J. Tobón</b> (Colombia)	70
10:05	A RARE CASE OF ERDHEIM-CHESTER DISEASE (ECD) MIMICKING IGG4-RELATED DISEASE (IGG4-RD) <b>E. Sokol</b> , V. Vaslyev, S. Palshina, A. Pavlovskaya, N. Kokosadze (Russia)	71
10:10	PREVALENCE AND CLINICAL SIGNIFICANCE OF ANTITHYROID ANTIBODIES IN CHILDREN WITH IMMUNE THROMBOCYTOPENIC PURPURA-OUR EXPERIENCE <b>D. Škorić</b> , J. Kovacevic, G. Milosevic (Serbia)	72
10:15	EFFECTS OF RITUXIMAB (RTX) THERAPY IN ADULT PATIENTS WITH HENOCH-SHONLEIN PURPURA (HSP) <b>F. Roberta</b> , C. Naretto, G. Quattrocchio, M. Ferro, M. Paola, B. Giulietta, D. Roccatello (Italy)	73
10:20	AUTOIMMUNE HEMOLYTIC ANEMIA AND HODGKIN LYMPHOMA: A RARE ASSOCIATION <b>M. Kechida</b> , N. Lorenzo Villalba, R. Klii, W. Bouteraa, S. Hammami, I. Khochtali (Tunisia)	74

10:00 - 10:30

Station 8

## EPD08: HOW CAN WE IMMUNOMODULATE AUTOIMMUNE CONDITIONS?

	<b>Chair: J.C. Aguillón</b> (Chile)	75
10:00	TRANSCRIPTIONAL PROGRAMS OF MONOCYTE-DERIVED TOLEROGENIC DENDRITIC CELLS FROM RHEUMATOID ARTHRITIS PATIENTS AND HEALTHY SUBJECTS OBTAINED BY MODULATION WITH DEXAMETHASONE AND MONOPHOSPHORYL LIPID A <b>J.C. Aguillón</b> , K. Schinnerling, P. García-González, A. Sepúlveda, G. Ubilla, A.M. Mehdi, H.J. Nel, R. Thomas, R. Verdugo (Chile)	76
10:05	CONTRIBUTION OF CD8+ T CELLS IN THE PATHOPHYSIOLOGY OF AMYOTROPHIC LATERAL SCLEROSIS <b>E. Coque</b> , G. Espinosa, T. Vincent, C. Salsac, J. Hernandez, C. Raoul (France)	77
10:10	EXPLOITING ANNEXIN-INDUCED IMMUNOSUPPRESSION TO INDUCE ANTIGEN-SPECIFIC TOLERANCE <b>C. Eck</b> , H. Weyd, P.H. Krammer (Germany)	78
10:15	EFFECT OF HYPERLIPIDEMIA ON IL-17, IL-6 AND TGF- $\beta$ SERUM LEVELS <b>E.F. Elfi</b> , E. Darwin (Indonesia)	79
10:20	DRUG REPURPOSING FOR AUTOIMMUNE DISEASES- FINDING NEW AGENTS TO TARGET NEUTROPHIL ACTIVATION <b>S. Ghorbanalipoor</b> , R.J. Ludwig, D. Zillikens, K. Bieber (Germany)	80
10:25	DRUG RE-PURPOSING IDENTIFIES NOVEL B-CELL INHIBITORY DRUGS WITHIN THE PRESTWICK CHEMICAL LIBRARY® <b>K. Matsumoto</b> , K. Bieber, S. Ibrahim, D. Zillikens, R. Ludwig (Germany)	81

10:30 - 12:30

Hall 1

## PARALLEL SESSION 01: ETIOLOGY AND PATHOGENESIS OF AUTOIMMUNITY

	<b>Chair: G. Steiner</b> (Austria)	82
	<b>Chair: E. Rosenthal</b> (France)	83
	<b>Chair: C. Chang</b> (USA)	84
10:30	THE ROLE OF NUCLEIC ACIDS AND THEIR RECEPTORS IN THE PATHOGENESIS OF AUTOIMMUNE ARTHRITIS IN RATS AND MEN <b>G. Steiner</b> (Austria)	85
10:50	VASCULAR HYPOTHESIS REVISITED: ROLE OF STIMULATING ANTIBODIES AGAINST ANGIOTENSIN AND ENDOTHELIN RECEPTORS IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS <b>G. Riemekasten</b> (Germany)	86
11:10	ROLE OF MICROPARTICLES ON ENDOTHELIAL CELL FATE IN RHEUMATOID ARTHRITIS PATIENTS <b>C. Barbati</b> , C. Alessandri, T. Colasanti, M. Pendolino, V. Marta, F. Spinelli, F. Miranda, F. Conti, V. Guido (Italy)	87
11:20	ANTIGEN-DRIVEN SELECTION OF PLASMABLASTS, BUT NOT GENERAL GENETIC RESTRICTION OF NAIVE B CELLS, IS PATHOGNOMONIC FOR PEMPHIGUS VULGARIS PATIENT A. Recke, J. Bischof, W. Meng, C. Arolt, F. Baden, T. Vollbrandt, R. Glaeser, R.A. Manz, U. Hershberg, E. Schmidt, E.T. Luning Prak, S.M. Ibrahim, <b>C.M. Hammers</b> (Germany)	88
11:30	PANDEMRIX-ASSOCIATED NARCOLEPSY: SPECIFIC (AND UNEXPECTED) ANTIGEN-ASSOCIATED MOLECULAR MIMICRY COUPLED TO NON-SPECIFIC (AND EXPECTED) IMMUNOSTIMULATION <b>S.S. Ahmed</b> , W. Volkmuth, L. Steinman (Italy)	89
11:40	COMPARISON OF THE RELIABILITY OF CELIAC DISEASE SEROLOGY TO REFLECT INTESTINAL DAMAGE T. Matthias, <b>P. Jeremias</b> , S. Neidhoefer, A. Lerner (Germany)	90
11:50	A NOVEL FULLY HUMANIZED AND HIGHLY SENSITIVE ASSAY TO QUANTIFY NEUTROPHIL EXTRACELLULAR TRAPS (NETS) REVEAL ROS-INDEPENDENT NET RELEASE BY IMMUNE COMPLEXES Y.K.O. Teng, <b>T. Kraaij</b> , S.W.A. Kamerling, H.U. Scherer, R.E.M. Toes, T.J. Rabelink, C. Kooten (Netherlands)	91

12:00	ROLE OF EXTRACELLULAR VESICLES IN AUTOIMMUNE DISEASES <b>D. Turpin</b> (France)	92
12:10	IMMUNE RESET - LESSONS FROM IMMUNOABLATION: A PATHOGENIC IMMUNOLOGIC MEMORY IS DRIVING CHRONIC INFLAMMATION <b>T. Alexander</b> (Germany)	93
12:20	RETINOID-RELATED ORPHAN RECEPTOR GAMMA ADULT INDUCED KNOCKOUT MICE DEVELOPS LYMPHOBLASTIC LYMPHOMA <b>M. Liljevald</b> , P. Thulin, C. Johansson, L. Brändén, J. Börjesson, A.K. Sjögren, X. Xu, M. Bjursell, J. Hornberg, H. Shankaran, M. Söderberg, U. Andersson, J. Jirholt (Sweden)	94

**12:30-14:00****Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

10:30 - 12:30

MP3 &amp; 4

PARALLEL SESSION 02: **CELIAC DISEASE: NOVELTIES IN 2016**

	<b>Chair: M. Thomas</b> (Germany)	95
	<b>Chair: J. Kratzsch</b> (Germany)	96
	<b>Chair: T. Matthias</b> (Germany)	97
10:30	PREDICTIVE POWER OF ANTIBODY ASSAYS IN THE DIAGNOSTICS OF COELIAC DISEASE <b>M. Thomas</b> (Germany)	98
10:50	THE RELEVANCE OF HLA-DQ2/DQ8 DETERMINATION IN THE DIAGNOSIS OF CELIAC DISEASE <b>E. Tibenska</b> (Slovakia)	99
11:10	NEW THERAPEUTIC STRATEGIES IN CELIAC DISEASE <b>D. Leffler</b> (USA)	100
11:25	TG2 AND ANTI TG2: THE TWO SIDES OF THE COIN <b>K. Lindfors</b> (Finland)	101
11:40	ANTI-MICROBIAL TRANSGLUTAMINASE IS A NEW BIO-MARKER AND A POTENTIAL INDUCER OF CELIAC DISEASE <b>T. Matthias</b> , P. Jeremias, S. Neidhoefer, A. Lerner (Germany)	102
12:00	NEO-EPI TOPE SEROLOGY A POWERFUL TOOL IN GLUTEN ASSOCIATED CONDITIONS <b>K. Guzmán-López</b> , P. Jeremias, S. Neidhöfer, M. Torsten, A. Lerner, A. Plaza-López (Spain)	103
12:10	EVALUATION OF BIOPLEX 2200 FOR THE DETECTION OF IGA AND IGG ANTI-TRANSGLUTAMINASE AND DEAMINATED GLIADIN PEPTIDE ANTIBODIES IN CELIAC DISEASE <b>J. Irure-ventura</b> , E. Asensio, L. Riesco, D. Ramos, M. Toca, M. Lopez-Hoyos (Spain)	104
12:20	ANTIBODY DIAGNOSTICS IN PAEDIATRIC COELIAC DISEASE: REPORT ON AN ONGOING PROSPECTIVE MULTICENTRE TRIAL <b>J. Wolf</b> , D. Hasenclever, D. Petroff, T. Mothes (Germany)	105

12:30-14:00

Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

10:30 - 12:30

Hall 2

PARALLEL SESSION 03: **IVIG: THE BEST BIOLOGIC?**

	<b>Chair: D.R. Branch</b> (Canada)	106
	<b>Chair: M.G. Danieli</b> (Italy)	107
	<b>Chair: F. Käsermann</b> (Switzerland)	108
10:30	IVIG AND AUTOIMMUNE DISEASE - POTENTIAL NEXT GENERATION BIOLOGICS <b>A. Zuercher</b> , R. Spirig, A. Baz Morelli, F. Käsermann (Switzerland)	109
10:45	SMALL MOLECULE PHAGOCYTOSIS INHIBITORS FOR IMMUNE CYTOPENIAS <b>D.R. Branch</b> , M.K. Purohit, A. Bello, M.C. Bateau, E. Burke-Murphy, T.N. Tong, A. Neschadim, L.P. Kotra (Canada)	110
11:00	MONOVALENT FC RECEPTOR BLOCKADE BY AN ANTI-FCY RECEPTOR/ ALBUMIN FUSION PROTEIN X. Yu, M. Menard, J. Prechl, V. Bhakta, W. Sheffield, <b>A. Lazarus</b> (Canada)	111
11:15	SELECTIVE IMMUNO-MODULATORS OF FC RECEPTORS FOR IMPROVED THERAPY OF ORPHAN AUTOIMMUNE DISEASES <b>A. Manning</b> (USA)	112
11:35	THE ROLE OF SIALYLATION FOR THE ANTI-INFLAMMATORY ACTIVITY OF INTRAVENOUS IMMUNOGLOBULIN <b>I. Schwab</b> , N. Washburn, C.J. Bosques, A. Lux, F. Nimmerjahn (Germany)	113
11:50	SPECIFIC IVIG AND ANTI-IDIOTYPIC ANTIBODIES TO ANTI-CCP <b>M. Blank</b> (Israel)	114
12:00	LONG-TERM BENEFIT AND SAFETY OF FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN IN THE TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA CVID-LINKED <b>R. Morariu</b> , S. Agolini, V. Pedini, L. Marinangeli, A. Gabrielli, D. Maria Giovanna (Italy)	115
12:10	RESPONSE TO SUBCUTANEOUS IMMUNOGLOBULIN (SCIG) IN DIFFERENT ORGAN SYSTEMS IN IDIOPATHIC INFLAMMATORY MYOPATHIES V. Pedini, <b>C. Gelardi</b> , F. Lupidi, F. Logullo, A. Gabrielli, M.G. Danieli (Italy)	116
12:20	THERAPEUTIC MOROCCAN IVIG LOTS CONTAIN IGG ANTIBODIES AGAINST DIFFERENT HLA CLASS I AND II ALLELES <b>F. El Hilali</b> , Vadim Jucaud, A.E.I. H. El Hilali, M. Moumni, Hamid Mazouz (Morocco)	117

THURSDAY

12:30-14:00

Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

10:30 - 12:30

Hall 3

## PARALLEL SESSION 04: STANDARDIZATION AND HARMONIZATION IN AUTOANTIBODY TESTING

	<b>Chair: N. Bizzaro</b> (Italy)	118
	<b>Chair: J. Sheldon</b> (United Kingdom)	119
	<b>Chair: B. Gilburd</b> (Israel)	120
10:30	WHERE ARE WE IN STANDARDIZATION OF AUTOANTIBODY TESTING? <b>J. Sheldon</b> (United Kingdom)	121
10:50	HARMONIZATION OF AUTOANTIBODY TESTING: CLINICAL AND DIAGNOSTIC ISSUES <b>N. Bizzaro</b> (Italy)	122
11:10	THE INTERNATIONAL CONSENSUS ON STANDARDIZED NOMENCLATURE OF ANTINUCLEAR ANTIBODY HEP-2 CELL PATTERNS (ICAP) INITIATIVE - CURRENT STATUS AND INITIATIVES <b>E. Chan</b> , J. Damoiseaux, G. Carballo, K. Conrad, W. De Melo Cruvinel, P. Francescantonio, M. Fritzler, I. Garcia-De La Torre, M. Herold, T. Mimori, M. Satoh, C. Von Mühlen, L. Andrade (USA)	123
11:30	THE BURDEN OF THE VARIABILITY INTRODUCED BY THE ASSAY KIT AND THE COMPUTER-AIDED DIAGNOSIS SYSTEM IN ANA INDIRECT IMMUNOFLUORESCENCE TEST <b>M. Infantino</b> , F. Meacci, V. Grossi, F. Atzeni, P. Sarzi-Puttini, M. Benucci, P. Soda, M. Manfredi (Italy)	124
11:50	STANDARDIZATION IN THE DETECTION OF ANCA IN THE DIAGNOSIS AND FOLLOW-UP OF SMALL VESSEL VASCULITIS IS URGENTLY NEEDED <b>M. Oyaert</b> , K. Vande Keere, L. Van Hoovels (Belgium)	125
12:00	MULTI-CENTER HARMONIZATION OF FLOW CYTOMETERS FOR MULTI-COLOR ANALYSES OF A LARGE COHORT OF PATIENTS IN THE CONTEXT OF THE EUROPEAN IMI PROJECT "PRECISESADS" <b>J.O. Pers</b> , L. Le Lann, C. Maranon, N. Barbarroja, D. Alvarez, E. Trombetta, V. Gerl, A. Zuber, T. Cantaert, E. Neves, K. Kniesch, J. Ducreux, C. Jamin (France)	126
12:10	CAN NON-CONSENSUS ANTIPHOSPHOLIPID ANTIBODY ASSAY TECHNIQUES DIFFERENTIATE BETWEEN APS PATIENTS AND ANTIPHOSPHOLIPID ANTIBODY POSITIVE CARRIERS - TIME FOR RECONSIDERATION? <b>D. Roggenbuck</b> , P. Schierack, M. Mahler, P. Macor, M.O. Borghi, P.L. Meroni (Germany)	127



12:20	ROLE OF GLYCOXIDATED-HISTONES IN SYSTEMIC LUPUS ERYTHEMATOSUS <b>K. Alam</b> (India)	128
-------	-----------------------------------------------------------------------------------------	-----

**12:30-14:00****Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

**10:30 - 12:30****Hall 4****PARALLEL SESSION 05: THE INTEGUMENT AND ORAL MUCOSA**

	<b>Chair: M.D. Mignogna</b> (Italy)	129
	<b>Chair: S. Janket</b> (USA)	130
	<b>Chair: C. Selmi</b> (Italy)	131
10:30	HCV RELATED IMMUNO-MEDIATED OROFACIAL DISORDERS <b>M. Carrozzo</b> (United Kingdom)	132
10:50	CLINICO-PATHOLOGICAL FEATURES OF ORAL LICHEN PLANUS AND LICHENOID REACTIONS <b>S.B. Woo</b> (USA)	133
11:10	ORO-FACIAL GRANULOMATOSIS: AN UPDATE <b>S. Leuci</b> (Italy)	134
11:30	ORO-PHARYNGEAL BLISTERING DISEASES <b>M.D. Mignogna</b> (Italy)	135
11:50	MODIFIED IMMUNOTHERAPY FOR ALOPECIA AREATA <b>T. Yoshimasu</b> , N. Mikita, N. Kanazawa, Y. Yamamoto, F. Furukawa (Japan)	136
12:00	OVERLAPPING IGG4 RESPONSES TO SELF AND ENVIRONMENTAL ANTIGENS IN ENDEMIC PEMPHIGUS FOLIACEUS <b>Y. Qian</b> (USA)	137
12:10	FAMILIAL CHILBLAIN LUPUS CAUSED BY AN ACTIVATING MUTATION IN STING <b>N. König</b> , C. Fiehn, H.M. Lorenz, V. Tüngler, C. Günther, O. Chara, M.A. Lee-Kirsch (Germany)	138
12:20	VESICULAR BULLOUS PEMPHIGOID AND PSORIASIS: A VERY RARE ASSOCIATION <b>A. Lo Schiavo</b> , R.V. Puca, F. Romano (Italy)	139

**12:30-14:00****Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

10:30 - 12:30

Hall 5

## PARALLEL SESSION 06: CITRULLINATION (CCP)

	<b>Chair: G. Serre</b> (France)	140
	<b>Chair: A. Tanay</b> (Israel)	141
	<b>Chair: X. Bossuyt</b> (Belgium)	142
10:30	PATHOPHYSIOLOGICAL ROLE(S) OF ACPA <b>G. Serre</b> (France)	143
10:50	ACPA INDUCES PATHOGENIC CYTOKINE PROFILE IN LYMPHOCYTES AND OXIDATIVE BURST ACTIVITY IN NEUTROPHILS OF RHEUMATOID ARTHRITIS PATIENTS <b>S. Gertel</b> , Y. Shoenfeld, H. Amital (Israel)	144
11:10	ANTI-CARBAMYLATED PROTEIN ANTIBODIES: FINE-SPECIFICITY AND CROSS-REACTIVITY <b>M.K. Verheul</b> , T. Huizinga, R. Toes, L. Trouw (Netherlands)	145
11:30	ANTI-ALPHA-ENOLASE CITRULLINATED PEPTIDE 1 (CEP-1) ANTIBODIES AND PREDICTIVE RESPONSE TO TREATMENT IN RHEUMATOID ARTHRITIS: PRELIMINARY DATA <b>M. Fredi</b> , F. Gurrieri, I. Cavazzana, A. Tincani, F. Franceschini (Italy)	146
11:40	CONFIRMATION OF SEROLOGICAL ANTIBODIES AGAINST NOVEL CITRULLINATED PROTEINS IN EARLY RHEUMATOID ARTHRITIS <b>P. Schulz-Knappe</b> , A. Lueking, P. Schriek, M. Von Darl, H. Goehler, H.D. Zucht, J. Richter, S. Vordenbaeumen, J. Detert, G.R. Burmester, M. Schneider (Germany)	147
11:50	AMONG HUMAN MACROPHAGES POLARIZED TO DIFFERENT PHENOTYPES, THE M-CSF-ORIENTED CELLS PRESENT THE HIGHEST PRO-INFLAMMATORY RESPONSE TO THE RHEUMATOID ARTHRITIS-SPECIFIC IMMUNE COMPLEXES CONTAINING ACPA <b>C. Clavel</b> , L. Ceccato, F. Anquetil, G. Serre, M. Sebbag (France)	148
12:00	FIRST IN CLASS THERAPEUTIC ACPAS REDUCE INFLAMMATION BY INHIBITION OF NETOSIS <b>R. Chirivi</b> , J. Van Rosmalen, G. Schmets, H. Van Es, J. Raats (Netherlands)	149

- |       |                                                                                                                                                                                                  |     |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 12:10 | UNFOLDED PROTEIN RESPONSE GENE GADD34 (GROWTH ARREST AND DNA DAMAGE-INDUCIBLE GENE 34) IS OVEREXPRESSED IN RHEUMATOID ARTHRITIS AND RELATED TO ANTI-CITRULLINATED PROTEIN ANTIBODY CONCENTRATION | 150 |
|       | <b>G. Clavarino</b> , S. Adriouach, J.L. Quesada, M. Clay, M. Chevreau, C. Trocmé, L. Grange, P. Gaudin, E. Gatti, P. Pierre, J.Y. Cesbron, C. Dumestre-Pérard (France)                          |     |
| 12:20 | INCREASED RISK OF THROMBOEMBOLISM AMONG PATIENTS WITH VTE ASSOCIATION WITH RHEUMATOID ARTHRITIS                                                                                                  | 151 |
|       | <b>H. Amital</b> (Israel)                                                                                                                                                                        |     |

**12:30-14:00****Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

**12:30 - 14:00****MP3 & 4****Industry Supported Session:**

NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT

14:00 - 16:00

Hall 1

**PARALLEL SESSION 07: HYGIENE THEORY, MICROBIOME, PROBIOTICS**

	<b>Chair: L. Luján</b> (Spain)	152
	<b>Chair: M. Blank</b> (Israel)	153
	<b>Chair: D. Bogdanos</b> (Greece)	154
14:00	MICROBIOME AND AUTOIMMUNITY <b>O. Koren</b> (Israel)	155
14:20	THE MICROBIOME AND SLE: PROOF OF CONCEPT <b>G. Zandman-Goddard</b> , T. Kolitz, N. Katz-Agranov (Israel)	156
14:40	HELMINTHES DERIVATIVE FOR TREATING EXPERIMENTAL COLLAGEN INDUCED ARTHRITIS <b>T. Bashi</b> , M. Fridkin, A. Volkov, I. Barshack, M. Blank, Y. Shoenfeld (Israel)	157
14:55	NATURAL ANTIBODIES AGAINST SMALL LIPID EPITOPES AS PROTECTIVE FACTORS IN AUTOIMMUNITY AND ATHEROSCLEROSIS: A NEW DEVELOPMENT OF THE HYGIENE/MISSING OLD FRIENDS HYPOTHESIS <b>J. Frostegård</b> , W. Tao, L. Råstam, U. Lindblad, S. Lindeberg (Sweden)	158
15:10	FHHDM-1, A PEPTIDE SECRETED BY THE HELMINTH FASCIOLA HEPATICA PREVENTS AUTOIMMUNE DIABETES AND REDUCES DISEASE SEVERITY OF MULTIPLE SCLEROSIS IN MURINE MODELS <b>M. Lund</b> , J. Greer, B. O'Brien, J. Dalton, S. Donnelly (Australia)	159
15:20	SKIN MICROBIOME AND SYSTEMIC LUPUS ERYTHEMATOSUS: ASSOCIATION BETWEEN STAPHYLOCOCCUS AUREUS NASAL CARRIAGE AND DISEASE PHENOTYPE <b>F. Ceccarelli</b> , G. Iaiani, C. Perricone, A. Giordano, F. Miranda, F.R. Spinelli, L. Massaro, V.A. Pacucci, S. Truglia, C. Alessandri, G. Valesini, F. Conti (Italy)	160
15:30	ACTIVATION OF TLR4 BY DYSBIOTIC INTESTINAL MICROBIOTA FOLLOWING IL-1 RECEPTOR ANTAGONIST DEFICIENCY TRIGGERS TH17-MEDIATED ARTHRITIS <b>R. Rogier</b> , T. Ederveen, J. Boekhorst, H. Wopereis, S. Frambach, J. Garssen, P. Van der Kraan, M. Koenders, W. Van den Berg, S. Van Hijum, S. Abdollahi-Roodsaz (Netherlands)	161

15:40	THE GUT MICROBIOTA EXACERBATE SPONTANEOUS AUTOIMMUNE HEPATITIS DEVELOPMENT IN A MOUSE MODEL THROUGH TOLL-LIKE RECEPTOR-DEPENDENT MECHANISMS	162
	<b>K. Alexandropoulos</b> , E. Weinstein (USA)	
15:50	EFFECTS OF SOCIAL STRESS ON THE FUNCTION OF IMMUNE SYSTEM ARE PARTIALLY IMPRINTED ON THE GUT MICROBIOTA COMPOSITION	163
	<b>O. Avni</b> , O. Koren (Israel)	

**14:00 - 16:00****MP3 & 4****PARALLEL SESSION 08: NOVEL BIOLOGICS AND BIOSIMILARS**

	<b>Chair: J. Aelion</b> (USA)	164
	<b>Chair: A. Kromminga</b> (Germany)	165
	<b>Chair: C. Edwards</b> (United Kingdom)	166
14:00	ARE THERE DANGERS IN BIOLOGICAL THERAPY DOSE REDUCTION STRATEGIES?	167
	<b>C. Edwards</b> (United Kingdom)	
14:20	THE WANTED AND UNWANTED: IMMUNOGENICITY OF BIOLOGICALS	168
	<b>A. Kromminga</b> (Germany)	
14:40	BIOSIMILARS FROM A PRACTICING RHEUMATOLOGIST PERSPECTIVE	169
	<b>G.F. Schimizzi</b> (USA)	
15:00	POTENTIAL PITFALLS OF IMMUNOGENICITY AND PK ASSAYS: NEWS FROM THE BENCH	170
	<b>M. Schaab</b> (Germany)	
15:20	ANTIBODIES AGAINST CD74 AS BIOMARKERS OF AXIAL SPONDYLOARTHRITIS	171
	<b>T. Witte</b> (Germany)	
15:35	PROTEASOME INHIBITION WITH BORTEZOMIB AMELIORATES CLINICAL MANIFESTATIONS OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS BY PLASMA CELL DEPLETION AND TARGETING TYPE I INTERFERON ACTIVITY	172
	<b>T. Alexander</b> (Germany)	
15:50	BIOLOGICS AND BIOSIMILARS IN CLINICAL RHEUMATOLOGY PRACTICE- EXPERIENCE FROM SOUTH INDIA	173
	<b>S. Nallasivan</b> (India)	

14:00 - 16:00

Hall 2

## PARALLEL SESSION 09: B CELLS - PATHOGENESIS AND SUPPRESSION

	<b>Chair: A.K. Abbas</b> (USA)	174
	<b>Chair: Z. Vadasz</b> (Israel)	175
	<b>Chair: C. Putterman</b> (USA)	176
14:00	ARE B CELLS REQUIRED FOR THE DEVELOPMENT OF NEUROPSYCHIATRIC LUPUS? <b>C. Putterman</b> (USA)	177
14:20	RITUXIMAB IMMUNOTHERAPY IS ASSOCIATED WITH IMPROVEMENT OF PERIODONTAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS <b>J.O. Pers</b> , J. Coat, J. Demoersman, D. Cornec, V. Devauchelle-Pensec, A. Saraux (France)	178
14:40	THERAPEUTIC LONGTERM DEPLETION OF AUTOREACTIVE MEMORY NECESSITATES A COMBINED DEPLETION OF MEMORY PLASMA CELLS AND THEIR PROGENITORS A. Taddeo, C. Qingyu, L. Khodadadi, T. Alexander, G. Burmester, A. Radbruch, F. Hiepe, <b>B. Hoyer</b> (Germany)	179
15:00	BAFF, BCMA, CD20: HOW THEY ARE EXPRESSED IN LUPUS NEPHRITIS? C.A. Jimenez, J.P. Suso, F.E. Ospina, A.Y. Sánchez, C.A. Cañas, <b>G. Tobón</b> (Columbia)	180
15:10	B CELLS REGULATE HUMORAL RESPONSE THROUGH THE CONTROL OF FOLLICULAR HELPER T CELLS IN HEALTHY INDIVIDUALS AND SJOGREN'S PATIENTS BUT ARE DEFECTIVE IN SLE PATIENTS A. Achour, <b>J.O. Pers</b> , P. Youinou, C. Jamin (France)	181
15:20	BLOOD AND SALIVARY GLAND BAFF-DRIVEN B-CELL HYPERACTIVITY IN RITUXIMAB NON-RESPONDER PATIENTS WITH PRIMARY SJOGREN'S SYNDROME D. Cornec, S. Costa, V. Devauchelle-Pensec, S. Jousse-Joulin, P. Marcourelles, J.M. Berthelot, L. Chiche, E. Hachulla, P.Y. Hatron, V. Goeb, O. Vittecoq, A. Saraux, <b>J.O. Pers</b> (France)	182
15:30	REGULATORY B CELLS IN SYSTEMIC SCLEROSIS (SSC) ISOLATED OR CONCOMITANT WITH HASHIMOTO THYROIDITIS (HT) I. Gatto, G. Mangino, P. Fallahi, A. Antonelli, <b>M. Centanni</b> (Italy)	183
15:40	LOW-DOSE RITUXIMAB RETREATMENT REGIMEN FOR PATIENTS WITH MIXED CRYOGLOBULINEMIA <b>S. Colantuono</b> , M. Visentini, M. Mitrevski, A. Boni, M. Fiorilli, M. Casato (Italy)	184

- 15:50 ALTERNATIVELY ACTIVATED DENDRITIC CELLS DERIVED FROM SYSTEMIC LUPUS ERYTHEMATOSUS HAVE TOLEROGENIC PHENOTYPE AND IMMUNOMODULATORY FUNCTION 185  
**M.Y. Mok**, H. Wu, Y. Lo (Hong Kong)

## 14:00 - 16:00

## Hall 3

### PARALLEL SESSION 10: IMMUNOMODULATION BY VITAMIN D AND IVIG

- Chair: P. van Paassen** (Netherlands) 186  
**Chair: T. Marshall** (USA) 187  
**Chair: J. Damoiseaux** (Netherlands) 188
- 14:00 VITAMIN D AS AN IMMUNOMODULATOR, PROTECTIVE OR HARMFUL? - AN INTRODUCTION 189  
**C. Dias** (Portugal)
- 14:20 WHAT MORE IS THERE TO DISCOVER ABOUT VITAMIN D? 190  
**T. Marshall** (USA)
- 14:40 SYSTEMIC LUPUS ERYTHEMATOSUS AND VITAMIN D 191  
**L. Andreoli** (Italy)
- 15:00 C-REACTIVE PROTEIN AS AUXILIARY ELEMENT CONTROLLING IGG-ANTIBODY ACTIVITY AND CLINICAL OUTCOME IN (AUTO)IMMUNE THROMBOCYTOPENIAS 192  
**G. Vidarsson** (Netherlands)
- 15:20 IMMUNOTHERAPY IN INFLAMMATORY HEART FAILURE: TO WAIT, TO MODULATE OR TO SUPPRESS? 193  
**P. van Paassen** (Netherlands)
- 15:40 VITAMIN-D DEFICIENCY AS A RISK FACTOR FOR IMMUNODEFICIENCY AND AUTOIMMUNITY IN PATIENTS WITH ASIA DUE TO SILICONE BREAST IMPLANTS 194  
**M.J.L. Colaris**, M. De Boer, R.R. Van der Hulst, J.W. Cohen Tervaert (Netherlands)
- 15:50 THERAPY WITH EPICUTANEOUS APPLICATION OF MOG PLUS VITAMIN D ANALOGUE IS HIGHLY EFFECTIVE IN EXPERIMENTAL ENCEPHALOMYELITIS 195  
**S.F.G. Zorzella-Pezavento**, L.A.N. Mimura, T.F.C. Fraga-Silva, L.L.W. Ishikawa, T.G.D. França, A. Sartori (Brazil)

14:00 - 16:00

Hall 4

## PARALLEL SESSION 11: SYSTEMIC SCLEROSIS: NEW APPROACHES

	<b>Chair: M. Matucci Cerinic</b> (Italy)	196
	<b>Chair: G. Riemekasten</b> (Germany)	197
	<b>Chair: L. Mouthon</b> (France)	198
14:00	NEW CHALLENGES IN THE DIAGNOSIS OF SYSTEMIC SCLEROSIS: DO ANTIBODIES REALLY COUNT? <b>M. Matucci Cerinic</b> (Italy)	199
14:20	CHOOSING WISELY: HEALTHCARE ECONOMICS OF AUTOANTIBODY TESTING IN SCLERODERMA <b>M. Fritzler</b> (Canada)	200
14:40	IMPLICATION OF B LYMPHOCYTES IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS <b>L. Mouthon</b> (France)	201
15:00	ANTIBODIES AGAINST CHEMOKINE RECEPTORS CXCR3 AND CXCR4 ARE MARKERS FOR LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS <b>G. Riemekasten</b> , F. Weigold, D. Dragun, E. Siegert, H. Heidecke (Germany)	202
15:20	CHEMERIN SERUM LEVELS IN SYSTEMIC SCLEROSIS: A NOVEL MARKER OF EARLY AND ACTIVE DISEASE? C. Chighizola, E. Raschi, F. Ingegnoli, D. Privitera, T. Schioppo, C. Artusi, S. Zeni, A. Murgò, M.O. Borghi, <b>P.L. Meroni</b> (Italy)	203
15:30	HUMAN ADIPOSE DERIVED MESENCHYMAL STEM CELLS: A POTENT THERAPY IN SYSTEMIC SCLEROSIS <b>A. Maria</b> , K. Toupet, G. Fonteneau, M. Maumus, C. Bony, N. Pirot, A. Le Quellec, C. Jorgensen, D. Noël, P. Guilpain (France)	204
15:40	LOCALIZED SCLERODERMA: EXTRA-CUTANEOUS MANIFESTATIONS AND ASSOCIATION WITH OTHER AUTOIMMUNE DISEASES IN A SERIES OF 78 CASES <b>W.A. Sifuentes Giraldo</b> , C. Sobrino Grande, L. Villalobos Sánchez, A. Alía Jiménez, E. De Las Heras Alonso, C. De la Puente Bujidos, M.L. Gámir Gámir (Spain)	205
15:50	MYSTERY OF T-REGULATORY CELLS IN SYSTEMIC SCLEROSIS <b>G. Slobodin</b> (Israel)	206



14:00 - 16:00

Hall 5

PARALLEL SESSION 12: **NOVEL AUTOANTIGENS: DFS70, 14-3-3 $\eta$** 

	<b>Chair: N. Bizzaro</b> (Italy)	207
	<b>Chair: S. Naides</b> (USA)	208
	<b>Chair: C. Casiano</b> (USA)	209
14:00	THE DFS70/LEDGFP75 ANTIGEN <b>C. Casiano</b> (USA)	210
14:20	DIAGNOSTIC ACCURACY OF NEW IMMUNOBLOT METHODS FOR THE DETECTION OF ANTI-DENSE FINE SPECKLES (DFS70) ANTIBODIES <b>N. Bizzaro</b> , E. Tonutti, F. Cucchiario, F. Pesente, M. Fabris, M. Infantino, M. Tampoia, D. Villalta (Italy)	211
14:40	IMPROVED ANTI-NUCLEAR ANTIBODY (ANA) SCREENING USING A NOVEL HEP2 SUBSTRATE <b>K. Malyavantham</b> , V. Ramsperger, E. Berleth, R. Paramanathan, M. Herold, W. Klotz, L. Suresh (USA)	212
14:50	COMPARISON OF FULLY AUTOMATED IIF SYSTEM AND CHEMILUMINESCENT IMMUNOASSAY FOR THE DETECTION OF ANTI-DFS70 ANTIBODIES IN PATIENTS WITH AND WITHOUT SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES <b>O. Shovman</b> , B. Gilburd, C. Chayat, H. Amital, A. Watad, A. Guy, C. Bentow, M. Mahler, Y. Shoenfeld (Israel)	213
15:00	CLINICAL RELEVANCE OF ANTI-DFS70 AUTOANTIBODIES <b>K. Conrad</b> , N. Röber, U. Höpner, M. Aringer, S. Rudolph, A. Gräßler, K. Lüthke, L. Unger, M. Mahler (Germany)	214
15:20	THE USE OF ANTI-DFS70 ANTIBODIES IN THE STUDY OF PATIENTS WITH SARD SUSPICION IS COST-EFFECTIVE <b>S. Gundín</b> , J. Irure-ventura, E. Asensio, D. Ramos, M. Mahler, V. Martínez-Taboada, M. López-Hoyos (Spain)	215
15:30	SEEKING CLARIFICATION FOR THE POSITION OF ANTI-DFS70 ANTIBODY TESTING IN ANA TEST ALGORITHMS: RESULTS FROM AN ITALIAN STUDY <b>M. Infantino</b> , C. Bentow, M. Mahler, M. Benucci, F. Li Gobbi, F. Atzeni, P. Sarzi-Puttini, V. Grossi, F. Meacci, M. Manfredi (Italy)	216
15:40	14-3-3 $\eta$ , A NEW DIAGNOSTIC MARKER- STATE OF THE ART <b>S. Naides</b> (USA)	217

16:00-16:30

Exhibition

COFFEE BREAK &amp; EXHIBITION



16:00 - 16:30

Station 1

**EPD09: THE MOTHER AND THE CHILD: AUTOIMMUNE RELATIONSHIP**

- Chair: B. Böckle** (Austria) 218
- 16:00 GENDER AND SEX DETERMINE THE CLINICAL COURSE OF LUPUS ERYTHEMATOSUS 219  
**B. Böckle, N. Sepp** (Austria)
- 16:05 ANTI-PHOSPHOLIPID ANTIBODIES AD FEMALE INFERTILITY: A REVISION OF THE LITERATURE 220  
**C. Chighizola, G. De Jesus, Branch** (Italy)
- 16:10 PREGNANCY IN SECONDARY ITP - IMMUNE TROMBOCYTOPENIC PURPURA, SLE - SYSTEMIC LUPUS ERYTHEMATOSUS AND APS - ANTIPHOSPHOLIPID SYNDROME 221  
**M. Dapcevic** (Montenegro)
- 16:15 AUTO-ANTIBODIES PROFILE IN PATIENTS WITH OBSTETRIC COMPLICATIONS 222  
**Y. Lounici, R. Djidjik** (Algeria)
- 16:20 REVIEW CAUSES ASSOCIATED TO FOETAL DEATH IN 38 PATIENTS 223  
**M. Nuñez Beltran, A. Comins Boo, J. Ochoa Grullón, K. Llano Hernandez, E. Rodriguez De Frias, M. Fernandez-Arquero, M.P. Gasca, P. Coronado, M.A. Herraiz, S. Sanchez-Ramon** (Spain)
- 16:25 CYTOKINES PROFILE IN PATIENTS WITH EXPANDED NATURAL KILLER CELLS AND RECURRENT REPRODUCTIVE FAILURE 224  
**E. Rodriguez Frias, R. Ramos Medina, B. Alonso, M. Nuñez Beltran, A. Comins, S. Sánchez Ramón** (Spain)

16:00 - 16:30

Station 2

## EPD10: ETIOLOGY AND MECHANISM OF AUTOIMMUNITY

	<b>Chair: G. Murdaca</b> (Italy)	225
16:00	PYODERMA GANGRENOSUM IN A PATIENT WITH JUVENILE DERMATOMYOSITIS: A RARE PRESENTATION <b>T. Castro</b> , P. Bernardi, S. Lotufo (Brazil)	226
16:05	POTENTIAL IMPLICATIONS OF THE ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION IN AUTOIMMUNE DISEASES <b>A. Circiumaru</b> , G. Chiritoiu, L. Sima, M. Bojinca (Romania)	227
16:10	IMMUNE MECHANISMS OF IFN-ALPHA IN RELAPSING AND MONOPHASIC RAT EXPERIMENTAL AUTOIMMUNE UVEITIS <b>X. Liu</b> , M. Diedrichs-Möhrling, G. Wildner (Germany)	228
16:15	EVALUATION OF SOLUBLE HLA-G IN SYSTEMIC SCLEROSIS <b>G. Murdaca</b> , P. Contini, M. Borro, S. Negrini, F. Puppo (Italy)	229
16:20	FOOD INTOLERANCE DEPENDENT AUTO-IMMUNITY. IS IT A NEW SYNDROME? <b>A.G. Sahan</b> , E. Demirpehlivan, A. Yilmaz, H. Sivgin, M. Sagcan, E. Bastug, K. Tuna (Turkey)	230
16:25	INVOLVEMENT OF POST-TRANSLATIONAL MODIFICATION BY REACTIVE OXYGEN SPECIES OF NEURONAL PROTEINS IN THE PATHOLOGY OF MULTIPLE SCLEROSIS <b>C. Vinci</b> (United Kingdom)	231

16:00 - 16:30

Station 3

## EPD11: SLE: MORE SYSTEMIC THAN SYSTEMIC

Chair: **S. Bettio** (Italy) 232

16:00 BELIMUMAB IS EFFECTIVE AND REDUCE THE FREQUENCY OF FLARE IN PATIENTS WITH REFRACTORY ARTHRITIS IN A CLINICAL PRACTICE SETTING 233

**S. Bettio**, R. Reggia, M. Zen, M. Frassi, M. Larosa, L. Andreoli, L. Friso, A. Zanola, F. Saccon, L. Iaccarino, A. Tincani, A. Doria (Italy)

16:05 INCREASES CD19CD27C38 B-LYMPHOCYTES IN PATIENTS WITH SYSTEMIC RHEUMATIC DISEASES ARE NOT INFLUENCED BY IMMUNOSUPPRESSIVE THERAPY 234

**A. Budkova**, S. Lapin, I. Kudryavtsev, I. Trishina, A. Maslyansky (Russia)

16:10 CD4+CD25-FOXP3+ T-CELLS AS A MARKER FOR SYSTEMIC LUPUS NEPHRITIS IN SUEZ CANAL UNIVERSITY HOSPITAL 235

**O. Dessouki**, L. Metwally, N. El-Maraghy, M. Ghaly, S. Younes (Egypt)

16:15 DISTAL RENAL TUBULAR ACIDOSIS AS THE PRESENTING ILLNESS OF SYSTEMIC LUPUS NEPHRITIS : A CASE STUDY V.S SELVAN, ONG. ZY KHOO TECK PUAT HOSPITAL, SINGAPORE 236

**S. Senthamilveerasamy** (Singapore)

16:20 PROTEIN PROFILING REVEALS MOLECULAR SUBGROUPS IN SYSTEMIC LUPUS ERYTHOMATOSUS 237

**A. Zandian**, H. Idborg, B. Ayoglu, M. Uhlén, I. Gunnarsson, E. Svenungsson, J.M. Schwenk, P.J. Jakobsson, P. Nilsson (Sweden)

16:00 - 16:30

Station 4

## EPD12: STEPS IN AUTOIMMUNE DIAGNOSTICS

	<b>Chair: A. Radice</b> (Italy)	238
16:00	AUTOANTIBODIES BINDING TO MACROPAIN SUBUNIT C2 IN AOSD H. Marius, W. Torsten, F. Eugen, M. Frank, G. Wolfgang, F. Dirk, H. Dirk, S. Reinhold E, <b>N. Baerlecken</b> (Germany)	239
16:05	EFFECT OF STORAGE CONDITIONS ON C3 AND C4 COMPLEMENT COMPONENTS IN SERUM <b>R. Galovic</b> , N. Tomić Sremec, A. Kozmar (Croatia)	240
16:10	EVALUATION OF A RECENTLY DEVELOPPED ENZYME LINKED IMMUNOSORBENT ASSAY FOR THE DETERMINATION OF ANTI- PHOSPHOLIPASE A2 RECEPTOR ANTIBODIES <b>A.S. Messiaen</b> , M. Speeckaert, W. Uyttenbroeck, J. Penders, L. Van Hoovels, C. Verfaillie, L. Persijn, C. Bonroy (Belgium)	241
16:15	THE VALUE OF ELECTROMYOGRAPHY IN THE DIAGNOSTIC OF INFLAMMATORY MYOPATHIES - A PROSPECTIVE STUDY ON PATIENTS WITH WEAKNESS AND MUSCLE PAIN <b>M.M. Negru</b> , A. Doran, F. Berghea, A. Balanescu, V. Bojinca, D. Opris, L. Groseanu, I. Saulescu, S. Daia, D. Predeteanu, R. Ionescu (Romania)	242
16:20	DIAGNOSTIC PERFORMANCE OF ANTI-M-TYPE PHOSPHOLIPASE A2 RECEPTOR (PLA2R) ANTIBODIES IN IDIOPATHIC MEMBRANOUS NEPHROPATHY (IMN) <b>A. Radice</b> , B. Trezzi, G. Ghiggeri, P. Napodano, M. D'Amico, T. Stellato, R. Brugnano, F. Ravera, D. Rolla, G. Pesce, R. Scanziani, F. Londrino, D. Santoro, G. Ortisi, R.A. Sinico (Italy)	243
16:25	MUCOUS MEMBRANE PEMPHIGOID: CLINICOPATHOLOGICAL STUDY IN EIGHTY SEVEN CASES OF ORAL MUCOSA, UNIVERSITY OF CHILE <b>R. Sáez-Salgado</b> , D. Adorno, I. Espinoza, M. Solar (Chile)	244

16:00 - 16:30

Station 5

## EPD13: CANCER AND AUTOIMMUNITY

- Chair: C. Jamin** (France) 245
- 16:00 IN THE SEARCH OF A HIDDEN TUMOUR: UTILITY OF ONCONEURAL ANTIBODIES 246  
**J.L. García de Veas Silva**, M.V. Fernandez Varela, M.D.S. Lopez Velez, J.V. Garcia Lario, R. Ruiz Requena, T. De Haro Muñoz (Spain)
- 16:05 IDENTIFICATION AND ROLE OF REGULATORY B CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 247  
 A. Mohr, A. Bordron, **J.O. Pers**, C. Jamin (France)
- 16:10 ANGIOEDEMA: A CORRELATE/CONSEQUENCE OF PSA-SECRETING PROSTATE CANCER? 248  
**D. Maddox**, K. Rossow (USA)
- 16:15 NON-ORGAN SPECIFIC AUTOIMMUNITY IN CANCER PATIENTS IS ASSOCIATED WITH METASTATIC DISEASE AND POORER PROGNOSIS IN A FIVE-YEAR FOLLOW-UP STUDY 249  
**S. Mancini**, P. Sena, F. Mariani, P. Muratori, L. Muratori, C. Degli Esposti, A. Manenti, M.T. Mascia, L. Roncucci (Italy)
- 16:20 SCREENING THE AUTOIMMUNE RESPONSE OF PROSTATE CANCER IDENTIFIED PROSTEIN REACTIVITY ASSOCIATION TO CANCER STAGE 250  
**E. Pin**, F. Henjes, A. Häggmark, M.G. Hong, B. Forsström, A. Zandian, C. Fredolini, B. Ayoglu, F. Wiklund, A. Bjartell, P. Nilsson, J.M. Schwenk (Sweden)
- 16:25 THE CLINICAL SIGNIFICANCE OF ANTI-MITOTIC SPINDLE APPARATUS ANTIBODY (MSA) AND ANTI-CENTROMERE ANTIBODY DETECTED IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) 251  
**L. Tan** (China)

16:00 - 16:30

Station 6

## EPD14: VASCULITIS: THE AUTOIMMUNE INFLAMMATION OF THE VESSELS

	<b>Chair: I. Marie</b> (France)	252
16:00	LONG-TERM FOLLOW-UP OF AORTIC INVOLVEMENT IN RELAPSING POLYCHONDROITIS <b>I. Marie</b> (France)	253
16:05	VASCULITIS INDUCED BY TNF- ALPHA INHIBITORS- REPORT OF 2 CASES <b>R. Olteanu</b> , A. Zota, C. Stoian (Romania)	254
16:10	STANDARDIZATION OF ANCA IIF AS SCREENING TOOL FOR THE DIAGNOSIS AND FOLLOW-UP OF SMALL VESSEL VASCULITIS IS URGENTLY NEEDED <b>M. Oyaert</b> , K. Vande Keere, L. Van Hoovels (Belgium)	255
16:15	FROSTED BRANCH ANGIITIS: A RARE MANIFESTATION OF BEHCET'S DISEASE. THE ROLE OF ANTI-TNF THERAPY <b>P. Sierzputowski</b> , C. Silvestre, I. Goncalves, T. Marques, M.J. Gomes (Portugal)	256

16:00 - 16:30

Station 7

## EPD15: NOVEL THERAPIES IN AUTOIMMUNITY

Chair: **M. Diedrichs-Möhring** (Germany) 257

- 16:00 TARGETING DIHYDROOROTATE DEHYDROGENASE FOR TREATING INFLAMMATION AND CHORIORETINAL NEOVASCULARIZATION IN RELAPSING-REMITTING AND CHRONIC EXPERIMENTAL AUTOIMMUNE UVEITIS 258  
**M. Diedrichs-Möhring**, S. Niesik, J. Leban, S. Strobl, F. Obermayr, S. Thureau, G. Wildner (Germany)
- 16:05 PERIPHERAL BLOOD B-CELL PHENOTYPE IS AFFECTED BY TNF-INHIBITORS AND TOCILIZUMAB TREATMENT IN RHEUMATOID ARTHRITIS 259  
**R.A. Moura**, C. Quaresma, A.R. Vieira, M.J. Gonçalves, J. Polido-Pereira, V. Romão, N. Martins, H. Canhão, J.E. Fonseca (Portugal)
- 16:10 COMBINATORIAL ANTIBODY PHAGE DISPLAY LIBRARIES CONSTRUCTED FROM B-CELLS INFILTRATING BRAIN TISSUE OF PEOPLE WITH PROGRESSIVE MULTIPLE SCLEROSIS 260  
C. Maggiore, G. Giovannoni, J. Martin, **A. Nissim** (United Kingdom)
- 16:15 MILD BLOCKADE OF KV2.1 CHANNEL POTENTIATES GLP-1'S INSULINOTROPIC EFFECTS IN ISLETS AND REDUCES ITS DOSES REQUIRED FOR IMPROVING GLUCOSE TOLERANCE IN DIABETIC MALE MICE 261  
**R. Sukma Rita**, K. Dezaki, T. Yada (Indonesia)
- 16:20 TNF, IL-1 BETA AND LPS INDUCES ANNEXIN-A5 SECRETION IN HUMAN ENDOTHELIAL AND OSTEOARTHRITIS-DERIVED CHONDROCYTES 262  
**D. Thiyagarajan**, A. Frostegård, J. Frostegård (Sweden)



16:00 - 16:30

Station 8

## EPD16: THE BUGS AND US: INTERRELATIONSHIP OF AUTOIMMUNITY

- |       |                                                                                                                                                                                                                                                                                                                                                 |     |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
|       | <b>Chair: B. Donatini</b> (France)                                                                                                                                                                                                                                                                                                              | 263 |
| 16:00 | METHOTREXATE (MTX) AND ANTI-TNF TREATMENT IMPROVE ENDOTHELIAL FUNCTION (EF) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) AND ANKYLOSING SPONDYLITIS (AS)<br><b>G. Deyab</b> , I. Hokstad, S. Agewall, M.C. Småstuen, I. Hollan (Norway)                                                                                | 264 |
| 16:05 | CROHN DISEASE (CD) WITH ORAL LESIONS IS ASSOCIATED WITH A DECREASED ORAL PORTAGE OF HUMAN PAPILLOMAVIRUS 16 OR 18 (HPV 16/18)<br><b>B. Donatini</b> , I. Le Blaye (France)                                                                                                                                                                      | 265 |
| 16:10 | CHIKUNGUNYA VIRAL ARTHRITIS IN MEXICO: INFLAMMATORY BIOMARKERS MAY BE PREDICTORS OF CHRONIC ARTHRITIS<br><b>J. Sepulveda-Delgado</b> , O. Vera-Lastra, O. Gomez-Cruz, K. Trujilo-Murillo, I. Fernandez-Salas, L. Jara (Mexico)                                                                                                                  | 266 |
| 16:15 | COMPARASION OF INTERLEUKIN-1 BETA (IL-1 $\beta$ ) IN SALIVA ON PERIODONTAL DISEASE<br><b>N. Kasuma</b> , A. Aida Fitria (Indonesia)                                                                                                                                                                                                             | 267 |
| 16:20 | A DISTINCT CUTANEOUS MICROBIOTA PROFILE IN AUTOIMMUNE BULLOUS DISEASE PATIENTS<br>M. Miodovnik, <b>A. Kunstner</b> , E. Langan, D. Zilikens, R. Glaser, E. Sprecher, J.F. Baines, E. Schmidt, S.M. Ibrahim (Germany)                                                                                                                            | 268 |
| 16:25 | ENHANCED LEVELS OF NATURAL ANTI-IFN-GAMMA AUTOANTIBODIES IN PATIENTS WITH VISCERAL LEISHMANIASIS DETECTED WITH A NOVEL CAPTURE IMMUNOASSAY. IMPLICATIONS FOR DISEASE PATHOGENESIS<br><b>W. Van der Meide</b> , E. Pinelli, A. Tarasov, R. Groenestein, E. Don, H. Van Lith, T. Kortbeek, S. Tarasov, O. Epstein, P. Van der Meide (Netherlands) | 269 |

16:30 - 18:30

Hall 1

PARALLEL SESSION 13: **VASCULITIDES**

	<b>Chair: F. Fervenza</b> (USA)	270
	<b>Chair: W.L. Gross</b> (Germany)	271
	<b>Chair: U. Specks</b> (USA)	272
16:30	FROM PATHOGENESIS TO TREATMENT OF MEMBRANOUS NEPHROPATHY IN 2016 <b>F. Fervenza</b> (USA)	273
16:50	FROM UNDERSTANDING PATHOGENESIS TO TARGETED THERAPY IN ANCA-ASSOCIATED VASCULITIS <b>U. Specks</b> (USA)	274
17:10	IGG4 RELATED DISEASE - A VASCULITIS MIMIC <b>D. D'Cruz</b> (United Kingdom)	275
17:25	IDIOPATHIC ANCA ASSOCIATED VASCULITIDES VERSUS AAV WITH PROBABLE ETIOLOGY: CLINICAL AND IMMUNOLOGICAL ASPECTS <b>W.L. Gross</b> (Germany)	276
17:40	CRYOFIBRINOGENEMIAS : AN UPDATE <b>M. Michaud</b> (France)	277
17:50	THE ROLE OF HYDROXYCHLOROQUINE IN ANCA POSITIVE AND NEGATIVE VASCULITIS A. Casian, S. Sangle, <b>D. D'Cruz</b> (United Kingdom)	278
18:00	EFFICACY OF BIOLOGICAL-TARGETED TREATMENTS IN TAKAYASU ARTERITIS: MULTICENTER RETROSPECTIVE STUDY OF 49 PATIENTS <b>A. Mekinian</b> , C. Comarmond, M. Resche Regon, T. Mirault, J. Kahn, M. Lambert, J. Sibilia, A. Néel, P. Cohen, M. Hie, S. Berthier, I. Marie, H. Devilliers, M. Vandenhende, C. Lavigne, G. Muller, Z. Amoura, S. Abad, M. Hamidou, L. Guillevin, R. Dhote, B. Godeau, E. Messas, P. Cacoub, O. Fain, D. Saadoun (France)	279
18:10	RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN ANCA-ASSOCIATED VASCULITIDES: PROSPECTIVE DATA FROM THE EUROPEAN VASCULITIS SOCIETY (EUVAS) TRIALS <b>A. Kronbichler</b> , J. Leierer, G. Mayer, A. Casian, K. Westman, P. Hoglund, D. Jayne (Austria)	280

## 18:20 COGAN SYNDROME: FRENCH NATIONWIDE RETROSPECTIVE STUDY OF 40 PATIENTS

281

C. Durtette, **A. Mekinian**, O. Fain, E. Hachulla, A. Graslands, T. Papo, P. Jacques, J.E. Kahn, T. Zenone, C. Landron, B. De Wazieres, R. Dhote, C. Deligny, G. Gondran, E. Pertuiset, T. Quemeneur, B. Lioger, P. Seve, C. Lavigne, M. Hamidou, C. Blanchard Delaunay (France)

16:30 - 18:30

MP3 &amp; 4

PARALLEL SESSION 14: **VACCINES AND AUTOIMMUNITY**

	<b>Chair: L. Tomljenovic</b> (Canada)	282
	<b>Chair: C. Dwoskin</b> (USA)	283
	<b>Chair: D. Kanduc</b> (Italy)	284
16:30	FROM HBV TO HPV: DESIGNING VACCINES FOR EXTENSIVE AND INTENSIVE VACCINATION CAMPAIGNS WORLDWIDE <b>D. Kanduc</b> (Italy)	285
16:50	ANALYSIS OF MOUSE OVARIAN RESERVE UPON ADMINISTRATION OF EITHER HUMAN-PAPILLOMAVIRUS VACCINE OR ALUMINUM <b>N. Gruber</b> , O. Pinhas-Hamiel, M. Blank, L. Kalich-Philosoph, D. Galiani, N. Dekel, Y. Shoenfeld (Israel)	286
17:10	CHRONIC FATIGUE SYNDROME FOLLOWING HUMAN PAPILLOMA VIRUS VACCINATION; IS LATENT EPIPHARYNGITIS TO BLAME? <b>O. Hotta</b> , A. Tanaka, A. Torigoe, K. Imai, N. Ieiri (Japan)	287
17:20	QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE AND THE YOUNG ADOLESCENT OVARY: REVIEW OF SAFETY RESEARCH FOLLOWING TWO CASE SERIES OF PREMATURE OVARIAN INSUFFICIENCY <b>D. Little</b> (Australia)	288
17:30	5 CASE SERIES OF PREMATURE OVARIAN FAILURE WITHIN 3 YEARS OF HPV VACCINE INOCULATION IS THIS ASIA SYNDROME AND WHAT ARE THE IMPLICATIONS? <b>H. Ward</b> (Australia)	289
17:40	POST-VACCINATION INFLAMMATORY SYNDROME: A NEW SYNDROME? <b>G. Giannotta</b> (Italy)	290
17:50	VACCINATION AND IMMUNE THROMBOCYTOPENIC PURPURA: A MOLECULAR MIMICRY SPREADING TO AN AUTOIMMUNE DISEASE <b>M. Bizjak</b> (Slovenia)	291
18:00	AUTOIMMUNE REACTION AFTER ANTI-TETANUS VACCINATION- DESCRIPTION OF 4 CASES AND REVIEW OF THE LITERATURE <b>N. Ruhrman-Shahar</b> , Y. Levy (Israel)	292
18:10	VACCINES, ADJUVANTS AND AUTOIMMUNITY <b>L. Eça Guimarães</b> , B. Baker, C. Perricone, Y. Shoenfeld (Portugal)	293
18:20	REVERSE VACCINES TO TREAT DEGENERATIVE DISEASES <b>P. De Haan</b> (Netherlands)	294

16:30 - 18:30

Hall 2

## PARALLEL SESSION 15: AUTOIMMUNE PATHWAYS IN MULTIPLE SCLEROSIS, MYASTHENIA GRAVIS AND THE CENTRAL NERVOUS SYSTEM

	<b>Chair: R. Milo</b> (Israel)	295
	<b>Chair: S. Berrih-Aknin</b> (France)	296
	<b>Chair: A. Bar Or</b> (Canada)	297
16:30	B-CELL BIOLOGY IN MULTIPLE SCLEROSIS <b>A. Bar Or</b> (Canada)	298
16:50	THERAPEUTIC STRATEGIES TARGETING B-CELLS IN MULTIPLE SCLEROSIS <b>R. Milo</b> (Israel)	299
17:10	POLYMERASE 1 INHIBITOR RAM-589.555 - AN INNOVATIVE TARGETED TREATMENT FOR MULTIPLE SCLEROSIS <b>A. Achiron</b> , R. Falb, M. Roi, M. Gurevich (Israel)	300
17:25	MYASTHENIA GRAVIS: NEW CONCEPT OF THE PATHOPHYSIOLOGY <b>S. Berrih-Aknin</b> (France)	301
17:40	ANOCTAMIN 2 IDENTIFIED AS AN AUTOIMMUNE TARGET IN MULTIPLE SCLEROSIS <b>B. Ayoglu</b> , N. Mitsios, I. Kockum, M. Khademi, A. Zandian, R. Sjöberg, B. Forsström, J. Bredenberg, M. Uhlen, T. Waterboer, L. Alfredsson, J. Mulder, J. Schwenk, T. Olsson, P. Nilsson (USA)	302
17:50	AUTOANTIBODIES AGAINST THE FLOTILLIN COMPLEX IN OPTIC NEURITIS ASSOCIATED WITH MULTIPLE SCLEROSIS S. Hahn, G. Trendelenburg, M. Scharf, Y. Denno, S. Brakopp, B. Teegen, C. Probst, K.P. Wandinger, M. Buttman, M. Vom Dahl, T. Kämpfel, S. Jarius, H. Gold, W. Stöcker, <b>L. Komorowski</b> (Germany)	303
18:00	AUTOIMMUNITY ANNEXIN AND ANXIETY <b>R. Weiss</b> , A. Bitton, M. Elgart, L. Nahary, I. Benhar, M. Blank, J. Chapman (Israel)	304
18:10	INTEGRATIVE TREATMENT OF MULTIPLE SCLEROSIS. THE PSYCHO-NEURO-IMMUNO-TOXICOLOGY APPROACH <b>B. Brunes</b> (Sweden)	305
18:20	ANXIETY AND DEPRESSION IN INFLAMMATORY RHEUMATIC DISEASES <b>M. Petric</b> , D. Martinovic Kaliterna, D. Perkovic, M. Nuic, I. Bozic, M. Radic, D. Marasovic Krstulovic, K. Boric (Croatia)	306

16:30 - 18:30

Hall 3

## PARALLEL SESSION 16: INDUCTION, DETERMINATION AND THE PATHOGENIC ROLE OF AUTOANTIBODIES

- Chair: T. Mimori** (Japan) 307
- Chair: R. Eming** (Germany) 308
- Chair: M. Ehrenfeld** (Israel) 309
- 16:30 CLINICAL SIGNIFICANCE AND NEW DETECTION SYSTEMS OF MYOSITIS-SPECIFIC AUTOANTIBODIES 310  
**T. Mimori**, S. Sato, M. Kuwana, M. Fujimoto (Japan)
- 16:50 A PHAGE DISPLAY SCREEN FOR NOVEL THERANOSTIC AUTOANTIBODIES IN RHEUMATOID ARTHRITIS 311  
**P. Vandormael**, D. Quaden, P. Verschueren, V. Somers (Belgium)
- 17:05 ANALYTICAL AND CLINICAL COMPARISON OF TWO FULLY AUTOMATED IMMUNOASSAY SYSTEMS FOR THE DETECTION OF AUTOANTIBODIES TO EXTRACTABLE NUCLEAR ANTIGENS 312  
**P. Van der Pol**, L.E. Bakker-Jonges, J.H.S.A.M. Kuijpers, H. Hooijkaas, M.W.J. Schreurs (Netherlands)
- 17:20 ASSOCIATION BETWEEN AUTOANTIBODIES AND PREGNANCY OUTCOME IN PATIENTS UNDERGOING FIRST IN VITRO FERTILIZATION AND EMBRYO TRANSFER TREATMENT: A NESTED CASE-CONTROL STUDY 313  
**X. Chen**, L.H. Diao, Y.Y. Li, C.Y. Huang, J. Saarimaki, T. Zhang, R.C. Lian, J. Xu, Y. Zeng (China)
- 17:30 RELATIONSHIP BETWEEN AUTOANTIBODIES TO OXIDIZED LIPOPROTEINS AND ANGIOGRAPHIC DATA IN PATIENTS WITH CORONARY STENOSIS 314  
**S. Urazgildeeva**, L. Vasina, M. Muzalevskaya, A. Titkov, V. Gurevich (Russia)
- 17:40 AUTOANTIBODIES AGAINST BONE MORPHOGENETIC PROTEIN 7 IN FRACTURE PATIENTS 315  
**A. Schuette**, A. Moghaddam, P. Seemann, G. Schmidmaier, L. Schomburg (Germany)
- 17:50 COMPARATIVE SURVEY OF ADVERSE EVENTS RELATED TO HIGH COST IMMUNOBIOLOGICAL MEDICINES OF SPECIALIZED COMPONENTS OF PHARMACEUTICAL ASSISTANCE TO TREAT COMPLEX DISEASES 316  
**I.C. Gubert**, V.C. Zanetti, J. Santos, E.L. Feller (Brazil)

- 18:00 EVALUATION OF STAT4, TRAF3IP2 AND HCP5 GENES IN SJOGREN'S SYNDROME: ASSOCIATION WITH DISEASE SUSCEPTIBILITY AND CLINICAL ASPECTS 317  
**S. Colafrancesco**, C. Perricone, R. Priori, G. Picarelli, C. Ciccacci, P. Borgiani, G. Valesini (Italy)
- 18:10 AUTOANTIBODIES BINDING TO STATHMIN AS MARKER OF POLYNEUROPATHY IN PRIMARY SJOGREN SYNDROME 318  
R. Sabrina, W. Torsten, M. Stangel, S. Reinhold E, **N. Baerlecken** (Germany)
- 18:20 AUTO ANTIBODY PROFILING OF PATIENTS WITH SCHIZOPHRENIA 319  
**D. Just**, A. Häggmark, E. Lindholm Carlström, E. Jönsson, J.L. Cunningham, P. Nilsson (Sweden)

16:30 - 18:30

Hall 4

## PARALLEL SESSION 17: THE AUTOIMMUNE BASIS OF REPRODUCTIVE FAILURE

- Chair: C. Huang** (China) 320
- Chair: J. Kwak-Kim** (USA) 321
- Chair: C. De Carolis** (Italy) 322
- 16:30 THE PREVALENCE OF ANTIPHOSPHOLIPID ANTIBODIES, ANTI-THYROID ANTIBODIES AND ANTI-NUCLEAR ANTIBODIES IN PATIENTS EXPERIENCING INFERTILITY, REPEATED IMPLANTATION FAILURE AND RECURRENT MISCARRIAGE 323  
**C. Huang**, X. Chen, L. Diao, R. Lian, T. Zhang, J. Xu, Y. Zeng (China)
- 16:50 CELLULAR AND HUMORAL AUTOIMMUNITY IN RECURRENT PREGNANCY LOSSES AND MULTIPLE IMPLANTATION FAILURES, AND A POSSIBLE ROLE OF VITAMIN D 324  
**J. Kwak-Kim** (USA)
- 17:10 RECURRENT SPONTANEOUS ABORTION: THE GOOD, THE BAD AND THE UGLY 325  
**C. De Carolis**, C. Perricone, R. Perricone (Italy)
- 17:30 RISK FACTORS FOR REPRODUCTIVE FAILURE IN ANTIPHOSPHOLIPID SYNDROME 326  
**S. De Carolis**, S. Salvi, A. Botta, G. Del Sordo, S. Tabacco, A. Lanzone (Italy)
- 17:50 HLA -DQ2/DQ8 HAPLOTYPES IN RECURRENT PREGNANCY LOSS WOMEN: IS THERE A COMMON LINK WITH CELIAC DISEASE? 327  
S. D'ippolito, A. Gasbarrini, G. Scambia, **N. Di Simone** (Italy)
- 18:00 HUMAN IGG ANTINUCLEAR ANTIBODIES INDUCE PREGNANCY LOSS IN MICE BY INCREASING IMMUNE-COMPLEX DEPOSITION IN PLACENTAL TISSUE: POSSIBLE MECHANISM UNDERLYING THE POOR OBSTETRIC OUTCOME 328  
**S. D'ippolito**, M. Veglia, R. Marana, F. Di Nicuolo, R. Castellani, V. Bruno, A. Fiorelli, F. Ria, G. Maulucci, M. De Spirito, G. Migliara, G. Scambia, N. Di Simone (Italy)
- 18:10 EFFECT OF TUMOR NECROSIS FACTOR INHIBITOR PLUS INTRAVENOUS IMMUNOGLOBULIN TREATMENT ON PREGNANCY OUTCOMES IN WOMEN WITH RECURRENT IMPLANTATION FAILURE: A RETROSPECTIVE SINGLE CENTER STUDY 329  
**L. Diao**, C. Huang, X. Chen, J. Saarimaki, P. Liang, R. Lian, Y. Zeng (China)
- 18:20 INTRALIPIDS THERAPY IN CHRONIC HISTIOCYTIC INTERVILLOSITIS 330  
A. Bilgar, F. Olivier, C. Lionel, N. Pascale, **M. Arsene** (France)



16:30 - 18:30

Hall 5

## PARALLEL SESSION 18: AUTOIMMUNE HEMATOLOGICAL DISEASES

	<b>Chair: D. Cines</b> (USA)	331
	<b>Chair: M. Lee-Kirsch</b> (Germany)	332
	<b>Chair: M. Abu Shakra</b> (Israel)	333
16:30	STRUCTURAL BASIS OF AUTOANTIGEN FORMATION IN HEPARIN-INDUCED THROMBOCYTOPENIA Zheng Cai, Mark I. Greene, <b>D. Cines</b> (USA)	334
16:50	LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTORS IN AUTOIMMUNITY <b>T. Witte</b> (Germany)	335
17:10	PATHOPHYSIOLOGY AND LABORATORY DIAGNOSIS OF PERNICIOUS ANAEMIA <b>B.H. Toh</b> (Australia)	336
17:20	EPISODIC ANGIOEDEMA WITH EOSINOPHILIA (GLEICH SYNDROME): A SURVEY OF 29 CASES <b>N. Abisror</b> , F. Olivier, M. Arsene, L. Guillaume, M. Chafika, N. Nicolas, B. Alice, H. Julien, H.B. Mathilde, A. Christian, J. Pierre Yves, T. Sebastien, Q. Thomas, D. Jean Francois, L. Isabelle, L. Francois, K. Jean Emmanuel (France)	337
17:30	ASSESSMENT OF ENDOTHELIAL DAMAGE AND CARDIAC INJURY IN A NEW MOUSE MODEL OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA <b>M. Le Besnerais</b> , B. Membrey, L. Drouot, S. Grange, A. Kopic, P. Mulder, P. Coppo, O. Boyer, J. Martinet, V. Richard, Y. Benhamou (France)	338
17:40	INHERITED THROMBOPHILIA IN WOMEN WITH POOR APL-RELATED OBSTETRIC HISTORY: PREVALENCE AND OUTCOMES. SURVEY OF 203 CASES FROM THE EUROAPS* COHORT <b>J. Alijotas-Reig</b> , R. Ferrer-Oliveras, A. Ruffati, A. Tincani, E. Lefkou, M.T. Bertero, E. Esteve-Valverde, G. Espinosa, E. Coloma-Bazan, R. Cervera, E. LLurba, S. De Carolis, P. Rovere-Querini, A. Kuzenko, T. Del Ross, A. Robles-Marhuenda, T. Melnichuk, V. Canti, M. Fredi, K. Lundelin, A. Ruano, C. Nalli, E. Picardo, E. Silvestro, A. Martí-Cañamares, L. Saez-Comet, K.I. Mayer-Pickel, A. Mekinian, I. Farran-Codina (Spain)	339
17:50	FACTORS RELATED TO ERYTHROCYTE AUTOANTIBODY PRODUCTION IN TRANSFUSION DEPENDENT THALASSEMIA <b>A. Kurniawan</b> , D. Atmakusuma, L. Sukrisman (Indonesia)	340

- 18:00 ERYTHROCYTE'S CD59 REVERSIBLE DEFICIENCY PARTICIPATES IN COLD AGGLUTININ AUTO-IMMUNE HEMOLYSIC ANEMIA (CA-AIHA) PATHOGENESIS 341  
**M. Brun**, S. Cointe, S. Robert, C. Nicolino-Brunet, J.P. De Jaureguiberry, K. Mazodier, M.O. Chandesris, J.M. Durand, J.R. Harle, J. Chiaroni, F. Dignat-George, R. Lacroix, G. Kaplanski (France)
- 18:10 AN IDIOPATHIC THROMBOCYTOPENIC PURPURA WITH POLINEUROPATHY 342  
**P. David**, V. Katchan, Y. Shoenfeld (Brazil)
- 18:20 SPONTANEOUS RUPTURE OF KIDNEY IN A CHRONIC REFRACTORY IDIOPATHIC THROMBOCYTOPENIC PURPURA CASE: A RARE EVENT 343  
**A. Bajpayee**, N. Bajpai (India)

WEDNESDAY

THURSDAY

FRIDAY

SATURDAY

SUNDAY


INDEX

ACKNOWLEDGEMENTS



# SCIENTIFIC PROGRAM

## FRIDAY, APRIL 8, 2016



# 10<sup>TH</sup>

INTERNATIONAL CONGRESS  
ON **AUTOIMMUNITY**

APRIL 6-10, 2016, LEIPZIG, GERMANY

# JOIN US IN MELBOURNE

ABSTRACT SUBMISSION DEADLINE:

**13 SEPTEMBER 2016**

12<sup>TH</sup> INTERNATIONAL CONGRESS ON SLE &  
7<sup>TH</sup> ASIAN CONGRESS ON AUTOIMMUNITY

# LUPUS 2017



**26-29 MARCH 2017**

**MELBOURNE, AUSTRALIA**

[www.lupus2017.org](http://www.lupus2017.org)



# FRIDAY, APRIL 8, 2016

8:00 - 10:00

Hall 1

## PLENARY SESSION 2

Chair: <b>A.K. Abbas</b> (USA)	344
Chair: <b>E. Toubi</b> (Israel)	345
Chair: <b>G.C. Tsokos</b> (USA)	346

### 8:00 MAI AWARD CEREMONY

8:10 THE GENETIC INTERPLAY OF AUTOIMMUNITY <b>C. Perricone</b> (Italy)	347
---------------------------------------------------------------------------	-----

8:30 NARCOLEPSY AS AN AUTOIMMUNE DISEASE <b>M. Arango</b> , S. Kivity, T. Sasaki, M. Blank, M. Matsuura, Y. Shoenfeld (Israel)	348
-----------------------------------------------------------------------------------------------------------------------------------	-----

9:00 AUTOIMMUNITY AND IMMUNODEFICIENCY - TWO SIDES OF THE SAME COIN? <b>R.E. Schmidt</b> (Germany)	349
-------------------------------------------------------------------------------------------------------	-----

### LIFETIME CONTRIBUTION TO AUTOIMMUNITY AWARD 2016

9:30 PREGNANCY IN PATIENTS WITH AUTOIMMUNE DISEASE: A REALITY IN 2016 <b>A. Tincani</b> (Italy)	350
----------------------------------------------------------------------------------------------------	-----

FRIDAY

10:00-10:30

Exhibition

COFFEE BREAK &amp; EXHIBITION



10:00 - 10:30

Station 1

## EPD17: APS DIAGNOSTICS

- Chair: K. Devreese** (Belgium) 351
- 10:00 POSITIVE ANTI-CARDIOLIPINE ANTIBODIES DURING SEPSIS AND CORRELATION WITH SOFA SCORE 352  
**M. Ben Azaiz**, U. MuşabaK, A. Abouda, J. Ayachi, Z. Hajjej, I. Labbene, R. Oueslati, E. Ghazouani, M. Ferjani (Tunisia)
- 10:05 ROLE OF ANTI-DOMAIN-1- $\beta$ 2GLYCOPROTEIN I ANTIBODIES IN THE DIAGNOSIS AND RISK STRATIFICATION OF ANTIPHOSPHOLIPID SYNDROME 353  
A.S. De Craemer, J. Musial, **K. Devreese** (Belgium)
- 10:10 EPIDEMIOLOGY OF THE ANTIPHOSPHOLIPID SYNDROME WITH PARTICULAR REFERENCE TO SEX - A RETROSPECTIVE STUDY AT THE UNIVERSITY HOSPITAL GRAZ, AUSTRIA 354  
**A. Gries**, C. Gabron, H.K. Lackner, T. Gary, M. Brodmann, A. Pichler, B. Binder, E. Aberer, K. Mayer-Pickel, U. Demel, S. Horn, V. Kolovetsiou-Kreiner, U. Lang (Austria)
- 10:15 EVALUATION OF SERUM PROFILES OF ANTIPHOSPHOLIPID ANTIBODIES IN A LARGE ROUTINE COHORT AND UTILITY OF ANTIPHOSPHOLIPID IGA ANTIBODIES DETECTED BY BIOPLEX IN SERONEGATIVE PATIENTS 355  
**J. Irure-ventura**, E. Asensio, F. Jurado, D. Ramos, M. Toca, L. Alvarez-Rodríguez, V. Martínez-Taboada, M. López-Hoyos (Spain)
- 10:20 SCREENING FOR APS DIAGNOSIS USING NON-CRITERIA ANTIPHOSPHOLIPID ANTIBODY TESTS WITH A HIGH POSITIVE PREDICTIVE VALUE: ANTI-BETA2-GPI DOMAIN I AND HOSPHATIDYLSERINE-DEPENDENT ANTIPROTHROMBIN ANTIBODIES 356  
**H. Nakamura**, K. Oku, K. Omura, M. Kato, T. Bohgaki, A. Olga, T. Horita, S. Yasuda, T. Atsumi (Japan)
- 10:25 LATENT CLASS ANALYSIS AS POSSIBLE SOLUTION FOR THE EVALUATION OF ANTIPHOSPHOLIPID ANTIBODY ASSAYS IN VIEW OF THE LACK OF A REFERENCE STANDARD 357  
**M. Thaler**, A. Bietenbeck, U. Steigerwald, E. Lindhoff-Last, P. Luppá (Germany)

10:00 - 10:30

Station 2

EPD18: **PATHOGENETIC AVENUES IN AUTOIMMUNE DISEASES**

	<b>Chair: R. Leite Dantas</b> (Germany)	358
10:00	ADVANCED GLYCATION END PRODUCTS (AGES) AND SOLUBLE RECEPTORS FOR AGES (SRAGE) IN ADULT-ONSET STILL'S DISEASE: ASSOCIATION WITH DISEASE ACTIVITY PARAMETERS A. Abou-Raya, M. Kamel, <b>S. Abou-Raya</b> (Egypt)	359
10:05	ALLERGY; ORIGINATION AND THE CAUSE & EFFECT-PROFILE <b>L. Behroo</b> (Iran)	360
10:10	SARCOIDOSIS AND AUTOIMMUNITY: FROM GENETIC BACKGROUND TO ENVIRONMENTAL FACTORS <b>S. Bindoli</b> , J.J. Torres-Ruiz, C. Perricone, M. Bizjak, Y. Shoenfeld (Italy)	361
10:15	EPITOPES OF HUMAN AND MICROBIAL TRANSGLUTAMINASES ARE SIMILARLY RECOGNIZED BY CELIAC DISEASE SERA <b>P. Jeremias</b> , K. Prager, S. Neidhoefer, T. Matthias (Germany)	362
10:20	TREG LYMPHOCYTES SUPPRESS MONOCYTE-MEDIATED PSORIASIS UPON INDUCTION OF TNF $\alpha$ <b>R. Leite Dantas</b> , B. Brachvogel, S. Ludwig, V. Wirlex (Germany)	363
10:25	CRITICAL ROLES OF TONEBP SIGNALING IN MIGRATION AND INVASION OF RHEUMATOID SYNOVIOCYTES <b>Y.J. Park</b> , H. Eun-Jin, L. Naeun, C. Chul-Soo, K. Wan-Uk (Republic of Korea)	364

FRIDAY

E-POSTERS

10:00 - 10:30

Station 3

## EPD19: SLE: WHAT CAN WE LEARN ABOUT AUTOIMMUNITY?

- Chair: B. Admou** (Morocco) 365
- 10:00 AUTOANTIBODIES AND SYSTEMIC LUPUS ERYTHEMATOSUS CLINICAL SUBSETS 366  
M. Rami, I. Brahim, R. Hazime, L. El Moumou, **B. Admou** (Morocco)
- 10:05 ASSOCIATION OF THE UNCOUPLING PROTEINS POLYMORPHISMS WITH SUSCEPTIBILITY TO ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS 367  
**C.M. Gambino**, G. Accardi, A. Aiello, B.G. Gioia, M. Midiri, G. Guggino, G. Candore, C. Caruso (Italy)
- 10:10 MEMORY TASKS AND SYMPTOMS OF DEPRESSION AND ANXIETY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS 368  
**M. Larosa**, S. Rinaldi, L. Iaccarino, A. Ghirardello, G. Arcara, M. Gatto, S. Mondini, A. Doria (Italy)
- 10:15 ANTINUCLEAR ANTIBODY (ANA) TITER AND PATTERN VARY ACCORDING TO DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS 369  
**M. Prado**, A. Dellavance, L.E.C. Andrade (Brazil)
- 10:20 CRITICALLY ILL PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - CASE SERIES FROM A MEDICAL INTENSIVE CARE UNIT IN SOUTHERN INDIA 370  
**M. Thabah**, B.D. Pandey, N. Balamurugan, V. Chaturvedi (India)
- 10:25 THE CHARACTERISTICS OF ANTIGEN PRESENTING CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 371  
**A. Wardowska**, Z. Smolenska, M. Pikula, M. Zielinski, P. Trzonkowski (Poland)



10:00 - 10:30

Station 4

## EPD20: WHAT'S NEW IN AUTOIMMUNE DIAGNOSTICS?

- Chair: L.M. De Winter** (Belgium) 372
- 10:00 THE ISOTYPE REPERTOIRE OF ANTIBODIES AGAINST NOVEL UH-RA PEPTIDES IN RHEUMATOID ARTHRITIS 373  
**L.M. De Winter**, P. Geusens, J. Lenaerts, J. Vanhoof, P. Stinissen, V. Somers (Belgium)
- 10:05 THE USE OF A CURRENT METHODOLOGY (ALBIA) FOR THE SIMULTANEOUS MEASUREMENT OF ANTI-DSDNA AND ANTI-NUCLEOSOME (ANUA OR ANTI-CHROMATIN) ANTIBODIES: TWO INDEPENDENT MARKERS OF SLE 374  
**M. Infantino**, M. Benucci, F. Atzeni, P. Sarzi-Puttini, F. Meacci, V. Grossi, H. Scholz, M. Crisostomo, M. Manfredi (Italy)
- 10:10 IS THE MEASUREMENT OF IMMUNOGLOBULIN A ALWAYS NECESSARY IN THE STUDY OF CELIAC DISEASE ? 375  
**J. Jimenez**, A. Julia, O. Joaquin, F. Pere, H.D.L. Carmen (Spain)
- 10:15 BIG DATA-DERIVED DEMOGRAPHIC AND LABORATORY PROFILE OF INDIVIDUALS PRESENTING WITH THE ANTINUCLEAR ANTIBODY DENSE FINE SPECKLED PATTERN 376  
A. Mathias, J.D. Sá, A. Dellavance, F.J. Muramoto, **L.E. Andrade** (Brazil)
- 10:20 EVALUATION OF ANTI-DFS70 ANTIBODIES PRE-ABSORPTION PROTOCOL FOR ANA-IIF HEP-2 TESTING IN THE DIAGNOSTIC APPROACH OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES 377  
E. Pipi, E. Synodinou, A. Lemoni, K. Soufleros, M. Alexandridou, Barka C., I. Siampani, M. Aggelakos, C. Sfontouris, **A. Tsirogianni** (Greece)
- 10:25 ACUTE PHASE PROTEINS AND INTERLEUKIN-6 ARE IMPORTANT IN DISTINGUISHING BETWEEN GIANT CELL ARTERITIS POSITIVE AND NEGATIVE PATIENTS 378  
**P. Zigon**, K. Lakota, T. Kuret, M. Tomšič, S. Cučnik, S. Sodin-Šemrl, A. Hočevar (Slovenia)

10:00 - 10:30

Station 5

## EPD21: CNS INVOLVEMENT IN AUTOIMMUNITY

Chair: **M. Adawi** (Israel) 379

10:00 NEUROMYELITIS OPTICA (DEVIC'S DISEASE - NMO) COMPLICATED BY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): CLINIC-PATHOLOGICAL REPORT AND REVIEW OF THE LITERATURE 380

**M. Adawi** (Israel)

10:05 THE ETIOLOGY OF ACUTE ENCEPHALITIS IN ASIAN POPULATION 381  
T.J. Kim, J.I. Byun, K. Chu, **S.J. Ahn** (Republic of Korea)

10:10 PARTIAL 13Q TRISOMY AND ANTIPHOSPHOLIPID ANTIBODIES: A CASE REPORT 382

**C. Brogna**, D. Romeo, V. Milano, R. De Santis, G. Zampino, E. Mercuri (Italy)

10:15 THE CLINICAL UTILITY OF ANTI-NEURONAL ANTIBODIES IN NERVOUS SYSTEM DISORDERS 383

**A.G. Grondona**, T. Silvestri, E. Magrini (Italy)

10:20 A COMPARISON OF THREE COMMERCIAL TESTS FOR DETECTING ANTI-GANGLIOSIDE ANTIBODIES IN PATIENTS WITH WELL-CHARACTERIZED DYSIMMUNE PERIPHERAL NEUROPATHIES 384

**S. Hue**, J.P. Lefaucheur, A. Creange, M. Chalah, C. Dehouille (France)

10:25 CLINICAL MANIFESTATIONS AND IMMUNOTHERAPY OUTCOME OF NON-RETINAL ANTI-RECOVERIN ANTIBODY AUTOIMMUNE SYNDROME 385

**J. Jun** (Republic of Korea)

10:00 - 10:30

Station 6

## EPD22: SYSTEMIC SCLEROSIS: HOW CAN WE OVERCOME AN UNKNOWN ETIOLOGY?

- Chair: N. Fabien** (France) 386
- 10:00 PREVALENCE AND SPECIFICITY OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) IN ALGERIAN PATIENTS WITH SYSTEMIC SCLEROSIS 387  
**L. Aissa**, O. Nerdjess, Y.B. Youcef (Algeria)
- 10:05 EVALUATING CHOROIDAL CHARACTERISTICS IN SYSTEMIC SCLEROSIS USING ENHANCED DEPTH IMAGING OPTICAL COHERENCE TOMOGRAPHY 388  
**D. Arslan Tas**, E. Esen, S. Sizmaz, I. Turk, I. Unal, N. Demircan (Turkey)
- 10:10 PATIENT-REPORTED OUTCOMES REFLECT CHANGES IN DIGITAL ULCERS STATUS IN PATIENTS WITH SYSTEMIC SCLEROSIS 389  
**C. Bruni**, T. Ngcozana, F. Braschi, S. Guiducci, S. Bellando-Randone, L. Tofani, C. Denton, D. Furst, M. Matucci-Cerinic (Italy)
- 10:15 B CELLS FROM SYSTEMIC SCLEROSIS PATIENTS EXHIBIT DECREASED REGULATORY PROPERTIES 390  
**D. Catalán**, O. Aravena, A. Ferrier, A. Ramírez, J.C. Aguillón, L. Soto (Chile)
- 10:20 CLINICAL AND IMMUNOLOGICAL FEATURES IN A COHORT OF 228 PATIENTS WITH SYSTEMIC SCLEROSIS 391  
C. Grange, C. Mausservey, C. Khouatra, D. Jullien, P. Seve, J.C. Lega, **F. Nicole**, A. Hot (France)
- 10:25 CREST SYNDROME AND MENETRIER DISEASE, A UNIQUE ASSOCIATION 392  
**A. Watts Soares**, J. Espirito Santo, M. Lobo Antunes, C. Noronha, A.I. Reis (Portugal)

FRIDAY

E-POSTERS

10:00 - 10:30

Station 7

## EPD23: ARE THERE BREAKTHROUGHS IN THE THERAPY OF AUTOIMMUNE DISEASES?

Chair: **D. Reinhold** (Germany) 393

- 10:00 UTILITY OF TOCILIZUMAB ON CLINICAL MANIFESTATIONS OF EROSIIVE OSTEOARTHRITIS, AN IMMUNE DISEASE? 394  
**S.H. Juan Manuel**, J. GalvezRomero, W. LopezRodriguez, F. IslasJacome (Mexico)
- 10:05 BONE MARROW DERIVED DENDRITIC CELLS MODIFIED BY LENTIVIRAL-MEDIATED RELB SHRNA POSSESS TOLEROGENIC PHENOTYPE AND FUNCTIONS ON LUPUS SPLENIC LYMPHOCYTES 395  
H. Wu, Y. Lo, **M.Y. Mok** (Hong Kong)
- 10:10 ZINC ASPARTATE (UNIZINK®) SUPPRESSES T CELL ACTIVATION IN VITRO AND TREATS EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS 396  
**D. Reinhold**, D. Straubel, C. Schubert, K. Guttek, K. Grüngreif, S. Brocke (Germany)
- 10:15 GENERATION AND CHARACTERIZATION OF "TNF RECEPTOR ONE SILENCER" (TROS) IN TRANSGENIC HTNFR1 MICE 397  
**S. Steeland**, C. Libert, R. Vandenbroucke (Belgium)
- 10:20 ARGX-113, A NOVEL FC-BASED THERAPEUTIC APPROACH FOR ANTIBODY-INDUCED PATHOLOGIES 398  
**P. Ulrichs**, T. Dreier, N. Ongena, T. Van Hauwermeiren, J. Enriquez, H. De Haard (Belgium)
- 10:25 EFFECTS OF SUBSTANCES WITH ANTIOXIDANT ACTIVITY ON NEUTROPHIL EXTRACELLULAR TRAP FORMATION 399  
**N. Vorobjeva**, B. Pinegin (Russia)

10:00 - 10:30

Station 8

## EPD24: IMMUNOMODULATION: BETTER THAN IMMUNOSUPPRESSION

- |       |                                                                                                                                                                                                                                                                                                         |     |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
|       | <b>Chair: L. Ishikawa</b> (Brazil)                                                                                                                                                                                                                                                                      | 400 |
| 10:00 | MYCOPHENOALTE MOFETIL AS A SECOND LINE THERAPY IN AUTOIMMUNE DISEASES<br>A. Danza, <b>D. Graña</b> , V. Domínguez, A. Vargas, B. Adriana, M. Goñi (Uruguay)                                                                                                                                             | 401 |
| 10:05 | DANGYUJA ( <i>CITRUS GRANDIS</i> OSBECK) TOPICAL TREATMENT ATTENUATES SKIN INFLAMMATION IN MOUSE EAR INDUCED WITH 12-O-TETRADECANOYLPHORBOL-13-ACETATE (TPA)<br><b>K.H.I.N.M. Herath</b> , S.J. Bing, J. Cho, A. Kim, W. Lee, J.H. Um, E.J. Han, G. Ahn, G.O. Kim, J.C. Lee, Y. Jee (Republic of Korea) | 402 |
| 10:10 | IMMUNOMODULATORY EFFECT OF HYDROXYCHLOROQUINE IN BONE MARROW-DERIVED DENDRITIC CELLS AND COLLAGEN-INDUCED ARTHRITIS: PRELIMINARY RESULTS<br><b>L.L. Ishikawa</b> , L. Oliveira, R. Morales, L.A. Mimura, T.F. Fraga-Silva, S.F. Zorzella-Pezavento, R. Thomé, L. Verinaud, A. Sartori (Brazil)          | 403 |
| 10:15 | CD4+CD25+ CELLS ARE ESSENTIAL IN THE INDUCTION AND MAINTAINING OF IMMUNOLOGICAL TOLERANCE IN CHICKENS INOCULATED WITH XENOGENEIC ANTIGENS AT A LATE STAGE OF EMBRYONIC DEVELOPMENT<br>Y. Xiaoxue, <b>Z. Li</b> (China)                                                                                  | 404 |

FRIDAY

E-POSTERS

10:30 - 12:30

Hall 1

## PARALLEL SESSION 19: T CELLS IN AUTOIMMUNITY

- Chair: R.E. Schmidt** (Germany) 405
- Chair: C. Dias** (Portugal) 406
- Chair: T. Witte** (Germany) 407
- 10:30 THERAPY WITH RITUXIMAB - EFFECTS ON T CELL RESPONSE 408  
**R.E. Schmidt** (Germany)
- 10:50 IL-17 PRODUCING PATHOGENIC T LYMPHOCYTES CO-EXPRESS CD20 AND ARE DEPLETED BY RITUXIMAB IN PRIMARY SJOGREN'S SYNDROME 409  
**A. Alunno**, F. Carubbi, O. Bistoni, E. Bartoloni, P. Di Benedetto, P. Cipriani, R. Giacomelli, R. Gerli (Italy)
- 11:00 T-CELL ACTIVATION IS ASSOCIATED WITH HYPOCOMPLEMENTEMIA IN PRIMARY ANTIPHOSPHOLIPID SYNDROME 410  
**J.A. Carbone Campoverde**, E. Sarmiento, G. Antonio, N. Lanio, E. Fernandez-Cruz (Spain)
- 11:10 PURINERGIC CONTROL OF T FOLLICULAR HELPER CELLS IN AUTOIMMUNITY 411  
**C.E. Faliti**, L. Perruzza, G. Pellegrini, R. Gualtierotti, P.L. Meroni, E. Traggiai, F. Grassi (Switzerland)
- 11:20 IL-17 ANTAGONISTICALLY REGULATES GM-CSF PRODUCTION DURING T CELL DEVELOPMENT EX VIVO AND DURING EXPERIMENTAL ARTHRITIS 412  
**D.M. Roeleveld**, R. Rogier, P.M. Van der Kraan, W.B. Van den Berg, I.P. Wicks, M.I. Koenders (Netherlands)
- 11:30 CHARACTERIZING THE FUNCTION OF P-GLYCOPROTEIN IN HUMAN T CELL SUBSETS DEMONSTRATE DIFFERENT KINETIC PATTERNS 413  
**L. Yrtlid**, H. Grindebacke, K. Pardali, J. Jirholt, A. Rudin (Sweden)
- 11:40 MIR-146A SUPPRESSED T CELL APOPTOSIS BY REGULATING FAF1 IN PATIENTS OF RHEUMATOID ARTHRITIS 414  
**L. Jingyi**, G. Qiuye, W. Ying, W. Yuzhang (China)
- 11:50 STATIN REPRESSES HUMAN DENDRITIC CELL MATURATION INDUCED BY OXLDL AND LIMITS THE CONSEQUENT T CELL PROLIFERATION 415  
**A. Liu**, Y. Zhang, J. Sun, J. Frostegard (Sweden)

- 12:00 REGULATORY T CELL COMPENSATION FAILURE: POSSIBLE MECHANISM FOR THE DYSREGULATION OF IMMUNE RESPONSE IN MURINE MODEL OF SYSTEMIC LUPUS ERYTHEMATOSUS 416  
**K. Handono**, H. Kalim, E. Mustofa, S. Murwani, P. Mirza Zaka (Indonesia)
- 12:10 THE CD38 ABSENCE AFFECTS THE SPLENIC FOXP3+CD4+ T REGULATORY CELLS DEVELOPMENT IN A MURINE MODEL 417  
**J.C. Pérez Lara**, H. Romero Ramirez, G. Lopez Herrera, J.C. Rodriguez Alba (Mexico)
- 12:20 HIGHLY SENSITIVE DETECTION OF NEUTROPHIL ELASTASE PROTEASE ACTIVITY ON IMMUNE COMPLEX ACTIVATED CELLS 418  
**R. Akbarzadeh**, C. Schultz, X. Yu, F. Petersen (Germany)

12:30-14:00

Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

FRIDAY

10:30 - 12:30

MP3 &amp; 4

## PARALLEL SESSION 20: **DIAGNOSTICS - PATHOGENESIS AND AUTOANTIBODY STANDARDIZATION**

	<b>Chair: E. Matsuura</b> (Japan)	419
	<b>Chair: C. Galarza-Maldonado</b> (Ecuador)	420
	<b>Chair: L.E. Andrade</b> (Brazil)	421
10:30	WHY STANDARDIZATION ON AUTOANTIBODY TESTING IS CRITICAL FOR AUTOIMMUNITY DIAGNOSTICS <b>L.E. Andrade</b> (Brazil)	422
10:50	IMMUNO-THERA-DIAGNOSTICS (THERANOSTICS) IN AUTOIMMUNITY AND ONCOLOGY <b>E. Matsuura</b> (Japan)	423
11:10	P29ING4 IMMUNE COMPLEX AS MARKER FOR INFLAMMATORY JOINT INVOLVEMENT <b>N. Baerlecken</b> , W. Torsten, G. Ralph, K. Matthias, S. Reinhold E, B. Michael (Germany)	424
11:20	SEQUENCE SPECIFICITY OF AUTOANTIBODIES AGAINST NUCLEIC ACID ANTIGENS - OPENING UP THE BLACK BOX C. Macaubas, E. Fox, I. Balboni, E. Mellins, I. Solov'yov, <b>K. Astakhova</b> (Denmark)	425
11:30	CLINICAL ASSOCIATIONS AND ANTIGENIC SPECIFICITY OF HIGHLY POSITIVE ANTI-NUCLEOLAR AUTOANTIBODIES IN A MULTICENTRIC COHORT L. De Chaisemartin, A. Roide, F. Fernani-Oukil, M.A. Dragon-Durey, C. Johanet, <b>P. Nicaise-Roland</b> , S. Chollet-Martin (France)	426
11:40	AUTOANTIBODIES DETECTED IN PATIENTS WITH ANKYLOSING SPONDYLITIS USING CDNA PHAGE DISPLAY <b>D. Quaden</b> , P. Vandormael, J. Vanhoof, P. Geusens, V. Somers (Belgium)	427
11:50	DIAGNOSTIC PERFORMANCE OF NOVEL SSC-ASSOCIATED ANTI-BICD2 AUTOANTIBODIES: RESULTS OF A GERMAN SYSTEMIC SCLEROSIS COHORT D. Wirtz, <b>J. Schulte-Pelkum</b> , P. Budde, P. Schulz-Knappe, H.D. Zucht, K. Conrad, N. Röber (Germany)	428
12:00	DETECTION OF AUTOANTIBODIES BY INDIRECT IMMUNOFLUORESCENCE IN A PATHOLOGY DEPARTMENT. <b>J. Rajcani</b> (Slovakia)	429



- 12:10 HIGH-THROUGHPUT SCREENING DISCOVERS NOVEL AUTOANTIBODIES IN AUTOIMMUNE DISEASES: THE SEROTAG APPROACH IN SYSTEMIC LUPUS, SYSTEMIC SCLEROSIS AND RHEUMATOID ARTHRITIS 430  
**P. Schulz-Knappe**, A. Lueking, P. Budde, H.D. Zucht, H. Göhler, R. Brinks, J. Richter, S. Vordenbäumen, M. Schneider (Germany)
- 12:20 HARMONIZATION OF AUTOIMMUNE DIAGNOSTICS AND LABORATORY COMPETENCE: ANA REFLEX TEST 431  
**C. Bonaguri**, A. Melegari, T. Trenti, A. Russo, L. Battistelli, A. Picanza, M. Galante, R. Aloe, G. Lippi (Italy)

**12:30-14:00****Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

FRIDAY

10:30 - 12:30

Hall 2

### PARALLEL SESSION 21: SLE - IS IT THE CLASSICAL AUTOIMMUNE DISEASE?

	<b>Chair: G. Zandman-Goddard</b> (Israel)	432
	<b>Chair: A. Doria</b> (Italy)	433
	<b>Chair: Y. Levy</b> (Israel)	434
10:30	PITFALLS IN LUPUS <b>M. Schneider</b> (Germany)	435
10:50	NEW BIOLOGIC TARGET IN SLE <b>A. Doria</b> (Italy)	436
11:10	A VERY LONG TERM OBSERVATIONAL ANALYSIS ON THE EFFECTS OF AN INTENSIFIED B LYMPHOCYTE DEPLETION SCHEDULE WITHOUT IMMUNOSUPPRESSIVE MAINTENANCE IN THE TREATMENT OF LUPUS NEPHRITIS: SOME EVIDENCE OF AUTOIMMUNE PROCESS RESETTING <b>D. Roccatello</b> (Italy)	437
11:30	BELIMUMAB DECREASES FLARE FRQUENCY AND HINDERS DAMAGE ACCRUAL IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM CLINICAL PRACTICE SETTING <b>L. Iaccarino</b> , S. Bettio, R. Reggia, M. Zen, M. Frassi, L. Andreoli, L. Nalotto, M. Gatto, M. Larosa, A. Zanola, A. Tincani, A. Doria (Italy)	438
11:40	CELIAC DISEASE COEXISTENT WITH SLE: A CASE-CONTROL STUDY <b>S. Dahan</b> , D. Ben Ami Shor, H. Amital (Israel)	439
11:50	MORPHOLOGICAL AND FUNCTIONAL EYE INVOLVEMENT IN PATIENTS AFFECTED BY SYSTEMIC LUPUS ERYTHEMATOSUS AND SJOGREN SYNDROME <b>P. Conigliaro</b> , C. Canofari, G. Draghessi, C. Valeri, L. Novelli, P. Triggianese, G. Aloe, R. Perricone, M. Cesareo (Italy)	440
12:00	ENHANCED VH REPLACEMENT IN ANTIBODY REPERTOIRE OF CIRCULATING PLASMA CELLS AND ITS CORRELATION WITH EPSTEIN-BARR VIRUS IN SYSTEMIC LUPUS ERYTHEMATOSUS <b>K. Su</b> , Y. Yu, S. Li, M. Hearsh-Holmes, A.C. Cannella, W.W. Chatham, R.P. Kimberly, J.R. O'Dell, L.W. Klassen, R.H. Carter, Z. Zhang (USA)	441
12:10	ELUCIDATING THE PATHOGENIC ROLES OF IGG AND IGM APOPTOTIC CELL-REACTIVE ANTIBODIES ON DENDRITIC CELLS AND DETERMINANT SPREADING IN LUPUS <b>M. Malik</b> , P. Arora, R. Sachdeva, V.G. Ramachandran, R. Pal (India)	442

12:20 SYSTEMIC LUPUS ERYTHEMATOSUS AND ANCA-ASSOCIATED VASCULITIS OVERLAP SYNDROME IN PATIENTS WITH BIOPSY-PROVEN GLOMERULONEPHRITIS

443

**P.A. Jarrot**, L. Chiche, B. Hervier, L. Daniel, V. Vuiblet, N. Bardin, B. Terrier, Z. Amoura, E. Andrés, E. Rondeau, M. Hamidou, P. Rieu, J.L. Pennaforte, E. Daugas, B. Dussol, X. Puechal, G. Kaplanski, N. Jourde-Chiche (France)

**12:30-14:00****Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

FRIDAY

10:30 - 12:30

Hall 3

**PARALLEL SESSION 22: KIDNEY INVOLVEMENT IN AUTOIMMUNITY**

	<b>Chair: C. Pusey</b> (United Kingdom)	444
	<b>Chair: P. Ronco</b> (France)	445
	<b>Chair: D. D'Cruz</b> (United Kingdom)	446
10:30	KIDNEY INVOLVEMENT IN SYSTEMIC VASCULITIS <b>C. Pusey</b> (United Kingdom)	447
10:50	KIDNEY INVOLVEMENT IN SLE <b>L. Lightstone</b> (United Kingdom)	448
11:10	THE PROBLEM WITH PATIENTS WITH BOTH ANCA AND ANTI-GBM ANTIBODIES <b>S. McAdoo</b> (United Kingdom)	449
11:25	IMPACT OF ANCA IN PATIENTS WITH LUPUS NEPHRITIS <b>T. Turner-Stokes</b> (United Kingdom)	450
11:40	CLINICAL USEFULNESS OF AUTOANTIBODIES TO M-TYPE PHOSPHOLIPASE A2 RECEPTOR (PLA2R) FOR MONITORING DISEASE ACTIVITY IN IDIOPATHIC MEMBRANOUS NEPHROPATHY (IMN) <b>A. Radice</b> , B. Trezzi, U. Maggiore, F. Pregnotato, T. Stellato, P. Napodano, D. Rolla, G. Pesce, M. D'Amico, D. Santoro, F. Londrino, F. Ravera, G. Ortis, R.A. Sinico D. Roccatello (Italy)	451
11:50	ANTICOAGULATION AND LONG TERM OUTCOMES IN PATIENTS WITH RENAL ARTERY STENOSIS AND ANTIPHOSPHOLIPID SYNDROME A. Casian, S. Sangle, N. Jordan, S. Mannou Stathopoulou, <b>D. D'Cruz</b> (United Kingdom)	452
12:00	EPITOPE SPREADING IN PLA2R1 IS ASSOCIATED WITH BAD PROGNOSIS IN MEMBRANOUS NEPHROPATHY <b>B. Seitz-Polski</b> , G. Dolla, C. Payre, S. Benzaken, V. Esnault, G. Lambeau (France)	453
12:10	THE ROLE OF OSTEOPONTIN AS A CANDIDATE BIOMARKER OF RENAL INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS <b>C. Garufi</b> , F.R. Spinelli, S. Truglia, F. Ceccarelli, F. Miranda, V. Pacucci, C. Alessandri, G. Valesini, F. Conti (Italy)	454

12:20 A NEW FORM OF ANTIPHOSPHOLIPID SYNDROME ASSOCIATED TO CHRONIC KIDNEY DISEASE?

455

**M. Serrano**, J.A. Martinez-Flores, D. Perez Mendez, C.M. Oscar, M. Sevilla, F. Garcia, E. Gonzalez, E. Paz-Artal, J.M. Morales, A. Serrano (Spain)

**12:30-14:00**

**Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

FRIDAY

**10:30 - 12:30****Hall 4****PARALLEL SESSION 23: AUTOIMMUNITY IN DERMATOLOGY**

	<b>Chair: R. Ahmed</b> (USA)	456
	<b>Chair: A. Kuhn</b> (Germany)	457
	<b>Chair: E. Schmidt</b> (Germany)	458
10:30	BENEFIT OF THE COMBINATION OF IVIG AND RITUXIMAB IN TREATING BLISTERING DISEASES <b>R. Ahmed</b> (USA)	459
10:45	A PEMPHIGUS PARADIGM: NEW ROLE FOR FCRN AS A DELIVERY VEHICLE FOR AUTOANTIBODIES TO INTRACELLULAR SELF-ANTIGENS <b>S.A. Grando</b> (USA)	460
11:00	NEW THERAPIES IN IMMUNE-MEDIATED SKIN DISEASES <b>T. Luger</b> (Germany)	461
11:15	DETECTION OF CIRCULATING AUTOANTIBODIES AND THEIR CORRELATION WITH BULLOUS PEMPHIGOID <b>M. Sardy</b> (Germany)	462
11:30	MULTIVARIANT DIAGNOSIS OF AUTOIMMUNE BLISTERING DISEASES <b>E. Schmidt</b> (Germany)	463
11:45	NEW TREATMENTS OF EXPERIMENTAL EPIDERMOLYSIS BULLOSA ACQUISITA <b>R. Ludwig</b> (Germany)	464
12:00	EFFECT OF A CLASSICAL PATHWAY SPECIFIC INHIBITOR ON BULLOUS PEMPHIGOID SERA-INDUCED COMPLEMENT ACTIVATION <b>A. Kasprick</b> , R. Ludwig, C. Hass, C. Kauderer, E. Dr. Schmidt, F. Petersen, S. Panicker (Germany)	465
12:10	FUMARIC ACID ESTERS IN CUTANEOUS LUPUS ERYTHEMATOSUS- A PROSPECTIVE, OPEN-LABEL, PHASE II PILOT STUDY A. Kuhn, <b>A. Landmann</b> , N. Patsinakidis, V. Ruland, S. Nozinic, A.M. Perusquia Ortiz, C. Sauerland, T. Luger, A. Tsianakas, G. Bonsmann (Germany)	466
12:20	TBA <b>A. Gul</b> (Turkey)	467

**12:30-14:00****Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

10:30 - 12:30

Hall 5

## PARALLEL SESSION 24: EXPERIMENTAL ANIMAL MODELS OF AUTOIMMUNE DISEASES

	<b>Chair: L. Gershwin</b> (USA)	468
	<b>Chair: M. Lidar</b> (Israel)	469
	<b>Chair: O. Hamiel</b> (Israel)	470
10:30	AUTOIMMUNITY IN DOMESTIC ANIMALS <b>L. Gershwin</b> (USA)	471
10:50	ROLE OF SERPINB3 IN PREVENTION AND TREATMENT OF COLLAGEN INDUCED ARTHRITIS (CIA) IN BALB/C MICE <b>S. Bindoli</b> , R. Luisetto, N. Bassi, M. Beggio, A. Ghirardello, L. Iaccarino, P. Pontisso, Y. Shoenfeld, A. Doria (Italy)	472
11:05	A NEW TNF-ALPHA INDUCIBLE TRANSGENIC MOUSE MODEL FOR PSORIATIC ARTHRITIS: CHARACTERIZATION OF THE PHENOTYPE REVERSIBILITY <b>V. Wixler</b> (Germany)	473
11:20	ENHANCED PASSIVE TRANSFER-TRAUMA MODEL FOR COMPLEX REGIONAL PAIN SYNDROME: EVIDENCE FOR AUTOANTIBODY-PAIN V. Tekus, Z. Helyes, J. Hawkes, <b>A. Goebel</b> (United Kingdom)	474
11:30	THE CD38 DEFICIENCY INDUCES AN AUTOIMMUNE-LIKE PHENOTYPE IN OLD MICE <b>M. Dominguez Pantoja</b> , L. Santos-Argumedo, H. Romero-Ramirez, G. Lopez-Herrera, F. Garcia-Garcia, J.C. Rodriguez-Alba (Mexico)	475
11:40	GALECTIN-3 AMELIORATES BEHAVIORAL DISORDERS IN NZBWF1 MICE LUPUS MODEL <b>R. Luisetto</b> , N. Bassi, A. Ghirardello, F. Saccon, A. Scanu, F. Leite de Oliveira, A. Doria (Italy)	476
11:50	GALECTIN-3 DELAYS THE ONSET OF GLOMERULONEPHRITIS AND PROLONGS SURVIVAL IN LUPUS-PRONE MICE (NZB/NZW F1) <b>F. Saccon</b> , R. Luisetto, N. Bassi, M. Gatto, A. Ghirardello, F.L. De Oliveira, A. Doria (Italy)	477
12:00	USE OF TOLL-LIKE RECEPTOR AGONISTS FOR THE DEVELOPMENT OF EXPERIMENTAL MYASTHENIA GRAVIS MODELS WITH THYMIC HYPERPLASIA M. Robinet, B. Villeret, S. Berrih-Aknin, <b>R. Le Panse</b> (France)	478

- 12:10 WHAT DETERMINES RELAPSING-REMITTING AUTOIMMUNE DISEASE? LESSONS FROM THE RAT MODEL OF EXPERIMENTAL AUTOIMMUNE UVEITIS (EAU) 479  
**G. Wildner**, M. Diedrichs-Möhrling, U. Kaufmann, C. Von Toerne, A. Kungl (Germany)
- 12:20 A NOVEL MOUSE MODEL FOR ANTI-LAMININ 332 MUCOUS MEMBRANE PEMPFIGOID 480  
**E.N. Heppe**, F.S. Schulze, D. Zillikens, S. Goletz, E. Schmidt (Germany)

**12:30-14:00**

**Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

**12:30 - 14:00**

**MP3 & 4**

**Industry Supported Session:**

NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT



14:00 - 16:00

Hall 1

## PARALLEL SESSION 25: PREDICTION, MONITORING AND PERSONALIZED MEDICINE

- Chair: J.M. Anaya** (Colombia) 481
- Chair: V. Stejskal** (Sweden) 482
- Chair: R.A. Levy** (Brazil) 483
- 14:00 PERSONALIZED MEDICINE: CLOSING THE GAP BETWEEN KNOWLEDGE AND CLINICAL PRACTICE 484  
**J.M. Anaya** (Colombia)
- 14:20 INCREASED PREVALENCE OF METAL SENSITIZATION IN PATIENTS WITH MULTIPLE SCLEROSIS, PARKINSON'S DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS 485  
**V. Stejskal**, B. Brunes, D. Magnusson, T. Reynolds (Sweden)
- 14:30 HIGH LEVELS OF MEMORY B CELLS PREDICT ABATACEPT EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS 486  
**Y. Renaudineau**, P. Gazeau, G. Carvajal Alegria, V. Devauchelle-Pensec, P. Pochard, J.O. Pers, A. Saraux, D. Cornec (France)
- 14:40 IMMUNOGENICITY OF TNF $\alpha$  INHIBITORS IN RHEUMATOID ARTHRITIS: RELATIONSHIP BETWEEN DRUG BIOAVAILABILITY/ANTI-DRUG ANTIBODIES AND CLINICAL OUTCOMES 487  
C. Grossi, F. Pregnotato, C. Bodio, E.G. Favalli, M. Biggioggero, A. Becciolini, R. Gorla, M. Filippini, P.C. Sarzi Puttini, R. Talotta, R. Caporali, V. Grosso, I. Hollan, M.O. Borghi, K. Bendtzen, **P.L. Meroni** (Italy)
- 14:50 CLUSTERED AUTOANTIBODY REACTIVITY PROFILES AND DEFINITION OF HOMOGENEOUS SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENT GROUPS 488  
P. Budde, H.D. Zucht, H. Göhler, P. Rengers, S. Vordenbäumen, **P. Schulz-Knappe**, M. Schneider (Germany)
- 15:00 A CD4 T-CELL CENTRAL MEMORY (TCM) BIOMARKER SUCCESSFULLY PREDICTS TREATMENT RESPONSE IN RECENT-ONSET TYPE 1 DIABETES (T1D) 489  
**C. Beam**, C. Maccallum, M. Peakman (USA)
- 15:10 A PILOT STUDY TO BENCHMARK BIOMARKERS IN SLE: WHICH BIOMARKERS ARE ADVANTAGEOUS FOR MONITORING DISEASE ACTIVITY? 490  
**R. Biesen**, T. Rose, G.R. Burmester, A. Grutzkau, F. Hiepe (Germany)

- 15:20 MONITORING FUNCTIONAL B-CELL MARKERS AND SUBSETS AS BENEFICIAL TOOL TO PREDICT MULTIPLE SCLEROSIS DEVELOPMENT 491  
**L. Rijvers**, J. Van Langelaar, R.M. Van der Vuurst de Vries, J.M. Hogervorst, M.J. Melief, A.F. Wierenga-Wolf, R.Q. Hintzen, M.M. Van Luijn (Netherlands)
- 15:30 IMBALANCES IN TH1/TH17 CELL SUBSETS ARE ASSOCIATED WITH DISEASE DEVELOPMENT IN EARLY MULTIPLE SCLEROSIS 492  
**J. Van Langelaar**, R.M. Van der Vuurst de Vries, L. Rijvers, A.F. Wierenga-Wolf, M.J. Melief, M. Janssen, M.M. Van Luijn, R.Q. Hintzen (Netherlands)
- 15:40 USE OF A CELL-BASED REPORTER GENE ASSAY FOR THERAPEUTIC DRUG MONITORING OF PATIENTS ON ANTI-TNF- $\alpha$  THERAPY 493  
**S. Berthold**, C. Lallemand, M. Tovey (Sweden)
- 15:50 SEX DIFFERENCES IN PSORIATIC ARTHRITIS: EVALUATION OF A REAL-LIFE COHORT OF 2,118 ITALIAN PATIENTS TREATED WITH METHOTREXATE 494  
**E. Generali**, C. Selmi, G. Carrara, C.A. Scirè (Italy)

14:00 - 16:00

MP3 &amp; 4

## PARALLEL SESSION 26: **EASI SESSION - ANCA AND ANCA-ASSOCIATED VASCULITIS**

	<b>Chair: Y. Shoenfeld</b> (Israel)	495
	<b>Chair: N. Olschowka</b> (Germany)	496
	<b>Chair: J. Damoiseaux</b> (Netherlands)	497
14:00	ANCA STUDY WITH SAMPLES FROM DIFFERENT CENTERS IN EUROPE, COMPARING DIFFERENT METHODS <b>X. Bossuyt</b> (Belgium)	498
14:20	THE CLINICAL PRESENTATION AND THERAPY OF DISEASE RELATED TO ANCA <b>M. Segelmark</b> (Sweden)	499
14:40	ANCA DIAGNOSTICS: AN EASI-SURVEY ON THE DAILY PRACTICE IN EUROPEAN COUNTRIES <b>J. Damoiseaux</b> (Netherlands)	500
15:00	THE NEW REFERENCE MATERIAL OF THE IRMM FOR MPO AND PR3 <b>J. Sheldon</b> (United Kingdom)	501
15:10	ANCA DIAGNOSTICS IN AUSTRIA: EASI QUESTIONNAIRE AND QUALITY ASSESSMENT SCHEMES <b>M. Herold</b> (Austria)	502
15:20	ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES ASSOCIATED WITH INFECTIVE ENDOCARDITIS <b>I. Marie</b> (France)	503
15:30	SHOULD AND CAN ANCA MEASUREMENTS BE STANDARDIZED? <b>E. Monogioudi</b> , G. Martos, D.P. Hutu, J. Sheldon, H. Schimmel, P.L. Meroni, H. Emons, I. Zegers (Belgium)	504
15:40	ANCA DETECTION : 27 YEARS EXPERIENCE WITH FOCUS ON INFECTION AND DOUBLE POSITIVITY (PR 3 AND MPO) ANCA <b>A. Chevailler</b> (France)	505
15:50	PROGNOSTIC VALUES OF ANCA SPECIFICITIES <b>L. Mouthon</b> (France)	506

14:00 - 16:00

Hall 2

### PARALLEL SESSION 27: AUTOIMMUNE ASPECTS OF NEUROLOGICAL DISEASES

	<b>Chair: A. Achiron</b> (Israel)	507
	<b>Chair: V. Somers</b> (Belgium)	508
	<b>Chair: D. Karussis</b> (Israel)	509
14:00	ANTI-NMDA RECEPTOR ENCEPHALITIS <b>J. Dalmau</b> (Spain)	510
14:20	FROM VGKC TO LGI1 AND CASPR2 ENCEPHALITIS: THE EVOLUTION OF A DISEASE OVER TIME <b>M.J. Titulaer</b> (Netherlands)	511
14:40	B CELL ANALYSIS AND BIOMARKER DISCOVERY IN NEUROLOGIC AND AUTOIMMUNE DISEASES <b>V. Somers</b> (Belgium)	512
15:00	RETT SYNDROME: AN AUTOIMMUNE DISEASE ? <b>J. Hayek</b> , C. De Felice, S. Leoncini, C. Signorini, A. Cortelazzo, A.M. Papini, P. Rovero, L. Ciccoli (Italy)	513
15:10	NEUROPROTECTION AFFECTED BY IMMUNOMODULATORY TREATMENT WITH GLATIRAMER ACETATE <b>R. Aharoni</b> , M. Sela, R. Arnon (Israel)	514
15:20	MAPPING THE EPITOPE OF ANTIBODIES TO SURFACE DOPAMINE-2 RECEPTOR IN THE FIRST EPISODE OF ACUTE PSYCHOSIS N. Sinmaz, D. Pilli, J. Starling, V. Merheb, R. Dale, <b>F. Brilot</b> (Australia)	515
15:30	REPEATED INFECTIONS INDUCE AN AUTOIMMUNE TH17 CELL PHENOTYPE IN THE BRAIN AND IMPAIR BLOOD-BRAIN BARRIER INTEGRITY: A MOUSE MODEL FOR PANS/PANDAS <b>T. Cutforth</b> , D. Knowland, E. Smith, T. Dileepan, M. Hsu, M. Platt, P.P. Cleary, D. Agalliu (USA)	516
15:40	THE PROFILES OF CYTOKINES/CHEMOKINES IN THE CEREBROSPINAL FLUIDS OF PATIENTS WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT OF CONNECTIVE TISSUE DISEASES <b>T. Yoshio</b> , H. Okamoto, S. Hirohata, S. Minota (Japan)	517

- 15:50 THE RELATIONSHIP BETWEEN NEUROINFLAMMATION, AUTOIMMUNE ACTIVATION, OXIDATIVE STRESS, MERCURY LEVELS, AND LOSS OF BRAIN CONNECTIVITY IN AUTISM SPECTRUM DISORDER 518  
J. Kern, D. Geier, **M. Geier** (USA)

**14:00 - 16:00****Hall 3****PARALLEL SESSION 28: PEPTIDES AND NEW MOLECULES IN THERAPEUTICS**

- Chair: V. Barak** (Israel) 519  
**Chair: C. Jamin** (France) 521  
**Chair: S. Gertel** (Israel) 520
- 14:00 SEMAPHORIN 3A, A POTENTIAL IMMUNE REGULATOR IN FAMILIAL MEDITERRANEAN FEVER 522  
**Z. Vadasz** (Israel)
- 14:20 IMMUNO-MODULATION OF NAIVE RHEUMATOID ARTHRITIS PATIENTS PBMC WITH A MULTI-EPI TOPE PEPTIDE DELINEATED FROM CITRULLINATED AUTOANTIGENS 523  
**S. Gertel**, S. Vainer, G. Serre, Y. Shoenfeld, H. Amital (Israel)
- 14:40 VACCINATION WITH PEPTIDE MIMOTOPES OF MOUSE CD20 ANTIGEN PROLONGS SURVIVAL IN LUPUS PRONE MICE BWF1 524  
E. Favoino, I.E. Favia, M. Prete, G. Di Lernia, **F. Perosa** (Italy)
- 15:00 AN APTAMER FOR NEUTRALIZATION OF PATHOGENIC AUTOANTIBODIES DIRECTED AGAINST G-PROTEIN COUPLED RECEPTORS PRESENT IN PATIENTS WITH CARDIOMYOPATHY: STEPS TO A NEW TREATMENT OPTION 525  
I. Schimke, **J. Mueller**, G. Wallukat, A. Haberland, P. Goettel, N.P. Becker, K. Wenzel (Germany)
- 15:15 NOVEL PEPTIDES FOR INDUCTION OF TOLERANCE AND TREATMENT IN A LONG-TERM MOUSE MODEL OF GRAVES' DISEASE AND ORBITOPATHY 526  
**M. Ungerer**, H.P. Holthoff, Z. Li, J. Fassbender, G. Münch (Germany)
- 15:30 TREATMENT OF HCT116 CELLS WITH GLIADIN, TRANSGLUTAMINASES AND COMPLEXES THEREOF, IMITATING CELIAC DISEASE 527  
P. Jeremias, B. Tanja, T. Matthias, S. Neidhoefer, **A. Lerner** (Germany)
- 15:45 NEO-EPI TOPEES BETWEEN GLIADIN PEPTIDES AND TISSUE / MICROBIAL TRANSGLUTAMINASES SHOW STRUCTURAL MEDIATED IMMUNOREACTIVE EPI TOPEES IN CELIAC DISEASE PATIENTS 528  
**P. Jeremias**, S. Neidhoefer, A. Lerner, T. Matthias (Germany)

14:00 - 16:00

Hall 4

PARALLEL SESSION 29: **AUTOIMMUNE LIVER DISEASES**

	<b>Chair: M.E. Gershwin</b> (USA)	529
	<b>Chair: P. Invernizzi</b> (Italy)	530
	<b>Chair: L. Muratori</b> (Italy)	531
14:00	NOVEL TREATMENTS IN PRIMARY BILIARY CHOLANGITIS <b>P. Invernizzi</b> (Italy)	532
14:20	AUTOIMMUNE LIVER DISEASES: AN UPDATE ON IMMUNOPATHOLOGICAL ASPECTS <b>D. Bogdanos</b> (Greece)	533
14:40	DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF AUTOANTIBODIES IN AUTOIMMUNE HEPATITIS <b>L. Muratori</b> (Italy)	534
15:00	DYSREGULATION OF INTERFERON INTERPLAY LEADS TO FEMALE PREDOMINANT AUTOIMMUNE CHOLANGITIS: IMPLICATIONS FOR THE ETIOLOGY OF HUMAN AUTOIMMUNE CHOLANGITIS <b>H. Young</b> , J. Valencia, S. Kim, T. Back, M. Karwan, D. Feng, B. Gao, O. Park, K. Tsuneyama, P. Leung, M.E. Gershwin, H. Bae (USA)	535
15:20	OVERLAP SYNDROMES AND AUTOIMMUNE LIVER DISEASE: A FIVE YEAR REVISED EXPERIENCE OF AN AUTOIMMUNITY DIAGNOSIS LABORATORY M. Albuquerque, <b>M.J. Sousa</b> , R. Ribeiro, M.F. Menezes, J.G. Sousa, G. Sousa (Portugal)	536
15:30	COMBINED DETERMINATION OF AUTOIMMUNE LIVER DISEASE SPECIFIC AUTOANTIBODIES BY CYTOBEAD® ASSAY <b>M. Sowa</b> , J. Scholz, K. Grossmann, R. Hiemann, N. Röber, B. Glauche, K. Conrad, D. Roggenbuck (Germany)	537
15:40	DIAGNOSTIC ACCURACY OF TWO TESTS FOR DETERMINATION OF ANTI-M2 IN THE DIAGNOSIS OF PRIMARY BILIARY CIRRHOSIS. IS POSSIBLE TO PREDICT THE COURSE OF THE DISEASE? <b>A.M. Alfano</b> , M. Battistini, G. Crotti, A. Ferrini, C. Mancinetti, T. Manetta, C. Marchese, P. Merlach, A. Romito, M.T. Tambuzzo (Italy)	538
15:50	FRUCTOSYLATION OF HUMAN SERUM ALBUMIN AND ITS POSSIBLE ROLE IN LIVER DISEASES <b>A. Zaman</b> , K. Alam (India)	539

14:00 - 16:00

Hall 5

## PARALLEL SESSION 30: TYPE 1 DIABETES MELLITUS

- Chair: M. von Herrath** (USA) 540
- Chair: I. Lazurova** (Slovakia) 541
- Chair: C. Dias** (Portugal) 542
- 14:00 PATHOLOGY OF HUMAN TYPE 1 AND 2 DIABETES: SURPRISING NEW FINDINGS AND PARADIGM SHIFTS 543  
**M. Von Herrath** (USA)
- 14:20 PANCREATITIS AFTER HUMAN PAPILLOMAVIRUS VACCINATION: A CASE OF MOLECULAR MIMICRY 544  
**M. Bizjak**, O. Bruck (Slovenia)
- 14:40 A PANEL OF CIRCULATING IMMUNE-RELATED AND ISLET-SPECIFIC MIRNAS AS BIOMARKERS OF EARLY DISEASE PROGRESS AND BETA CELL LOSS IN NOD MICE 545  
**Z. Guo**, R. Roat, J. Christopherson, C. Free, M. Hossain (USA)
- 14:50 MODULATION OF AUTOIMMUNE T CELL REACTION IN PATIENTS WITH TYPE 1 DIABETES BY TOLEROGENIC DENDRITIC CELLS 546  
**K. Dáňová**, A. Grohová, Z. Sumník, J. Lébl, O. Cinek, S. Pruhová, S. Koloušková, B. Obermanová, L. Petrželková, R. Spíšek, L. Palová-Jelínková (Czech Republic)
- 15:00 ANTIBODIES TO POST-TRANSLATIONALLY MODIFIED INSULIN IN TYPE 1 DIABETES 547  
**R. Strollo** (Italy)
- 15:10 CAN AUTOIMMUNE TYPE-1-DIABETES BE PREVENTED BY ANTI-IDIOTYPIC ANTIBODIES? 548  
L. Pärnpuu, K.L. Jensen, C.P. Engmose, C. Schafer-Nielsen, S. Shah, P. Marcatili, P. Chames, **C.H. Brogren** (Denmark)
- 15:20 GLYCO-OXIDATIVE DAMAGE TO HUMAN DNA: A POSSIBLE REASON FOR TYPE 1 DIABETES AUTOIMMUNITY 549  
**Moinuddin**, S. Ahmad (India)
- 15:30 COMORBIDITY OF CHILDHOOD COELIAC DISEASE AND TYPE 1 DIABETES: AN IMMUNOLOGICAL STUDY 550  
**R. Uibo**, T. Vorobjova, K. Metsküla, O. Uibo (Estonia)

- 15:40 EFFECT OF P21 DEFICIENCY ON MURINE AUTOIMMUNE PANCREATITIS 551  
**G.M. Seleznik**, T. Reding, L. Peter, A. Zabel, S. Sonda, R. Graf  
(Switzerland)
- 15:50 FOLLOW UP OF VALUE OF THE INTRARENAL RESISTIVITY INDICES  
AND DIFFERENT RENAL BIOMARKERS FOR EARLY IDENTIFICATION OF  
DIABETIC NEPHROPATHY IN TYPE 1 DIABETIC PATIENTS 552  
**S.M.A. El Dayem**, A.A. Battah, A.E.M. El Bohy, M. Hamed (Egypt)



14:00 - 16:00

Station 8

## PARALLEL SESSION 30B: NEW HORIZONS IN AUTOIMMUNE THERAPY

	<b>Chair: P.L. Meroni</b> (Italy)	553
	<b>Chair: D. Roggenbuck</b> (Germany)	554
	<b>Chair: C. Blandizzi</b> (Italy)	555
14:00	CONSISTENCY OF MONOCLONAL ANTIBODIES: FROM PRODUCTION TO CLINICAL PRACTICE <b>C. Blandizzi</b> (Italy)	556
14:20	CARDIOVASCULAR COMORBIDITIES IN INFLAMMATORY ARTHRITIS: THE ROLE OF TNF INHIBITORS <b>P.L. Meroni</b> , N. Ronda, I. Hollan (Italy)	557
14:40	THE ZIKA VIRUS ASSOCIATED WITH AUTOIMMUNITY: GBS AS A CASE IN POINT <b>C. Chang</b> (USA)	558
15:00	THE ROLE OF LIPOPROTEIN OXIDATIVE INFLAMMATION AND $\beta$ 2-GLYCOPROTEIN I IN INNATE IMMUNITY OF EARLY ATHEROSCLEROSIS E. Matsuura, <b>L. Lopez</b> (USA)	559
15:10	SUCCESSFUL TREATMENT OF EOSINOPHILIC FASCIITIS USING EXTRACORPOREAL PHOTOPHERESIS <b>J. Végh</b> (Hungary)	560
15:20	CANNABIS AS AN ANTI INFLAMMATORY TREATMENT <b>T. Naftali</b> (Israel)	561
15:30	ANTIGEN-SPECIFIC DOWNREGULATION OF IMMUNOPATHOLOGICAL EVENTS IN AN EXPERIMENTAL AUTOIMMUNE KIDNEY DISEASE <b>A.Z. Barabas</b> , C. Cole, R. Lafreniere (Canada)	562
15:40	VITAMIN D SUPPLEMENTATION EFFECTS ON FOXP3 EXPRESSION IN T CELLS AND FOXP3+/IL-17A RATIO AND CLINICAL COURSE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: STUDY IN A PORTUGUESE COHORT. <b>A. Marinho</b> , C. Carvalho, D. Boleixa, A. Bettencourt, B. Leal, J. Guimarães, E. Neves, J.C. Oliveira, I. Almeida, F. Farinha, P.P. Costa, C. Vasconcelos, B. Martins da Silva (Portugal)	563
15:50	A TALE OF TWO ANTIBODIES: BETA ADRENERGIC AND MUSCARINIC CHOLINERGIC ANTIBODIES ASSOCIATED WITH SIMULTANEOUS ERYTHROMELALGIA AND RAYNAUD'S PHENOMENON <b>J. Schofield</b> , C. Scheibenbogen, M. Nagel, H. Heidecke (USA)	564

16:00-16:30

Exhibition

COFFEE BREAK &amp; EXHIBITION



16:00 - 16:30

Station 1

**EPD25: TYPE 1 DIABETES MELLITUS: THE SWEET AND THE AUTOIMMUNE**

- Chair: D. Kulshrestha** (Taiwan) 565
- 16:00 RELATIONSHIP BETWEEN HYPERGLYCEMIA LEVELS AND INTERLEUKIN 6 (IL-6) IN PATIENTS WITH DIABETES MELLITUS  
**A. Amir** (Indonesia) 566
- 16:05 PREDICTIVE BIOMARKERS FOR DIABETES REVERSAL IN NOD MICE BY CLINICAL-GRADE PRO-INSULIN AND IL-10 SECRETING *LACTOCOCCUS LACTIS* IN COMBINATION WITH LOW-DOSE ANTI-CD3. 567  
T. Takiishi, **D. Cook**, H. Korf, G. Sebastiani, F. Mancarella, C. Wasserfall, L. Steidler, P. Rottiers, F. Dotta, G. Conny, C. Mathieu (Belgium)
- 16:10 RELATIONSHIPS BETWEEN CAROTID ARTERY INTIMA MEDIA THICKNESS AND INTERLEUKIN-6 LEVELS IN YOUNG PATIENTS WITH TYPE 1 DIABETES MELLITUS 568  
**V. Gurevich**, S. Sayganov, E. Minadze (Russia)
- 16:15 LOW CD25 EXPRESSION ON T REGULATORY CELLS DEFINES THE REGULATORY COMPARTMENT IN PATIENTS WITH TYPE 1 DIABETES 569  
**J. Kayserova**, Z. Parackova, K. Sismova, Z. Sumnik, S. Kolouskova, J. Lebl, A. Sediva (Czech Republic)
- 16:20 TRANSGENIC EXPRESSION OF AUTOIMMUNE REGULATOR (AIRE) IN DENDRITIC CELLS ATTENUATES AUTOIMMUNE DIABETES IN NOD MICE BY SUPPRESSING PROINFLAMMATORY CYTOKINES SECRETING T CELLS 570  
**D. Kulshrestha**, H.K. Sytwu (Taiwan)
- 16:25 ASSOCIATION OF TYPE 1 DIABETES WITH ORGAN SPECIFIC AUTOIMMUNE DISEASE 571  
**N. Ouikhlef**, Y. Bouali, A. Louail, S. Djemi, A. Benhalima (Algeria)

16:00 - 16:30

Station 2

EPD26: **EXPERIMENTAL MODELS: FROM MICE TO MEN**

- Chair: Y. Sofyan** (Indonesia) 572
- 16:00 ETANERCEPT, INFLIXIMAB AND TNF ABLATION IN MACROPHAGES EFFECTIVELY AMELIORATE EXPERIMENTAL ARTHRITIS IN HUMANIZED TNF KNOCK-IN MICE 573  
**M. Drutskaya**, R. Zvartsev, E. Gorshkova, A. Zhdanova, K.S. Atretkhany, G. Efimov, A. Kruglov, S. Nedospasov (Russia)
- 16:05 HUMAN PERIPHERAL BLOOD LYMPHOCYTES MAINTAIN POLYCLONAL AND ANTIGEN-SPECIFIC REACTIVITY AFTER ENGRAFTMENT INTO NOD-SCID IL2R $\gamma$ NULL MICE: FIRST STEPS TOWARDS A HUMANIZED MODEL OF AUTOIMMUNE ARTHRITIS 574  
**K. Schinnerling**, C. Schäfer, M. Jaxaira, L. Soto, J.C. Aguillón (Chile)
- 16:10 THE EFFECTS OF GENISTEIN SOYBEAN TOWARD SERUM FIBROBLAST GROWTH FACTOR 2 LEVELS AND KIDNEY FIBROSIS IN DIABETIC NEPHROPATHY RATS 575  
**Y. Sofyan** (Indonesia)
- 16:15 NEONATAL CORTICOSTERONE ADMINISTRATION REDUCES THE BEHAVIOURAL AND BRAIN WHITE MATTER ALTERATIONS ASSOCIATED WITH EXPOSURE TO GROUP-A-BETA-HAEMOLITIC STREPTOCOCCUS IN MICE 576  
**C. Spinello**, S. Macrì, R. Magliozzi, G. Laviola (Italy)
- 16:20 SOMATIC MUTATIONS IN CLONALLY EXPANDED LYMPHOCYTES IN PATIENTS WITH NEWLY DIAGNOSED RHEUMATOID ARTHRITIS 577  
**P. Savola**, T. Kelkka, H. Rajala, A. Kuuliala, K. Kuuliala, S. Eldfors, P. Ellonen, S. Lagstrom, R. Kumar Khajuria, T. Jaatinen, R. Koivuniemi, H. Repo, J. Saarela, K. Porkka, M. Leirisalo-Repo, S. Mustjoki (Finland)

FRIDAY

E-POSTERS

16:00 - 16:30

Station 3

## EPD27: SLE: NOVEL ASPECTS

- Chair: C.H. Suh** (Republic of Korea) 578
- 16:00 OUTCOME OF FILIPINO CHILDREN WITH LUPUS NEPHRITIS TREATED WITH A MODIFIED TREATMENT REGIMEN USING CYCLOPHOSPHAMIDE 579  
**M.T. Collante**, C. Bernal (Philippines)
- 16:05 THE ANTI-INFLAMMATORY COMPOUND OXACYCLODODECINDIONE COULD SERVE AS A LEAD STRUCTURE FOR THE DEVELOPMENT OF NEW THERAPEUTICS IN THE TREATMENT OF SLE 580  
**L. Schmidtke**, J. Henke, J. Weinmann-Menke, G. Erkel, H. Kleinert, A. Pautz (Germany)
- 16:10 ANTI-TNF-INDUCED LUPUS - A DISTINCT CLINICAL ENTITY 581  
**O. Shovman**, T. Shalev, Y. Shoenfeld (Israel)
- 16:15 NEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) IN PEDIATRIC LUPUS: PREVALENCE, CLINICAL ASSOCIATIONS AND CORRELATION WITH OTHER AUTOANTIBODIES 582  
**M. Smara**, Y. Meddour, S. Chaib-Mamouzi (Algeria)
- 16:20 VITAMIN D AND BONE MINERAL DENSITY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS 583  
**C.H. Suh**, J.Y. Jung, H.A. Kim (Republic of Korea)
- 16:25 TACROLIMUS-BASED REGIMENS IN THE TREATMENT FOR LUPUS NEPHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS 584  
Y.K.O. Teng, **T. Kraaij**, O.W. Bredewold, T.W.J. Huizinga, T.J. Rabelink (Netherlands)

16:00 - 16:30

Station 4

## EPD28: METHODS IN AUTOIMMUNE DIAGNOSTICS

- Chair: B. Torres Rives** (Cuba) 585
- 16:00 TITLE ANTI-HMGCR ANTIBODY DETECTION METHODS: IN-HOUSE VS COMMERCIAL ELISA 586  
**M. Alvarado**, A. Marin, D. Alvarez-De la Sierra, C. Franco, E. Balada, M.A. Martinez, M. Labrador Horrillo, I. Pinal Fernandez, C. Juarez, A. Selva O'Callaghan (Spain)
- 16:05 COMPARISON OF TWO ANTI-DOUBLE-STRAND-DNA ANTIBODIES ASSAYS : CRITHIDIA LUCILIAE SUBSTRATE READ BY AUTOMATED FLUORESCENT MICROSCOPE VERSUS CHEMILUMINESCENT IMMUNOASSAY 587  
**T. Belmondo**, S. Harzoun, M. Nasser, S. Hue (France)
- 16:10 DIFFERENTIAL CYTOKINE AND REGULATORY CELLS IN DISCOID AND SUBACUTE CUTANEOUS LUPUS 588  
**J. Furuzawa-carballeda**, S. Méndez-Flores, G. Hernández-Molina, A.B. Enríquez, D. Faz-Muñoz, Y. Esquivel, C. Pacheco-Molina (Mexico)
- 16:15 EVALUATION OF NOVEL ANA SCREENING METHOD: COMBINED USE OF AUTOMATED IIF AND CTD SCREEN CHEMILUMINESCENT IMMUNOASSAY 589  
**N. Gallo**, M. Arzenton, L. Penello, M. Seguso, M. Plebani (Italy)
- 16:20 AUTOMATED IFA METHODS COMPARE WELL WITH ESTABLISHED MANUAL IFA SCREENING AND TITRATION FOR ANA HEP-2 590  
J. Blecken, T. Matthias, A. Frey, M. Daves, A. Joos, **S. Platzgummer** (Italy)
- 16:25 IMMUNOLOGICAL MARKERS IN CUBAN PATIENTS WITH NON-INFECTIOUS UVEITIS 591  
**B. Torres Rives**, G. Martinez T, C. Rodriguez, M. Maite, I. Rodriguez, V. Sánchez, M. Benítez, I. Ambou, D. Vilches (Cuba)

FRIDAY

E-POSTERS

16:00 - 16:30

Station 5

## EPD29: CELIAC - DON'T MISS THE DIAGNOSIS

- Chair: A. Lerner** (Germany) 592
- 16:00 CELIAC DISEASE SCREENING IN AN ALGERIAN COHORT OF CHILDREN WITH TYPE 1 DIABETES 593  
**I. Allam**, R. Djidjik (Algeria)
- 16:05 ISOLATION AND LONG-TERM PRIMARY CULTURE OF SMALL INTESTINAL EPITHELIAL CELLS AS A MODEL FOR FURTHER STUDIES 594  
J. LukačBajalo, D. Cerne, M. Hadzija, G. Majdič, R. Orel, **B. Bozic** (Slovenia)
- 16:10 SERUM IGA ANTI-TGT NEGATIVE CASES IN CELIAC DISEASE SUSPECTED ADULT PATIENTS. THE NEED OF A POPULATION-SPECIFIC CUT-OFF VALUE 595  
**J.A. Garrote**, V. Ruiperez, H. Nunez, S. Perez-Zaragoza, F. Sanchez-Martin, E. Arranz (Spain)
- 16:15 ANTI-ENTEROCYTE AUTOANTIBODIES IN PEDIATRIC CELIAC DISEASE 596  
**A. Lerner**, R. Kushak, J. Patricia, T. Matthias, H. Winter (Germany)
- 16:20 THE ROLE OF ADVANCED AUTOMATION TECHNOLOGIES ON EARLY DIAGNOSIS OF CELIAC DISEASE (CD): CLINICAL AND DIAGNOSTIC IMPROVEMENTS AND CORRELATION WITH DUODENAL MUCOSAL DAMAGE 597  
**G. Previtali**, L. Licini, F. Nembrini, R. Ravasio, G. Azzarà, M. Seghezzi, C. Brascia, T. Benedetti, G. Lazzari, C. Maestroni, F. Noris, M.G. Alessio (Italy)
- 16:25 IMMUNOLOGICAL UPDATE ON CELIAC DISEASE DIAGNOSTICS 598  
**K. Tumangelova-Yuzeir**, E. Ivanova-Todorova, T. Velikova, Z. Spassova, D. Kyurkchiev, I. Altankova (Bulgaria)

16:00 - 16:30

Station 6

## EPD30: SJOGREN'S SYNDROME: THE ULTIMATE B CELL STIMULATION

	<b>Chair: K. Malyavantham</b> (USA)	599
16:00	SJOGREN SYNDROME - A CASE OF SPASTIC PARAPARESIS <b>R. Alves</b> , F. Correia, C. Soares, L. Afonso (Portugal)	600
16:05	THE PRESENTATION OF SJÖGREN'S SYNDROME AS UNEXPLAINED COUGH - A PROSPECTIVE STUDY OF A FOCUSED EVALUATION M. Koslow, <b>S. Kivity</b> , V. Vishnevskaja-Dai, I. Ben-Dov (Israel)	601
16:10	INVESTIGATION OF ANTI-NUCLEAR AUTOANTIBODIES (ANAS) IN A CHINESE PRIMARY SJÖGREN'S SYNDROME (PSS) COHORT USING MULTIPLEX LINE IMMUNOASSAYS (LIAS) <b>K. Malyavantham</b> , G. Shi, Y. Wang, Y. Liu, C. Dynski-Trumble, L. Shen, L. Suresh (USA)	602
16:15	RHEUMATOID FACTOR ISOTYPES AND ANTI-RO 52/60 AUTOANTIBODIES IN PRIMARY SJÖGREN'S SYNDROME WITH EXTRAGLANDULAR MANIFESTATIONS <b>B. Meek</b> , H. Kelder, A. Claessen, A.J. Van Houte, E.J. Ter Borg (Netherlands)	603
16:20	AN EVALUATION OF SERUM AUTOANTIBODIES REVEALS TWO MAIN GROUPS IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME <b>Y. Renaudineau</b> , C. Capaldo, G. Carvajal Alegria, B. Bendaoud, S. Jousse-Joulin, J.O. Pers, A. Saraux, V. Devauchelle-Pensec (France)	604
16:25	A CASE OF PULMONARY ALVEOLAR HEMORRHAGE WITH PRIMARY SJÖGREN'S SYNDROME <b>S. Ugurlu</b> , K. Erdam (Turkey)	605

FRIDAY

E-POSTERS

16:00 - 16:30

Station 7

EPD31: **MYASTHENIA GRAVIS & MULTIPLE SCLEROSIS**

Chair: **C. Pistono** (Italy) 606

- 16:00 INVARIANT NATURAL KILLER T CELLS FROM PATIENTS WITH PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS DISPLAY A PROINFLAMMATORY PHENOTYPE 607  
**A. Cossarizza**, S. De Biasi, M. Nasi, A.M. Simone, E. Bianchini, D. Ferraro, F. Vitetta, L. Gibellini, T. Trenti, M. Pinti, P. Sola (Italy)
- 16:05 MAY AHR BE INVOLVED IN AUTOIMMUNE MYASTHENIA GRAVIS? 608  
**N. Dragin**, J.A. Villegas, R. Khansa, R. Marieke, L.P. Rozen, B.A. Sonia (France)
- 16:10 INVOLVEMENT OF OXIDATIVE STRESS ON HSP70-2 PROTEIN EXPRESSION IN MULTIPLE SCLEROSIS (MS) 609  
**C. Pistono**, C. Boiocchi, C. Monti, G. Nosari, M. Cuccia, C. Montomoli, R. Bergamaschi (Italy)
- 16:15 HLA GENES AS MODIFIERS OF RESPONSE TO IFN- $\beta$ -1A THERAPY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS 610  
**M. Taheri**, A. Sayad, G. Solgi, A. Movafagh, M.D. Omrani, M. Mazdeh (Iran)
- 16:20 MONITORING AND ITS CLINICAL RELEVANCE OF LYMPHOCYTE SUBSETS DURING INNOVATIVE MULTIPLE SCLEROSIS TREATMENT STRATEGIES 611  
**K. Thomas**, M. Kaufmann, J. Blankenburg, J. Eisele, T. Ziemssen (Germany)
- 16:25 CYTOKINE PRODUCTION IN PERIPHERAL BLOOD CELLS OF PATIENTS WITH MULTIPLE SCLEROSIS 612  
**S. Zivancevic Simonovic**, O. Mihaljevic, G. Toncev, I. Kostic, I. Majstorovic, O. Milosevic-Djordjevic (Serbia)



16:00 - 16:30

Station 8

## EPD32: IVIG, INNATE IMMUNITY: HOW TO RESTORE THE IMMUNE SYSTEM TO NORMAL

- Chair: Y. Kronimus** (Germany) 613
- 16:00 GENERATION OF MONOCLONAL AUTOANTIBODIES FOR EFFECTIVE IMMUNIZATION IN PATIENTS WITH ALZHEIMER'S AND PARKINSON'S DISEASE 614  
**A. Albus**, M. Jördens, M. Möller, R. Dodel (Germany)
- 16:05 THE EFFECT OF MICROBIOME/TOLL-LIKE RECEPTOR INTERACTIONS ON SUSCEPTIBILITY TO TYPE 1 DIABETES 615  
**A. Baxter**, M. Jordan, D. Stanley, R. Moore, B. Crowley (Australia)
- 16:10 MANAGEMENT OF ADVERSE EVENTS IN THE TREATMENT OF PATIENTS WITH IMMUNOGLOBULIN THERAPY : A REVIEW OF EVIDENCE 616  
P. Cherin, I. Marie, M. Michallet, E. Pelus, J. Dantal, J.C. Crave, **J.C. Delain**, J.F. Viallard (France)
- 16:15 FC GLYCOSYLATION OF NATURALLY OCCURRING AUTOANTIBODIES IN PARKINSON'S AND ALZHEIMER'S DISEASE 617  
**Y. Kronimus**, I. Kuhn, R. Dodel (Germany)
- 16:20 CLINICAL SIGNIFICANCE OF COMPLEMENT SYSTEM ANALYTICS EXTRACTED FROM BIG DATA BANKS 618  
**U. Nydegger**, P. Medina Escobar, L. Risch, T. Lung (Switzerland)
- 16:25 INCREASED NLRC4 INFLAMMASOMES AND THEIR CORRELATIONS WITH DISEASE ACTIVITY IN AUTOIMMUNE HEPATITIS 619  
**L. Wang**, W. Jiao, K. Zhang, F.S. Wang (China)

16:30 - 18:30

Hall 1

## PARALLEL SESSION 31: ENVIRONMENTAL FACTORS AND SEX HORMONES IN AUTOIMMUNITY

	<b>Chair: A. Vojdani</b> (USA)	620
	<b>Chair: U. Sack</b> (Germany)	621
	<b>Chair: M. Cutolo</b> (Italy)	622
16:30	ENVIRONMENTAL BASIS OF AUTOIMMUNITY <b>M.E. Gershwin</b> (USA)	623
16:50	XENOBIOTICS AND AUTOIMMUNITY <b>A. Vojdani</b> , J. Lambert (USA)	624
17:10	ESTROGENS AS ENHANCERS OF THE IMMUNE RESPONSE AND AUTOIMMUNITY <b>M. Cutolo</b> (Italy)	625
17:30	CORRELATION OF TISSUE AUTOANTIBODIES AND FOOD IMMUNE REACTIVITY IN RANDOMLY SELECTED PATIENT SPECIMENS <b>J. Lambert</b> , A. Vojdani (USA)	626
17:45	GENDER AND AUTOIMMUNITY: A SPOTLIGHT ON THE ROLE OF PROGESTOGENS <b>I. Tan</b> (USA)	627
18:00	GENE SHARING BETWEEN EPSTEIN-BARR VIRUS AND HUMAN IMMUNE-RESPONSE GENES <b>D. Dreyfus</b> (USA)	628
18:10	A HIGH FIBRE DIET CAN MODULATE HALLMARKS OF INFLAMMATION AND AUTOIMMUNITY CULMINATING IN REDUCED NEPHRITIS IN A MODEL OF SYSTEMIC LUPUS ERYTHEMATOSUS <b>T. Gottschalk</b> , E. Tsantikos, M. Hibbs (Australia)	629
18:20	SOLUBLE SYNDECAN-1: A POTENTIAL NOVEL BIOMARKER OF SMALL BOWEL MUCOSAL DAMAGE IN CHILDREN WITH CELIAC DISEASE D. Yablecovitch, A. Oren, S. Ben-Horin, E. Fudim, R. Eliakim, F.M. Konikoff, U. Kopylov, T. Matthias, <b>A. Lerner</b> (Germany)	630

16:30 - 18:30

MP3 &amp; 4

## PARALLEL SESSION 32: RHEUMATOID ARTHRITIS - CHALLENGES IN THE NEW ERA

	<b>Chair: F. Atzeni</b> (Italy)	631
	<b>Chair: S.B Abramson</b> (USA)	632
	<b>Chair: P. Langevitz</b> (Israel)	633
16:30	INFECTIONS AND BIOLOGIC AGENTS IN RA <b>F. Atzeni</b> (Italy)	634
16:50	CARDIAC IMPAIRMENT IN RHEUMATOID ARTHRITIS AND INFLUENCE OF ANTI TNF-ALPHA THERAPY <b>I. Lazurova</b> , L. Tomáš (Slovakia)	635
17:10	PREVENTION OF CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS <b>N. Ronda</b> , I. Hollan (Italy)	636
17:25	ISCHEMIC HEART DISEASE IN RHEUMATOID ARTHRITIS PATIENTS: CASE-CONTROL STUDY <b>A. Watad</b> (Israel)	637
17:40	ASSOCIATION BETWEEN DUFFY GENOTYPE AND THE ACTIVITY OF RHEUMATOID ARTHRITIS IN COLOMBIAN PATIENTS C. Saavedra-Díaz, F.E. Ospina, A. Hormaza, C.A. Cañas, C. Fong, G. Barreto, <b>G. Tobón</b> , F. Bonilla-Abadía (Colombia)	638
17:50	GENETIC ASSOCIATION OF ANGIOTENSIN CONVERTING ENZYME-INDEL POLYMORPHISM WITH RHEUMATOID ARTHRITIS SUSCEPTIBILITY IN SOUTH GUJARAT POPULATION OF INDIA <b>D. Patel</b> , A. Dhangar, R. Shah, N. Laddha, P. Kumar, M. Dwivedi (India)	639
18:00	RHEUMATOID ARTHRITIS PATIENTS HAVE ALTERATIONS IN INHERENTLY AUTOREACTIVE 9G4+ B CELLS IN PERIPHERAL BLOOD <b>R.A. Moura</b> , M.J. Leandro, V. Reddy, J.E. Fonseca, G. Cambridge (United Kingdom)	640
18:10	REDUCTION OF AUTOPHAGY CORRELATES WITH A FAVORABLE CLINICAL OUTCOME IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH DMARDS <b>M. Vomero</b> , C. Alessandri, M. Pendolino, C. Barbati, T. Colasanti, M. Di Franco, C. Iannuccelli, M. Sorice, A. Capozzi, E. Ortona, M. Pierdominici, W. Malorni, F. Conti, G. Valesini (Italy)	641

18:20 IL-18 BINDING PROTEIN FROM BENCH TO BEDSIDE: IL-18/IL-18BP IMBALANCE IN SECONDARY HEMOPHAGOCYTIC SYNDROME PATIENTS. A COMPLETE REMISSION IN A BABY TREATED WITH IL-18 BINDING PROTEIN

**D. Novick**, C.A. Dinarello, G. Kaplanski (Israel)

642

16:30 - 18:30

Hall 2

### PARALLEL SESSION 33: GENETICS AND EPIGENETICS OF AUTOIMMUNE DISEASES

	<b>Chair: Q. Lu</b> (China)	643
	<b>Chair: Y. Tomer</b> (USA)	644
	<b>Chair: K. Yamamoto</b> (Japan)	645
16:30	THE REAL CULPRIT IN SYSTEMIC LUPUS ERYTHEMATOSUS: ABERRANT DNA METHYLATION <b>Q. Lu</b> (China)	646
16:50	THE COMMON MECHANISMS OF AUTOIMMUNITY <b>J.M. Anaya</b> (Colombia)	647
17:10	GENETICS AND ENVIRONMENT SHAPE PHENOTYPES OF ANCA VASCULITIDES <b>W.L. Gross</b> (Germany)	648
17:30	AN IN SILICO APPROACH REVEALS, IN B CELLS FROM PRIMARY SJOGREN'S SYNDROME PATIENTS, ASSOCIATIONS BETWEEN GENETIC AND EPIGENETIC FACTORS <b>Y. Renaudineau</b> , C. Le Dantec, A. Charras, O.D. Konsta, W.H. Brooks, M.L. Arleevskaya, A. Bordron (France)	649
17:40	EXPLORING AUTOIMMUNITY IN A COHORT OF CHILDREN WITH GENETICALLY-CONFIRMED AICARDI-GOUTIERES SYNDROME <b>M. Cattalini</b> , J. Galli, L. Andreoli, I. Olivieri, G. Ariaudo, M. Fredi, N. Carabellese, S.G. Iagsa, S. Orcesi, A. Tincani, E. Fazzi (Italy)	650
17:50	FUNCTIONAL AND MULTI-OMIC APPROACHES TO THE SHARED GENETIC BASIS ACROSS PEDIATRIC AUTOIMMUNITY <b>Y.R. Li</b> , J. Li, D. Zhao, R.N. Baldassano, E.T.L. Prak, H. Li, B.J. Keating, H. Hakonarson (USA)	651
18:00	DNA METHYLATION AND GENE EXPRESSION CHANGES IN MONOZYGOTIC TWINS REVEAL THE CONTRIBUTION OF THE INNATE IMMUNE SYSTEM IN MYASTHENIA GRAVIS <b>S. Mamrut</b> , N. Avidan, F. Truffault, E. Staun-Ram, M. Frenkian, S. Berrih-Aknin, A. Miller (Israel)	652

- 18:10 PREDICTIVE VALUE OF POLYMORPHISMS OF GENES INVOLVED IN INFLAMMATION FOR THE CLINICAL RESPONSE TO TNFA INHIBITORS IN RHEUMATOID ARTHRITIS 653  
F. Pregnolato, C. Grossi, C. Bodio, E.G. Favalli, M. Biggioggero, A.E. Penatti, A. Marchesoni, R. Gorla, M. Filippini, P.C. Sarzi Puttini, R. Talotta, R. Caporali, V. Grosso, R. Pellerito, M.O. Borghi, **P.L. Meroni** (Italy)
- 18:20 COMPUTATIONAL ANALYSIS OF AUTOIMMUNE DISEASES RELATED GENES SNPS 654  
**A. Tekcan** (Turkey)

16:30 - 18:30

Hall 3

PARALLEL SESSION 34: **EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES**

	<b>Chair: R. Cervera</b> (Spain)	655
	<b>Chair: D. Wahl</b> (France)	656
16:30	INTRODUCTION <b>R. Cervera</b> (Spain)	657
16:35	LONG STANDING APS <b>A. Tincani</b> (Italy)	658
16:50	BETA-2-GLYCOPROTEIN I STANDARD <b>P.L. Meroni</b> (Italy)	659
17:05	TRAPS TRIAL <b>V. Pengo, A. Hoxha, A. Banzato, E. Bison, G. Zoppellaro, J.S. Padayatti, G. Denas, A. Ruffatti</b> (Italy)	660
17:20	HYDROXYCHLOROQUINE AS SECONDARY THROMBOPROPHYLAXIS IN PRIMARY APS <b>C. Belizna</b> (France)	661
17:25	ADDITIONAL TREATMENTS IN HIGH RISK OBSTETRIC ANTIPHOSPHOLIPID SYNDROME. A EUROPIAN FORUM ON ANTIPHOSPHOLIPID PROJECT A. Ruffatti, <b>A. Hoxha, M. Favaro, A. Banzato, V. Pengo</b> (Italy)	662
17:35	UPDATE FROM THE PEDIATRIC APS REGISTRY <b>T. Avcin</b> (Slovenia)	663
17:50	APS ACTION <b>P.L. Meroni</b> (Italy)	664
18:05	10TH MEETING OF THE EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES <b>D. Wahl</b> (France)	665
18:20	DISCUSSION	

FRIDAY

16:30 - 18:30

Hall 4

**PARALLEL SESSION 35: BIG DATA ANALYSIS, REGISTRIES, AND EPIDEMIOLOGICAL STUDIES IN AUTOIMMUNITY**

	<b>Chair: M. Praver</b> (USA)	666
	<b>Chair: X. Zeng</b> (China)	667
	<b>Chair: H. Amital</b> (Israel)	668
16:30	BIG DATA ANALYSIS IN HEALTH RESEARCH <b>M. Praver</b> (USA)	669
16:50	THE REGISTRY OF RHEUMATIC DISEASES IN CHINA <b>X. Zeng</b> (China)	670
17:10	THE REGISTRY OF TAKAYASU ARTERITIS IN CHINA <b>X. Tian</b> (China)	671
17:30	WHAT CAN WE LEARN FROM REAL LIFE DATABASES? <b>H. Amital</b> (Israel)	672
17:50	REGISTRIES IN RHEUMATOID ARTHRITIS <b>P. Sarzi-Puttini</b> (Italy)	673
18:10	THE ANNUAL INCIDENCE/PREVALENCE OF AUTOIMMUNE DISEASES IS INCREASING WORLDWIDE <b>A. Lerner</b> , P. Jeremias, T. Matthias (Germany)	674
18:20	HYPOGONADAL PATIENTS WITH AUTOIMMUNE DISEASES (CROHN'S DISEASE, PSORIASIS) BENEFIT FROM LONG-TERM TREATMENT WITH TESTOSTERONE - REAL-LIFE DATA FROM A REGISTRY STUDY <b>F. Saad</b> , A. Haider, A. Traish, L. Gooren (Germany)	675



16:30 - 18:30

Hall 5

PARALLEL SESSION 36: **SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS AND HEREDITARY PERIODIC FEVER SYNDROME**

	<b>Chair: M. Galeazzi</b> (Italy)	676
	<b>Chair: S. Kivity</b> (Israel)	677
	<b>Chair: D. Rigante</b> (Italy)	678
16:30	SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS <b>R. Cimaz</b> (Italy)	679
16:50	HEREDITARY PERIODIC FEVER SYNDROMES <b>L. Cantarini</b> (Italy)	680
17:10	AUTOPHAGY AND AUTOIMMUNITY <b>G. Valesini</b> (Italy)	681
17:30	THE CONTINUUM OF AUTOIMMUNITY AND AUTOINFLAMMATION <b>E. Pras</b> (Israel)	682
17:50	THE CHOLINERGIC ANTI-INFLAMMATORY PATHWAY: A POSSIBLE MECHANISM OF ACTION OF ANTI-CHOLINESTERASES IN AN ANIMAL MODEL OF AUTOIMMUNE ARTHRITIS <b>M. Gowayed</b> , R. Refaat, A. Attia, H. El-Abhar, C. Baerwald (Egypt)	683
18:00	AUTOIMMUNE FAMILY - A GLANCE IN THE CLINIC L. Groseanu, <b>M. Duna</b> , A. Balanescu, V. Bojinca, I. Saulescu, D. Opris, C. Constantinescu, A. Borangiu, S. Daia-Iliescu, M.M. Negru, R. Ionescu (Romania)	684
18:10	COEXISTENCE OF FAMILIAL MEDITERRANEAN FEVER (FMF), JUVENILE PSORIATIC ARTHRITIS (JPSA) AND SECONDARY HYPOGONADISM <b>H. Sargsyan</b> (Armenia)	685
18:20	DISCUSSION	



WEDNESDAY

THURSDAY

FRIDAY

SATURDAY

SUNDAY


INDEX

ACKNOWLEDGEMENTS



# SCIENTIFIC PROGRAM

## **SATURDAY**, APRIL 9, 2016



# 10<sup>TH</sup>

INTERNATIONAL CONGRESS  
ON **AUTOIMMUNITY**

APRIL 6-10, 2016, LEIPZIG, GERMANY

# Autoimmunity Reviews



Co-Editors-in-Chief

Y. Shoenfeld • M.E. Gershwin



2014 Impact Factor\*

**7.933**

\*Journal Citation Reports  
published by  
Thomson Reuters 2015

Supports  
Open Access



For the full aims & scope, visit:

[journals.elsevier.com/autoimmunity-reviews](http://journals.elsevier.com/autoimmunity-reviews)

# SATURDAY, APRIL 9, 2016

8:00 - 10:00

Hall 1

## PLENARY SESSION 3

	<b>Chair: J. Dayer</b> (Switzerland)	686
	<b>Chair: M.E. Gershwin</b> (USA)	687
	<b>Chair: C. Vasconcelos</b> (Portugal)	688
8:00	THE INTERRELATIONSHIP OF MICROBIOME AND AUTOIMMUNITY <b>S.B. Abramson</b> (USA)	689
8:30	MEMBRANOS NEPHROPATHY AS A CLASSICAL AUTOIMMUNE DISEASE <b>P. Ronco</b> (France)	690
9:00	THE MOSAIC OF AUTOIMMUNITY IN 2016: NEW FACTORS AND NOVEL IMMUNOMODULATIONS <b>Y. Shoenfeld</b> (Israel)	691
9:30	THE SKIN IN SYSTEMIC AUTOIMMUNE DISEASES - UNMET NEEDS! <b>A. Kuhn</b> (Germany)	692

10:00-10:30

Exhibition

COFFEE BREAK &amp; EXHIBITION



10:00 - 10:30

Station 1

EPD33: **APS: NOVELTIES**

- Chair: G. Medina** (Mexico) 693
- 10:00 AUTOANTIBODY PROFILE AND CLINICAL ASSOCIATIONS IN 176 ADULT ITALIAN SYSTEMIC SCLEROSIS PATIENTS 694  
T. Schioppo, **L. Cesana**, F. Ingegnoli, P.L. Meroni, C. Bentow, M. Mahler, S. Vettori, G. Valentini (Italy)
- 10:05 RIVAROXABAN IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (APS) - OWN EXPERIENCE IN 23 CASES 695  
**E. Haladyj**, M. Olesińska (Poland)
- 10:10 CLINICAL OUTCOME AFTER ANTIPHOSPHOLIPID ANTIBODIES NEGATIVIZATION IN PRIMARY ANTIPHOSPHOLIPID SYNDROME. A 5 -YEAR FOLLOW-UP STUDY 696  
**G. Medina**, E. Briones García, M.P. Cruz-Domínguez, O.I. Florez-Durante, L.J. Jara (Mexico)
- 10:15 EFFICACY OF HYDROXYCHLOROQUINE ON MESENTERIC AND CAROTID ARTERIAL THROMBOSIS IN A MOUSE MODEL OF ANTIPHOSPHOLIPID SYNDROME 697  
**S. Miranda**, M. Lebesnerais, Y. Benhamou, L. Galas, D. Schapman (France)
- 10:20 TITLE: ANTI-PHOSPHOLIPID ANTIBODIES AND PARATHYROID HORMONE: A GENDER STUDY 698  
**A. Vitagliano**, A.M. D'ursi, P. Amato, A. Sorrentino, C. Mirello, P. Sabatini (Italy)
- 10:25 BUDD-CHIARI SYNDROME AS THE PRESENTING MANIFESTATION OF ANTIPHOSPHOLIPID SYNDROME 699  
**A. Mota**, C. Eira, R. Silvério, N. Ribeiro, A. Monteiro (Portugal)

10:00 - 10:30

Station 2

EPD34: **GENE, FAMILIES, RNA**

- Chair: A. Paradowska-Gorycka** (Poland) 700
- 10:00 ASSOCIATION OF PTPN22 GENE POLYMORPHISMS WITH AUTOIMMUNE DISEASE IN PEDIATRIC PATIENTS WITH TYPE 1 DIABETES FROM ALGERIA 701  
H. Mesbah-Amroun, A. Boukercha, A. Bouzidi, K. Ait-Abdesslam, D. Bouziane, **C. Touil-Boukoffa** (Algeria)
- 10:05 DNA DEMETHYLATION OF THE TIM-3 PROMOTER IS CRITICAL FOR ITS STABLE EXPRESSION ON T CELLS 702  
**F.C. Chou**, C.C. Kuo, H.Y. Chen, H.H. Chen, H.K. Sytwu (Taiwan)
- 10:10 MICRORNA-146A EXPRESSION AS PUTATIVE BIOMARKER IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS 703  
**C. Carvalho**, B. Leal, A. Bettencourt, A. Marinho, I. Almeida, F. Farinha, P. Pinho e Costa, C. Vasconcelos, B. Martins da Silva (Portugal)
- 10:15 ASSOCIATION OF HLA-DRB1 ALLELES WITH MIXED CONNECTIVE TISSUE DISEASE (MCTD) 704  
**A. Paradowska-Gorycka**, S. Barbara, O. Marzena, F.G. Anna, M. Malgorzata, C. Zenobia, Z. Zbigniew, J. Monika (Poland)
- 10:20 THE GENETICS OF AUTOIMMUNITY: A PROTOTYPE OF MULTIFACTORIAL INHERITANCE 705  
**E. Pras** (Israel)

10:00 - 10:30

Station 3

## EPD35: SLE: THE LEADING AUTOIMMUNE CONDITION

- Chair: S. Vento** (Botswana) 706
- 10:00 DECREASED FREQUENCY AND ACTIVATED PHENOTYPE OF BLOOD CD27+IGG+B LYMPHOCYTES IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS 707  
**Z. Chen**, H.H. Zhang, M.T. Li, X.F. Zeng (China)
- 10:05 SURVIVAL OF PREDNISONE-FREE REMISSION IN SLE PATIENTS WITH SEROLOGICALLY ACTIVE CLINICAL QUIESCENT DISEASE 708  
**L. Nalotto**, F. Ometto, M. Zen, M. Gatto, S. Bettio, L. Iaccarino, A. Ghirardello, A. Doria (Italy)
- 10:10 AUTOIMMUNE DISEASES IN LOW AND MIDDLE INCOME COUNTRIES: A NEGLECTED, YET IMPORTANT ISSUE IN GLOBAL HEALTH 709  
**S. Vento**, F. Cainelli (Botswana)
- 10:15 THYMIC EPITHELIAL PROGENITOR/STEM CELLS TRANSPLANTATION IN AUTOIMMUNE DISEASES 710  
**B. Wozniewicz**, M. Wozniewicz, R. Swierzewski, I. Nawrot, R. Janas (Poland)
- 10:20 A RARE CASE OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND MORPHEA 711  
**S. Wydya Yenny**, I. Isramiharti, G. Akhyar, P. Kampar, Y. Yenita, N. Najirman (Indonesia)



10:00 - 10:30

Station 4

EPD36: **DIAGNOSTICS: FROM THE LAB TO THE CLINIC**

- Chair: S. Kivity** (Israel) 712
- 10:00 ROLE OF VOLATILE COMPOUNDS RELEASED BY SYNOVIAL FLUID IN THE EVALUATION OF OSTEOARTHRITIS AND INFLAMMATORY DISEASES OF THE KNEE JOINT 713  
A. Bergamini, R. Perricone, **M.S. Chimenti**, G.L. Fonti, C. Canofari, E. Martinelli, C. Di natale, R. Capuano, L. Lugari (Italy)
- 10:05 REAL-WORLD VALIDATION OF AN AUTOMATED INDIRECT IMMUNOFLUORESCENCE ANTI-NUCLEAR ANTIBODY SYSTEM 714  
**R.A. Booth** (Canada)
- 10:10 ANCA TESTING IN AUSTRIA - SOME MORE RESULTS OF THE EASI QUESTIONNAIRE 715  
**M. Herold**, W. Klotz, T. Horn, Members of EASI Austria (Austria)
- 10:15 NEUTROPHIL LYMPHOCYTE RATIO IN PATIENTS WITH AUTOIMMUNE DISEASES 716  
A. Israeli, E. Maor, S. Gad, O. Har-Noy, Y. Sidi, R. Brenner, **S. Kivity** (Israel)
- 10:20 ANTI-PHOSPHOLIPASE A2 RECEPTOR ANTIBODIES IN DANISH PATIENTS WITH MEMBRANOUS NEPHROPATHY 717  
**T. Korsholm**, H. Birn, J.W. Gregersen, E. Krarup, B.B. Pedersen, A. Oczachowska-Kulik, P. Ivarsen (Denmark)
- 10:25 EVALUATION OF DIAGNOSTIC PRACTICE ON TESTING AND REPORTING ANTINEUTROPHIL CYTOPLASMATIC AUTOANTIBODIES (ANCA) IN NORTH ESTONIAN MEDICAL CENTRE 718  
**M. Mägi**, M. Kütt (Estonia)

10:00 - 10:30

Station 5

## EPD37: CNS: BRAIN, AUTOIMMUNITY AND BEYOND

- Chair: C. Hoffmann** (Netherlands) 719
- 10:00 ASSOCIATION OF ANTI-YO, ANTI-HU AND ANTI-SOX1 ANTIBODIES IN CSF IN PATIENT WITH LIMBIC AND PARALIMBIC ENCEPHALITIS IN THE SETTING OF SMALL CELL LUNG CARCINOMA 720  
I. Gañán Nieto, P. González Urra, A. Tejada Velarde, **A. Carrasco Sayalero**, A. Jiménez-Escrig (Spain)
- 10:05 MRNA ELECTROPORATION IS AN EFFECTIVE TOOL TO INDUCE LONG-TERM MYELIN EXPRESSION BY HUMAN TOLEROGENIC DENDRITIC CELLS 721  
**J. Derdelinckx**, W.P. Lee, M. De Laere, P. Cras, B. Willekens, Z.N. Berneman, N. Cools (Belgium)
- 10:10 INTIMATE RELATIONSHIPS, DISEASE'S BURDEN AND IMMUNE STATUS - A LONGITUDINAL STUDY IN WOMEN WITH SLE 722  
**M. Figueiredo-Braga**, M. Figueiredo, M. Bernardes, G. Terroso, L. Costa (Portugal)
- 10:15 ANALYSIS OF AUTO-ANTIBODIES IN PSYCHOTIC DISORDER 723  
**C. Hoffmann**, J. Stevens, M. Mané Damas, S. Zong, G. Nogales-Gadea, P. Molenaar, M.J. Titulaer, M.W.J. Schreurs, M. Losen, A. Szoke, M. Leboyer, M. De Hert, N.J.M. Van Beveren, M.H. De Baets, W.A. Buurman, J. Van Os, B.P. Rutten, P. Martinez-Martinez (Netherlands)
- 10:20 HUMAN MONOCLONAL NMDA RECEPTOR AUTO-ANTIBODIES ARE SUFFICIENT FOR ENCEPHALITIS PATHOGENESIS 724  
J. Kreye, N. Wenke, M. Chayka, J. Leubner, R. Murugan, N. Maier, H. Wardemann, **H. Prüss** (Germany)
- 10:25 THE NEW M23-BASED ELISA ASSAY FOR ANTI-AQUAPORIN 4 AUTOANTIBODIES: SENSITIVITY, SPECIFICITY AND DIRECT COMPARISON WITH IIF METHOD 725  
**M. Tampoia**, F. Marnetto, L. Abbracciavento, L. Granieri, P. Valentino, A. Bertolotto, R. Fumarulo (Italy)

10:00 - 10:30

Station 6

EPD38: **VASCULITIS: A SYSTEMIC AUTOIMMUNE CONDITION**

- Chair: N. Lorenzo Villalba** (Spain) 726
- 10:00 AUTOIMMUNE ASSOCIATED ORBITAL INFLAMMATORY MASSES AND RESPONSE TO IMMUNOSUPPRESSIVE THERAPY 727  
A. Casian, S. Sangle, R. Malaiya, P. Lutalo, L. Nel, B. Menon, H. Varma, M. Stanford, **D. D'Cruz** (United Kingdom)
- 10:05 DESCRIPTION OF CLINICAL JOINT MANIFESTATION OF HYPOVITAMINOSIS D PATIENTS AT RHEUMATOLOGY OUTPATIENT CLINIC OF DR. HASAN SADIKIN GENERAL HOSPITAL IN WEST JAVA INDONESIA 2012 -2015 728  
S. Dewi, **R.H. Malik** (Indonesia)
- 10:10 MICROHEMATURIA AND MILD PROTEINURIA IN A PREVIOUS HEALTHY YOUNG MAN 729  
**N. Lorenzo Villalba**, N. Sablon, Y. Parodis, M.B. Alonso, M. Kechida, Z. Cordoba, J.C. Rodriguez (Spain)
- 10:15 THE CLINICAL RELEVANCE OF ALPHA-1-ANTITRYPSIN PHENOTYPE IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS 730  
**M. Pervakova**, V. Emanuel, S. Lapin, O. Titova, I. Belyaeva, A. Chudinov, T. Blinova, O. Napalkova, T. Bulgakova (Russia)
- 10:20 A RARE CASE OF MICROSCOPIC POLYANGIITIS IN CHILDHOOD 731  
P. Miteva, D. Roussinov, T. Tzanova, S. Monov, **R. Shumnalieva** (Bulgaria)
- 10:25 GRANULOMATOSIS WITH POLYANGIITIS AND NEUROENDOCRINE INTESTINAL TUMOR: AN UNIQUE AND CHALLENGING COMBINATION 732  
A.I. Reis, **A. Watts Soares**, M. Lobo Antunes, C. Noronha, J. Espirito Santo, A. Grilo (Portugal)

10:00 - 10:30

Station 7

## EPD39: IL17 - WHY MIOSSEC IS RIGHT

- Chair: H. Kalim** (Indonesia) 733
- 10:00 IL-6/ IL-17A PRODUCTION CORRELATE WITH NO SYNTHASE 2 EXPRESSION DURING PRIMARY SJOGREN'S SYNDROME: THEIR INVOLVEMENT IN DISEASE IMMUNOPATHOGENESIS 734  
S. Benchabane, A. Boudjelida, R. Toumi, H. Belguendouz, P. Youinou, **C. Touil-Boukoffa** (Algeria)
- 10:05 ARE MESENCHYMAL STEM CELLS (MSCS) ABLE TO CONTROL PRO-INFLAMMATORY T CELLS? 735  
**G. Almanzar**, M. Riekert, J. Heim, K. Hofner, M. Schmalzing, H.P. Tony, N. Schutze, M. Prelog (Germany)
- 10:10 REDUCTION OF IL-1 $\beta$  AND IL-17 IN NICOTINE-TREATED PBMC OF MULTIPLE SCLEROSIS PATIENTS 736  
**E. Costantini**, M. Reale, C. D'Angelo, M. Di Nicola, A.M. Tata, M. Di Bari (Italy)
- 10:15 SERUM LEVEL OF INTERLEUKIN-17 (IL-17) AND TRANSFORMING GROWTH FACTOR- $\beta$  (TGF- $\beta$ ) ON GRAVES' DISEASE PATIENTS 737  
**E. Darwin**, D. Elvira (Indonesia)
- 10:20 CORRELATION OF IL-17 URINARY EXCRETION WITH ACTIVITY INDEX, CHRONICITY INDEX, AND DISEASE ACTIVITY IN LUPUS NEPHRITIS 738  
H. Kalim, **H. Kusworini**, A. Gunawan, M. Suyoso (Indonesia)
- 10:25 INTRATHECAL IL-17/IL-6 AXIS ACTIVATION IN ANTI-NMDA RECEPTOR ENCEPHALITIS 739  
J.I. Byun, S.T. Soon-Tae, K.H. Jung, J.S. Sunwoo, **J.A. Lim**, T.J. Kim, S.J. Ahn, K.I. Park, S.K. Lee, K. Chu (Republic of Korea)

10:00 - 10:30

Station 8

EPD40: **IVIG: THE BIOLOGIC OF PREFERENCE**Chair: **S. Dahan** (Israel)

740

10:00 EFFICACY OF HIGH DOSE INTRAVENOUS IMMUNOGLOBULINS IN A DIFFICULT CASE OF DERMATOMYOSITIS OVERLAPPING NECROTIZING AUTOIMMUNE MYOSITIS

741

C. Canofari, F. Sunzini, C. Barbato, G. Fonti, **P. Conigliaro**, A. Bergamini, R. Perricone (Italy)

10:05 THE EFFECT OF INTRAVENOUS IMMUNOGLOBULIN ON *EX VIVO* ACTIVATION OF HUMAN LEUKOCYTES

742

S. Gusev, **S. Dahan**, D. Ben-Ami Shor, M. Blank, Y. Shoenfeld (Israel)

10:10 INTRAVENOUS IMMUNOGLOBULIN AS MONOTHERAPY FOR MYASTHENIA GRAVIS DURING PREGNANCY

743

**J. Gamez**, M. Salvado, M. Casellas, S. Manrique, F. Castillo (Spain)

10:15 EFFICACY AND SAFETY OF I10, A NOVEL 10% INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA: AN OPEN-LABEL MULTICENTRE STUDY

744

A. Salama, M. Stulginskis, Y. Popovych, D. Woszczyk, B. Slama, M. Kappler, **A. Sadoun**, F. Rodeghiero (France)

10:20 OPTIMISING THE EFFECTOR FUNCTION BALANCE OF FC-MULTIMERS FOR TREATMENT OF AUTO-ANTIBODY MEDIATED DISEASE

745

**T. Rowley**, F. Fallah-Arani, D. Humphreys (United Kingdom)

10:30 - 12:30

Hall 1

## PARALLEL SESSION 37: SYSTEMIC LUPUS ERYTHEMATOSUS - THE CHALLENGE

	<b>Chair: S. Navarra</b> (Philippines)	746
	<b>Chair: Y. Naparstek</b> (Israel)	747
	<b>Chair: H. Young</b> (USA)	748
10:30	CASE STUDIES IN DIFFICULT LUPUS <b>S. Navarra</b> (Philippines)	749
10:50	TIME RELATED SYSTEM FOR GLOBAL VIEW OF SLE PATIENTS (TOAD) <b>C. Vasconcelos</b> (Portugal)	750
11:10	ANTI-PTX3 ANTIBODIES DELAY GLOMERULONEPHRITIS AND IMPROVE SURVIVAL IN NZB/NZW F1 MICE <b>M. Gatto</b> , A. Ghirardello, R. Luisetto, M. Beggio, N. Bassi, D. Del Prete, L. Iaccarino, A. Doria (Italy)	751
11:20	A META-ANALYSIS OF SERUM AND CEREBROSPINAL FLUID AUTOANTIBODIES IN NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS <b>R. Ho</b> , Y. Lu, C. Ho, M. Zhang (Singapore)	752
11:30	IMPAIRMENT OF GAS6/MERTK SYSTEM IN LUPUS NEPHRITIS <b>M. Bellan</b> , F. Goegan, S. Pagani, L. Salmi, L. Castello, G.C. Avanzi, M. Quaglia, P. Stratta, M. Pirisi, P.P. Sainaghi (Italy)	753
11:40	A META-ANALYSIS OF TACROLIMUS USE IN LUPUS NEPHRITIS J. Hannah, A. Casian, <b>D. D'Cruz</b> (United Kingdom)	754
11:50	OVERLAP SYNDROME BETWEEN FAMILIAL MEDITERRANEAN FEVER AND SYSTEMIC LUPUS ERYTHEMATOUS IN 12-YEARS OLD FEMALE PATIENT <b>A. Gagro</b> , V. Drkulec, J. Cepin-Bogovic, I. Skaric, K. Kondza, G. Roic, V. Herceg-Cavrak, A. Tesija Kuna, I. Vukasovic (Croatia)	755
12:00	DISCOVERY AND INITIAL VALIDATION OF AUTOANTIBODIES AGAINST THE MAJOR VAULT PROTEIN (MVP) IN SYSTEMIC LUPUS ERYTHEMATOSUS P. Budde, S. Vordenbäumen, H.D. Zucht, <b>P. Schulz-Knappe</b> , S. Matthias (Germany)	756
12:10	CHIKUNGUNYA FEVER PRESENTING AS A SYSTEMIC DISEASE WITH FEVER, ARTHRITIS AND RASH- OUR EXPERIENCE IN ISRAEL <b>A. Tanay</b> (Israel)	757
12:20	DISCUSSION	

12:30-14:00

Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

10:30 - 12:30

MP3 &amp; 4

## PARALLEL SESSION 38: INFECTION AND AUTOIMMUNITY - TWO EDGES OF THE SWORD

	<b>Chair: C. Lunardi</b> (Italy)	758
	<b>Chair: D. Bogdanos</b> (Greece)	759
	<b>Chair: M. Sticherling</b> (Germany)	760
10:30	EMERGING ISSUES: FROM MICROBIOME TO INFECTOME IN AUTOIMMUNITY <b>D. Bogdanos</b> (Greece)	761
10:50	AUTOIMMUNITY AND INFECTION IN COMMON VARIABLE IMMUNODEFICIENCY (CVID) <b>C. Lunardi</b> (Italy)	762
11:10	AUTOANTIGEN DISCOVERY IN PATIENTS WITH ANTIBIOTIC-REFRACTORY LYME ARTHRITIS <b>A. Steere</b> , J.T. Crowley, A. Pianta, K. Strle, Q. Wang, E.E. Drouin, C.E. Costello (USA)	763
11:20	EPSTEIN-BARR VIRUS INFECTION REACTIVATION AS A RISK FACTOR FOR THE DEVELOPMENT OF DRYNESS SYMPTOMS AND POTENTIAL FACTOR IN THE DEVELOPMENT OF PRIMARY SJOGREN'S SYNDROME <b>M. Maslinska</b> , B. Kwiatkowska (Poland)	764
11:30	EPSTEIN-BARR VIRUS INFECTION IN THE PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS <b>P. Sierzputowski</b> , J. Ruivo, P. Alcantara (Portugal)	765
11:40	UPSCALE RHEUMONOLOGY : FROM MICROBES TO MICROBIOME TO MICROTECHNOLOGIES : ENRICHING BEDSIDE P4 RHEUMATOLOGY <b>P. Pispati</b> (India)	766
11:50	A PROSPECTIVE STUDY OF DIRECT-ACTING ANTIVIRAL AGENTS FOR HEPATITIS C VIRUS-ASSOCIATED MIXED CRYOGLOBULINEMIA <b>M. Visentini</b> , S. Colantuono, M. Mitrevski, M. Del Padre, A. De Santis, M. Fiorilli, A. Pulsoni, M. Casato (Italy)	767
12:00	ARE ENDOGENOUS RETROVIRUSES IMPORTANT IN HUMAN AUTOIMMUNITY? <b>B.A. Nexø</b> , M.J. Laska (Denmark)	768

- 12:10 VIRAL NONSTRUCTURAL PROTEIN 1 (NS1) STIMULATES  
AUTOIMMUNITY BY DESTRUCTION OF SELF-TOLERANCE 769  
**K. Puttaraksa**, H. Pirttinen, R. Lagier, S. Naides, L. Gilbert (Finland)
- 12:20 EVIDENCE FOR AUTOIMMUNE ENCEPHALITIS IN PEDIATRIC  
AUTOIMMUNE NEUROPSYCHIATRIC DISORDER ASSOCIATED WITH  
STREPTOCOCCAL INFECTIONS (PANDAS) 770  
**S. Swedo** (USA)

12:30-14:00

Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING



10:30 - 12:30

Hall 2

## PARALLEL SESSION 39: HIGHLIGHTS IN DIAGNOSTICS

	<b>Chair: K. Conrad</b> (Germany)	771
	<b>Chair: M. Sowa</b> (Germany)	772
	<b>Chair: M. Mahler</b> (USA)	773
10:30	NEXT GENERATION AUTOANTIBODY DETECTION BY HIGHLY FLEXIBLE CYTOBEAD® TECHNOLOGY <b>M. Sowa</b> , R. Hiemann, J. Scholz, K. Grossmann, D. Reinhold, K. Conrad, D. Roggenbuck (Germany)	774
10:50	CELLULAR IMMUNE DIAGNOSTICS IN AUTOIMMUNITY <b>U. Sack</b> (Germany)	775
11:10	ANTI-PAD3 ANTIBODIES AS A PROMISING MARKER TO MEASURE JOINT DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS A. Seaman, E. Darrah, M. Infantino, M. Benucci, M. Manfredi, F. Meacci, <b>M. Mahler</b> (USA)	776
11:30	INCIDENCE OF AQP4-IGG SEROPOSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDERS IN THE NETHERLANDS: ONE IN A MILLION <b>D. Hamann</b> , E.D. Van Pelt-Gravesteijn, Y.Y.M. Wong, I.A. Ketelslegers, D.A.M. Siepman, R.Q. Hintzen (Netherlands)	777
11:40	DIFFERENTIAL DIAGNOSIS OF AUTOIMMUNE LIMBIC ENCEPHALITIS BY MULTIPARAMETRIC SEROLOGICAL TESTING S. Lederer, B. Teegen, L. Komorowski, J. Fraune, <b>K. Fechner</b> , W. Stöcker, C. Probst (Germany)	778
11:50	DO ANTI-SMOOTH MUSCLE ANTIBODIES PREDICT DEVELOPMENT OF AUTOIMMUNE HEPATITIS IN ASYMPTOMATIC INDIVIDUALS? - A RETROSPECTIVE COHORT REVIEW R. Healey, L. Corless, P. Gordins, <b>S. Holding</b> (United Kingdom)	779
12:00	THE SEROTAG® APPROACH: FROM DISCOVERY TO VALIDATED ASSAYS IN LESS THAN THREE YEARS. A CASE STUDY ON NOVEL SYSTEMIC SCLEROSIS AUTOANTIGENS <b>J. Schulte-Pelkum</b> , P. Budde, H.D. Zucht, D. Wirtz, P. Schulz-Knappe, N. Hunzelmann, B. Maurer, K. Conrad, M. Schneider (Germany)	780

- 12:10 GOODPASTURE'S SYNDROME: INDIRECT IMMUNOFLOURESCENCE AS AN ESSENTIAL TEST FOR THE DETECTION OF CIRCULATING ANTI-GLOMERULAR BASEMENT MEMBRANE ANTIBODIES 781  
**C. Dumestre-Perard**, A. Gauthier, G. Clavarino, P.L. Carron, D. Giovannini, S. Colliard, J.Y. Cesbron (France)
- 12:20 VERIFICATION OF CRYOGLOBULINS IN CRYOPRECIPITATES BY NEPHELOMETRY 782  
**I. Francova**, K. Maličková, M. Hindřoř (Czech Republic)

**12:30-14:00**

**Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

10:30 - 12:30

Hall 3

## PARALLEL SESSION 40: INNATE IMMUNITY AND NATURAL AUTOANTIBODIES (IVIG)

	<b>Chair: A. Issekutz</b> (Canada)	783
	<b>Chair: A. Zuercher</b> (Switzerland)	784
	<b>Chair: Z. Sthoeger</b> (Israel)	785
10:30	INTRODUCTION TO IVIG EFFECTS ON INNATE IMMUNE CELLS <b>S. Kaveri</b> (France)	786
10:40	POTENTIATION BY IVIG OF NK CELL PROLIFERATION IN RESPONSE TO CYTOKINES AND DURING T CELL ACTIVATION B. Derfalvi, D. Rowter, <b>A. Issekutz</b> , F. Kaesermann (Canada)	787
11:00	EXPERIENCE IN IVIG THERAPY FOR SELECTED WOMEN WITH RECURRENT REPRODUCTIVE FAILURE AND NK CELL EXPANSION <b>S. Sanchez-Ramon</b> (Spain)	788
11:20	IVIG MODULATION OF DENDRITIC CELL/APC FUNCTION AND/OR ON IL-33 RELATED CYTOKINE NETWORK <b>J. Kwekkeboom</b> (Netherlands)	789
11:40	USE OF IVIG FOR THE PREVENTION OF GVHD IN NSG MICE: THE ROLE OF NK CELLS <b>J. Gregoire-Gauthier</b> , F. Fontaine, L. Benchimol, M.M. Dieng, E. Haddad (Canada)	790
11:50	PERIPHERAL BLOOD AND SPLENIC NATURAL KILLER CELLS IN PRIMARY IMMUNE THROMBOCYTOPENIA: PHENOTYPE, FUNCTION AND EFFECT OF IVIG M. Ebbo, A. Grados, L. Benarous, S. Audonnet, M. Mahevas, B. Godeau, J.F. Viallard, C. Piperoglou, C. Cognet, C. Farnarier, J.R. Harlé, F. Vely, <b>N. Schleinitz</b> (France)	791
12:00	ALTERED B CELL HOMEOSTASIS AND TOLL-LIKE RECEPTOR 9-DRIVEN RESPONSE IN PATIENTS AFFECTED BY AUTOIMMUNE POLYGLANDULAR SYNDROME TYPE 1 (APECED) <b>A. Fierabracci</b> , V. Perri, R. Scarpa, M. Valenzise, E. Giancchetti, L. Lopergolo, M.M. Rosado, E. Giorda, A. Crinò, M. Cappa, S. Garelli, C. Betterle (Italy)	792

- 12:10 IL-37: THERAPEUTIC POTENTIAL OF A NATURAL INHIBITOR OF INNATE IMMUNITY DURING EXPERIMENTAL ARTHRITIS 793  
**M. Koenders**, L. Joosten, P. Van der Kraan, W. Van den Berg, C. Dinarello (Netherlands)
- 12:20 ANIMAL MODELS OF TYPE I INTERFERONOPATHIES 794  
**R. Behrendt**, K. Peschke, B. Hiller, T. Schumann, M. Achleitner, A. Hennig, M. Schulz, S. Biedermann, S.R. Ada, A. Gerbaulet, A. Roers (Germany)

**12:30-14:00**

**Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

10:30 - 12:30

Hall 4

## PARALLEL SESSION 41: UCTD, MCTD AND OTHER CONNECTIVE TISSUE DISEASES

	<b>Chair: M. Mosca</b> (Italy)	795
	<b>Chair: M. Olesinska</b> (Poland)	796
	<b>Chair: C. Belizna</b> (France)	797
10:30	PREDICTING, MONITORING AND PREVENTING: UNDIFFERENTIATED CONNECTIVE TISSUE DISEASES AND EARLY LUPUS <b>M. Mosca</b> (Italy)	798
10:50	PREDICTING, MONITORING AND PREVENTING - ACTIVITY AND DAMAGE IN MCTD <b>M. Olesinska</b> (Poland)	799
11:10	ASSESSMENT OF CYTOMEGALOVIRUS-SPECIFIC CELL-MEDIATED IMMUNITY FOR THE PREDICTION OF CYTOMEGALOVIRUS SPONTANEOUS CLEARANCE IN HIGH-RISK KIDNEY TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS VIREMIA <b>M. Lochouarn Andreani</b> , S. Benzaken, L. Albano, E. Cassuto, A. Jeribi, A. Caramella, V. Giordanengo, G. Bernard, V. Esnault, B. Seitz-Polski (France)	800
11:20	POST-STEROID NEUROPSYCHIATRIC MANIFESTATIONS ARE SIGNIFICANTLY MORE FREQUENT IN SLE COMPARED WITH OTHER AUTOIMMUNE DISEASES AND PREDICT BETTER PROGNOSIS COMPARED WITH DE NOVO NPSLE <b>S. Yasuda</b> , Y. Shimizu, M. Kanda, M. Kono, H. Nakamura, R. Hisada, K. Omura, S. Shiamura, H. Shida, M. Kato, K. Oku, T. Bohgaki, T. Horita, T. Atsumi (Japan)	801
11:30	FAST AND COMPLETE RESTORATION OF HAIR GROWTH BY SELECTIVE JAK1 INHIBITION IN THE C3H/HEJ MOUSE MODEL OF ALOPECIA AREATA <b>A. Astrand</b> , S. Jackson, G. Skogberg, L. Jinton, L. Oberg, N. Krutrök, A. Thorén, E. Samuelsson, A. Lundqvist, C. Wingren, K. Björhall, M. Ahlefeldt, H. Sanganee, M. Devalajara, M. Nilsson, P. Lyne (Sweden)	802
11:40	THE AUTOIMMUNE DISEASES OF THE EYES <b>F.A. De Andrade</b> (Brazil)	803

- 11:50 STAT6 DEFICIENCY AMELIORATES SEVERITY OF GRAVES' DISEASE BY SUPPRESSING THYROID EPITHELIUM HYPERPLASIA  
 DISEASE BY SUPPRESSING STAT6 DEFICIENCY AMELIORATES SEVERITY OF GRAVES' DISEASE BY SUPPRESSING THYROID EPITHELIUM HYPERPLASIA 804  
**L. Wang**, X. Jiang, Y. Chu (China)
- 12:00 THE AVIDITY OF PR3-ANCA IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS DURING FOLLOW-UP 805  
 M. Kemna, W. Schlumberger, P. Van Paassen, C. Dähnrich, J. Damoiseaux, **J.W. Cohen Tervaert** (Netherlands)
- 12:10 NEUTROPHIL-EXTRACELLULAR TRAPS CAUSE ANCA-INDUCED GLOMERULONEPHRITIS IN A COMPLEMENT DEPENDENT MANNER AND IS CONTROLLED BY THE NECROPTOSIS PATHWAY 806  
**A. Schreiber**, A. Linkermann, S. Krautwald, U. Jerke, R. Kettritz (Germany)
- 12:20 FREQUENCY OF GARDASIL-SPECIFIC MEMORY LYMPHOCYTES IS INCREASED IN PATIENTS WITH SELF-REPORTED HEALTH EFFECTS AFTER GARDASIL VACCINATION 807  
**V. Stejskal**, D. Downing, C. Plothe, K. Viborg (Sweden)

**12:30-14:00**

**Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

**10:30 - 12:30****Hall 5****PARALLEL SESSION 42: PREGNANCY AND AUTOIMMUNITY**

	<b>Chair: A. Tincani</b> (Italy)	808
	<b>Chair: P.L. Meroni</b> (Italy)	809
	<b>Chair: S. De Carolis</b> (Italy)	810
10:30	THE USE OF SYNTHETIC AND BIOLOGIC DMARDS IN PREGNANCY <b>R.A. Levy</b> , G.R.D. Jesús, N.R.D. Jesús, E.M. Klumb (Brazil)	811
10:50	IVIG AND RECURRENT AUTOIMMUNE PREGNANCY LOSS <b>H. Carp</b> (Israel)	812
11:10	MANAGEMENT OF PREGNANCY IN SLE AND APS <b>C. Dias</b> (Portugal)	813
11:30	THE ROLE OF COMPLEMENT IN THE PHYSIOLOGY AND PATHOLOGY OF THE REPRODUCTIVE SYSTEM <b>F. Tedesco</b> (Italy)	814
11:50	ANGIOGENIC FACTORS AND CLINICAL CHARACTERISTICS IN PREGNANT WOMEN WITH OBSTETRIC AND THROMBOTIC ANTIPHOSPHOLIPID SYNDROME <b>K. Mayer-Pickel</b> (Austria)	
12:10	SAFETY OF ANTI TNF- $\alpha$ AGENTS IN PATIENTS WITH CHRONIC ARTHRITIDES DURING PREGNANCY AND BREASTFEEDING: A CASE-CONTROL MONOCENTRIC STUDY <b>G. Mazza</b> , L. Andreoli, C. Bazzani, R. Reggia, M. Agosti, M. Filippini, R. Gorla, M. Taglietti, A. Lojacono, M. Motta, A. Tincani (Italy)	817

SATURDAY

**12:30-14:00****Exhibition**

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

14:00 - 16:00

Hall 1

## PARALLEL SESSION 43: ANA DIAGNOSTICS AND IMMUNOFLUORESCENCE

	<b>Chair: J. Damoiseaux</b> (Netherlands)	818
	<b>Chair: L.E. Coelho Andrade</b> (Brazil)	819
	<b>Chair: E. Chan</b> (USA)	820
14:00	AUTOANTIBODIES AS BIOMARKERS IN MYOSITIS <b>G. Pruijn</b> (Netherlands)	821
14:20	ANA AND ANCA DETECTION IN DAILY CLINICAL PRACTICE: EURO PATTERN VERSUS CONVENTIONAL MICROSCOPY <b>J. Damoiseaux</b> (Netherlands)	822
14:40	THE INCREDIBLE SUCCESS STORY OF IMMUNOFLUORESCENCE <b>W. Stoecker</b> (Germany)	823
15:00	COMBINED ANTINUCLEAR ANTIBODY AND ANTI-RO52 ANTIBODY ASSAYS IMPROVE THE SEROLOGICAL DIAGNOSIS OF IDIOPATHIC INFLAMMATORY MYOPATHIES <b>M. Infantino</b> , M. Manfredi, M. Francesca, V. Grossi, M. Benucci, G. Morozzi, E. Tonutti, M. Tampoaia, W. Meyer, A. Ott, N. Bizzaro (Italy)	824
15:10	THE MAJORITY OF PATIENTS NEGATIVE FOR ANA-IIFA AND POSITIVE FOR ANA-MULTIPLEX BECOME IIFA POSITIVE IN THREE YEARS <b>D. Perez</b> , J.A. Martínez-Flores, M. Serrano, O. Cabrera-Marante, M. Sevilla, E. Paz-Artal, J.M. Morales, A. Serrano (Spain)	825
15:20	FLUORESCENCE ENZYME IMMUNOASSAY IN THE DETECTION OF PARIETAL CELL AND INTRINSIC FACTOR AUTOANTIBODIES: WHAT'S NEW? G. Pesce, M. Bagnasco, <b>M.P. Panozzo</b> , D. Villalta, A. Antico, N. Bizzaro (Italy)	826
15:30	ANTI-CN-1A (MUP44, NT5C1A) IGG SEROLOGIC ASSAY FOR THE DIAGNOSIS OF SPORADIC INCLUSION BODY MYOSITIS (SIBM) E. Cho, G. Shen, D. Karayev, A.L. Metzger, R.I. Morris, <b>S.L. Kramp</b> , C. Dähnrich, W. Schlumberger (Germany)	827
15:40	THE CHOICE OF ANA AUTOMATED SCREENING: IMPACT AND BENEFIT <b>A. Melegari</b> , C. Bonaguri, A. Russo, C. Vezzosi, B. Venturelli, E. De Santis, T. Trenti (Italy)	828
15:50	COMPARISON OF THE CLINICAL UTILITY IN THE DETECTION OF ANTI-NUCLEAR ANTIBODIES BETWEEN THE ELIA CTD SCREEN AND INDIRECT IMMUNOFLUORESCENCE ON HEP-2 CELLS <b>C. Robier</b> , O. Amouzadeh-Ghadikolai, M. Stettin, G. Reichl (Austria)	829



12:30 - 14:00

MP3 &amp; 4

**Industry Supported Session:**

NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT

14:00 - 16:00

Hall 1

**PARALLEL SESSION 44: T-REG, B-REG, TOLERANCE AND AUTOIMMUNITY**

	<b>Chair: E. Toubi</b> (Israel)	830
	<b>Chair: D. D'Cruz</b> (United Kingdom)	831
	<b>Chair: J.E. Fonseca</b> (Portugal)	832
14:00	MOLECULAR MASCULINIZATION OF REGULATORY T CELLS <b>G.C. Tsokos</b> (USA)	833
14:20	FOXP3 HIGHIL-10 HIGH B REGULATORY CELLS IN SLE <b>E. Toubi</b> (Israel)	834
14:40	REGULATORY B LYMPHOCYTES IN ISOLATED HASHIMOTO THYROIDITIS (HT) AND/OR ASSOCIATED WITH CELIAC DISEASE (CD) I. Gatto, M.G. Santaguida, G. Mangino, C. Virili, G. Romeo, <b>M. Centanni</b> (Italy)	835
14:50	ROLE OF CD38 IN THE HUMAN CD4+CD25+FOXP3+CD127- PERIPHERAL T REGULATORY LYMPHOCYTES <b>M.A. Lara Salazar</b> , N.V. Méndez Huerta, L. Berrón Ruiz, H. Romero Ramírez, J.C. Rodriguez Alba (Mexico)	836
15:00	REDUCED FREQUENCIES AND ALTERED PHENOTYPES OF REGULATORY B CELLS IN PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS <b>D. Söderberg</b> , P. Eriksson, J. Ernerudh, M. Segelmark (Sweden)	837
15:10	GRANZYME B PRODUCING B-CELLS HAVE IMMUNOREGULATORY FUNCTION AND ARE DIMINISHED IN PATIENTS WITH ANCA-VASCULITIS <b>B. Wilde</b> , S. Dolf, A. Kribben, J. Zhu, J.W. Cohen Tervaert, O. Witzke (Germany)	838
15:20	REGULATORY CD19+CD24HIGHCD38HIGH B CELLS ARE SIGNIFICANTLY DEPLETED IN PATIENTS WITH ATHEROSCLEROSIS AND HAVE ALTERED INTERLEUKIN-10 PRODUCTION <b>I.E. Dumitriu</b> , P. Baruah, J.C. Kaski (United Kingdom)	839

## SCIENTIFIC PROGRAMME

- 15:30 THE ROLE OF T-REGULATOR EXPRESSION IN AUTOIMMUNE THYROID DISEASE AND ITS ASSOCIATION WITH THYROID ANTIBODY 840  
**D. Elvira** (Indonesia)
- 15:40 GLUCOCORTICOID HORMONE INFLUENCE IN VIVO DIFFERENTIATION AND ENHANCE IN VITRO EXPANSION OF FUNCTIONAL REGULATORY T CELLS 841  
**T. Berki**, E. Ugor, R. Pap, L. Prenek, F. Boldizsár, P. Németh (Hungary)
- 15:50 STUDY ON THE RELATIONSHIP BETWEEN REGULATORY B CELLS AND THE ACTIVITY OF RHEUMATOID ARTHRITIS 842  
**G. Wu** (China)

14:00 - 16:00

Hall 2

PARALLEL SESSION 45: **AUTOIMMUNITY AND ENDOCRINOLOGY**

- Chair: G. Kahaly** (Germany) 843
- Chair: A. Antonelli** (Italy) 844
- Chair: T. Davies** (USA) 845
- 14:00 THE ASSOCIATION OF OTHER AUTOIMMUNE DISEASES IN PATIENTS WITH THYROID AUTOIMMUNE DISORDERS 846  
**A. Antonelli**, S.M. Ferrari, D. Giuggioli, M. Colaci, C. Ferri, P. Fallahi (Italy)
- 14:20 TYPE 1 DIABETES AND MULTIPLE ENDOCRINE AUTOIMMUNE DISORDERS 847  
**G. Kahaly** (Germany)
- 14:40 AUTOIMMUNE THYROID DISEASES: FROM GENE MAPPING TO NOVEL DRUG TARGETS 848  
**Y. Tomer** (USA)
- 14:55 HOW SOME TSH RECEPTOR ANTIBODIES DICTATE THYROCYTE DEATH - IMPLICATIONS FOR AUTOIMMUNITY 849  
**T. Davies**, S. Morshed (USA)
- 15:10 CIRCULATING CXCL10 IS INCREASED IN NON-SEGMENTAL VITILIGO, IN PRESENCE OR ABSENCE OF AUTOIMMUNE THYROIDITIS 850  
**S.M. Ferrari**, P. Fallahi, G. Santaguida, C. Virili, I. Ruffilli, F. Ragusa, M. Centanni, A. Antonelli (Italy)
- 15:20 INCIDENCE OF THYROID DISORDERS IN MIXED CRYOGLOBULINEMIA: RESULTS FROM A LONGITUDINAL FOLLOW-UP 851  
**P. Fallahi**, S.M. Ferrari, I. Ruffilli, G. Elia, D. Giuggioli, M. Colaci, C. Ferri, A. Antonelli (Italy)
- 15:30 SERUM THYROID HORMONE AUTOANTIBODIES IN SUBJECTS WITH CHRONIC HEPATITIS C, AND WITH GRAVES' DISEASES OR HASHIMOTO'S THYROIDITIS 852  
**S. Benvenga**, R. Vita, M.R. Galletti, M. Mandolino, F. Di Bari, S.M. Ferrari, P. Fallahi, A. Antonelli (Italy)
- 15:40 TSH RECEPTOR A SUBUNIT IMMUNIZATION OF MICE LEADS TO A LONG-TERM MODEL OF GRAVES' ORBITOPATHY 853  
**M. Ungerer**, H.P. Holthoff, M. Lohse, G. Muench (Germany)
- 15:50 THE IMPORTANCE OF IMMUNOMODULATORY TREATMENT IN THYROID AUTOIMMUNITY REPRODUCTIVE FAILURE PATIENTS 854  
**G. Gabriela**, F. Leila, J. Gisela, G. Maria, M. Soledad, V. Gustavo, P. Sergio (Argentina)

14:00 - 16:00

Hall 3

## PARALLEL SESSION 46: NOVEL STUDIES IN AUTOIMMUNE DISEASES

	<b>Chair: J.W. Cohen Tervaert</b> (Netherlands)	855
	<b>Chair: B.S. Porat Katz</b> (Israel)	856
	<b>Chair: F. Tedesco</b> (Italy)	857
14:00	CANNABINOIDS AND AUTOIMMUNE DISEASES: A SYSTEMATIC REVIEW <b>V. Katchan</b> (Spain)	858
14:20	SOME LIKE IT HOT: SPICY FOOD (CAPSAICIN) AND AUTOIMMUNITY <b>S. Dahan</b> (Israel)	859
14:40	IRREGULAR ANTIBODIES IN NO HEMOLYTIC AUTOIMMUNE DISEASES ARE ABLE TO INDUCE ERYTHROCYTE LYSIS MEDIATED BY COMPLEMENT AND MACROPHAGES P.E. López-Díaz, M.D.R. Ruiz-Olivera, L.A. Hernández-Osorio, S.R. Aguilar-Ruiz, <b>H. Torres-aguilar</b> (Mexico)	860
14:50	PHOSPHATIDYLCHOLINE SUPPLEMENTATION ATTENUATES SIDE EFFECTS OF HUMAN PAPILLOMAVIRUS VACCINE IN MICE <b>M. Arango</b> , S. Kivity, L. Tomijenovic, M. Blank, Y. Shoenfeld (Israel)	861
15:00	BLOOD BRAIN BARRIER DISRUPTION BY LIPOPOLYSACCHARIDE IN MICE: A USEFUL APPROACH FOR EVALUATION OF NEUROPSYCHIATRIC-LUPUS. M.T. Arango, S. Goldman, Y. Mardor, Y. Shoenfeld, M. Blank, I. Cooper, <b>S. Kivity</b> (Israel)	862
15:10	BELIMUMAB IN PATIENTS WITH SLE AND PERSISTENT PROTEINURIA DESPITE THE STANDARD THERAPY <b>L. Friso</b> , L. Iaccarino, R. Reggio, S. Bettio, M. Frassi, M. Gatto, L. Andreoli, L. Nalotto, A. Zanola, A. Tincani, A. Doria (Italy)	863
15:20	TOLEROGENIC EFFECT OF ACTIVE VITAMIN D IN EXPERIMENTAL MODELS OF RHEUMATOID ARTHRITIS AND MULTIPLE SCLEROSIS <b>L.L. Ishikawa</b> , L.A. Mimura, T.F. Fraga-Silva, A. Missio, S.F. Zorzella-Pezavento, F. Chiuso-Minicucci, A. Sartori (Brazil)	864
15:30	DISTINCT DISTRIBUTION PATTERNS OF LARGE VESSEL VASCULITIS ASSESSED WITH 18F-FDG PET/CT: A CLUSTER AND PRINCIPAL COMPONENT ANALYSIS STUDY <b>A. Soriano</b> , G. Pazzola, L. Boiardi, F. Muratore, P. Macchioni, R. Aldigeri, M. Casali, A. Versari, C. Salvarani (Italy)	865

15:40 CHURG-STRAUSS SYNDROME: SILICONE IMPLANT OR SINGULAIR (OR  
COULD BE BOTH?)

866

**P. David**, A. Dagan, Y. Shoenfeld, J.W. Cohen Tervaert, M. Colaris,  
M. De Boer (Brazil)

15:50 DISCUSSION

14:00 - 16:00

Hall 4

PARALLEL SESSION 47: **EPSTEIN-BARR VIRUS  
DRIVEN INFLAMMATORY DISEASES: FROM PRIMARY  
IMMUNODEFICIENCIES TO AUTOIMMUNE DISEASES (NEDA  
SESSION)**

	<b>Chair: C. Vasconcelos</b> (Portugal)	867
	<b>Chair: B. Martins da Silva</b> (Portugal)	868
	<b>Chair: A. Marinho</b> (Portugal)	869
14:00	IMMUNOGENETIC PREDISPOSING FACTORS FOR CHRONIC EBV INFECTION - SESSION 1	870
	<b>B. Leal</b> (Portugal)	
14:20	IMMUNOGENETIC PREDISPOSING FACTORS FOR CHRONIC EBV INFECTION - SESSION 2	871
	<b>C. Carvalho</b> (Portugal)	
14:40	EBV CHRONIC INFECTION AND AUTOIMMUNITY: LESSON FROM A PRIMARY IMMUNODEFICIENCY - CASE 1	872
	<b>R. Costa</b> (Portugal)	
14:55	EBV CHRONIC INFECTION AND AUTOIMMUNITY: LESSON FROM LYMPHOHISTIOCYTOSIS - CASE 2	873
	<b>R. Alves</b> (Portugal)	
15:10	EBV CHRONIC INFECTION: CASE REPORTS DISCUSSION	874
	<b>A. Marinho</b> (Portugal)	
15:30	STEM CELL THERAPY FOR AUTOIMMUNE AND PRIMARY IMMUNODEFICIENCIES: STRATEGIES TO AVOID EBV	875
	<b>R. Handgretinger</b> (Germany)	
15:50	DISCUSSION	

14:00 - 16:00

Hall 5

PARALLEL SESSION 48: **PEARLS IN AUTOIMMUNITY: TOP CANDIDATES FOR THE MAI AWARD 2016**

	<b>Chair: A. Kuhn</b> (Germany)	876
	<b>Chair: Z. Tellier</b> (France)	877
	<b>Chair: D. Roccatello</b> (Italy)	878
14:00	VITAMIN D STATUS IS ASSOCIATED WITH IMPROVED CLINICAL AND IMMUNOLOGICAL OUTCOME IN RELAPSING REMITTING MULTIPLE SCLEROSIS <b>J. Smolders</b> , R. Hupperts, J. Damoiseaux (Netherlands)	879
14:15	MELATONIN CONTRIBUTES TO THE SEASONALITY OF MULTIPLE SCLEROSIS RELAPSES <b>M. Farez</b> (Argentina)	880
14:30	ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN AUTOANTIBODIES AS BIOMARKERS OF DEMYELINATING DISEASES IN HUMANS F. Tea, S. Ramanathan, T.K. Nguyen, V. Merheb, R.C. Dale, <b>F. Brilot</b> (Australia)	881
14:45	AUTOANTIBODIES TO COMPLEMENT FACTOR H IN PATIENTS WITH NEUROMYELITIS OPTICA B. Uzonyi, Z. Szabo, E. Trojnar, K. Uray, S. Hyvarinen, H.H. Nielsen, A. Erdei, T.S. Jokiranta, Z. Prohaszka, Z. Illes, <b>M. Jozsi</b> (Hungary)	882
15:00	THE NUCLEOLUS AND INACTIVE X CHROMOSOME NEXUS - A MECHANISM FOR CREATION OF AUTOANTIGENS <b>W. Brooks</b> , Y. Renaudineau (USA)	883
15:15	ENHANCED SENSITIVITY OF TREX1-DEFICIENT CELLS TO COLD AND UV-IRRADIATION PREDISPOSES TO AUTOIMMUNITY F. Schmidt, N. Berndt, N. Zimmermann, P. Knuschke, M.A. Lee-Kirsch, <b>C. Günther</b> (Germany)	884
15:30	EFFECT OF EXPERIMENTAL ANTIPHOSPHOLIPID SYNDROME ON WHITE MATTER, HIPPOCAMPUS DENTATE GYRUS CELL PROLIFERATION AND NEUROBLAST DIFFERENTIATION <b>K. Frauenknecht</b> , P. Leukel, R. Weiss, H.D. Von Pein, A. Katzav, J. Chapman, C.J. Sommer (Switzerland)	885

- 15:40 NEUROPEPTIDE Y AS REGULATOR OF MACROPHAGE PHENOTYPE AND FUNCTIONS: A NEUROIMMUNE CUE IN ATHEROSCLEROSIS REGRESSION?886  
**B. Buttari**, E. Profumo, R. Businaro, I.J. Elenkov, R. Riganò (Italy)
- 15:50 COGNITIVE DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 10 YEARS PROSPECTIVE COHORT STUDY 887  
**F. Ceccarelli**, C. Perricone, C. Pirone, L. Massaro, C. Alessandri, C. Mina, M. Marianetti, F.R. Spinelli, G. Valesini, F. Conti (Italy)



16:00-16:30

Exhibition

COFFEE BREAK &amp; EXHIBITION BREAK



16:00 - 16:30

Station 1

### EPD41: THYROID: AVENUES IN DISEASE DIAGNOSTICS

- Chair: U. Gul** (Turkey) 888
- 16:00 AUTOIMMUNE THYROID DISORDERS IN PATIENTS WITH PSORIASIS 889  
**U. Gul**, M. Gonul (Turkey)
- 16:05 ENHANCING EFFECT OF TOTAL IMMUNOGLOBULIN E LEVELS ON GRAVES' HYPERTHYROIDISM 890  
**I. Molnár**, S.V. Eva (Hungary)
- 16:10 THE CHARACTERISTIC OF AUTOIMMUNITY IN HASHIMOTO'S THYROIDITIS 891  
**P. Sobolevskaia**, Y. Stroev, V. Utekhin, L. Churilov, D. Baranov, A. Yakovenko (Russia)
- 16:15 A CLINICALLY PRACTICAL APPROACH FOR THE DIAGNOSIS AND TREATMENT OF HASHIMOTO'S ENCEPHALOPATHY 892  
**R. Tozzoli**, G. Montagna, M. Imperiali, P. Agazzi, F. D'Aurizio, U. Feldt-Rasmussen, L. Giovanella (Italy)
- 16:20 DETECTION OF ORGAN-SPECIFIC ANTI-THYROID AUTOANTIBODIES IN PATIENTS WITH NON-ORGAN-SPECIFIC AUTOIMMUNE DISEASES 893  
N. Zotos, M. Gianniki, E. Tatsina, D. Bougias, A. Papadopoulou, A. Fasouloglou, C. Mitsis, C. Briasoulis, E. Chrisostomou, A. Pournou, **N. Tsifetaki** (Greece)
- 16:25 APPLICATION OF RECOMBINANT PROTEINS IN THE ANALYSIS OF THE EPITOPES OF THYROID AUTOANTIGENS 894  
**A. Zubkov**, E. Shamkina, N. Kuzmina (Russia)

16:00 - 16:30

Station 2

## EPD42: CITRULLINATION: AN IMPORTANT FACTOR IN AUTOIMMUNE CONDITIONS

Chair: **C. Bentow** (USA) 895

- 16:00 ADDED VALUE OF IGA ISOTYPE FOR ANTI-CITRULLINATED PROTEIN ANTIBODIES IN THE DIAGNOSIS FOR RHEUMATOID ARTHRITIS 896  
**M. Mahler, C. Bentow, T. Webb, L. Cesana, P. Roux-Lombard, M. Nissen, C. Lamacchia, C. Gabay** (USA)
- 16:05 COMPARATIVE EVALUATION OF 3 ASSAYS FOR THE DETECTION OF ANTI-CCP ANTIBODIES 897  
**F. Coutant, S. Genebrier, K. Messaoudi, N. Fabien, B. Evrard, P. Rouzaire** (France)
- 16:10 CYCLIC CITRULLINATED PEPTIDES AS ACPA-NEUTRALIZERS IN RHEUMATOID ARTHRITIS 898  
**C. Eriksson, C. Fernandes-Cerqueira, S. Gunasekera, U. Göransson, P.J. Jakobsson** (Sweden)
- 16:15 HYPOXIA PROMOTES C5A-ASSOCIATED INFLAMMATION VIA MIR-342-3P 899  
**S. Liu, L. Song, L. Yi, X. Cao** (China)
- 16:20 EVALUATION OF ANTI-CITRULLINATED PROTEIN ANTIBODY ASSAY IN AN ITALIAN REFERENCE CENTER FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS 900  
**G. Morozzi, S. Manganelli, M.R. Bacarelli, G. Pucci, A. Simpatico, S. Cheleschi, M. Mahler, C. Bentow, C. Scapellato, M. Galeazzi** (Italy)
- 16:25 ANTI-MUTATED CITRULLINATED VIMENTIN ANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME: DIAGNOSTIC VALUE AND RELATIONSHIP WITH CLINICAL FEATURES 901  
**C. Perricone, C. Alessandri, N. Agmon Levin, F. Conti, E. Ortona, M. Pendolino, A. Capozzi, F. De Lunardo, R. Macini, S. Truglia, F.R. Spinelli, F. Ceccarelli, M. Sorice, Y. Shoenfeld, G. Valesini** (Italy)

16:00 - 16:30

Station 3

## EPD43: LIVER: A PIECE OF THE MOSAIC OF AUTOIMMUNITY

- Chair: **C. Bonaguri** (Italy) 902
- 16:00 EVOLUTION OF AUTOIMMUNE HUMORAL RESPONSE AND LIVER BIOCHEMISTRY PROFILE IN ASYMPTOMATIC INDIVIDUALS WITH ANTIMITOCHONDRIAL ANTIBODIES 903  
**D. Baldo**, A. Dellavance, M.L.G. Ferraz, L.E.C. Andrade (Brazil)
- 16:05 MULTICENTER ITALIAN STUDY ABOUT AN AUTOIMMUNE PROFILE TESTING FOR CLINICAL MANAGEMENT OF PRIMARY BILIARY CIRRHOSIS 904  
**C. Bonaguri**, A. Melegari, A. Russo, A. Picanza, M. Parmeggiani, L. Belloni, E. Savi, R. Buonocore, T. Trenti, R. Aloe, G. Lippi (Italy)
- 16:10 NEUROLOGICAL MANIFESTATIONS IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS 905  
**C. Kaliouli-Antonopoulou**, X. Koufomichali, O. Boulamatsi, S. Kokkoris, M. Agrogianni, A. Ioannidou, E. Pappa, C. Drakoulis (Greece)
- 16:15 EVALUATION OF A NEW TEST FOR THE DETECTION OF AMA-M2 ANTIBODIES 906  
A. Mendes, **I. Baptista-Fernandes**, A. Valente, J. Faro-viana (Portugal)
- 16:20 ANTIBODY-NEGATIVE AUTOIMMUNE HEPATITIS IN AN 11 YEAR OLD BOY 907  
**A. Sauerbrey**, K. Luecke, H. Kosmehl (Germany)

16:00 - 16:30

Station 4

## EPD44: ANA DIAGNOSTICS: THE ULTIMATE PROCEDURE

- Chair: **A. Radice** (Italy) 908
- 16:00 ANA SCREENING METHODS IN THE DIAGNOSIS OF CONNECTIVE TISSUE DISEASES: AN ITALIAN MULTICENTER STUDY 909  
 B. Trezzi, M. Lupetti, F. Pregnotato, M.O. Borghi, C. Alpini, S. Finazzi, F. Franceschini, R. Gerli, L. Giovannelli, A. Ghirardello, M.G. Giudizi, G. Morozzi, F. Pratesi, V. Riccieri, P. Sabatini, G. Sebastiani, M. Tonello, **A. Radice** (Italy)
- 16:05 THE DIAGNOSTIC PERFORMANCE OF AN AUTOMATED FLUORESCENCE ENZYME IMMUNOASSAY FOR ANTI-DSDNA ANTIBODIES IN A CLINICAL ROUTINE SETTING WITH RHEUMATOLOGIC OUTPATIENTS 910  
**B. Schlueter** (Germany)
- 16:10 NEW ALGORITHM FOR NEGATIVE/POSITIVE DISCRIMINATION OF ANTI-NUCLEAR ANTIBODIES DETECTION ON AUTOMATED FLUORESCENCE MICROSCOPE 911  
**V. Stojkovic**, L. Lutteri, E. Cavalier (Belgium)
- 16:15 DETECTION OF ANTINUCLEAR ANTIBODIES AND ANTI-DS DNA ANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS UNDER TREATMENT WITH ADALIMUMAB 912  
 N. Zotos, M. Gianniki, E. Tatsina, A. Papadopoulou, C. Georgiou, A. Fasouloglou, E. Mosheta, E. Chrisostomou, D. Bougias, A. Pournou, L. Papageorgiou, **N. Tsifetaki** (Greece)

16:00 - 16:30

Station 5

## EPD45: ADDITIONAL ASPECTS OF GASTROINTESTINAL AUTOIMMUNITY

- Chair: D. Bogdanos** (Greece) 913
- 16:00 MYCOBACTERIUM AVIUM INDUCED PARATUBERCULOSIS AND CROHN'S DISEASE SHARE COMMON ANTIBODY PROFILES 914  
**S. Rentouli**, C. Liaskos, G. Athanasios, M. Mytilinaiou, A. Koutsoumpas, C. Billinis, D. Bogdanos (Greece)
- 16:05 A PATIENT WITH AUTOIMMUNE HEPATITIS AND AUTOIMMUNE PANCREATITIS; A CASE REPORT OF AN UNCOMMON AUTOIMMUNE DISEASE ASSOCIATION IN PATIENT WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) 915  
**D. Dajcman**, N. Potocnik Dajcman (Slovenia)
- 16:10 DISTINCT ANTI-IFI16 AND ANTI-GP2 ANTIBODIES IN INFLAMMATORY BOWEL DISEASE AND THEIR VARIATION WITH INFLIXIMAB THERAPY 916  
**M. De Andrea**, V. Caneparo, L. Pastorelli, L.F. Pisani, B. Bruni, F. Prodam, D. Roggenbuck, M. Vecchi, S. Landolfo, M. Gariglio (Italy)
- 16:15 ANTI-SACCHAROMYCES CEREVISIAE ANTIBODIES IN PATIENTS WITH ANTI- $\beta$ 2 GLYCOPROTEIN I ANTIBODIES 917  
A. Mankai, S. Layouni, **M. Ghozzi**, I. Ghedira (Tunisia)
- 16:20 DIGESTIVE TRACT SARCOIDOSIS 918  
E. Ghrenassia, **A. Mekinian**, O. Fain (France)
- 16:25 THE ROLE OF IL-22 IN CHRONIC GUT INFLAMMATION INDUCED BY INFECTION WITH SALMONELLA ENTERICA 919  
**A. Seydel**, M. Hoffmann, H. Petruschke, U. Schwertassek, J. Lehmann (Germany)

16:00 - 16:30

Station 6

EPD46: **VASCULITIS: THE GREAT IMITATOR**

- Chair: S. Ohlsson** (Sweden) 920
- 16:00 GRANULOMATOSIS WITH POLYANGIITIS AND FACIAL PALSY: INSIGHT IN THE AUTOIMMUNE PATHOGENESIS 921  
G. Iannella, A. Greco, **G. Granata**, A. Manno, B. Pasquariello, D. Angeletti, D. Didona, G. Magliulo (Italy)
- 16:05 LONG TERM OUTCOME OF PATIENTS WITH LOW LEVEL OF CRYOGLOBULIN (< 0.05 G/L) 922  
**I. Marie** (France)
- 16:10 PROPYLTHIOURACIL ANCA ASSOCIATED VASCULITIS - INDUCED OR NOT? 923  
**R. Marques**, J. Rua, A.C. Lucas, C. Ferreira, J. Fortuna, A. Rodrigues (Portugal)
- 16:15 NEUTROPHILS FROM ANCA-ASSOCIATED VASCULITIS PATIENTS SHOW AN INCREASED CAPACITY TO ACTIVATE THE COMPLEMENT SYSTEM VIA THE ALTERNATIVE PATHWAY 924  
**S. Ohlsson**, L. Holm, L. Skattum, T. Hellmark (Sweden)
- 16:20 A CASE OF REFRACTORY TAKAYASU ARTERITIS AND PSORIATIC ARTHRITIS: ACHIEVING REMISSION WITH TNFA INHIBITOR (ADALIMUMAD)925  
F. Sunzini, L. Novelli, C. Barbato, C. Canofari, G.L. Fonti, **M.S. Chimenti**, R. Perricone (Italy)

16:00 - 16:30

Station 7

## EPD47: PERSONALIZED AND PRECISION TRENDS IN AUTOIMMUNITY

- Chair: B. Gundogdu** (Turkey) 926
- 16:00 LONG TERM SURVIVAL OF HALF DOSE ETANERCEPT: EXTENDED FOLLOW-UP OF A PROSPECTIVE CLINICAL STUDY 927  
**F. Ometto**, B. Raffener, C. Botsios, L. Friso, D. Astorri, L. Bernardi, L. Punzi, A. Doria (Italy)
- 16:05 THERAPEUTIC DRUG MONITORING OF USTEKINUMAB IN SERUM OF PSORIATIC PATIENTS: SENSE OR NONSENSE? 928  
 E. De Keyser, C. Busard, E. Coussens, **L. Grine**, E. Botti, L. Meuleman, M. Van De Kerckhove, H. Boonen, A. Stockman, A. Costanzo, J. Lambert, P. Spuls (Belgium)
- 16:10 NON-INTERVENTIONAL STUDY TO DESCRIBE THE SAFETY, TOLERABILITY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE AN INADEQUATE RESPONSE TO NON-BIOLOGIC DMARD 929  
**S. Aligrudic**, K. Kazic, N. Miketic, A. Bulatovic, D. Lutovac, N. Sjekloca, A. Kovacevic (Montenegro)
- 16:15 ABNORMAL B-CELL SUBSET DISTRIBUTION IN PATIENTS WITH POLYMYALGIA RHEUMATICA IS CORRECTED UNDER TOCILIZUMAB MONOTHERAPY 930  
**Y. Renaudineau**, G. Carvajal Alegria, D. Cornec, S. Jousse-Joulin, J.O. Pers, A. Sarau, V. Devauchelle-Pensec (France)
- 16:20 FACTORS ASSOCIATED WITH RESPONSE TO ABATACEPT IN RHEUMATOID ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW 931  
**J.C. Sarmiento-Monroy**, C. Villota-Eraso, R.D. Mantilla (Colombia)
- 16:25 REFRACTORY ADULT-ONSET STILL'S DISEASE SUCCESSFULLY TREATED WITH ETANERCEPT: A CASE REPORT 932  
**B. Gundogdu** (Turkey)

16:00 - 16:30

Station 8

## EPD48: THE SKIN AS THE MIRROR OF AUTOIMMUNITY

- Chair: R. Slezak** (Czech Republic) 933
- 16:00 A CASE OF GENERALIZED MORPHEA LOCATED ON INSTEP, MEDIAL AND LATERAL ANKLES IN A 9-YEAR OLD GIRL 934  
**G. Akhyar**, I. Isramiharti, A. Fadilla (Indonesia)
- 16:05 REDUCED SKIN BLISTERING IN EXPERIMENTAL EPIDERMOLYSIS BULLOSA ACQUISITA AFTER ANTI-TNF TREATMENT 935  
 K. Bieber, M. Hirose, **A. Kasprick**, U. Samavedam, J. Klöpfer, K. Kalies, D. Zillikens, R. Ludwig (Germany)
- 16:10 CARDIOVASCULAR RISK IN BEHÇET'S DISEASE- A CASUISTIC STUDY 936  
**M. Cunha**, M. Gonçalves, C. Cunha, G. Alves, S. Freitas, P. Cunha, J. Cotter (Portugal)
- 16:15 TREATMENT WITH STATIN REVERSES ALOPECIA AREATA IN THE MOUSE MODEL 937  
**J. Jimenez**, G. DelCanto, J. Cervantes, E. Darwin, E. Maranda, A. Lens, T. Wikramanayake, L. Schachner (USA)
- 16:20 CLINICAL FACTORS AFFECTING THE EFFECTIVENESS OF THE THERAPY OF PEMPHIGUS VULGARIS - A RETROSPECTIVE STUDY 938  
**R. Slezak**, O. Kopecky, V. Radochova, I. Drizhal (Czech Republic)



16:30 - 18:30

Hall 1

## PARALLEL SESSION 49: NEW THERAPEUTIC AVENUES IN AUTOIMMUNE DISEASES

- Chair: M. Galeazzi** (Italy) 939
- Chair: G. Pruijn** (Netherlands) 940
- Chair: D. Naor** (Israel) 941
- 16:30 DEFINITE RESULTS OF THE THERAPY WITH DEKAVIL IN RHEUMATOID ARTHRITIS 942  
**M. Galeazzi** (Italy)
- 16:50 IS THE SPECIFIC DEPLETION OF AUTOANTIBODY-SECRETING PLASMA CELLS A REALISTIC THERAPEUTIC APPROACH? 943  
**F. Hiepe** (Germany)
- 17:10 NOVEL THERAPEUTIC TARGETS IN AUTOIMMUNITY - TGF-BETA3 AS A NOVEL TARGET OF IMMUNOTHERAPY 944  
**K. Yamamoto** (Japan)
- 17:30 ANTI-INFLAMMATORY REGENERATIVE ACTIVITY OF A CD44-DERIVED PEPTIDE 945  
**D. Naor**, L. Eshkar Sebban, K.O. Amar, S. Cohen (Israel)
- 17:50 COMPARATIVE EFFECTIVENESS OF IMMUNE-CELL DEPLETION AND A TARGETED THERAPY AGAINST LT LTBR-SIGNALING IN THE TREATMENT OF AUTOIMMUNE PANCREATITIS 946  
**G.M. Seleznik**, R. Theresia, S. Sabrina, S. Stephan, B. Jeffrey, H. Mathias, G. Rolf (Switzerland)
- 18:05 SM101, A NOVEL RECOMBINANT, SOLUBLE, HUMAN FCGIIB RECEPTOR, IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY 947  
**S. Tillmanns**, C. Kolligs, D. D'Cruz, A. Doria, E. Hachulla, R. Voll, M. Tansey (Germany)
- 18:20 LONG TERM USE OF HYDROXYCHLOROQUINE REDUCES ANTIPHOSPHOLIPID ANTIBODIES TITRES IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME 948  
**E. Nuri**, M. Taraborelli, L. Andreoli, M. Gerosa, L. Argolini, P.L. Meroni, A. Tincani (Italy)

16:30 - 18:30

MP3 &amp; 4

## PARALLEL SESSION 50: ANTIPHOSPHOLIPID SYNDROME (APS) - DIAGNOSTICS AND CHALLENGES FOR THE FUTURE

	<b>Chair: S.R. Binder</b> (USA)	949
	<b>Chair: T. Koike</b> (Japan)	950
	<b>Chair: V. Pengo</b> (Italy)	951
16:30	INTRODUCTION <b>V. Pengo</b> (Italy)	952
16:40	COMPLEMENT AND THROMBOSIS IN THE ANTIPHOSPHOLIPID SYNDROME <b>T. Atsumi</b> (Japan)	953
17:00	CIGARETTE SMOKING AND ANTI-PHOSPHOLIPID ANTIBODIES - WHAT IS THE CONNECTION? <b>S.R. Binder</b> (USA)	954
17:20	ANTI-BETA2GPI ANTIBODIES: IS THE DOMAIN SPECIFICITY REALLY IMPORTANT? <b>P.L. Meroni</b> (Italy)	955
17:40	IMMUNOMODULATION OF EXPERIMENTAL APS WITH DOMAIN 1 OF B2GPI <b>M. Blank</b> (Israel)	956
17:50	ANTIPHOSPHOLIPID ANTIBODY-MEDIATED INCREASE OF TISSUE FACTOR IN ARTERIAL WALL IS RELATED TO INCREASED THROMBUS SIZE IN A MOUSE MODEL <b>R. Willis</b> , P. Grant, Z. Romay-Penabad, E. Papalardo, M. Jamaluddin, R. Rudrangji, E.B. Gonzalez, A.R. Brasier (USA)	957
18:00	THE EFFICACY OF HYDROXYCHLOROQUINE FOR OBSTETRICAL OUTCOME IN ANTI-PHOSPHOLIPID SYNDROME: DATA FROM A EUROPEAN MULTICENTER RETROSPECTIVE STUDY <b>A. Mekinian</b> , M.G. Lazzaroni, J. Aliojotas reig, A. Kuzenko, A. Ruffatti, P. Levy, V. Canti, K. Bremme, B. Holy, T. Bertero, R. Dhote, F. Maurier, L. Andreoli, L. Carbillon, P. Nicaise Roland, A. Tincani, O. Fain (France)	958
18:10	MOLECULAR MAPPING OF THROMBIN/B 2GLYCOPROTEIN-I(B2GPI) INTERACTION REVEALS THE MECHANISM OF B2GPI ANTICOAGULANT FUNCTIONS: IMPLICATIONS IN THE PATHOGENESIS OF APS <b>V. De Filippis</b> , D. Peterle, S. Tescari, N. Pozzi, A. Banzato, V. Pengo, R. De Cristofaro, L. Acquasaliente (Italy)	959
18:20	THE ROLE OF MICROBIOTA IN THE PATHOGENESIS OF ANTIPHOSPHOLIPID SYNDROME <b>M. Versini</b> , P.Y. Jeandel, T. Piche, E. Rosenthal (France)	960

16:30 - 18:30

Hall 2

PARALLEL SESSION 51: **AUTOIMMUNE SYNDROME INDUCED BY ADJUVANTS (ASIA - SHOENFELD'S SYNDROME)**

- Chair: L.J. Jara Quezada** (Mexico) 961
- Chair: L. Andreoli** (Italy) 962
- Chair: J. Alijotas-Reig** (Spain) 963
- 16:30 SEVERE MANIFESTATIONS OF AUTOIMMUNE SYNDROME INDUCED BY ADJUVANTS (ASIA) 964  
**L.J. Jara Quezada**, G. Garcia-Collinot, G. Medina, M.D.P. Cruz-Dominguez, R.A. Carranza-Muleiro, O.L. Vera-Lastra, M.A. Saavedra (Mexico)
- 16:45 THE ROLE OF VITAMIN D IN ASIA SYNDROME 965  
**J.W. Cohen Tervaert** (Netherlands)
- 17:00 AUTOINFLAMMATORY/ AUTOIMMUNE SYNDROME INDUCED BY ADJUVANTS (ASIA) RELATED TO SILICONE AND NON-SILICONE BIOIMPLANTS. ANALYSIS OF A LARGE SPANISH COHORT 966  
**J. Alijotas-Reig**, E. Esteve-Valverde (Spain)
- 17:15 ARE THE AUTOIMMUNE/INFLAMMATORY SYNDROME INDUCED BY ADJUVANTS (ASIA) AND THE UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE (UCTD) RELATED TO EACH OTHER? A CASE-CONTROL STUDY OF ENVIRONMENTAL EXPOSURES 967  
**F. Scanzi**, L. Andreoli, M. Martinelli, M. Taraborelli, I. Cavazzana, N. Carabellese, R. Ottaviani, F. Allegri, F. Franceschini, N. Agmon-Levin, Y. Shoenfeld, A. Tincani (Italy)
- 17:30 EXPLANTATION OF SILICONE BREAST IMPLANTS AS A TREATMENT OF ASIA DUE TO SILICONE IMPLANT INCOMPATIBILITY SYNDROME (SIIS): AN OUTCOME ANALYSIS 968  
**M. De Boer**, M.J. Colaris, R. Van der Hulst, J.W. Cohen Tervaert (Netherlands)
- 17:40 NEW INSIGHTS IN OVINE ASIA SYNDROME: CLINICOPATHOLOGICAL CHANGES IN EXPERIMENTALLY INDUCED ANIMALS 969  
**L. Luján** (Spain)
- 17:50 ANIMAL MODELS OF ADJUVANT AND VACCINE-INDUCED AUTOIMMUNE DISEASES 970  
**J. Torres-Ruiz**, Y. Shoenfeld, M. Blank (Mexico)

## SCIENTIFIC PROGRAMME

- 18:00 GELBLEED AND RUPTURE OF SILICONE BREASTIMPLANTS INVESTIGATED BY LIGHT-, ELECTRONMICROSCOPY AND ENERGY DISPERSIVE X-RAY ANALYSIS OF INTERNAL ORGANS AND NERVOUS TISSUE IN A DECEASED WOMAN 971  
**R. Kappel**, L. Boer, H. Dijkman (Netherlands)
- 18:10 PHOSPHATIDYLCHOLINE ALLEVIATES ASIA; AUDIT AND CASE STUDIES 972  
**D. Downing**, P. Kane, V. Stejskal (United Kingdom)
- 18:20 PHOSPHORYLCHOLINE - A MIRACULOUS COMPOUND IN IMMUNOLOGY AND AUTOIMMUNITY 973  
**J. Omersel**, Y. Shoenfeld (Slovenia)

16:30 - 18:30

Hall 3

## PARALLEL SESSION 52: THE AUTOIMMUNE ASPECTS OF PSORIASIS, MYOSITIS AND ATHEROSCLEROSIS

	<b>Chair: Z. Szekanecz</b> (Hungary)	974
	<b>Chair: G. Valesini</b> (Italy)	975
	<b>Chair: S. Kaveri</b> (France)	976
16:30	GENETICS OF INFLAMMATORY ATHEROSCLEROSIS S. Poliska, E. Végh, M. Csumita, A. Pusztai, G. Kerekes, G. Szücs, S. Szántó, G. Zahuczky, L. Nagy, <b>Z. Szekanecz</b> (Hungary)	977
16:50	PSORIASIS AND AUTOIMMUNITY <b>M. Sticherling</b> (Germany)	978
17:10	THE CLINICAL UTILITY OF ANTI-HMGCR ANTIBODIES IN IMMUNE MEDIATED NECROTIZING MYOPATHY FOLLOWING STATIN EXPOSURE O. Shovman, <b>B. Gilburd</b> , C. Chayat, C. Bentow, M. Mahler, Y. Shoenfeld (Israel)	979
17:25	SERUM HMW ADIPONECTIN, RBP-4, VISFATIN, APELIN AND HMGB1 LEVELS IN MILD PSORIATIC PATIENTS M. Auriemma, A. Capo, <b>E. Costantini</b> , C. D'Angelo, P. Amerio, M. Reale (Italy)	980
17:40	OSMOREGULATORY PATHWAYS ARE ACTIVATED IN POLYMYOSITIS: INCREASED EXPRESSION OF OSMOLYTE ACCUMULATORS IN MUSCLE FIBERS AND IMMUNE CELLS <b>B. De Paepe</b> , J. Ronnelid, S. Jens, J. De Bleecker (Belgium)	981
17:50	IMPACT OF B1-ADRENERGIC RECEPTOR POLYMORPHISMS ON THE INTERACTION WITH AGONISTIC AUTOANTIBODIES IN DILATED CARDIOMYOPATHY <b>F. Boege</b> , B. Bornholz (Germany)	982
18:00	HIGH SENSITIVITY C-REACTIVE PROTEIN AS AN INDEPENDENT RISK FACTOR COMPARED TO TO CLASSIC CARDIOVASCULAR RISK FACTORS IN ACUTE MYOCARDIAL INFARCTION <b>E.F. Elfi</b> , P. Mayorita (Indonesia)	983

- 18:10 ANTI-TNF-ALPHA DRUGS DIFFERENTLY AFFECT TNF-ALPHA/STNF-R SYSTEM AND MONOCYTE SUBSETS IN PATIENTS WITH PSORIASIS 984  
**A. Cossarizza**, L. Gibellini, S. De Biasi, E. Bianchini, R. Bartolomeo, A. Fabiano, M. Manfredini, F. Ferrari, G. Albertini, T. Trenti, G. Carnevale, M. Nasi, M. Pinti, G. Pellacani (Italy)
- 18:20 THE ROLE OF VITAMIN D IN AUTOIMMUNITY RELATED ATHEROSCLEROSIS AND HEART DISEASE 985  
**S. Sokolovic**, R. Alimanovic-Alagic, L. Dzananovic (Bosnia and Herzegovina)

16:30 - 18:30

Hall 4

## PARALLEL SESSION 53: THE AUTOIMMUNE SIDE OF INFLAMMATORY ARTHRITIS AND AUTOINFLAMMATION

- Chair: R. Perricone** (Italy) 986
- Chair: A. Doria** (Italy) 987
- Chair: Y. Levo** (Israel) 988
- 16:30 AUTOANTIBODIES IN INFLAMMATORY ARTHRITIS 989  
**R. Perricone** (Italy)
- 16:50 A LIPOSOMAL STEROID NANO-DRUG: A NEW APPROACH FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES 990  
**Y. Naparstek** (Israel)
- 17:05 AUTOANTIBODY PROFILE OF ADULT PATIENTS WITH CHILDHOOD ONSET TYPE 2 AUTOIMMUNE HEPATITIS 991  
M. Woynarowski, M. Wozniak, B. Cukrowska, A. Wierbicka, **S.D. Lytton** (Germany)
- 17:20 TOLL-LIKE RECEPTOR 2 IS OVER EXPRESSED IN FAMILIAL MEDITERRANEAN FEVER PATIENTS AND IS INHIBITED BY TREATMENT WITH COLCHICINE 992  
**I. Ben Zvi**, V. Hornung, A. Livneh, H. Ben-David (Israel)
- 17:30 NEUROSYPHILIS: FROM INFECTION TO AUTOINFLAMMATION? ROLE OF REGULATORY T CELLS 993  
**S. Javor**, A. Parodi, G. Ciccarese, F. Drago (Italy)
- 17:40 ASSOCIATIONS BETWEEN ICAM-1 GENE POLYMORPHISMS AND THE FIRST STAGE OF CKD WITH DAMP-HEAT CONSTITUTION 994  
**W. Fangning**, F. Liuchang, L. Xiaojun, C. Zhitan, Z. Shanshan, F. Huanjian, Z. Xiaofeng (China)
- 17:50 IDENTIFICATION OF CARBAMYLATED ALPHA-1-ANTI-TRYPSIN AS AN ANTIGENIC TARGET OF ANTI-CARBAMYLATED PROTEIN ANTIBODIES IN RHEUMATOID ARTHRITIS PATIENTS 995  
**M.K. Verheul**, A. Yee, A. Seaman, G. Janssen, A. De Ru, R. Cordfunke, J.W. Drijfhout, P. Van Veelen, R. Toes, M. Mahler, L. Trouw (Netherlands)
- 18:00 IN DEPTH IMMUNOPHENOTYPIC ANALYSIS IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) I: A CROSSECTIONAL STUDY 996  
**E. Quesada-Masachs**, D. Alvarez-de la Sierra, M. Garcia Prat, V. Bittermann, A. Marin Sanchez, C. Modesto Caballero, M. Martinez Gallo (Spain)

## SCIENTIFIC PROGRAMME

- 18:10 SERUM MATRIX METALLOPROTEINASE 3 ELEVATED FROM NORMAL  
PREDICTING FLARE IN PATIENTS WITH RHEUMATOID ARTHRITIS 997  
J. Ma, J. Lin, D. Zheng, Y. Mo, L. Chen, **L. Dai** (China)
- 18:20 A NOVEL NFAT5 INHIBITOR FOR SUPPRESSION OF CHRONIC ARTHRITIS 998  
Y.J. Park, H. Eun-Jin, L. Naeun, C. Chul-Soo, **K. Wan-Uk** (Republic of  
Korea)



16:30 - 18:30

Hall 5

PARALLEL SESSION 54: **CYTOKINES AND AUTOIMMUNITY**

	<b>Chair: T. Avcin</b> (Slovenia)	999
	<b>Chair: M. Lee-Kirsch</b> (Germany)	1000
	<b>Chair: R. Gerli</b> (Italy)	1001
16:30	SYSTEMIC EFFECTS OF IL-17 <b>P. Miossec</b> (France)	1002
16:50	TYPE I INTERFERONOPATHIES - AN EXPANDING SPECTRUM OF IMMUNE DYSREGULATION <b>M. Lee-Kirsch</b> (Germany)	1003
17:10	THE ROLE OF STAT SIGNALLING PATHWAYS IN THE PATHOGENESIS OF SLE <b>T. Avcin</b> (Slovenia)	1004
17:30	IL-17A GOVERNS TISSUE DESTRUCTION IN BULLOUS PEMPHIGOID <b>L. Chakievska</b> , S. Roy, S. Goletz, C. Hölscher, D. Zillikens, E. Schmidt, F. Schulze (Germany)	1005
17:40	GM-CSF IS THE MAJOR INFLAMMATORY CYTOKINE DRIVING EAE PATHOGENESIS AND IS REGULATED BY MICRO-RNA 223 (MIR-223) <b>S. Miller</b> , I. Ifergan, T. Davidson, C. Jones, M. Sleeman (USA)	1006
17:50	THE TWO FACES OF IL-22: MORE THAN A PATHOGENIC CYTOKINE IN EXPERIMENTAL ARTHRITIS D. Roeleveld, F. Apparailly, L. Parga, F. Van de Loo, C. Jorgensen, <b>M. Koenders</b> (Netherlands)	1007
18:00	TARGETED THERAPY OF AUTOIMMUNE ARTHRITIS USING IL-27, A NEW MEMBER OF THE IL-12 FAMILY <b>K. Moudgil</b> , R. Meka, S. Venkatesha, B. Acharya, E. Ruoslahti (USA)	1008
18:10	SIGNIFICANCE OF INTERLEUKIN-6/STAT PATHWAY FOR THE GENE EXPRESSION OF REG I ALPHA, A NEW AUTO-ANTIGEN IN SJOGREN'S SYNDROME PATIENTS, IN SALIVARY DUCT EPITHELIAL CELLS <b>T. Fujimura</b> , T. Fujimoto, A. Itaya-Hironaka, T. Miyaoka, K. Yoshimoto, S. Sakuramoto-Tsuchida, A. Yamauchi, M. Takeda, H. Tsujinaka, Y. Tanaka, S. Takasawa (Japan)	1009
18:20	ACTIVE IMMUNIZATION AGAINST IL-17A COULD PREVENT THE PROGRESSIVITY OF AUTOANTIBODY PRODUCTION IN PRISTANE INDUCED LUPUS MICE MODEL H. Kalim, <b>K. Handono</b> , D. Hasanah, M. Zaka Pratama (Indonesia)	1010



WEDNESDAY

THURSDAY

FRIDAY

SATURDAY

SUNDAY


INDEX

ACKNOWLEDGEMENTS



# SCIENTIFIC PROGRAM

## SUNDAY, APRIL 10, 2016



# 10<sup>TH</sup>

INTERNATIONAL CONGRESS  
ON **AUTOIMMUNITY**

APRIL 6-10, 2016, LEIPZIG, GERMANY

# Journal of Autoimmunity



Co-Editors-in-Chief

**M.E. Gershwin • Y. Shoenfeld**



2014 Impact Factor\*

**8.410**

\*Journal Citation Reports  
published by  
Thomson Reuters 2015

Supports  
Open Access



For the full aims & scope, visit:

[journals.elsevier.com/journal-of-autoimmunity](http://journals.elsevier.com/journal-of-autoimmunity)

# SUNDAY, APRIL 10, 2016

## 8:00 - 10:00

## MP3 & 4

### PLENARY SESSION 4

	<b>Chair: J. Kalden</b> (Germany)	1011
	<b>Chair: S. Navarra</b> (Philippines)	1012
	<b>Chair: R. Perricone</b> (Italy)	1013
8:00	BIOLOGIC VS. CLINICAL TARGETS IN SLE MANAGEMENT <b>A. Doria</b> (Italy)	1014
8:30	SILICONE AND AUTOIMMUNITY <b>J.W. Cohen Tervaert</b> (Netherlands)	1015
9:00	AUTOIMMUNE ATHEROSCLEROSIS IN 3D: HOW IT DEVELOPS, HOW TO DIAGNOSE AND WHAT TO DO <b>Z. Szekanecz</b> (Hungary)	1016
9:30	TARGETING B CELLS IN AUTOIMMUNE DISEASES <b>T. Dörner</b> (Germany)	1017

## 10:00-10:30

## Foyer Area Level 1

COFFEE BREAK



SUNDAY

10:30 - 12:30

MP3 &amp; 4

PARALLEL SESSION 55: **SJOGREN'S SYNDROME**

	<b>Chair: S. Naguwa</b> (USA)	1018
	<b>Chair: A. Tzioufas</b> (Greece)	1019
	<b>Chair: J. Pers</b> (France)	1020
10:30	CLINICAL COMPLICATIONS IN PRIMARY SJOGREN'S SYNDROME <b>R. Gerli</b> (Italy)	1021
10:50	CUTTING EDGE RX IN SJOGREN'S SYNDROME <b>S. Naguwa</b> (USA)	1022
11:10	THERAPY OF SJOGREN'S SYNDROME: CURRENT KNOWLEDGE AND FUTURE PROSPECTS <b>A. Tzioufas</b> (Greece)	1023
11:30	THE ROLE OF SPECKLE TRACKING ECHOCARDIOGRAPHY TO DETECT EARLY MYOCARDIAL ALTERATION IN PRIMARY SJOGREN SYNDROME <b>L. Gianturco</b> , F. Atzeni, P. Sarzi Puttini, M. Turiel (Italy)	1024
11:45	ASSOCIATION BETWEEN SJOGREN SYNDROME, FIBROMYALGIA, AND ORGAN SPECIFIC NOVEL AUTOANTIBODIES <b>A. Lichtbroun</b> (USA)	1025
12:00	HYPOTHYROIDISM AMONG SLE PATIENTS: A CASE-CONTROL STUDY <b>A. Watad</b> (Israel)	1026
12:10	NEUROLOGICAL INVOLVEMENT AS THE INITIAL MANIFESTATION IN PRIMARY SJOGREN'S SYNDROME M. Polo-Trujillo, J.C. Naranjo, J.P. Suso, A. Echeverri, <b>G. Tobón</b> (Colombia)	1027
12:20	DISCUSSION	

10:30 - 12:30

Hall 2

PARALLEL SESSION 56: **IMMUNOMANIPULATION**

	<b>Chair: G. Wick</b> (Austria)	1028
	<b>Chair: C. Belizna</b> (France)	1029
	<b>Chair: P. Cherin</b> (France)	1030
10:30	HYDROXYCHLOROQUINE IN ANTIPHOSPHOLIPID SYNDROME <b>C. Belizna</b> (France)	1031
10:50	MYOPATHY AND NEUROPATHY EXPERIENCE FOR IMMUNOGLOBULINS <b>P. Cherin</b> (France)	1032
11:10	ORAL TOLERIZATION AGAINST MYCOBACTERIAL HSP65 FOR PREVENTION OF ATHEROSCLEROSIS - DEFINITION OF ATHEROGENIC PEPTIDES <b>G. Wick</b> (Austria)	1033
11:30	THE IMPACT OF CONVENTIONAL AND BIOLOGICAL DMARDS ON BONE BIOLOGY <b>J.E. Fonseca</b> (Portugal)	1034
11:45	NOVEL APPROACHES FOR IMMUNOTHERAPY IN MS AND RELATED AUTOIMMUNE NEUROLOGICAL DISEASES <b>D. Karussis</b> (Israel)	1035
12:00	USE OF LONG TERM SUBSCUTANEOUS IMMUNOGLOBULINS IN INFLAMMATORY MYOPATHIES : A RETROSPECTIVE ANALYSIS OF 19 PATIENTS <b>P. Cherin</b> , B. Cristina, O. Cartry, G. Lascu-Dubos, C. De Jaeger, J.C. Crave, J.C. Delain, E. Hachulla (France)	1036
12:10	PROTEIN AND RNA-IMMUNOPRECIPITATION FOR THE IDENTIFICATION OF RARE AUTOANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES <b>N. Isailovic</b> , A. Ceribelli, E. Generali, M. De Santis, M. Massarotti, M. Satoh, C. Selmi (Italy)	1037
12:20	SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN A WOMEN WITH ABORTION AND MULTIPLE SCLEROSIS <b>J.A. Carbone Campoverde</b> , E. Sarmiento, E. Fernandez-Cruz (Spain)	1038

10:30 - 12:30

Hall 3

## PARALLEL SESSION 57: THE AUTOIMMUNE ORIGIN OF CELIAC AND GASTROINTESTINAL DISEASES

- Chair: N. Bizzaro** (Italy) 1039
- Chair: N. Gallo** (Italy) 1040
- Chair: E. Capoluongo** (Italy) 1041
- 10:30 ANTI-TRANSGLUTAMINASE ANTIBODIES BY CLIA: PERFORMANCE CHARACTERISTICS AND HARMONIZATION 1042  
**N. Gallo** (Italy)
- 10:50 LABORATORY TESTING IN CELIAC DISEASE: NAVIGATING BETWEEN QUALITY AND EFFICIENCY 1043  
**E. Capoluongo** (Italy)
- 11:10 HLA-DQ GENOTYPING COMBINED WITH SEROLOGICAL MARKERS FOR THE DIAGNOSIS OF COELIAC DISEASE 1044  
**M.J. Sousa**, R. Ribeiro, M. Albuquerque, J.G. Sousa, M.F. Menezes, G. Sousa (Portugal)
- 11:20 GASTROINTESTINAL AUTOIMMUNITY AND UNEXPLAINED INFERTILITY 1045  
**G. Gabriela**, M. Soledad, J. Gisela, V. Gustavo, F. Leila, P. Agustin (Argentina)
- 11:30 FECAL CALPROTECTIN IN SYSTEMIC SCLEROSIS 1046  
**I. Marie** (France)
- 11:40 ASSOCIATION OF MICROSCOPIC COLITIS WITH AUTOIMMUNE DISEASES IN A SERIES OF 97 CASES 1047  
**W.A. Sifuentes Giraldo**, M. Llop Vitaltella, C. Bouruncle Alaluna, C. González-García, E. Loza Santamaría, J.L. Morell Hita, A. López San Román (Spain)
- 11:50 FREQUENCY OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCAS) IN PRIMARY SCLEROSING CHOLANGITIS (PSC) WITH OR WITHOUT INFLAMMATORY BOWEL DISEASES (IBD) AND IN SUBTYPES OF AUTOIMMUNE HEPATITIS (AIH) 1048  
**J. Goldbaum Crescente**, A. Dellavance, C. Pires Abrantes-Lemos, M. Augusto Diniz, F. Jose Carrilho, L.E. Coelho Andrade, E.L. Rachid Cancado (Brazil)



- 12:00 UTILITY OF SERUM AND MORPHOLOGICAL MARKERS IN THE  
DETECTION OF CHRONIC ATROPHIC GASTRITIS 1049  
**M.P. Panozzo**, M. Franceschi, G. Baldassarre, A. Morini, A. Visona',  
D. Villalta, A. Antico, N. Bizzaro (Italy)
- 12:10 EFFICACY OF ARYL HYDROCARBON RECEPTOR-ACTIVATING  
PHYTOSUBSTANCES IN A REFINED CHRONIC DEXTRAN SULFATE  
SODIUM-INDUCED COLITIS MODEL 1050  
**M. Hoffmann**, A. Seydel, S. Riemschneider, J. Kohlschmidt,  
U. Schwertassek, J. Lehmann (Germany)
- 12:20 FECAL BIOMARKERS AND AUTOANTIBODIES IN PATIENTS WITH  
INFLAMMATORY BOWEL DISEASE (IBD) 1051  
**T. Bulgakova**, S. Lapin, O. Shukina, A. Haritonov, A. Kharitidis, H. Bang,  
A. Krämer (Russia)

10:30 - 12:30

Hall 4

## PARALLEL SESSION 58: NEW AUTOIMMUNE DISEASES, CANCER AND AUTOIMMUNITY

- |       |                                                                                                                                                                                                                                                                                                                                                                             |      |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
|       | <b>Chair: I. Ben Zvi</b> (Israel)                                                                                                                                                                                                                                                                                                                                           | 1052 |
|       | <b>Chair: C. Perricone</b> (Italy)                                                                                                                                                                                                                                                                                                                                          | 1053 |
|       | <b>Chair: J.W. Cohen Tervaert</b> (Netherlands)                                                                                                                                                                                                                                                                                                                             | 1054 |
| 10:30 | THE AUTOIMMUNE SIDE OF RHEUMATIC FEVER<br><b>C. Perricone</b> (Italy)                                                                                                                                                                                                                                                                                                       | 1055 |
| 10:50 | A UNIFYING HYPOTHESIS FOR IGG4-MEDIATED AUTOIMMUNITY<br><b>M. Huijbers</b> , S. Van der Maarel, E. Niks, J. Plomp, J. Verschuuren (Netherlands)                                                                                                                                                                                                                             | 1056 |
| 11:05 | AUTOIMMUNITY AND CANCER INTER RELATIONSHIPS: 2016<br><b>E. Giat</b> , M. Ehrenfeld (Israel)                                                                                                                                                                                                                                                                                 | 1057 |
| 11:20 | AORTIC ANEURYSM ASSOCIATED WITH SLE : AN AUTOIMMUNE DISEASE AGGRAVATING AN ATHEROSCLEROTIC PROCESS- A CASE-CONTROL STUDY<br><b>H. Amital</b> (Israel)                                                                                                                                                                                                                       | 1058 |
| 11:30 | EXACERBATION OF ACUTE EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY ENHANCING SERUM LEVEL OF LACTIC ACID AS A POTENTIAL BIOMARKER OF MULTIPLE SCLEROSIS PROGRESSION FOLLOWING ADMINISTRATION OF MELATONIN<br><b>S. Dokoohaki</b> , M. Gharghani, H. Sadeghi, A. Ghanbari, N. Farhadi, M.A. Dokoohaki (Iran)                                                                  | 1059 |
| 11:40 | AUTOIMMUNITY PREFERENTIALLY TARGETS THE RNA-PROTEIN SYNTHESIZING MACHINERY IN BREAST CANCER<br><b>M.C. Maroun</b> , L. Grossman, R. Arshad, F. Fernández-Madrid (USA)                                                                                                                                                                                                       | 1060 |
| 11:50 | THE AUTOANTIBODY PROFILE IN BREAST CANCER SERA SUGGESTS THAT AUTOIMMUNITY MAY BE INVOLVED IN ITS PATHOGENESIS<br><b>F. Fernandez-Madrid</b> , L. Grossman, R. Arshad, M.C. Maroun (USA)                                                                                                                                                                                     | 1061 |
| 12:00 | HALLMARKS OF AUTOANTIBODIES IN CANCER. GD3 DISIALYLATED GLYCOPHINGOLIPID AND CD34 ANTIGEN REVEALING PATTERN FOUND IN THE MELANOMA IMMUNOGLOBULIN REPERTOIRE<br><b>B. Kotlan</b> , G. Liskay, M. Blank, T. Balatoni, J. Olasz, E. Farkas, L. Toth, A. Szollar, L. Gobor, A. Savolt, S. Horvath, K. Eles, K. Czirbesz, M. Godeny, O. Csuka, M. Kasler, Y. Shoenfeld (Hungary) | 1062 |

- 12:10 A NOVEL MOUSE MODEL OF PRIMARY SJÖGREN'S SYNDROME WITH INTERSTITIAL LUNG DISEASE 1063  
J. Zheng, Q. Huang, F. Deng, R. Huang, W. Zhao, X. Yue, F. Petersen, **X. Yu** (Germany)
- 12:20 IMPROVEMENT OF LIPOPROTEIN FUNCTIONS RELATED TO CELL CHOLESTEROL TRAFFICKING IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB 1064  
**N. Ronda**, D. Greco, M.P. Adorni, F. Zimetti, R. Gualtierotti, F. Ingegnoli, O. Borghi, F. Bernini, P. Meroni (Italy)

10:30 - 12:30

Hall 5

### PARALLEL SESSION 59: IL-6 AND JAK INHIBITION: NEW ACHIEVEMENTS

	<b>Chair: F. Atzeni</b> (Italy)	1065
	<b>Chair: D. Novick</b> (Israel)	1066
	<b>Chair: M. Benucci</b> (Italy)	1067
10:30	IL-6 INHIBITION: LONG-TERM RESULTS IN RHEUMATOID ARTHRITIS <b>P. Sarzi-Puttini</b> (Italy)	1068
10:50	IMMUNOGENICITY AND IL-6 INHIBITION (OR TOCILIZUMAB) <b>M. Benucci</b> , F. Meacci, M. Infantino, P. Sarzi-Puttini, F. Atzeni, M. Manfredi, V. Grossi (Italy)	1069
11:10	TOCILIZUMAB THERAPY IN ISRAELI PATIENTS WITH RHEUMATOID ARTHRITIS <b>M. Abou Shakra</b> (Israel)	1070
11:30	JAK INHIBITORS IN AUTOIMMUNITY <b>P.C. Taylor</b> (United Kingdom)	1071
11:50	MELATONIN ENHANCES INTERLEUKIN-10 EXPRESSION AND REPRESSES CHEMOTAXIS TO INHIBIT INFLAMMATION <i>IN SITU</i> AND AMELIORATE THE SEVERITY OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS <b>S.J. Chen</b> (Taiwan)	1072
12:05	SERUM LEVELS OF IL-6 AND IL-10 IN PATIENTS WITH INHERITED EPIDERMOLYSIS BULLOSA M. Tampoia, <b>L. Abbracciavento</b> , R. Fumarulo (Italy)	1073
12:20	CYTOKINE LEVELS ARE ASSOCIATED WITH THE SEVERITY OF SYMPTOMS IN MAJOR DEPRESSION <b>V. Barak</b> , Y. Madi, A. Yogev, M. Bar-Gad, H. Amital, Y. Shoenfeld, D. Amital (Israel)	

WEDNESDAY

THURSDAY

FRIDAY

SATURDAY


SUNDAY

INDEX

ACKNOWLEDGEMENTS



# INDEX OF AUTHORS



# 10<sup>TH</sup>

INTERNATIONAL CONGRESS  
ON **AUTOIMMUNITY**

APRIL 6-10, 2016, LEIPZIG, GERMANY

Impact Factor  
4.352

# Journal of Innate Immunity

*welcomes your contribution ...*

Editors-in-Chief

**Heiko Herwald, Lund**  
**Arne Egesten, Lund**

Editorial Board

**B. Beutler**, Dallas, Tex.  
**V. Brinkmann**, Berlin  
**G.D. Brown**, Aberdeen  
**B. Dahlbäck**, Malmö  
**F.R. DeLeo**, Hamilton, Mont.  
**D. Hartl**, Tübingen  
**J. Hoffmann**, Strasbourg  
**M. Holub**, Prague  
**M. Hornef**, Hannover  
**T. Kaisho**, Yokohama City  
**J.D. Lambeth**, Atlanta, Ga.  
**G. McFadden**, Gainesville, Fla.  
**E. Medina**, Braunschweig  
**A. Mowat**, Glasgow  
**P.M. Murphy**, Bethesda, Md.  
**V. Nizet**, La Jolla, Calif.  
**J.E. Pease**, London  
**J. Potempa**, Krakow  
**C.S. Reiss**, New York, N.Y.  
**J.A. Russell**, Vancouver, B.C.  
**D. Schneider**, Stanford, Calif.  
**J.-M. Schröder**, Kiel  
**T. Seya**, Sapporo  
**O. Soehnlein**, Munich  
**C. Speth**, Innsbruck  
**U. Theopold**, Stockholm  
**J.A.G. van Strijp**, Utrecht  
**M.A. Williams**, Bethesda, Md.  
**V. Witko Sarsat**, Paris  
**M.A. Zasloff**, Washington, D.C.

The *Journal of Innate Immunity* is a bimonthly journal covering all aspects in the area of innate immunity, including evolution of the immune system, molecular biology of cells involved in innate immunity, pattern recognition and signals of 'danger', microbial corruption, host response and inflammation, mucosal immunity, complement and coagulation, sepsis and septic shock, molecular genomics, and development of immunotherapies.

The journal publishes original research articles, short communications and reviews.

## Benefits for Authors

- Cost-effective publishing (no submission fee and no page charges for papers of 5 or fewer printed pages)
- Free online color figures
- Rapid and fair peer-review process
- Full listing in all relevant bibliographic databases (PubMed/MEDLINE, Web of Science etc.)
- Author's choice for open access publishing



Find out more:

[www.karger.com/jin](http://www.karger.com/jin)

**KARGER**

Abad, S.	279
Abbas, A.K.	17, 18, 19, 20, 21, 22, 174, 344
Abbracciavento, L.	725, 1 073
Abdollahi-Roodsaz, S.	161
Aberer, E.	354
Abisror, N.	337
Abo El magd E.B.	552
Abu Shakra, M.	333, 1 070
Abouda, A.	352
Abou-Raya, A.	359
Abou-Raya, S.	359
Abramson, S.B.	689
Accardi, G.	367
Acharya, B.	1 008
Achiron, A.	300, 507
Achleitner, M.	794
Achour, A.	181
Acquasaliente, L.	959
Ada, S.R.	794
Adawi, M.	379, 380
Admou, B.	365, 366
Adorni, M.P.	1 064
Adorno, D.	244
Adriana, B.	401
Adriouach, S.	150
Aelion, J.	164
Afonso, L.	600
Agalliu, D.	516
Agazzi, P.	892
Agewall, S.	264
Aggelakos, M.	377
Agmon Levin, N.	901
Agmon-Levin, N.	967
Agnieszka, W.	991
Agolini, S.	115
Agosti, M.	817
Agrogianni, M.	905
Aguilar-Ruiz, S.R.	860
Aguillón, J.C.	75, 76, 390, 574
Agustin, P.	1 045
Aharoni, R.	514
Ahlefeldt, M.	802
Ahmad, S.	549
Ahmed A. battah	552
Ahmed, R.	456, 459
Ahmed, S.S.	89
Ahn, G.	402
Ahn, S.J.	381, 739
Aida Fitria, A.	267

Aiello, A.	367
Aissa, L.	387
Ait-Abdesslam, K.	701
Akbarzadeh, R.	418
Akhyar, G.	711, 934
Alam, K.	128, 539
Albano, L.	800
Albertini, G.	984
Albrecht-Walz, I.	56
Albuquerque, M.	536, 1 044
Albus, A.	614
Alcantara, P.	765
Aldigeri, R.	865
Alessandra Banzato	660
Alessandri, C.	87, 160, 454, 641, 887, 901
Alessio, M.G.	597
Alexander, T.	93, 172, 179
Alexandridou, M.	377
Alexandropoulos, K.	162
Alfano, A.M.	538
Alfredsson, L.	302
Alia Jiménez, A.	205
Alice, B.	337
Aligrudic, S.	929
Alijotas-Reig, J.	339, 963
Alimanovic-Alagic, R.	985
Alijotas reig, J.	958
allam, I.	593
Allegri, F.	967
Almanzar, G.	735
Almeida, I.	563, 703
Aloe, G.	440
Aloe, R.	431, 904
Alonso, B.	224
Alonso, M.B.	729
Alpini, C.	909
Altankova, I.	598
Alunno, A.	409
Alvarado, M.	586
Alvarez, D.	126
Alvarez-De la Sierra, D.	996, 586
Álvarez-Rodríguez, L.	355
Alves, G.	936
Alves, R.	600, 873
Amar, K.O.	945
Amato, P.	698, 34

Ambou, I.	591
Amelia Ruffatti	660
Amerio, P.	980
Amir, A.	566
Amital, H.	144, 151, 213, 439, 523, 668, 672, 1 058
Amoura, Z.	279, 443
Amouzadeh-Ghadikolai, O.	829
Anaya, J.M.	481, 484, 647
Andersson, E.	66
Andersson, U.	94
Andrade, L.	123
Andrade, L.E.	376, 421
Andrade, L.E.C.	369, 903
Andreoli, L.	191, 233, 438, 650, 817, 863, 948, 958, 962, 967
Andrés, E.	443
Angeletti, D.	921
Anna, F.G.	704
Anquetil, F.	148
Antico, A.	826, 1 049
Antonelli, A.	183, 844, 846, 850, 851, 852
Antonio, G.	410
Aparicio-Hernandez, M.B.	53
Apparailly, F.	1 007
Arango, M.	348, 861
Arango, M.T.	862
Aravena, O.	390
Arcara, G.	368
Argolini, L.	948
Ariaudo, G.	650
Ariela Hoxha	660
Aringer, M.	214
Arleevskaya, M.L.	649
Arnon, R.	514
Arolt, C.	88
Arora, P.	442
Arranz, E.	595
Arsene, M.	330, 337
Arshad, R.	1 060, 1 061
Arslan Tas, D.	388
Artusi, C.	203
Arzenton, M.	589
Asensio, E.	104, 215, 355
Astakhova, K.	425
Astorri, D.	927
Åstrand, A.	802

Athanasios, G.	914	Barbati, C.	87, 641	Benítez, M.	591
Atmakusuma, D.	340	Barbato, C.	741, 925	Bentow, C.	213, 694, 895, 896, 900, 979
Atrekhany, K.S.	573	Bardin, N.	443	Benucci, M.	124, 374, 776, 824, 1 067, 1 069
Atsumi, T.	356, 801, 953	Bareau, M.C.	110	Benvenga, S.	852
Attia, A.	683	Barka C.	377	Benzaken, S.	453, 800
Atzeni, F.	58, 124, 374, 631, 634, 1 024, 1 065, 1 069	Barreto, G.	638	Bergamaschi, R.	609
audonnet, S.	791	Barrett, E.	63	bergamini, A.	713, 741
Augusto Diniz, M.	1 048	Barshack, I.	157	Berghea, F.	242
Auriemma, M.	980	Bartolomeo, R.	984	Berki, T.	841
Authier, J.	5	Bartoloni, E.	409	Berleth, E.	212
Avanzi, G.C.	753	Baruah, P.	839	Bernal, C.	579
Avcin, T.	663, 999, 1 004	Bashi, T.	157	Bernard, G.	800
Avidan, N.	652	Bassi, N.	472, 476, 477, 751	Bernardes, M.	722
Avila, V.	36	Bastug, E.	230	Bernardi, L.	927
Avni, O.	163	Battistelli, L.	431	Bernardi, P.	226
Ayachi, J.	352	Battistini, M.	538	Berndt, N.	884
Ayoglu, B.	237, 250, 302	Baxter, A.	615	Berneman, Z.N.	721
Azzarà, G.	597	Baz Morelli, A.	109	Bernini, F.	1 064
B. Trezzi	451	Bazzani, C.	817	Berrih-Aknin, S.	296, 301, 478, 652
Bacarelli, M.R.	900	Beam, C.	489	Berrón Ruiz, L.	836
Back, T.	535	Becciolini, A.	487	Bertero, M.T.	339
Baden, F.	88	Becker, N.P.	525	Bertero, T.	958
Bae, H.	535	Beggio, M.	472, 751	Berthelot, J.M.	182
BAERLECKEN, N.	318, 424, 239	Behrendt, R.	794	Berthier, S.	279
Baerwald, C.	683	Behroo, L.	360	Berthold, S.	493
Bagnasco, M.	826	Belguendouz, H.	734	Bertolotto, A.	725
Baines, J.F.	268	Belizna, C.	661, 797, 1 029, 1 031	Bettencourt, A.	563, 703
Bajpai, N.	343	Bellan, M.	59, 753	Betterle, C.	792
Bajpayee, A.	343	Bellando-Randone, S.	389	Bettio, S.	232, 233, 438, 708, 863
Baker, B.	293	Bello, A.	110	Bhakta, V.	111
Bakker-Jonges, L.E.	312	Belloni, L.	904	Bianchini, E.	607, 984
Balada, E.	586	Belmondo, T.	587	Bieber, K.	80, 81, 935
Balamurugan, N.	370	Belyaeva, I.	730	Biedermann, S.	794
Balanescu, A.	242, 684	Ben Ami Shor, D.	439	Biesen, R.	490
Balaton, T.	1 062	Ben Azaiz, M.	352	Bietenbeck, A.	357
Balboni, I.	425	Ben Zvi, I.	992, 1 052	Biggioggero, M.	487, 653
Baldassano, R.N.	651	Ben-ami Shor, D.	742	Bilgar, A.	330
Baldassarre, G.	1 049	benarous, L.	791	Billinis, C.	914
Baldo, D.	903	Benchabane, S.	734	Binder, B.	354
Bang, H.	1 051	Bendaoud, B.	604	Binder, S.R.	949, 954
Banzato, A.	662, 959	Ben-David, H.	992	Bindoli, S.	361, 472
Baptista-fernandes, I.	906	Ben-Dov, I.	601	Bing, S.J.	402
Bar Or, A.	297, 298	Bendtzen, K.	487	Birgitta Brunes	305
Barabas, A.Z.	562	Benedetti, T.	597	Birn, H.	717
Barak, V.	519	Benhalima, A.	571	Bischof, J.	88
Baranov, D.	891	BENHAMOU, Y.	338, 697	Bistoni, O.	409
Barbara, S.	704	Benhar, I.	304	Bittermann, V.	996
Barbarroja, N.	126	Ben-Horin, S.	630		



Bitton, A.	304	Börjesson, J.	94	Bruni, B.	916
Bizjak, M.	291, 361, 544	Bornholz, B.	982	Bruni, C.	389
Bizzaro, N.	118, 122, 207, 211, 824, 826, 1 039, 1 049	Borro, M.	229	Bruno, V.	328
Bjartell, A.	250	Bosques, C.J.	113	Budde, P.	428, 430, 488, 756, 780
Björhall, K.	802	Bossuyt, X.	142, 498	Budkova, A.	234
Bjursell, M.	94	Botsios, C.	927	Bulatovic, A.	929
Blanchard Delaunay, C.	281	Botta, A.	326	Bulgakova, T.	730, 1 051
Blandizzi, C.	555, 556	Botti, E.	928	Buonocore, R.	904
Blank, M.	114, 153, 157, 286, 304, 348, 742, 861, 862, 956, 970, 1 062	Bouali, Y.	571	Burke-Murphy, E.	110
Blankenburg, J.	611	Boudjelida, A.	734	Burlingame, R.W.	65
Blecken, J.	590	Bougias, D.	893, 912	Burmester, G.	179
Blinova, T.	730	Boukercha, A.	701	Burmester, G.R.	147, 490
Bocassini, L.	58	Boulamatsi, O.	905	Busard, C.	928
Böcher, O.	56	Bourunclé Alaluna, C.	1 047	Businaro, R.	886
Böckle, B.	218, 219	Bouteraa, W.	74	Buttari, B.	886
Bodio, C.	487, 653	Bouziane, D.	701	Buttmann, M.	303
Boege, F.	982	Bouzidi, A.	701	Buurman, W.A.	723
Boekhorst, J.	161	Boyer, O.	338	BYUN, J.I.	381, 739
Boer, L.	971	Bo ena Cukrowska	991	C. Bentow	216
Bogdanos, D.	154, 533, 759, 761, 913, 914	Bozic, B.	594	Cabrera-Marante, O.	825
Bohgaki, T.	356, 801	Bozic, I.	306	Cadusseau, J.	4, 8
Boiardi, L.	865	Brachvogel, B.	363	Cainelli, F.	709
Boiocchi, C.	609	Brahim, I.	366	Cambridge, G.	640
Bojinca, M.	227	Brakopp, S.	303	Cañas, C.A.	70, 180, 638
Bojinca, V.	242, 684	Branch, .	220	Candore, G.	367
Boldizsár, F.	841	Branch, D.R.	106, 110	Caneparo, V.	916
Boleixa, D.	563	Brändén, L.	94	Canhão, H.	259
Bonaguri, C.	431, 828, 902, 904	Braschi, F.	389	cannella, A.C.	441
Bongiovanni, S.	58	Brascia, C.	597	Canofari, C.	713, 741, 440, 925
Boni, A.	184	Brasier, A.R.	957	Cantaert, T.	126
Bonilla-Abadía, F.	70, 638	Bravo, J.C.	70	Cantarini, L.	680
Bonometti, R.	59	Bredenber, J.	302	Canti, V.	339, 958
Bonroy, C.	241	Bredewold, O.W.	584	Cao, S.	51
Bonsmann, G.	466	Brekken, R.	33	Cao, X.	899
Bony, C.	204	Bremme, K.	958	Capaldo, C.	604
Boonen, H.	928	Brenner, R.	716	Capo, A.	980
Booth, R.A.	714	Briasoulis, C.	893	Capoluongo, E.	1 041, 1 043
Bor, S.	59	Brilot, F.	515, 881	Caporali, R.	487, 653
Borangiu, A.	684	Brinks, R.	430	Capozzi, A.	641, 901
Bordron, A.	247, 649	Briones García, E.	696	Cappa, M.	792
Borghi, M.O.	127, 203, 487, 653, 909	Brocke, S.	396	Capuano, R.	713
Borghi, O.	1 064	Brodmann, M.	354	Carabellese, N.	650, 967
Borgiani, P.	317	Brogna, C.	382	Caramella, A.	800
Boric, K.	306	Brogren, C.H.	548	Carballo, G.	123
		Brooks, W.	883	Carbillon, L.	958
		Brooks, W.H.	649	Carbone	410, 1 038
		Bruck, O.	544	Campoverde, J.A.	
		Brugnano, R.	243	Carmen, H.D.L.	375
		Brun, M.	341		
		Brunes, B.	485		

Carnavale Schianca, G.P.	59
Carnevale, G.	984
Carp, H.	812
Carranza-Muleiro, R.A.	964
Carrara, G.	494
Carrasco Sayalero, A.	720
Carron, P.L.	781
Carrozzo, M.	132
Carter, R.H.	441
Cartry, O.	1 036
Carubbi, F.	409
Caruso, C.	367
Carvajal Alegria, G.	486, 604, 930
Carvalho, C.	563, 703, 871
Casali, M.	865
Casato, M.	184, 767
Casellas, M.	743
Casian, A.	278, 280, 452, 727, 754
Casiano, C.	209, 210
Cassuto, E.	800
Castellani, R.	328
Castello, L.	753
Castillo, F.	743
Castro, T.	226
Catalán, D.	390
Cattalini, M.	44, 650
Cavalier, E.	911
Cavazzana, I.	146, 967
Ceccarelli, F.	160, 454, 887, 901
Ceccato, L.	148
Centanni, M.	183, 835, 850
Cepin-Bogovic, J.	755
Ceribelli, A.	1 037
erne, D.	594
Cervantes, J.	937
Cervar-Zivkovic, M.	815, 816
Cervera, R.	339, 655
Cesana, L.	694, 896
Cesareo, M.	440
Cesbron, J.Y.	150, 781
Chafika, M.	337
Chaib-mamouzi, S.	582
Chakievskaa, L.	1 005
Chalah, M.	384
Chalouas, L.	52
Chames, P.	548
Chamorro, M.	70

Chan, E.	123, 820
Chandesris, M.O.	341
Chang, C.	84, 558
Chapman, J.	304, 885
Chara, O.	138
Charras, A.	649
Charuel, J.L.	65
Chatham, W.W.	441
Chatterjee, S.K.	49
Chaturvedi, V.	370
Chayat, C.	213, 979
Chayka, M.	724
Cheleschi, S.	900
Chen, H.H.	702
Chen, H.Y.	702
Chen, L.	997
Chen, S.J.	1 072
Chen, X.	51, 313, 323, 329
Chen, Z.	51, 707
Cherin, P.	616, 1 030, 1 032, 1 036
CHERIEN, C.A.	65
Chevallier, A.	505
Chevreau, M.	150
Chiaroni, J.	341
Chiche, L.	182, 443
Chighizola, C.	203, 220
Chimenti, M.S.	713, 925
Chiriotiu, G.	227
Chirivi, R.	149
Chiuso-Minicucci, F.	864
Cho, E.	827
Cho, J.	402
Cho, Y.N.	48
Chollet-Martin, S.	426
Chou, F.C.	702
Chrisostomou, E.	893, 912
Christian, A.	337
Christopher Exley, E.S. & M.M.	1
Christopherson, J.	545
Chu, K.	381, 739
Chu, Y.	804
Chudinov, A.	730
Chul-Soo, C.	364, 998
Churilov, L.	891
Ciccacci, C.	317
Cicarese, G.	993
Ciccoli, L.	513
CIFU', A.	31

Cimaz, R.	679
Cinek, O.	546
Cines, D.	331
Cipriani, P.	409
Circiumaru, A.	227
Claessen, A.	603
Clavarino, G.	150, 781
Clavel, C.	148
Clay, M.	150
Cleary, P.P.	516
Coat, J.	178
Coelho Andrade, L.E.	819, 1 048
cognet, C.	791
Cohen Tervaeert, J.W.	194, 805, 838, 855, 866, 965, 968, 1 015, 1 054
Cohen, P.	279
Cohen, S.	945
Cointe, S.	341
Colaci, M.	846, 851
Colafrancesco, S.	317
Colantuono, S.	184, 767
Colaris, M.	866
Colaris, M.J.	968
Colaris, M.J.L.	194
Colasanti, T.	87, 641
Cole, C.	562
Collante, M.T.	579
Colliard, S.	781
Coloma-Bazan, E.	339
Comarmond, C.	279
Comins Boo, A.	223
Comins, A.	224
Comins-Boo, A.	32
Conigliaro, P.	741, 440
Conny, G.	567
Conrad, K.	123, 214, 428, 537, 771, 774, 780
Constantinescu, C.	684
Conti, F.	87, 160, 454, 641, 887, 901
Contini, P.	229
Cook, D.	567
Cools, N.	721
Cooper, I.	862
Coppo, P.	338
Coque, E.	77
Cordfunke, R.	995
Cordoba, Z.	729

Corless, L.	779
Cornec, D.	178, 182, 486, 930
Coronado, P.	223
Correia, F.	600
Cortelazzo, A.	513
Cossarizza, A.	607, 984
Costa, L.	722
Costa, P.P.	563
Costa, R.	872
Costa, S.	182
Costantini, E.	736, 980
Costanzo, A.	928
Costello, C.E.	763
Cotter, J.	936
Coussens, E.	928
Coutant, F.	897
Cras, P.	721
Crave, J.C.	616, 1 036
Creange, A.	384
Crinò, A.	792
Crisostomo, M.	63, 67, 374
Crisostomo, M.E.	62
Cristina, B.	1 036
Crotti, G.	538
Crowley, B.	615
Crowley, J.T.	763
Cruz-Domínguez, M.D.P.	964
Cruz-Domínguez, M.P.	696
Csuka, O.	1 062
Csumita, M.	977
Cucchiario, F.	211
Cuccia, M.	609
Curik, S.	378
Cui, L.	55
Cunha, C.	936
Cunha, M.	936
Cunha, P.	936
Cunill Monjo, V.	36
Cunningham, J.L.	319
Curcio, F.	31
Curila, K.	60
Cutforth, T.	516
Cutolo, M.	622, 625
Czirbesz, K.	1 062
D. Rolla	451
D. Santoro	451
Dagan, A.	866
Dahan, S.	439, 740, 742, 859

Dähnrich, C.	805, 827
Dai, L.	997
Daia, S.	242
Daia-Iliescu, S.	684
Dajcman, D.	915
Dale, R.	515
Dale, R.C.	881
Dalmau, J.	510
Dalton, J.	159
D'Amico, M.	243
Damoiseaux, J.	123, 188, 497, 500, 805, 818, 822, 879
D'Angelo, C.	736, 980
Daniel, L.	443
Daniel, M.G.	107, 116
Dá'ová, K.	546
Dantal, J.	616
Danza, A.	401
Dapcevic, M.	221
Dario Roccacello	437
Darrah, E.	776
Darwin, E.	79, 737, 937
Daugas, E.	443
D'Aurizio, F.	892
Daves, M.	590
David, P.	342, 866
Davidson, T.	1 006
Davies, T.	845, 849
Dayar, J.	686
D'Cruz, D.	754, 275, 278, 446, 452, 727, 831, 947
de Andrade, F.A.	803
De Andrea, M.	916
De Baets, M.H.	723
De Biasi, S.	607, 984
De Bleecker, J.	981
de Boer, M.	194, 866, 968
De Carolis, C.	322, 325
De Carolis, S.	326, 339, 810
De Chaisemartin, L.	426
De Craemer, A.S.	353
De Cristofaro, R.	959
De Felice, C.	513
De Filippis, V.	959
De Haan, P.	294
De Haard, H.	398
De Haro Muñoz, T.	246
De Hert, M.	723
de Jaeger, C.	1 036

De Jaureguiberry, J.P.	341
de Jesus, G.	220
De Keyser, E.	928
de la Puente Bujidos, C.	205
De Laere, M.	721
de Las Heras Alonso, E.	205
De Los Santos, I.	53
De Lunardo, F.	901
de Melo Cruvinel, W.	123
de Oliveira, F.L.	477
De Paepe, B.	981
de Ru, A.	995
De Santis, A.	767
De Santis, E.	828
De Santis, M.	1 037
De Santis, R.	382
De Spirito, M.	328
De Wazieres, B.	281
De Winter, L.M.	372, 373
Degandt, S.	68
Degli Esposti, C.	249
Dehoulle, C.	384
Dekel, N.	286
Del Padre, M.	767
Del Prete, D.	751
Del Ross, T.	339
Del Sordo, G.	326
Delain, J.C.	616, 1 036
DelCanto, G.	937
Deligny, C.	281
Dellavance, A.	369, 376, 903, 1 048
Demel, U.	354
Demircan, N.	388
demirpehlivan, E.	230
Demoersman, J.	178
Deng, F.	1 063
Denno, Y.	303
Denton, C.	389
Derdelinckx, J.	721
Derfalvi, B.	787
Dessouki, O.	235
Detert, J.	147
Devalajara, M.	802
Devauchelle-Pensec, V.	178, 182, 486, 604, 930
Devilliers, H.	279
Devos, H.	68

Devreese, K.	351, 353	Downing, D.	807, 972	Elisa Bison	660
Dewi, S.	728	Dr. Schmidt, E.	465	Ellonen, P.	577
Deyab, G.	264	Draghessi, G.	440	El-Maraghy, N.	235
Dezaki, K.	261	Dragin, N.	608	Elon Pras	705
Dhangar, A.	639	Drago, F.	993	Elvira, D.	737, 840
Dhote, R.	279, 281, 958	Dragon-Durey, M.A.	426	Emanuel, V.	730
Di Bari, F.	852	Dragun, D.	202	Eming, R.	308
Di Bari, M.	736	Drakoulis, C.	905	Emons, H.	504
Di Benedetto, P.	409	Dreier, T.	398	Engmose, C.P.	548
Di Franco, M.	641	Dreyfus, D.	628	Enrique Esteve-Valverde	966
Di Lernia, G.	524	Drijfhout, J.W.	995	Enríquez, A.B.	588
di natale, C.	713	Drizhal, I.	938	Enriquez, J.	398
Di Nicola, M.	736	Drkulec, V.	755	Epstein, O.	269
Di Nicuolo, F.	328	Drouin, E.E.	763	Erdam, K.	605
Di Simone, N.	327, 328	Drouot, L.	338	Erdei, A.	882
Diao, L.	323, 329	Drutsкая, M.	573	Eriksson, C.	898
Diao, L.H.	313	Ducreux, J.	126	Eriksson, P.	837
Dias, C.	189, 406, 542, 813	Dumestre-Pérard, C.	781, 150	Erkel, G.	580
Didona, D.	921	Dumitriu, I.E.	839	Ernerudh, J.	837
Diedrichs-Möhring, M.	228, 257, 258, 479	Duna, M.	684	Erschig, A.	38
Dignat-George, F.	341	Durand, J.M.	341	Escobar, J.	70
Dijkman, H.	971	D'ursi, A.M.	698, 34	ESEN, E.	388
Dileepan, T.	516	Durtette, C.	281	Eshkar Sebban, L.	945
Dinarello, C.	793	Dussol, B.	443	Esnault, V.	453, 800
Dinarello, C.A.	642	Dwivedi, M.	639	Espinosa, G.	77, 339
D'ippolito, S.	328, 327	Dwoskin, C.	283	Espinoza, I.	244
Dirk, F.	239	Dynski-Trumble, C.	602	Espirito Santo, J.	392, 732
Dirk, H.	239	Dzananovic, L.	985	Esquivel, Y.	588
Djemi, S.	571	ebbo, M.	791	Esteve-Valverde, E.	339
DJIDJIK, R.	593, 222	Ebel, A.	52	Eugen, F.	239
Dodel, R.	614, 617	Eça Guimarães, L.	16, 293	Eun-Jin, H.	364, 998
Dokoohaki, M.A.	1 059	Echeverri, A.	70, 1 027	Éva, S.V.	890
Dokoohaki, S.	1 059	Eck, C.	78	Evrard, B.	897
Dolff, S.	838	Ederveen, T.	161	Exley, C.	7
Dolla, G.	453	Edwards, C.	166, 167	F. Atzeni	216
Dominguez Pantoja, M.	475	Efimov, G.	573	F. El Hilali	117
Domínguez, V.	401	Ehrenfeld, M.	309, 1 057	F. Li Gobbi	216
Don, E.	269	Eira, C.	699	F. Londrino	451
Donatini, B.	263, 265	Eisele, J.	611	F. Meacci	216
Donnelly, S.	159	El Moumou, L.	366	F. Pregnotato	451
Doran, A.	242	El-Abhar, H.	683	F. Ravera	451
Doria, A.	233, 368, 433, 436, 438, 472, 476, 477, 708, 751, 863, 927, 947, 987, 1 014	Eldfors, S.	577	Fabiano, A.	984
Dörner, T.	1 017	Elenkov, I.J.	886	Fabien, N.	386, 897
Dotta, F.	567	Eles, K.	1 062	Fabris, M.	31, 211
Douglas B.C.	334	Elfi, E.F.	79, 983	Fadilla, A.	934
		Elgart, M.	304	Fain, O.	281, 918, 958
		Elia, G.	851	Fatb, R.	300
		Eliakim, R.	630	Faliti, C.E.	411
		Elie Haddad	790	Fallah-Arani, F.	745

Fallahi, P.	183, 846, 850, 851, 852
Fangning, W.	994
Farez, M.	880
Farhadi, N.	1 059
Farinha, F.	563, 703
Farkas, E.	1 062
farnarier, C.	791
Faro-viana, J.	906
Fasouloglou, A.	893, 912
Fassbender, J.	526
Favalli, E.G.	487, 653
Favaro, M.	662
Favia, I.E.	524
Favoino, E.	524
Faz-Muñoz, D.	588
Fazzi, E.	650
Fechner, K.	778
Feldt-Rasmussen, U.	892
Feller, E.L.	316
Feng, D.	535
Ferjani, M.	352
Fernandes-Cerqueira, C.	898
Fernandez Varela, M.V.	246
Fernandez-arquero, M.	223
Fernandez-Cruz, E.	410, 1 038
Fernández-Madrid, F.	1 061, 1 060
Fernandez-Salas, I.	266
Fernani-Oukil, F.	426
Ferrari, F.	984
Ferrari, S.M.	846, 850, 851, 852
Ferraro, D.	607
Ferraro, R.	44
Ferraz, M.L.G.	903
Ferreira, C.	923
Ferrer-Oliveras, R.	339
Ferri, C.	846, 851
Ferrier, A.	390
Ferrini, A.	538
Ferro, M.	73
Fervenza, F.	270, 273
Fiehn, C.	138
Fierabracci, A.	792
Figueiredo, M.	722
Figueiredo-Braga, M.	722

Filippini, M.	487, 653, 817
Finazzi, S.	909
Fiorelli, A.	328
Fiorilli, M.	184, 767
Florez-Durante, O.I.	696
Fong, C.	638
Fonseca, J.E.	259, 640, 832, 1 034
Fonteneau, G.	204
fonti, G.	741
Fonti, G.L.	713, 925
Forsström, B.	250, 302
Fortuna, J.	923
Fox, E.	425
Fraga-Silva, T.F.	403, 864
Fraga-Silva, T.F.C.	195
Frambach, S.	161
França, T.G.D.	195
Francesca, M.	824
Francescantonio, P.	123
Franceschi, M.	1 049
Franceschini, F.	146, 909, 967
FRANCO, C.	586
François Fontaine	790
Francois, L.	337
Francova, I.	782
Frank, M.	239
Frassi, M.	233, 438, 863
Frauenknecht, K.	885
Fraune, J.	778
Fredi, M.	146, 339, 650
Fredolini, C.	250
Free, C.	545
Freitas, S.	936
Frenkian, M.	652
Frey, A.	590
Fridkin, M.	157
Friso, L.	233, 863, 927
Fritzler, M.	123, 200
Frostegård, A.	262
Frostegård, J.	415, 158, 262
Fudim, E.	630
Fujimoto, M.	310
Fujimoto, T.	1 009
Fujimura, T.	1 009
Fumarulo, R.	725, 1 073
Furst, D.	389
Furukawa, F.	136
Furuzawa-carballada, J.	588

Fuster, M.R.	36
G. Ortis	451
G. Pesce	451
Gabay, C.	896
Gabriela, G.	854, 1 045
Gabrielli, A.	115, 116
Gabron, C.	354
Gad, S.	716
Gagro, A.	755
Galante, M.	431
Galarza-Maldonado, C.	420
GALAS, L.	697
Galeazzi, M.	676, 900, 939, 942
Galiani, D.	286
Galletti, M.R.	852
Galli, J.	650
Gallo, N.	589, 1 040, 1 042
Galovic, R.	240
GalvezRomero, J.	394
Gambino, C.M.	367
Gamez, J.	743
Gámir Gámir, M.L.	205
Gañán Nieto, I.	720
Gao, B.	535
García de Veas Silva, J.L.	246
Garcia Lario, J.V.	246
Garcia Prat, M.	996
Garcia, F.	455
Garcia-Collinot, G.	964
Garcia-De La Torre, I.	123
Garcia-Garcia, F.	475
García-González, P.	76
García-Segovia, A.	32
Garelli, S.	792
Gariglio, M.	916
Garrote, J.A.	595
Garssen, J.	161
Garufi, C.	454
Gary, T.	354
Gasbarrini, A.	327
Gasca, M.P.	223
Gatti, E.	150
Gatto, I.	183, 835
Gatto, M.	368, 438, 477, 708, 751, 863
Gaudin, P.	150
Gauthier, A.	781

Gazeau, P.	486	Giovannini, D.	781	Grange, L.	150
Geier, D.	12, 518	Giovannoni, G.	260	Grange, S.	338
Geier, M.	12, 518	Gisela, J.	854, 1 045	Granieri, L.	725
Gelardi, C.	116	Giudizi, M.G.	909	Grant, P.	957
Genebrier, S.	897	Giuggioli, D.	846, 851	Graslands, A.	281
Generali, E.	494, 1 037	Giulietta, B.	73	Grassi, F.	411
Gentian Denas	660	Glaeser, R.	88	Gräßler, A.	214
Georgiou, C.	912	Glaser, R.	268	Greco, A.	921
Gerbaulet, A.	794	Glauche, B.	537	Greco, D.	1 064
Gerl, V.	126	Gleason, C.	35	Greer, J.	159
Gerli, R.	409, 909, 1 001, 1 021	Gobor, L.	1 062	Gregersen, J.W.	717
Gerosa, M.	948	Godeau, B.	791, 279	Gregor, P.	60
Gershwin, L.	468, 471	Godeny, M.	1 062	Gries, A.	354
Gershwin, M.E.	529, 535, 623, 687	Goeb, V.	182	Grilo, A.	732
Gertel, S.	144, 520, 523	Goebel, A.	474	Grindebacke, H.	413
Geusens, P.	373, 427	Goegan, F.	753	Grine, L.	928
Ghaly, M.	235	Goehler, H.	147	Groenestein, R.	269
Ghanbari, A.	1 059	Goettel, P.	525	Grohová, A.	546
Gharghani, M.	1 059	Göhler, H.	430, 488	Grondona, A.G.	383
Ghazouani, E.	352	Gold, H.	303	Groseanu, L.	242, 684
Ghedira, I.	917	Goldbaum	1 048	Gross, W.L.	271, 276, 648
Ghiggeri, G.	243	Crescente, J.		Grossi, C.	487, 653
Ghillani-Dalbin, P.	65	Goldman, S.	862	Grossi, V.	124, 374, 824, 1 069
Ghirardello, A.	368, 472, 476, 477, 708, 751, 909	Goletz, S.	480, 1 005	Grossman, L.	1 060, 1 061
Ghorbanalipoor, S.	80	Gomes, M.J.	256	Grossmann, K.	537, 774
Ghozzi, M.	917	Gomez-Cruz, O.	266	Grosso, V.	487, 653
Ghrenassia, E.	918	Gonzalez-Ruiz, J.M.	53	Gruber, N.	286
Giacomo Zoppellaro	660	Goncalves, I.	256	Grüngreif, K.	396
Giacomelli, R.	409	Gonçalves, M.	936	Grutzkau, A.	490
Giacomello, R.	31	Gonçalves, M.J.	259	Gu, J.	51
Giancicchì, E.	792	Gondran, G.	281	Gualtierotti, R.	411, 1 064
Gianniki, M.	893, 912	Goñi, M.	401	Guaschino, G.	59
Giannotta, G.	290	Gonul, M.	889	GUBERT, I.C.	316
Gianturco, L.	58, 1 024	González Urra, P.	720	Guggino, G.	367
Giat, E.	1 057	González, E.	455, 36	Guido, V.	87
Gibbin, A.	59	Gonzalez, E.B.	35, 957	Guiducci, S.	389
Gibellini, L.	607, 984	González-García, C.	1 047	Guillaume, L.	337
Gilbert, L.	769	Gooren, L.	675	Guillevin, L.	279
Gilburd, B.	120, 213, 979	Göransson, U.	898	Guilpain, P.	204
Giliani, S.	44	Gordins, P.	779	Guimarães, J.	563
Gioia, B.G.	367	Gorla, R.	487, 653, 817	Guis, L.	52
Giorda, E.	792	Gorshkova, E.	573	Gu, A.	467
Giordanengo, V.	800	Gottschalk, T.	629	Gul, U.	888, 889
Giordano, A.	160	Gowayed, M.	683	Gunasekera, S.	898
Giordano, L.	44	grados, A.	791	Gunawan, A.	738
Giovanna, L.	892	Graf, R.	551	Gundin, S.	215
Giovannelli, L.	909	Graña, D.	401	Gundogdu, B.	926, 932
		Granata, G.	921	Gunnarsson, I.	237
		Grando, S.A.	460	Günther, C.	138, 884
		Grange, C.	391	Guo, Z.	545

Gurevich, M.	300	Henjes, F.	250	Hornung, V.	992
Gurevich, V.	314, 568	Henke, J.	580	Horvath, S.	1 062
Gurrieri, F.	146	Hennig, A.	794	Horvei, K.D.	42
Gusev, S.	742	Heppe, E.N.	480	Hossain, M.	545
Gustavo, V.	854, 1 045	Herath, K.H.I.N.M.	402	Hot, A.	391
Guttek, K.	396	Herceg-Cavrak, V.	755	Hotta Osamu Clinic,	14
Guy, A.	213	Hernandez, J.	77	Hotta, O.	287
GUZMÁN-LÓPEZ, K.	103	Hernández-Molina, G.	588	Hoxha, A.	662
H. El Hilali	117	Hernández-Osorio, L.A.	860	Hoyer, B.	179
Haberland, A.	525	Herold, M.	123, 212, 502, 715	Hsu, M.	516
Hábová, V.	60	Herraziz, M.A.	223	Huang, C.	320, 323, 329
Hachulla, E.	182, 281, 947, 1 036	Hershberg, U.	88	Huang, C.Y.	313
Hadzija, M.	594	Hervier, B.	443	Huang, Q.	1 063
Häggmark, A.	250, 319	Hibbs, M.	629	Huang, R.	1 063
Hahn, S.	303	Hie, M.	279	Huang, X.	33
Haider, A.	675	Hiemann, R.	537, 774	Huanjian, F.	994
Hajjej, Z.	352	Hiepe, F.	179, 490, 943	Hue, S.	384, 587
Hakonarson, H.	651	Hiller, B.	794	Hughes, G.	23
Haladyj, E.	695	Hin oš, M.	782	Huijbers, M.	1 056
Hamann, D.	777	Hintzen, R.Q.	491, 492, 777	Huizinga, T.	145
Hamid Mazouz	117	Hirohata, S.	43, 45, 517	Huizinga, T.W.J.	584
Hamidou, M.	279, 281, 443	Hirose, M.	935	Humphreys, D.	745
Hamiel, O.	13, 470	Hisada, R.	801	Hunzelmann, N.	780
Hammami, S.	74	Ho, C.	752	Hupperts, R.	879
HAMMERS, C.M.	88	Ho, R.	752	Hutsebaut, M.	68
Han, E.J.	402	Ho evar, A.	378	Hutu, D.P.	504
Handgretinger, R.	875	Hoffmann, C.	719, 723	Hyvarinen, S.	882
Handono, K.	416, 1 010	Hoffmann, M.	919, 1 050	Iaccarino, L.	233, 368, 438, 472, 708, 751, 863
Hannah, J.	754	Hoffmanová, I.	60	IAGSA, S.G.	650
Hardwick, T.	39	Hofner, K.	735	Iaiani, G.	160
Haritonov, A.	1 051	Hogervorst, J.M.	491	Iannella, G.	921
harlé, J.R.	341, 791	Hoglund, P.	280	Iannucelli, C.	641
Har-Noy, O.	716	Hokstad, I.	264	Ibañez, M.	36
Harzoun, S.	587	Holder, S.	64, 779	Ibrahim, S.	81
Hasanah, D.	1 010	Hollan, I.	264, 487, 557, 636	Ibrahim, S.M.	88, 268
Hasenclever, D.	105	Holl-Ulrich, K.	38	Idborg, H.	237
Hass, C.	465	Holm, L.	924	Ieiri, N.	287
Hatron, P.Y.	182	Hölscher, C.	1 005	Ifergan, I.	1 006
Hawkes, J.	474	Holthoff, H.P.	526, 853	Illes, Z.	882
Hayek, J.	513	Holy, B.	958	Imai, K.	287
Hazime, R.	366	Hong, M.G.	250	Imperiali, M.	892
Healey, R.	779	Hooijkaas, H.	312	Indriyaningrum, N.	46
Hearth-Holmes, M.	441	Höpner, U.	214	Infantino, M.	124, 211, 374, 776, 824, 1 069
Heidecke, H.	202, 564	Horita, T.	356, 801	Ingegnoli, F.	203, 694, 1 064
Heim, J.	735	Hormaza, A.	70, 638	Invernizzi, P.	530, 532
Hejazenia, F.	54	Horn, S.	354	Ioannidou, A.	905
Hellmark, T.	924	Horn, T.	715	Ionescu, R.	242, 684
Hellström, C.	66	Hornberg, J.	94	Irure-ventura, J.	104, 215, 355
Helyes, Z.	474				

Isabelle, L.	337	Jimenez, J.	375, 937	Kampar, P.	711
Isailovic, N.	1 037	Jimenez, M.R.	36	Kanazawa, N.	136
Ishikawa, L.	400	Jiménez-Escrig, A.	720	Kanda, M.	801
Ishikawa, L.L.	403, 864	Jin, H.M.	48	Kanduc, D.	11, 284, 285
Ishikawa, L.L.W.	195	Jingyi, L.	414	Kane, P.	972
IslasJacome, F.	394	Jinton, L.	802	Kaplanski, G.	341, 443, 642
Israeli, A.	716	Jirholt, J.	94, 413	Kappel, R.	971
Isramiharti, I.	711, 934	Joaquin, O.	375	Kappler, M.	744
Issekutz, A.	783, 787	Joëlle Gregoire-Gauthier	790	Karayev, D.	827
Itaya-Hironaka, A.	1 009	Johanet, C.	426	Karmakar, A.	49
Ivanova-Todorova, E.	598	Johansson, C.	94	Karussis, D.	509, 1 035
Ivarsen, P.	717	Jokiranta, T.S.	882	Karwan, M.	535
Jaatinen, T.	577	Jones, C.	1 006	Käsermann, F.	108, 109
Jackson, S.	802	Jönsson, E.	319	Kaski, J.C.	839
Jacques, P.	281	Joos, A.	590	Kasler, M.	1 062
Jakobsson, P.J.	237, 898	Joosten, L.	793	Kasprick, A.	465, 935
Jamaluddin, M.	957	Jordan, M.	615	Kasuma, N.	267
Jamin, C.	126, 181, 245, 247, 521	Jordan, N.	452	Katchan, V.	342, 858
Janas, R.	710	Jördens, M.	614	Kato, M.	356, 801
Janket, S.	130	Jorgensen, C.	204, 1 007	Katz-Agranov, N.	156
Janssen, G.	995	Jose Carrilho, F.	1 048	Katzav, A.	885
Janssen, M.	492	Jose Seena Padayattil	660	Kauderer, C.	465
Jara Quezada, L.J.	15, 961, 964	Jourde-Chiche, N.	443	Kaufmann, M.	611
Jara, L.	266	Jousse-Joulin, S.	182, 604, 930	Kaufmann, U.	479
Jara, L.J.	696	Jozsi, M.	882	Kaveri, S.	786, 976
Jarius, S.	303	Juan Manuel, S.H.	394	Kayserova, J.	569
Jarrot, P.A.	443	Juarez, C.	586	Kazic, K.	929
Jaume Alijotas-Reig	966	Julia, A.	375	Keating, B.J.	651
Javor, S.	993	Julia, M.R.	36	Kechida, M.	74, 729
Jaxaira, M.	574	Julien, H.	337	Kee, S.J.	48
Jayne, D.	280	Jullien, D.	391	Kelder, H.	603
Jean Emmanuel, K.	337	Jun, J.	385	Kelkka, T.	577
Jean Francois, D.	337	Jung, J.Y.	583	Kemna, M.	805
Jeandel, P.Y.	960	Jung, K.H.	739	Kerekes, G.	977
Jee, Y.	402	Jurado, F.	355	Kern, J.	518
Jeffrey, B.	946	Just, D.	319	Kerstein, A.	38
Jens, S.	981	Kaesermann, F.	787	Ketelslegers, I.A.	777
Jensen, K.L.	548	Kahaly, G.	843, 847	Kettritz, R.	806
Jeremias, P.	90, 102, 103, 362, 527, 528, 674	Kahn, J.	279	Khademi, M.	302
Jeribi, A.	800	Kahn, J.E.	281	khansa, R.	608
Jerke, U.	806	Kalden, J.	1 011	Kharitidis, A.	1 051
Jesús, G.R.D.	811	Kalich-Philosoph, L.	286	Khazaei, A.	54
Jesús, N.R.D.	811	Katies, K.	935	Khazaei, B.	54
Jiang, X.	804	Kalim, H.	46, 416, 733, 738, 1 010	Khazaei, H.A.	54
Jiao, W.	619	Kaliouli-antonopoulou, C.	905	Khochtali, I.	74
Jimenez, C.A.	180	Kamel, M.	359	Khodadadi, L.	179
		Kamerling, S.W.A.	91	Khouatra, C.	391
				Kim, A.	402
				Kim, G.O.	402
				Kim, H.A.	583
				Kim, J.E.	47



Kim, S.	535	Kozmar, A.	240	Lagier, R.	769
Kim, T.J.	381, 739	Kraaij, T.	91, 584	Lagstrom, S.	577
Kimberly, R.P.	441	Krämer, A.	1 051	Lakota, K.	378
Kivity, S.	348, 601, 677, 712, 716, 861, 862	Krammer, P.H.	78	Lallemand, C.	493
Klassen, L.W.	441	Kramp, S.L.	827	Lamacchia, C.	896
Kleinert, H.	580	Krarup, E.	717	Lambeau, G.	453
Klii, R.	74	Kratzsch, J.	96	Lambert, J.	624, 626, 928
Klöpffer, J.	935	Krautwald, S.	806	Lambert, M.	279
Klotz, W.	212, 715	Kreye, J.	724	Lamprecht, P.	38
Klumb, E.M.	811	Kribben, A.	838	Landmann, A.	466
Kniesch, K.	126	Kromminga, A.	165, 168	Landolfo, S.	916
Knowland, D.	516	Kronbichler, A.	280	Landron, C.	281
Knuschke, P.	884	Kronimus, Y.	613, 617	Lang, U.	354, 815, 816
Kockum, I.	302	Krotkova, A.	39	Langan, E.	268
Koenders, M.	161, 793, 1 007	Kruglov, A.	573	Langevitz, P.	633
Koenders, M.I.	412	Krutrök, N.	802	Lanio, N.	410
Kohlschmidt, J.	1 050	Kudryavtsev, I.	234	Lanzone, A.	326
Koike, T.	950	Kuhn, A.	457, 466, 692, 876	Lapin, S.	234, 730, 1 051
Koivuniemi, R.	577	Kuhn, I.	617	Lara Salazar, M.A.	836
Kokkoris, S.	905	Kuijpers, J.H.S.A.M.	312	Larosa, M.	233, 368, 438
Kokosadze, N.	71	Kulshrestha, D.	565, 570	Lascu-Dubos, G.	1 036
Kolitz, T.	156	Kumar Khajuria, R.	577	Laska, M.J.	768
Kolligs, C.	947	Kumar, P.	639	Lavigne, C.	279, 281
Koloušková, S.	569, 546	Kümpfel, T.	303	Laviola, G.	576
Kolovetsiou- Kreiner, V.	354, 816	Kungl, A.	479	Lavrovsky, Y.	39
Komorowski, L.	303, 778	Kunstner, A.	268	Layouni, S.	917
Kondza, K.	755	Kuo, C.C.	702	Lazarus, A.	111
König, N.	138	Kuret, T.	378	Lazurova, I.	541, 635
Konikoff, F.M.	630	Kurniawan, A.	340	Lazzari, G.	597
Kono, M.	801	Kushak, R.	596	Lazzaroni, M.G.	958
Konsta, O.D.	649	Kusworini, H.	738	Le Besnerais, M.	338
Kooten, C.	91	Kütt, M.	718	Le Blaye, I.	265
Kopecky, O.	938	Kuuliala, A.	577	Le Dantec, C.	649
Kopic, A.	338	Kuuliala, K.	577	Le Lann, L.	126
Kopylov, U.	630	Kuwana, M.	310	Le Panse, R.	478
Koren, O.	155, 163	Kuzenko, A.	339, 958	Le Quetlec, A.	204
Korf, H.	567	Kuzmina, N.	894	Leal, B.	563, 703, 870
Korsholm, T.	717	Kwak-Kim, J.	321, 324	Leandro, M.J.	640
Kortbeek, T.	269	Kwekkeboom, J.	789	Leban, J.	258
Koslow, M.	601	Kwiatkowska, B.	764	LEBESNERAIS, M.	697
Kosmehl, H.	907	Kyle, W.	9	Lébl, J.	569, 546
Kostic, I.	612	Kyurkchiev, D.	598	Leboyer, M.	723
Kotlan, B.	1 062	Labbene, I.	352	Lederer, S.	778
Kotra, L.P.	110	Labrador Horrillo, M.	586	Lee, C.	51, 55
Koufomichali, X.	905	Lackner, H.K.	354	Lee, J.C.	402
Koutsoumpas, A.	914	Lacroix, R.	341	Lee, J.W.	47
Kovacevic, A.	929	Laddha, N.	639	Lee, K.E.	47
Kovacevic, J.	72	Lafreniere, R.	562	Lee, S.K.	739
				Lee, S.S.	47
				Lee, W.	402
				Lee, W.P.	721

Lee-Kirsch, M.	332, 1 000, 1 003	Lindfors, K.	101	Lu, Y.	752
Lee-Kirsch, M.A.	138, 884	Lindhoff-Last, E.	357	Lucas, A.C.	923
Lefaucheur, J.P.	384	Lindholm Carlström, E.	319	Ludeña-Cruz, M.D.	53
Leffler, D.	100	Linkermann, A.	806	Ludwig, F.T.	39
Lefkou, E.	339	Lioger, B.	281	Ludwig, R.	81, 464, 465, 935
Lega, J.C.	391	Lionel Benchimol	790	Ludwig, R.J.	80
Lehmann, J.	919, 1 050	Lionel, C.	330	Ludwig, S.	363
Leierer, J.	280	Lippi, G.	431, 904	Luecke, K.	907
Leila, F.	854, 1 045	Liszky, G.	1 062	Lueking, A.	147, 430
Leirisalo-Repo, M.	577	Little, D.	288	Luetjens, C.M.	39
Leite Dantas, R.	358, 363	Liu, A.	415	Lugari, L.	713
Leite de Oliveira, F.	476	Liu, L.	51, 55	Luger, T.	461, 466
Lemoni, A.	377	Liu, S.	899	Luis Eduardo C. Andrade	422
Lenaerts, J.	373	Liu, X.	228	Luisetto, R.	472, 476, 477, 751
Lens, A.	937	Liu, Y.	602	Luján, L.	10, 152, 969
Leoncini, S.	513	Liuchang, F.	994	Luka Bajalo, J.	594
Lerner, A.	26, 90, 102, 103, 527, 528, 592, 596, 630, 674	Livneh, A.	992	Lunardi, C.	758, 762
Leroy, J.	52	Llano Hernandez, K.	223	Lund, M.	159
Leubner, J.	724	Llop Vilaltella, M.	1 047	Lundelin, K.	339
Leuci, S.	134	LLurba, E.	339	Lundqvist, A.	802
Leukel, P.	885	Lo Schiavo, A.	139	Lung, T.	618
Leung, P.	535	Lo, Y.	185, 395	Luning Prak, E.T.	88
Levo, Y.	988	Lobo Antunes, M.	392, 732	Lupetti, M.	909
Levy, P.	958	Lochouarn Andreani, M.	800	Lupidi, F.	116
Levy, R.A.	483, 811	Logullo, F.	116	Luppa, P.	357
Levy, Y.	292, 434	Lohse, M.	853	Lutalo, P.	727
Li, H.	651	Lojacono, A.	817	Lüthke, K.	214
Li, J.	51, 651	Londrino, F.	243	Lutovac, D.	929
Li, M.T.	707	Lopergolo, L.	792	Lutteri, L.	911
Li, Q.	51	Lopez Herrera, G.	417	Lüttich, T.	56
Li, S.	441	López San Román, A.	1 047	Lux, A.	113
Li, Y.R.	651	Lopez Velez, M.D.S.	246	Lyne, P.	802
Li, Y.Y.	313	Lopez, L.	559	M. Benucci	216
Li, Z.	404, 526	López-Díaz, P.E.	860	M. D'Amico	451
Lian, R.	323, 329	Lopez-Herrera, G.	475	M. Infantino	216
Lian, R.C.	313	López-Hoyos, M.	104, 215, 355	M. Mahler	216
Liang, P.	329	LopezRodriguez, W.	394	M. Manfredi	216
Liaskos, C.	914	Lorenz, H.M.	138	M. Moumni	117
Libert, C.	397	Lorenzo Villalba, N.	74, 726, 729	Ma, J.	997
Lichtbroun, A.	1 025	Losen, M.	723	Ma, Z.	55
Licini, L.	597	Lotufo, S.	226	Macaubas, C.	425
Lidar, M.	469	Louail, A.	571	Maccallum, C.	489
Lightstone, L.	448	Lounici, Y.	222	Macchioni, P.	865
Liljevald, M.	94	Loza Santamaría, E.	1 047	Macini, R.	901
Lim, J.A.	739	Lu, Q.	643, 646	Macor, P.	127
Lin, J.	997			Macri, S.	576
Lindblad, U.	158			Maddox, D.	248
Lindeberg, S.	158			Maestroni, C.	597

Maggiore, C.	260	Marcenaro, C.	52	Massaro, L.	160, 887
Mägi, M.	718	Marchese, C.	538	Massarotti, M.	1 037
Magliozzi, R.	576	Marchesoni, A.	653	Mathias, A.	376
Magliulo, G.	921	Marcorelles, P.	182	Mathias, H.	946
Magnusson, D.	485	Mardor, Y.	862	Mathieu, C.	567
Magrini, E.	383	Marek Woynarowski	991	Mathilde, H.B.	337
mahevas, M.	791	Maria Giovanna, D.	115	Matsumoto, K.	81
Mahler, M.	35, 127, 213, 214, 215, 694, 773, 776, 896, 900, 979, 995	Maria, A.	204	Matsuura, E.	419, 423, 559
Maier, N.	724	Maria, G.	854	Matsuura, M.	348
Maitte, M.	591	Marianetti, M.	887	Matthias, K.	424
Majdi, G.	594	Mariani, F.	249	Matthias, S.	756
Majstorovic, I.	612	Marie, I.	252, 253, 279, 503, 616, 922, 1 046	Matthias, T.	90, 97, 102, 362, 527, 528, 590, 596, 630, 674
Malaiya, R.	727	marieke, R.	608	Mattsson, C.	66
Malgorzata, M.	704	Marin Sanchez, A.	996	Matucci Cerinic, M.	196, 199
	991	Marin, A.	586	Matucci-Cerinic, M.	389
Mali ková, K.	782	Marinangeli, L.	115	Maulucci, G.	328
Malik, M.	442	Marinho, A.	563, 703, 869, 874	Maumus, M.	204
Malik, R.H.	728	Marius, H.	239	Maurer, B.	780
Malorni, W.	641	Mark I.G.	334	Maurier, F.	958
Malyavantham, K.	212, 599, 602	Marnetto, F.	725	Mausservey, C.	391
Mame Massar Dieng	790	Maroun, M.C.	1 060, 1 061	Mayer, G.	280
Mamrut, S.	652	Marques, R.	923	Mayer-Pickel, K.	815, 354, 816
Mancarella, F.	567	Marques, T.	256	Mayorita, P.	983
Mancinetti, C.	538	Marques-Garcia, F.	53	Mazdeh, M.	610
Mancini, S.	249	Marschner, G.	38	Mazodier, K.	341
Mandolfino, M.	852	Marshall, T.	187, 190	Mazza, G.	817
Mané Damas, M.	723	Marta, V.	87	McAdoo, S.	449
Manenti, A.	249	Martin, J.	260	Meacci, F.	124, 374, 776, 1 069
Manetta, T.	538	Martinelli, E.	713		
Manfredi, M.	124, 374, 776, 824, 1 069	Martinelli, M.	967	Meddour, Y.	582
Manfredini, M.	984	Martinet, J.	338	Medina Escobar, P.	618
Manganelli, S.	900	Martinez Gallo, M.	996	Medina, G.	693, 696, 964
Mangino, G.	183, 835	Martinez T, G.	591	Meek, B.	603
Mankai, A.	917	Martinez, M.A.	586	Mehdi, A.M.	76
Manning, A.	112	Martínez-Flores, J.Á.	455, 825	Meka, R.	1 008
Manno, A.	921	Martinez-Martinez, P.	723	Mekinian, A.	279, 281, 918, 958
	452	Martínez-Taboada, V.	215, 355	Melegari, A.	431, 828, 904
Manrique, S.	743	Martinovic Kaliterna, D.	306	Melief, M.J.	491, 492
Mantilla, R.D.	931	Martins da Silva, B.	563, 703, 868	Mellins, E.	425
Manz, R.A.	88	Martins, N.	259	Melnichuk, T.	339
Maor, E.	716	Martos, G.	504	members of EASI Austria, .	715
Marana, R.	328	Marzena, O.	704	Membrey, B.	338
Maranda, E.	937	Mascia, M.T.	249	Menard, M.	111
Maranon, C.	126	Maslińska, M.	764	Mendes, A.	906
Marasovic Krstulovic, D.	306	Maslyansky, A.	234	Méndez Huerta, N.V.	836
Marcatili, P.	548			Méndez-Flores, S.	588

Menezes, M.F.	536, 1 044	Mirza Zaka, P.	416	Mueller, A.	38
Meng, W.	88	Missio, A.	864	Mueller, J.	525
Menon, B.	727	Miteva, P.	731	Muench, G.	853
Mercuri, E.	382	Mitreviski, M.	184, 767	Mulder, J.	302
Merheb, V.	515, 881	Mitsios, N.	302	Mulder, P.	338
Merlach, P.	538	Mitsis, C.	893	Muller, G.	279
Meroni, P.	1 064	Miyaoka, T.	1 009	Münch, G.	526
Meroni, P.L.	27, 127, 203, 411, 487, 504, 553, 557, 653, 659, 664, 694, 809, 948, 955	Miyara, M.	65	Muramoto, F.J.	376
Mesbah-Amroun, H.	701	Mo, Y.	997	Muratore, F.	865
Messaoudi, K.	897	Modesto Caballero, C.	996	Muratori, L.	249, 531, 534
Messas, E.	279	Moertl, M.	816	Muratori, P.	249
Messiaen, A.S.	241	Moghaddam, A.	315	Murdaca, G.	225, 229
Metsküla, K.	550	Mohr, A.	247	Murgo, A.	203
Metwally, L.	235	Moinuddin, .	549	Murugan, R.	724
Metzger, A.L.	827	Mok, M.Y.	185, 395	Murwani, S.	416
Meuleman, L.	928	Mold, M.	3	Mu abaK, U.	352
Meyer, W.	824	Molenaar, P.	723	Musial, J.	353
Michael, B.	424	Molina Fuentes, A.	36	Musset, L.	65
Michallet, M.	616	Moll, C.	36	Mustjoki, S.	577
Michaud, M.	277	Möller, M.	614	Mustofa, E.	416
Michaud, S.A.	52	Molnár, I.	890	Muzalevsкая, M.	314
Midiri, M.	367	Mona Hamed	552	Mytilinaiou, M.	914
Migliara, G.	328	Mondini, S.	368	Naeun, L.	364, 998
Mignogna, M.D.	129, 135	Monika, J.	704	Naftali, T.	561
Mihaljevic, O.	612	Monogioudi, E.	504	Nagel, M.	564
Miketic, N.	929	Monov, S.	731	Naguwa , S.	1 018, 1 022
Mikita, N.	136	Montagna, G.	892	Nagy, L.	977
Milano, V.	382	Monteiro, A.	699	Nahary, L.	304
Miller, A.	652	Montes, M.	36	Naides, S.	208, 217, 769
Miller, S.	1 006	Monti, C.	609	Najirman, N.	711
Milo, R.	295, 299	Montomoli, C.	609	Nakamura, H.	356, 801
Milosevic, G.	72	Moore, R.	615	Nallasivan, S.	173
Milosevic- Djordjevic, O.	612	Morales, J.M.	455, 825	Nalli, C.	339
Mimori, T.	123, 307, 310	Morales, R.	403	Nalotto, L.	438, 708, 863
Mimura, L.A.	403, 864	Morariu, R.	115	Naor, D.	941, 945
Mimura, L.A.N.	195	Morell Hita, J.L.	1 047	Napalkova, O.	730
Mina, C.	887	Morini, A.	1 049	Naparstek, Y.	747, 990
Minadze, E.	568	Morozi, G.	824, 900, 909	Napodano, P.	243
Mineo, C.	33	Morris, R.I.	827	Naranjo, J.C.	1 027
Minota, S.	517	Morshed, S.	849	Naretto, C.	73
Miodovnik, M.	268	Mosca, M.	795, 798	Nasi, M.	607, 984
Miossec, P.	28, 1 002	Mosheta, E.	912	Nasser, M.	587
Miranda, F.	87, 160, 454	Mota, Â.	699	Navarra, S.	746, 749, 1 012
MIRANDA, S.	697	Mothes, T.	105	Navarro, E.P.	70
Mirault, T.	279	Motta, M.	817	Nawrot, I.	710
mirello, C.	698	Moudgil, K.	1 008	Nedospasov, S.	573
		Moulaei, N.A.	54	Néel, A.	279
		Moura, R.A.	259, 640	Negrini, S.	229
		Mouthon, L.	198, 201, 506	Negru, M.M.	242, 684
		Movafagh, A.	610	Neidhoefer, S.	90, 102, 362, 527, 528

Neidhöfer, S.	103	Oku, K.	356, 801	Pappa, E.	905
Nel, H.J.	76	Olasz, J.	1 062	Parackova, Z.	569
Nel, L.	727	Olesi ska, M.	796, 799, 695	Paradowska-Gorycka, A.	700, 704
Nembrini, F.	597	Olga, A.	356	Paramanathan, R.	212
Németh, P.	841	Oliveira, J.C.	563	Pardali, K.	413
Nerdjess, O.	387	Oliveira, L.	403	Parga, L.	1 007
Neschadim, A.	110	Olivier, F.	330, 337	Park, D.J.	47
Neves, E.	126, 563	Olivieri, I.	650	Park, K.I.	739
Nexø, B.A.	768	Olschowka, N.	496	Park, O.	535
Ngcozana, T.	389	Olsson, T.	302	Park, Y.J.	364, 998
Nguyen, T.K.	881	Olteanu, R.	254	Park, Y.W.	48
Nicaise Roland, P.	958	Omersel, J.	973	Parmeggiani, M.	904
Nicaise-Roland, P.	426	Ometto, F.	708, 927	Pärmpuu, L.	548
Nicolas, N.	337	Omrani, M.D.	610	Parodi, A.	993
Nicole, F.	391	Omura, K.	356, 801	Parodis, Y.	729
Nicolino-Brunet, C.	341	Ongena, N.	398	Pascale, N.	330
Nielsen, H.H.	882	Opris, D.	242, 684	Pasquariello, B.	921
Niesik, S.	258	Orcesi, S.	650	Pastorelli, L.	916
Niks, E.	1 056	Orel, R.	594	Patel, D.	639
Nilsson, M.	802	Oren, A.	630	Patricia, J.	596
Nilsson, P.	66, 237, 250, 302, 319	Ortisi, G.	243	Patsinakidis, N.	466
Nimmerjahn, F.	113	Ortona, E.	641, 901	Pautz, A.	580
Nissen, M.	896	Oscar, C.M.	455	Pavlovskaya, A.	71
Nissim, A.	260	Ospina, F.E.	180, 638	Payre, C.	453
Noël, D.	204	Ott, A.	824	Paz-Artal, E.	455, 825
Nogales-Gadea, G.	723	Ottaviani, R.	967	Pazzola, G.	865
Noris, F.	597	Oueslati, R.	352	Peakman, M.	489
Norman, G.L.	35	Ouikhlef, N.	571	Pedersen, B.B.	717
Noronha, C.	392, 732	Oyaert, M.	125, 255	Pedersen, H.L.	42
Nosari, G.	609	P. Napodano	451	Pedini, V.	115, 116
Novelli, L.	440, 925	P. Sarzi-Puttini	216	Pedrazzoli, R.	59
Novick, D.	642, 1 066	Pacheco-Molina, C.	588	Pellacani, G.	984
Nozinic, S.	466	Pacucci, V.	454	Pellegrini, G.	411
Nuic, M.	306	Pacucci, V.A.	160	Pellerito, R.	653
Nuñez Beltran, M.	223, 224	Pagani, S.	753	Pelus, E.	616
Nunez, H.	595	Pal, R.	442	Penatti, A.E.	653
Núñez-Beltrán, M.	32	Pallares, L.	36	Penders, J.	241
Nuri, E.	948	Palová-Jelínková, L.	546	Pendolino, M.	87, 641, 901
Nydegger, U.	618	Palshina, S.	71	Penello, L.	589
Öberg, L.	802	Pandey, B.D.	370	Pengo, V.	662, 951, 952, 959
Obermanová, B.	546	Panicker, S.	465	Pennaforte, J.L.	443
Obermayr, F.	258	Panozzo, M.P.	826, 1 049	Pere, F.	375
O'Brien, B.	159	Paola, M.	73	Pérez Lara, J.C.	417
Ochoa Grullón, J.	223	Pap, R.	841	Perez Mendez, D.	455
Ochoa-Grullón, J.	32	Papadopoulou, A.	893, 912	Perez, D.	825
Oczachowska-Kulik, A.	717	Papageorgiou, L.	912	Perez-Zaragoza, S.	595
O'Dell, J.R.	441	Papalardo, E.	957	Perkovic, D.	306
Ohlsson, S.	920, 924	Papini, A.M.	513	Perosa, F.	524
Okamoto, H.	517	Papo, T.	281	Perri, V.	792

Perricone, C.	160, 293, 317, 325, 347, 361, 887, 901, 1 053, 1 055	Pirttinen, H.	769	Punzi, L.	927
Perricone, R.	741, 325, 440, 713, 925, 986, 989, 1 013	Pisani, L.F.	916	Puppo, F.	229
Perruzza, L.	411	Pispati, P.	766	Purohit, M.K.	110
Pers, J.	1 020	Pistis, C.	31	Pusey, C.	444, 447
Pers, J.O.	126, 178, 181, 182, 247, 486, 604, 930	Pistono, C.	606, 609	Pusztai, A.	977
Persijn, L.	241	Pitann, S.	38	Puttaraksa, K.	769
Pertuiset, E.	281	Platt, M.	516	Putterman, C.	176, 177
Perusquía Ortiz, A.M.	466	Platzgummer, S.	590	Qian, Y.	137
Pervakova, M.	730	Plaza-López, A.	103	Qin, F.	55
Pesce, G.	243, 826	Plebani, M.	589	Qingyu, C.	179
Peschke, K.	794	Plomp, J.	1 056	Qiuye, G.	414
Pesente, F.	211	Plothe, C.	807	Quaden, D.	311, 427
Peter, L.	551	Pochard, P.	486	Quaglia, M.	753
Peterle, D.	959	Polido-Pereira, J.	259	Quaresma, C.	259
Petersen, F.	418, 465, 1 063	Poliska, S.	977	Quattrocchio, G.	73
Petric, M.	306	Polo-Trujillo, M.	1 027	Quemeneur, T.	281
Petroff, D.	105	Pomaredes, A.	52	Quesada, J.L.	150
Petruschke, H.	919	Pontisso, P.	472	Quesada-Masachs, E.	996
Petrželková, L.	546	Popovych, Y.	744	R.A. Sinico	451
Pianta, A.	763	Porat Katz, B.S.	856	Raats, J.	149
Picanza, A.	431, 904	Porkka, K.	577	Rabelink, T.J.	91, 584
Picardo, E.	339	Potocnik Dajcman, N.	915	Rachid Cancado, E.L.	1 048
Picarelli, G.	317	Pournou, A.	893, 912	Radbruch, A.	179
Piche, T.	960	Pozzi, N.	959	Radic, M.	306
Pichler, A.	354	Prado, M.	369	Radice, A.	451
Pierdominici, M.	641	Prager, K.	362	Radice, A.	238, 243, 908, 909
Pierre Yves, J.	337	Prak, E.T.L.	651	Radochova, V.	938
Pierre, P.	150	Pras, E.	682	Raffener, B.	927
Pieter, v.P.	186, 193	Pratesi, F.	909	Ragusa, F.	850
Pikula, M.	371	Praver, M.	666, 669	Rajala, H.	577
Pilli, D.	515	Prechl, J.	111	Rajcani, J.	429
Pin, E.	250	Predeteanu, D.	242	Ralph, G.	424
Pinal Fernandez, I.	586	Pregolato, F.	487, 653, 909	Ramachandran, V.G.	442
Pinegin, B.	399	Prelog, M.	735	Ramanathan, S.	881
Pinelli, E.	269	Prenek, L.	841	Rami, M.	366
Pinhas-Hamiel, O.	286	Prete, M.	524	Ramírez, A.	390
Pinho e Costa, P.	703	Previtali, G.	597	Ramos Medina, R.	224
Pinti, M.	607, 984	Priori, R.	317	Ramos, D.	104, 215, 355
piperoglou, C.	791	Privitera, D.	203	Ramsperger, V.	212
Pipi, E.	377	Probst, C.	303, 778	Raoul, C.	77
Pires Abrantes-Lemos, C.	1 048	Prodam, F.	916	Raschi, E.	203
Pirisi, M.	59, 753	Profumo, E.	886	Råstam, L.	158
Pirone, C.	887	Prohaszka, Z.	882	Ravasio, R.	597
Pirot, N.	204	Pruhová, Š.	546	Ravera, F.	243
		Pruijn, G.	821, 940	Reale, M.	736, 980
		Prüss, H.	724	Recke, A.	88
		Puca, R.V.	139	Reddy, V.	640
		Pucci, G.	900	Reding, T.	551
		Puechal, X.	443		
		Pulsoni, A.	767		

Rafaat, R.	683
Reggia, R.	233, 438, 817
Reggio, R.	863
Reicht, G.	829
Reinhold E, S.	239, 318, 424
Reinhold, D.	393, 396, 774
Reis, A.I.	392, 732
Rekvig, O.P.	42
Renaudineau, Y.	486, 604, 649, 883, 930
Rengers, P.	488
Rentouli, S.	914
Repo, H.	577
Resche Regon, M.	279
Reynolds, T.	485
Ria, F.	328
Ribeiro, N.	699
Ribeiro, R.	536, 1 044
Ricard Cervera	657
Riccieri, V.	909
Richard, V.	338
Richter, J.	147, 430
Riekert, M.	735
Riemekasten, G.	38, 86, 197, 202
Riemschneider, S.	1 050
Riesco, L.	104
Rieu, P.	443
Riganò, R.	886
Rigante, D.	678
Rijvers, L.	491, 492
Rinaldi, S.	368
Risch, L.	618
Roat, R.	545
Röber, N.	214, 428, 537
Robert, S.	341
Roberta, F.	73
Robier, C.	829
Robinet, M.	478
Robles-Marhuenda, Á.	339
Roccatello, D.	73, 878
Rodeghiero, F.	744
Rodrigues, A.	923
Rodriguez Alba, J.C.	417, 836
Rodriguez De Frias, E.	223
Rodriguez Frias, E.	224
Rodriguez, C.	591
Rodriguez, I.	591
Rodriguez, J.C.	729

Rodriguez-Alba, J.C.	475
Roeleveld, D.	1 007
Roeleveld, D.M.	412
Roers, A.	794
Roggenbuck, D.	127, 537, 554, 774, 916
Rogier, R.	161, 412
Roi, M.	300
Roic, G.	755
Roide, A.	426
Rolf, G.	946
Rolla, D.	243
Romano, F.	139
Romão, V.	259
Romay-Penabad, Z.	957
Romeo, D.	382
Romeo, G.	835
Romero Ramírez, H.	417, 836
Romero, R.L.	65
Romero-Ramirez, H.	475
Romito, A.	538
Ronco, P.	445, 690
Roncucci, L.	249
Ronda, N.	557, 1 064
Ronda, N.	636
Rondeau, E.	443
Ronnelid, J.	981
Rosado, M.M.	792
Rose, N.R.	24
Rose, T.	490
Rosenthal, E.	83, 960
Rossini, A.	59
Rossow, K.	248
Rottiers, P.	567
Roussinov, D.	731
Roux-Lombard, P.	896
Rouzaire, P.	897
Rovere-Querini, P.	339
Rovero, P.	513
Rowley, T.	745
Rowter, D.	787
Roy, S.	1 005
Rozen, L.P.	608
Rua, J.	923
Ruano, A.	339
Rudin, A.	413
Rudolph, S.	214
Rudrangi, R.	957

Ruffati, A.	339
Ruffatti, A.	662, 958
Ruffilli, I.	850, 851
Ruhrman-shahar, N.	292
Ruiperez, V.	595
Ruivo, J.	765
Ruiz Requena, R.	246
Ruiz-Olivera, M.D.R.	860
Ruland, V.	466
Ruoslahti, E.	1 008
Russo, A.	431, 828, 904
Rutten, B.P.	723
Sá, J.D.	376
Saad, F.	675
Saarela, J.	577
Saarimaki, J.	313, 329
Saavedra, M.A.	964
Saavedra-Díaz, C.	638
Sabatini, P.	698, 34, 909
Sablon, N.	729
Sabrina, R.	318
Sabrina, S.	946
Saccon, F.	233, 476, 477
Sacharidou, A.	33
Sachdeva, R.	442
Sack, U.	621, 775
Sadeghi, H.	1 059
Sadoun, A.	744
Sáez-Salgado, R.	244
Sagcan, M.	230
Sahan, A.G.	230
Sainaghi, P.P.	59, 753
Sakuma, Y.	45
Sakuramoto-Tsuchida, S.	1 009
Salama, A.	744
Salmi, L.	753
Salmon, J.	33
Salsac, C.	77
Salvado, M.	743
Salvarani, C.	865
Salvi, S.	326
Samavedam, U.	935
Samsonov, M.	39
Samuelsson, E.	802
Sánchez Ramón, S.	224
Sánchez, A.Y.	180
Sánchez, D.	60
Sánchez, V.	591

Sanchez-Martin, F.	595	Scheibenbogen, C.	564	Segelmark, M.	499, 837
Sánchez-Ramón, S.	223, 788, 32	Scherer, H.U.	91	Seghezzi, M.	597
Sanganeh, H.	802	Schierack, P.	127	Seguso, M.	589
Sangle 1st joint author, S.	452	Schimizzi, G.F.	169	Seitz-Polski, B.	800, 453
Sangle joint 1st author, S.	727	Schimke, I.	525	Sela, M.	514
Sangle, S.	278	Schimmel, H.	504	Seleznik, G.M.	551, 946
Santaguida, G.	850	Schinnerting, K.	76, 574	Selmi, C.	131, 494, 1 037
Santaguida, M.G.	835	Schioppo, T.	203, 694	Selva O'Callaghan, A.	586
Santoro, D.	243	schleinitz, N.	791	Sena, P.	249
Santos, J.	316	Schlembach, D.	816		236
Santos-Argumedo, L.	475	Schlueter, B.	910	Sepp, N.	219
Saroux, A.	486, 178, 182, 604, 930	Schlumberger, W.	805, 827	Sepúlveda, A.	76
Sardy, M.	462	Schmalzing, M.	735	Sepulveda-Delgado, J.	266
Sargsyan, H.	685	Schmets, G.	149	Seredkina, N.	42
Sarmiento, E.	410, 1 038	Schmidmaier, G.	315	Sergio, P.	854
Sarmiento-monroy, J.C.	931	Schmidt, E.	88, 268, 458, 463, 480, 1 005	Serrano, A.	455, 825
Sartori, A.	195, 403, 864	Schmidt, F.	884	Serrano, M.	455, 825
Sarzi Puttini, P.	1 024	Schmidt, R.E.	349, 405, 408	Serre, G.	140, 143, 148, 523
Sarzi Puttini, P.C.	487, 653	Schmidtke, L.	580	Seve, P.	281, 391
Sarzi-Puttini, P.	58, 124, 374, 673, 1 068, 1 069	Schneider, M.	147, 430, 435, 488, 780	Sevilla, M.	455, 825
Sasaki, T.	348	Schofield, J.	57, 61, 564	Seydel, A.	919, 1 050
Sato, S.	310	Scholz, H.	63, 67, 374	Sfontouris, C.	377
Satoh, M.	123, 1 037	Scholz, J.	537, 774	Shah, R.	639
Satya Wydy Yenny	711	Schomburg, L.	315	Shah, S.	548
Sauerbrey, A.	907	Schreiber, A.	806	Shalev, T.	581
Sauerland, C.	466	Schreurs, M.W.J.	312, 723	Shamkina, E.	894
Saulescu, I.	242, 684	Schriek, P.	147	Shankaran, H.	94
Savi, E.	904	Schubert, C.	396	Shanshan, Z.	994
Savola, P.	577	Schuetta, A.	315	Shardlow, E.	2
Savolt, A.	1 062	Schulte-Pelkum, J.	428, 780	Shaul, P.	33
Sayad, A.	610	Schultz, C.	418	Sheffield, W.	111
Sayganov, S.	568	Schulz, M.	794	Sheldon, J.	119, 121, 501, 504
Scambia, G.	327, 328	Schulze, F.	1 005	Shen, G.	827
Scanu, A.	476	Schulze, F.S.	480	Shen, L.	602
Scanzi, F.	967	Schulz-Knappe, P.	147, 428, 430, 488, 756, 780	Shi, G.	602
Scanziani, R.	243	Schumann, T.	794	Shiamura, S.	801
Scapellato, C.	900	Schutze, N.	735	Shida, H.	801
Scarpa, R.	792	Schwab, I.	113	Shimizu, Y.	801
Schaab, M.	170	Schwenk, J.	302	Shipaeva, E.	39
Schachner, L.	937	Schwenk, J.M.	237, 250	Shoenfeld, Y.	144, 157, 213, 286, 293, 342, 348, 361, 472, 495, 523, 581, 691, 742, 861, 862, 866, 901, 967, 970, 973, 979, 1 062
Schäfer, C.	574	Schwertassek, U.	919, 1 050	Shovman, O.	213, 581, 979
Schafer-Nielsen, C.	548	Scirè, C.A.	494	Shukina, O.	1 051
SCHAPMAN, D.	697	Seaman, A.	776, 995		
Scharf, M.	303	Sebastiani, G.	567, 909		
		Sebastien, T.	337		
		Sebbag, M.	148		
		Sediva, A.	569		
		Seemann, P.	315		



Shumnalieva, R.	731	Sokolovic, S.	985	Stephan, S.	946
Shums, Z.	35	Sola, D.	59	Stettin, M.	829
Siampani, I.	377	Sota, P.	607	Stevens, J.	723
Sibilia, J.	279	Solar, M.	244	Sthoeger, Z.	785
Sidi, Y.	716	Soledad, M.	854, 1 045	Sticherling, M.	760, 978
Siegert, E.	202	Solgi, G.	610	Stinissen, P.	373
Siepmann, D.A.M.	777	Solov'ov, I.	425	Stöcker, W.	303, 778
Sierzputowski, P.	256, 765	Somers, V.	311, 373, 427, 508, 512	Stockman, A.	928
Sifuentes Giraldo, W.A.	205, 1 047	Sommer, C.J.	885	Stoecker, W.	823
Signorini, C.	513	Sonda, S.	551	Stoian, C.	254
Silvério, R.	699	Song, H.	40	Stojkovic, V.	911
Silvestre, C.	256	Song, L.	899	Stratta, P.	753
Silvestri, T.	383	sonia, B.A.	608	Straubel, D.	396
Silvestro, E.	339	Soon-Tae, S.T.	739	Strle, K.	763
Sima, L.	227	Soriano, A.	865	Strobl, S.	258
Simon.D.Lytton	991	Sorice, M.	641, 901	Stroev, Y.	891
Simone, A.M.	607	sorrentino, A.	698	Strollo, R.	547
Simpatico, A.	900	Soto, L.	390, 574	Struck, F.	50, 56
Sinico, R.A.	243	Soufleros, K.	377	Stulginskis, M.	744
Sinmaz, N.	515	Sousa, G.	536, 1 044	SU, K.	441
Sismova, K.	569	Sousa, J.G.	536, 1 044	Suh, C.	578
ivgin, H.	230	Sousa, M.J.	536, 1 044	Suh, C.H.	583
sızmaz, S.	388	Soutschek, E.	56	Sukma Rita, R.	261
Sjekloca, N.	929	Sowa, M.	537, 772, 774	Sukrisman, L.	340
Sjöberg, R.	66, 302	Spassova, Z.	598	Šumnik, Z.	569, 546
Sjögren, A.K.	94	Specks, U.	272, 274	Sun, J.	415
Skaric, I.	755	Speeckaert, M.	241	Sun, X.	41
Skattum, L.	924	Spinelli, F.	87	Sunwoo, J.S.	739
Skogberg, G.	802	Spinelli, F.R.	160, 454, 887, 901	Sunzini, F.	741, 925
Škori , D.	72, 69	Spinello, C.	576	Suresh, L.	212, 602
Slama, B.	744	Spirig, R.	109	Suryana, B.P.P.	46
Sleeman, M.	1 006	Špišek, R.	546	Suso, J.P.	70, 180, 1 027
Slezak, R.	933, 938	Spradbery, D.	64	Suyoso, M.	738
Slobodin, G.	206	Sprecher, E.	268	Svenungsson, E.	237
Smara, M.	582	Spuls, P.	928	Swedo, S.	770
Småstuen, M.C.	264	Stanford, M.	727	Swierzewski, R.	710
Smith, E.	516	Stangel, M.	318	Synodinou, E.	377
Smolders, J.	879	Stanley, D.	615	Sytwu, H.K.	570, 702
Smolenska, Z.	371	Starling, J.	515	Szabo, Z.	882
Soares, C.	600	Staun-Ram, E.	652	Szántó, S.	977
Sobolevskaia, P.	891	Steeland, S.	397	Szekanecz, Z.	974, 977, 1 016
Sobrinho Grande, C.	205	Steere, A.	763	Szoke, A.	723
Soda, P.	124	Steidler, L.	567	Szollar, A.	1 062
Söderberg, D.	837	Steigerwald, U.	357	Szücs, G.	977
Söderberg, M.	94	Steiner, G.	82, 85	T. Stellato	451
Sodin-Šemrl, S.	378	Steinman, L.	89	Tabacco, S.	326
Sofyan, Y.	572, 575	Stejskal, V.	482, 485, 807, 972	Taddeo, A.	179
Soha M. Abd El Dayem	552	Stellato, T.	243	Taglietti, M.	817
Sokol, E.	71			Taheri, M.	610
				Takasawa, S.	1 009
				Takeda, M.	1 009

Takiishi, T.	567
Talotta, R.	487, 653
Tambuzzo, M.T.	538
Tampoia, M.	211, 725, 824, 1 073
Tan, I.	627
Tan, L.	251
Tan, W.	41
Tanaka, A.	287
Tanaka, Y.	1 009
Tanay, A.	141, 757
Tanja, B.	527
Tansey, M.	947
Tao, W.	158
Taraborelli, M.	948, 967
Tarasov, A.	269
Tarasov, S.	269
Tata, A.M.	736
Tatsina, E.	893, 912
Taylor, P.C.	1 071
Tea, F.	881
Tedesco, F.	814, 857
Teegen, B.	303, 778
Tejeda Velarde, A.	720
tekcan, A.	654
Tekus, V.	474
Tellier, Z.	877
Teng, Y.K.O.	91, 584
ter Borg, E.J.	603
Terrier, B.	443
Terroso, G.	722
Tescari, S.	959
Tesija Kuna, A.	755
Thabah, M.	370
Thakur, I.	49
Thaler, M.	357
Theresia, R.	946
Thiyagarajan, D.	37, 42, 262
Thomas, K.	611
Thomas, M.	95, 98
Thomas, Q.	337
Thomas, R.	76
Thomé, R.	403
Thorén, A.	802
Thulin, P.	94
Thurau, S.	258
Tian, X.	671
Tibenska, E.	99
Tillmanns, S.	947

Tincani, A.	146, 233, 339, 350, 438, 650, 658, 808, 817, 863, 948, 958, 967
Titkov, A.	314
Titova, O.	730
Titulaer, M.J.	511, 723
Tlaskalová- Hogenová, H.	60
Tobón, G.	180, 638, 1 027
Tobón, G.J.	70
Toca, M.	104, 355
Toes, R.	145, 995
Toes, R.E.M.	91
Tofani, L.	389
Toh, B.H.	336
Tomáš, .	635
Tomer, Y.	644, 848
Tomi Sremec, N.	240
Tomijenovíc, L.	861
Tomljenovic, L.	6, 282
Tomšič, M.	378
Toncev, G.	612
Tonello, M.	909
Tong, T.N.	110
Tonutti, E.	31, 211, 824
Tony, H.P.	735
Torigoe, A.	287
Torres Rives, B.	585, 591
Torres-aguilar, H.	860
Torres-Ruiz, J.	970
Torres-Ruiz, J.J.	361
Torsten, M.	103
Torsten, W.	239, 318, 424
Toth, L.	1 062
Toubi, E.	345, 830, 834
Touil-Boukoffa, C.	701, 734
Toumi, R.	734
Toupet, K.	204
Tovey, M.	493
Tozzoli, R.	892
Traggiai, E.	411
Traish, A.	675
Trendelenburg, G.	303
Trenti, T.	431, 607, 828, 904, 984
Trezzi, B.	243, 909
Triggianese, P.	440
Trishina, I.	234
Trocmé, C.	150
Trojnar, E.	882

Trombetta, E.	126
Trouw, L.	145, 995
Truffaut, F.	652
Truglia, S.	160, 454, 901
Trujillo-Murillo, K.	266
Trzonkowski, P.	371
Tsantikos, E.	629
Tsianakas, A.	466
Tsifetaki, N.	893, 912
Tsirogianni, A.	377
Tsokos, G.C.	346, 833
Tsujinaka, H.	1 009
Tsuneyama, K.	535
Tu ková, L.	60
Tumangelova- Yuzeir, K.	598
Tuna, K.	230
Tüngler, V.	138
Turiel, M.	58, 1 024
TURK, I.	388
Turner-Stokes, T.	450
Turpin, D.	92
Tzanova, T.	731
Tzioufas, A.	1 019, 1 023
U. Maggiore	451
Ubilla, G.	76
Ugor, E.	841
ugurlu, S.	605
Uhlén, M.	302, 237
Uibo, O.	550
Uibo, R.	550
Ulrichs, P.	398
Um, J.H.	402
Unal, I.	388
Unger, L.	214
Ungerer, M.	526, 853
Uray, K.	882
Urazgildeeva, S.	314
Urruticoechea, A.	36
Utekhin, V.	891
Uytenbroeck, W.	241
Uzonyi, B.	882
V. Grossi	216
Vadasz, Z.	175, 522
Vadim Jucaud	117
Vainer, S.	523
Vairo, D.	44
Valencia, J.	535
Valente, A.	906
Valentini, G.	694
Valentino, P.	725

Valenzise, M.	792
Valeri, C.	440
Vatesini, G.	160, 317, 454, 641, 681, 887, 901, 975
van Beveren, N.J.M.	723
Van De Kerckhove, M.	928
van de Loo, F.	1 007
van den Berg, W.	161, 793
van den Berg, W.B.	412
van der Hulst, R.	968
van der Hulst, R.R.	194
van der Kraan, P.	161, 793
van der Kraan, P.M.	412
van der Maarel, S.	1 056
van der Meide, P.	269
van der Meide, W.	269
van der Pol, P.	312
van der Vuurst de Vries, R.M.	491, 492
van Es, H.	149
van Hauwermeiren, T.	398
van Hijum, S.	161
Van Hoovels, L.	125, 241, 255
van Houte, A.J.	603
van Langelaar, J.	491, 492
van Lith, H.	269
van Luijn, M.M.	491, 492
van Os, J.	723
van Paassen, P.	805
van Pelt-Gravesteijn, E.D.	777
van Rosmalen, J.	149
van Veelen, P.	995
van Vollenhoven, R.	29
Vandam, W.	67
Vande Keere, K.	125, 255
Vandenbroucke, R.	397
Vandenhende, M.	279
Vandormael, P.	311, 427
Vanhoof, J.	373, 427
Vargas, A.	401
Varma, H.	727
Vasconcelos, C.	563, 688, 703, 750, 867
Vasina, L.	314
Vaslyev, V.	71
Vecchi, M.	916
Végh, E.	977

Végh, J.	560
Veglia, M.	328
Velikova, T.	598
vely, F.	791
Venkatesha, S.	1 008
Vento, S.	706, 709
Venturelli, B.	828
Vera-Lastra, O.	266
Vera-Lastra, O.L.	964
Verdugo, R.	76
Verfaillie, C.	241
Verheul, M.K.	145, 995
Verinaud, L.	403
Versari, A.	865
Verschueren, P.	311
Verschuuren, J.	1 056
Versini, M.	960
Vettori, S.	694
Vezzosi, C.	828
Viallard, J.F.	791, 616
Viborg, K.	807
Vidarsson, G.	192
Vieira, A.R.	259
Vilches, D.	591
Villalobos Sánchez, L.	205
Villalta, D.	211, 826, 1 049
Villegas, E.	36
Villegas, J.A.	608
Villeret, B.	478
Villota-Eraso, C.	931
Vincent, T.	77
Vinci, C.	231
Virili, C.	835, 850
Visentini, M.	184, 767
Vishnevskaja-Dai, V.	601
Visona', A.	1 049
Vita, R.	852
Vitagliano, A.	698, 34
Vitetta, F.	607
Vittecoq, O.	182
Vittorio Pengo	660
Vogeleere, P.	68
Vojdani, A.	620, 624, 626
Volkmuht, W.	89
Volkov, A.	157
Voll, R.	947
Vollbrandt, T.	88
vom Dahl, M.	303
Vomero, M.	641
von Darl, M.	147

von Herrath, M.	540, 543
von Mühlen, C.	123
Von Pein, H.D.	885
von Toerne, C.	479
Vordenbaeuemen, S.	147
Vordenbaeuemen, S.	430, 488, 756
Vorobjeva, N.	399
Vorobjova, T.	550
Vuiblet, V.	443
Vukasovic, I.	755
Wahl, D.	656, 665
Wahono, C.S.	46
Walker, R.	63, 67
Wallukat, G.	525
Wandinger, K.P.	303
Wang, A.	65
Wang, F.S.	619
Wang, H.	40
Wang, J.	55, 55
Wang, L.	619, 804
Wang, Q.	763
Wang, W.	40
Wang, Y.	41, 602
Wan-Uk, K.	364, 998
Ward, H.	289
Wardemann, H.	724
Wardowska, A.	371
Washburn, N.	113
Wasserfall, C.	567
Watad, A.	213, 637, 1 026
Waterboer, T.	302
Watts Soares, A.	392, 732
Webb, T.	896
Wei, M.	40
Wei, Q.	51
Weigold, F.	202
Weinmann-Menke, J.	580
Weinstein, E.	162
Weiss, R.	304, 885
Wen, L.	47
Wenke, N.	724
Wenzel, K.	525
Westman, K.	280
Weyd, H.	78
Wick, G.	1 028, 1 033
Wicks, I.P.	412
Wierenga-Wolf, A.F.	491, 492
Wiklund, F.	250
Wikramanayake, T.	937

Wilde, B.	838	Yee, A.	995	Zhang, H.H.	707
Wildner, G.	228, 258, 479	Yenita, Y.	711	Zhang, K.	619
Willekens, B.	721	Yi, L.	899	Zhang, M.	41, 752
Willis, R.	30, 35, 957	Yilmaz, A.	230	Zhang, T.	313, 323
Wilmot, R.	64	Yim, Y.R.	47	Zhang, X.	51
Wingren, C.	802	Ying, W.	414	Zhang, Y.	415
Winter, H.	596	Yoshimasu, T.	136	Zhang, Z.	441
Wirlex, V.	363	Yoshimoto, K.	1 009	Zhao, D.	651
Wirtz, D.	428, 780	Yoshio, T.	45, 517	Zhao, W.	1 063
Witte, T.	171, 335, 407	Youcef, Y.B.	387	Zhao, Z.	55
Witzke, O.	838	Youinou, P.	25, 181, 734	Zhdanova, A.	573
Wixler, V.	473	Younes, S.	235	Zheng C.	334
Wolf, J.	105	Young, H.	535, 748	Zheng, D.	997
Wolfgang, G.	239	Yrlid, L.	413	Zheng, J.	1 063
Wong, Y.Y.M.	777	Yu, X.	111, 418, 1 063	Zhitan, C.	994
Woo, S.B.	133	Yu, Y.	441	Zhou, S.	63
Wopereis, H.	161	Yue, X.	1 063	Zhu, J.	838
Woszczyk, D.	744	Yuzhang, W.	414	Zielinski, M.	371
Wozniwicz, B.	710	Zabel, A.	551	Ziemssen, T.	611
Wozniwicz, M.	710	Zahuczky, G.	977	Žigon, P.	378
Wu, G.	842	Zaka Pratama, M.	1 010	Zilikens, D.	268
Wu, H.	185, 395	Zaman, A.	539	Zillikens, D.	80, 81, 480, 935, 1 005
Xiao, H.	40	Zampino, G.	382	Zimetti, F.	1 064
Xiaofeng, Z.	994	Zandian, A.	237, 250, 302	Zimmermann, N.	884
Xiaojun, L.	994	Zandman-Goddard, G.	156, 432	Zivancevic Simonovic, S.	612
Xiaoxue, Y.	404	Zanetti, V.C.	316	Zong, S.	723
Xie, Y.	55	Zani, G.	44	Zorzella- Pezavento, S.F.	403, 864
Xu, J.	313, 323	Zanola, A.	233, 438, 863	Zorzella- Pezavento, S.F.G.	195
Xu, X.	94	Zbigniew, Z.	704	Zota, A.	254
Yablecovitch, D.	630	Zegers, I.	504	Zotos, N.	893, 912
Yada, T.	261	Zen, M.	233, 438, 708	Zuber, A.	126
Yakovenko, A.	891	Zeng, X.	667, 670	Zubkov, A.	894
Yamamoto, K.	645, 944	Zeng, X.F.	707	Zucht, H.D.	147, 428, 430, 488, 756, 780
Yamamoto, Y.	136	Zeng, Y.	313, 323, 329	Zuercher, A.	109, 784
Yamauchi, A.	1 009	Zeni, S.	203	Zvartsev, R.	573
Yanagida, T.	45	Zenobia, C.	704		
Yanyan He, Y.H.	40	Zenone, T.	281		
Yasuda, S.	356, 801				

WEDNESDAY

THURSDAY

FRIDAY

SATURDAY


SUNDAY

INDEX

ACKNOWLEDGEMENTS



# ACKNOWLEDGEMENTS & INDUSTRY SUPPORT



# 10<sup>TH</sup>

INTERNATIONAL CONGRESS  
ON **AUTOIMMUNITY**

APRIL 6-10, 2016, LEIPZIG, GERMANY

*The international forum for high-quality,  
innovative research in allergy and immunology*



# International Archives of **Allergy** and **Immunology**

*welcomes your contribution ...*

Editors-in-Chief  
**Rudolf Valenta, Vienna**  
**Barbara Bohle, Vienna**

Associate Editors

**F. Annunziato**, Florence  
**K. Blaser**, Davos  
**J. Bousquet**, Montpellier  
**A.W. Burks**, Chapel Hill, N.C.  
**D. Dombrowicz**, Lille  
**M. Ebisawa**, Sagamihara  
**H. Garn**, Marburg  
**P. Gevaert**, Ghent  
**T. Jakob**, Freiburg  
**V. Niederberger-Leppin**, Vienna  
**P.M. O'Byrne**, Hamilton, Ont.  
**M. Ollert**, Esch-sur-Alzette  
**R. Pawankar**, Tokyo  
**W.F. Pickl**, Vienna  
**A. Radbruch**, Berlin  
**H. Saito**, Tokyo  
**C.B. Schmidt-Weber**, Munich  
**T. Schwarz**, Kiel  
**W. Thomas**, Perth, W.A.  
**M. Triggiani**, Naples  
**R. van Ree**, Amsterdam

*International Archives of Allergy and Immunology* provides a forum for basic and clinical research in modern molecular and cellular allergology and immunology. Appearing monthly, the journal publishes original work in the fields of allergy, immunopathology, immunogenetics, immunopharmacology, immunoendocrinology, tumor immunology, mucosal immunity, transplantation and immunology of infectious and connective tissue diseases. In addition to original papers it features short communications, reviews, minireviews, commentaries and opinions. Supported by online submission and peer-review systems, a team of internationally renowned and committed editors guarantees a fair review process, high scientific quality and fast dissemination of significant and novel work.

## Benefits for Authors

- Cost-effective publishing (no submission fee and no page charges for papers of 5 or fewer printed pages)
- Free online color figures
- Rapid and fair peer-review process
- Full listing in all relevant bibliographic databases (PubMed/MEDLINE, Web of Science)
- Impact Factor: 2.673
- Author's choice for open access publishing

**KARGER**



Find out more:  
[www.karger.com/iaa](http://www.karger.com/iaa)

KI 16280

# ACKNOWLEDGEMENTS

---

## AWARDS

AESKU AWARD FOR A LIFETIME CONTRIBUTION TO AUTOIMMUNITY 2016



MOSAIC OF AUTOIMMUNITY AWARD (MAI) 2016



## DIAMOND SUPPORTERS



## PLATINUM SUPPORTERS



---

## GOLD SUPPORTERS



---

## SILVER SUPPORTERS



GRIFOLS



---

## BRONZE SUPPORTERS



Medicare International





## CONTRIBUTORS



## CO-CONTRIBUTORS



## EXHIBITORS



# INDUSTRY SYMPOSIA

WEDNESDAY, APRIL 6

HALL MP3&4

13:30-15:30

## THE INTERPLAY OF T-CELLS AND B-CELLS IN AUTOIMMUNE DISEASE

Sponsored by Bristol Myers Squibb

**Chairperson: Piercarlo Sarzi Puttini, Italy**



- 13:30-13:35 Introduction  
Piercarlo Sarzi Puttini, Italy
- 13:35-14:05 T-cells, B-cells and Autoantibodies in Autoimmune Disease  
Jens Thiel, Germany
- 14:05-14:35 Autoantibodies and Joint Destruction in Autoimmune Disease  
Georg Schett, Germany
- 14:35-15:05 Novel Therapy Strategies in the Treatment of Autoimmune Disease  
Roberto Caporali, Italy
- 15:05-15:30 Question and Answer Session, Wrap up and Closing  
Piercarlo Sarzi Puttini, Italy  
Jens Thiel, Germany  
Georg Schett, Germany  
Roberto Caporali, Italy

HALL 4

15:30-17:30

**FOR THE ACHIEVEMENT OF OPTIMAL EFFECTIVENESS  
BY NOVEL TREATMENT STRATEGY WITH IL-6 SIGNALING  
TARGETED THERAPY IN RA**


Sponsored by Chugai

**Chairpersons: Takao Koike, Kazuhiko Yamamoto, Japan**

- 15:30-15:35 Opening remarks: overview of Tocilizumab  
Takao Koike, Japan
- 15:35-16:00 Cumulative safety data for Tocilizumab  
Tatsuya Atsumi, Japan
- 16:00-16:25 Clinical, structural, and functional efficacy of Tocilizumab  
Yoshiya Tanaka, Japan
- 16:25-16:55 The importance of IL-6 signaling inhibition from the translational  
research  
Tsutomu Takeuchi, Japan
- 16:55-17:25 The relationship between bone loss and inflammatory cytokine in RA  
Georg Schett, Germany
- 17:25-17:30 Closing remarks: future treatment of IL-6 signal inhibition  
Kazuhiko Yamamoto, Japan

Innovation all for the patients



 A member of the Roche group

## THURSDAY, APRIL 7

HALL MP3&4

12:30-14:00

### A NEW AND INNOVATIVE PLATFORM IN IMMUNODIAGNOSTICS

Sponsored by Theradiag



**Chairperson: M. Philippe Lestage, France**

- 12:30-12:45 The trend for serological diagnosis of rheumatic diseases in China  
Xiaofeng Zeng, China
- 12:45-12:50 Q & A
- 12:50-13:15 The clinical performance of BioCLIA, a novel, automated and random-accessed Chemiluminescence immunoassay, in serological diagnosis of SLE patients and ANA screening in healthy individuals  
Jieruo Gu, China
- 13:15-13:20 Q & A
- 13:20-13:45 The development and evaluation of BioCLIA, a novel, automated and random-accessed chemiluminescence immunoanalyser for Autoantibody detection  
Charles Lee, China
- 13:45-13:50 Q & A

## FRIDAY, APRIL 8

HALL MP3&4

12:30-14:00

### LAB AND HEALTH ECONOMICS OF ANA SCREENING

Sponsored by Inova Diagnostics



**Chairpersons: Michael Mahler, USA**

**Eckart Mummert, USA**

- 12:30-13:10 An approach to prevention of SLE: economics and diagnostic testing  
Marvin Fritzer, Canada
- 13:15-13:35 Anti-DFS70 Antibodies: A useful biomarker in a pediatric case with suspected autoimmune disease  
Martina Fabris, Italy
- 13:40-14:00 Immunoabsorption of DFS70 antibodies during ANA screening reduces "false positive" results  
Nicola Bizzaro, Italy

## SATURDAY, APRIL 9

HALL MP3&4

12:30-14:00

### IMMUNOGLOBULIN THERAPY IN AUTOIMMUNE DISEASES: WHAT DO WE EXPECT?

Sponsored by LFB




**Chairpersons: Abdulgabar Salama, Germany**  
**Francesco Rodeghiero, Italy**

- 12:30-12:55 Quality and Clinical Safety of Immunoglobulin Therapies: Regulatory viewpoint  
Jacqueline Kerr\*, Germany
- 13:00-13:25 Are all human intravenous immunoglobulin (IVIg) the same?  
- How can the characteristics of IVIg improve tolerability in patients?  
Srini Kaveri, INSERM (Paris) / CNRS (India)  
- New insights in IVIg development process  
Philippe Paolantonacci, LFB, France
- 13:30-13:55 Management of ITP: are we comfortable with our knowledge?  
Francesco Rodeghiero, Italy


\* Important: Dr Kerr is not sponsored by LFB and has no disclosures with the pharmaceutical company.

# EXHIBITION MAP



# LIST OF EXHIBITORS

<b>Name</b>	<b>Booth</b>	<b>Name</b>	<b>Booth</b>
A.Menarini Diagnostics	5	HUMAN Gesellschaft für Biochemica und Diagnostica mbH	21
AESKU. Diagnostics GmbH & Co. KG	10	IBA GmbH	25
Association for the Advancement of Immunologic Diagnostics	Table top	illumina	29
Autoimmunity Network	38	Immco Diagnostics, A Trinity Biotech Company	19
Beckman Coulter	27	Immunodiagnostic Systems	22A
Bio-Rad Laboratories GmbH	4	Inova Diagnostics	1
Bio-Techne	24	Invitalis GmbH	07A
Bristol-Myers Squibb GmbH	9	LFB BIOMEDICAMENTS	11
BÜHLMANN Laboratories AG	33	Lupus 2016	35
CTL Europe GmbH	23	MEDIPAN GMBH	18
DEVEXI	36	ORGENTEC Diagnostika GmbH	17
DiaSorin S.p.A.	7	PEPperPRINT GmbH	22
Elsevier B.V.	34	Sensovation AG	31
Euro Diagnostica AB	32	Theradiag	14
EUROIMMUN AG	3	Thermo Fisher Scientific	6
Eurospital S.p.A.	30	Unomedical a Convatec Company	28
GRIFOLS	12	Wisepress Medical Bookshop	37



# Rooted in tradition, thriving by innovation

**Trusted autoimmune products that evolve with your laboratory**

Since pioneering autoimmune diagnostics with the introduction of the Kallestad® HEp-2 IFA slides, Bio-Rad Laboratories has been delivering high quality products to clinical laboratories worldwide. This commitment to quality has been

at the root of all of our innovations over the years – from the reliable PhD™ Ix System for EIA/IFA processing, to the BioPlex® 2200 System, the first and only fully automated, random access, multiplex platform for the detection of autoantibodies.

**For more info, contact your local Bio-Rad office | 1-800-224-6723 | [www.bio-rad.com/diagnostics](http://www.bio-rad.com/diagnostics)**

**BIO-RAD**



# The Journal of Rheumatology

**First Release Articles**  
**Current Issue**  
**Archives**  
**Authors/Reviewers**



## What you get

- **Current**
- **Clinical**
- **Definitive**

## Where you get it THE JOURNAL

To subscribe: visit [jrheum.org](http://jrheum.org) online or send in your completed coupon below

### Rates for 2016 calendar year USA/INTERNATIONAL

	Print + Online	Online Only
INDIVIDUALS:	\$350 US	\$285 US
INSTITUTIONAL:		
- Multisite #	On request	On request
- Multiuser (IP ranges)	\$1025 US	\$975 US
- Basic (up to 4 users)	\$550 US	\$500 US
TRAINEES*	\$215 US	\$150 US+
Airmail (ADD)	\$100 US	

For terms of access visit [jrheum.org](http://jrheum.org)  
 \*Supervisor certification required below.

NAME OF SUPERVISOR: \_\_\_\_\_  
 SUPERVISOR SIGNATURE: \_\_\_\_\_  
 SUPERVISOR TELEPHONE: \_\_\_\_\_

### Please enter my 2016 subscription to The Journal of Rheumatology

Name (please print) \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State/Province \_\_\_\_\_

Country \_\_\_\_\_ Zip/Postal Code \_\_\_\_\_

Contact E-mail \_\_\_\_\_

Amount Enclosed \$ \_\_\_\_\_ Bill Me \_\_\_\_\_

Telephone Number \_\_\_\_\_ Fax Number \_\_\_\_\_

VISA/MasterCard Number \_\_\_\_\_ Expiration Date \_\_\_\_\_

Signature \_\_\_\_\_ CVV \_\_\_\_\_

Mail completed form to: **The Journal of Rheumatology**  
 365 Bloor Street East, Suite 901 | Phone: (416) 967-5155  
 Toronto, Ontario Canada M4W 3L4 | Fax: (416) 967-7556  
 E-mail: [subscriptions@jrheum.com](mailto:subscriptions@jrheum.com)

All subscriptions are for the calendar year. Renewals for print subscriptions received after May 31, 2016 will be charged an additional \$5 per back issue. Back issues: 3 years including current year are available if in stock. Single copies are available at \$30 each. Claims: US 2 months, elsewhere 4 months from issue date, e.g., March 1 and May 1, respectively, for the January Issue. PRIVACY POLICY: For details of our privacy policy, visit our website at [www.jrheum.org](http://www.jrheum.org).

# Baxalta

**Your life. Our inspiration.**

Baxalta Incorporated is a global biopharmaceutical leader developing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Baxalta is driven by passion to make a meaningful impact for patients. At Baxalta, your life is our inspiration — that's the promise of the Baxalta spark.

[Baxalta.com](https://www.baxalta.com)

# SUPPORTER & EXHIBITOR PROFILES

## 10TH EUROPEAN LUPUS MEETING

Via Ripamonti 129  
Milan, 20141, Italy  
Booth #: 35  
[www.lupus2016.org](http://www.lupus2016.org)



The 10th European Lupus Meeting will be held in Venice on October 5-8, 2016. The Congress Chairpersons are Prof. Andrea Doria and Prof. Angela Tincani. The meeting is intended to present the latest clinical and experimental studies in the field of systemic lupus erythematosus. The scientific program will include lectures, symposia, abstract and poster sessions in order to give the chance to all the participants to present their personal contribution, pointing to knowledge growth and sharing.

## A.MENARINI DIAGNOSTICS

Via Sette Santi 3  
Firenze, 50131, Italy  
Booth #: 05



[www.menarinidiagnostics.com](http://www.menarinidiagnostics.com)

For the European healthcare community we are a dynamic and reliable partner providing diagnostics solutions thanks to our close relation with the market, and therefore, knowledge of its needs. With experience, flexibility, technology and reliability, our aim is to make diagnostics management easier, more effective and result cost efficiency. With our network of European affiliates and world wide partners, we offer innovative diagnostics tools for clinical laboratories as well as patient glucose self testing. Our major business lines are autoimmunity, clinical chemistry, glycated haemoglobin, immunohistochemistry, self monitoring Blood Glucose and urine and sediment analysis.

---

## **ABBVIE DEUTSCHLAND GMBH & CO. KG**

Mainzer Str. 81  
Wiesbaden, 65189, Germany  
abbvie.com



About AbbVie AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. AbbVie is represented in Germany with headquarters in Wiesbaden and a research and production site in Ludwigshafen. In total, AbbVie Deutschland has about 2600 employees. For further information on the company and its people, portfolio and commitments, please visit [www.abbvie.com](http://www.abbvie.com). Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

---

## **AESKU. DIAGNOSTICS GMBH & CO. KG**

Mikroforum Ring 2  
Wendelsheim, 55234, Germany  
Booth #: 10  
[www.aesku.com](http://www.aesku.com)



AESKU.DIAGNOSTICS is a research-focused manufacturer of innovative and efficient products and services for the early detection, diagnosis and prognosis of hemostasis, autoimmune & infectious diseases. Having launched over 150 different products together in more than 80 countries worldwide, AESKU® simplifies the lab routine with accurate, robust and reliable tests and lab automation systems. AESKU® offers unique diagnostic options: faster test systems, designed to improve clinical outcome, for the benefit of both patients and treating physicians, together with efficient systems for lab automation. AESKU® provides a solution for the three most used technologies in the diagnosis of autoimmune diseases.

## AMERICAN AUTOIMMUNE RELATED DISEASES ASSOCIATION

22100 Gratiot Ave  
 Eastpointe, 48021, USA  
[www.aarda.org](http://www.aarda.org)



The American Autoimmune Related Diseases Association is dedicated to the eradication of autoimmune diseases and the alleviation of suffering and the socioeconomic impact of autoimmune through fostering and facilitating collaboration in the areas of education, public awareness, research, and patient services in an effective, ethical and efficient manner. AARDA is the only national nonprofit health agency dedicated to bringing a national focus to autoimmunity, the major cause of serious chronic diseases. Approximately 50 million Americans, 20 percent of the population or one in five people, suffer from autoimmune diseases.

## AMORPHICAL LTD.

11 Haharash St.  
 Nes Ziona, 7403118, Israel  
[www.amorphical.com](http://www.amorphical.com)



Amorphical is a pioneering Israeli pharmaceutical company developing and manufacturing a proprietary synthetic form of calcium, Amorphous Calcium Carbonate (ACC). Our ACC-based therapeutics are in clinical development for the treatment of osteoporosis, hypoparathyroidism and a wide range of other calcium-related diseases. This novel technology is protected by several approved and pending patents. Inspired by the natural ability of the Australian Blue Crayfish to efficiently mobilize its calcium stores in order to shed and regrow its entire exoskeleton in only three days, Amorphical scientists have shown ACC's safety and efficacy in preclinical studies. Moreover, the company has demonstrated ACC's high bioavailability-twice that of conventional crystalline calcium.

## AUTOIMMUNITY RESEARCH FOUNDATION

3423 Hill Canyon Ave  
 Thousand Oaks, 91360, USA  
[AutoimmunityResearch.org](http://AutoimmunityResearch.org)



The Autoimmunity Research Foundation is a 501(c)3 charity whose educational and research efforts are focused on helping Health Professionals, and the public, understand the cause of Th1 chronic inflammatory disease. Many chronic and autoimmune conditions, including Fibromyalgia (FM), Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Chronic Fatigue Syndrome (CFS/ME), Post Treatment Lyme Disease Syndrome (PTLDS), Sarcoidosis, Depression, and Bipolar Disorder, are now succumbing to therapy based on our molecular description of inflammatory disease biology.

---

## **BAXALTA ITALY SRL**

Piazzale dell'Industria, 20  
Roma, 00144, Italy  
[www.baxalta.it](http://www.baxalta.it)



Baxalta Incorporated (NYSE: BXL) is a \$6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients' lives, Baxalta's broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International, Baxalta's heritage in biopharmaceuticals spans decades. Baxalta's therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.

---

## **BECKMAN COULTER**

22 rue Juste-Oliver  
Nyon, 1260, Switzerland  
Booth #: 27  
[www.beckman.com](http://www.beckman.com)



Beckman Coulter Life Sciences markets instrument systems, reagents and services that enable new discoveries in biology-based research and development. Our products are used in the forefront of genomics and proteomics. We are market leaders in centrifugation and flow cytometry. We have long been at the vanguard in capillary electrophoresis and laboratory automation and today our systems are some of the most advanced available. Beckman Coulter systems serve life science researchers in academic and commercial laboratories throughout the world and help advance the study of complex biological problems, including the causes of disease and the development of potential new drugs and therapies. For more information please visit [www.beckmancoulter.com](http://www.beckmancoulter.com)

## BIOMED CENTRAL

236 Gray's Inn Road  
London, WC1X 8HB, UK  
[www.biomedcentral.com](http://www.biomedcentral.com)



BioMed Central publishes over 290 peer-reviewed, open access journals spanning all areas of biology, medicine and health, including not only broad interest titles such as BMC Genomics but also high impact journals such as Genome Biology and Genome Medicine.

## BIO-RAD LABORATORIES GMBH

Heidemannstrasse 164  
München, D-80939, Germany  
Booth #: 04  
[www.bio-rad.com](http://www.bio-rad.com)



Bio-Rad Laboratories is a world leader in providing a broad range of products for the life science research and diagnostic markets. In our Clinical Diagnostics Group, we build the industry leading solutions for diabetes, blood virus, autoimmune and microbiology testing alongside immunohematology instruments, QC systems and much more. With over 300 clinical diagnostic tests for the in vitro test market, we are renowned worldwide for our commitment to quality and customer service in hospital, reference and transfusion labs, universities, major research institutions, biotechnology and pharmaceutical companies. Visit us and experience first-hand how we are empowering labs to make informed decisions.

## BIO-TECHNE

19 Barton Lane  
Abingdon Science Park, Abingdon, OX14 3NB, UK  
Booth #: 24  
[www.bio-techne.com](http://www.bio-techne.com)



Bio-Techne brings together some of the most referenced brands in life science - R&D Systems, Novus Biologicals, Tocris Bioscience, and ProteinSimple providing innovative, high-quality research tools, including: Bioactive proteins - R&D Systems premiere bioactive proteins Application-qualified Antibodies - a diverse and extensive analyte selection from Novus and R&D Systems Immunoassays - Legendary R&D Systems Quantikine ELISAs, our huge selection of Luminex Assays and cost effective Proteome Profiler Arrays. High quality small molecules - a unique collection of over 3,500 Tocris reagents Together we are Bio-Techne. Find out how we can be your partner and help you attain your research goals by visiting our stand.

---

## BRISTOL-MYERS SQUIBB GMBH

Arnulfstr. 29  
Munich, 80636, Germany  
Booth #: 09  
www.bms.com



Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit [www.bms.com](http://www.bms.com) or follow us on Twitter at [twitter.com/bmsnews](https://twitter.com/bmsnews).

---

## BÜHLMANN LABORATORIES AG

Baselstrasse 55  
Schönenbuch, 4124, Switzerland  
Booth #: 33  
www.buhlmannlabs.ch



BÜHLMANN is offering the broadest calprotectin product range with the BÜHLMANN fCAL® ELISA, BÜHLMANN fCAL® turbo and the quantitative Quantum Blue® fCAL rapid test. Quantum Blue® Infliximab trough level rapid test is our first therapeutic drug monitoring test. BÜHLMANN has launched its newest innovation, the IBDoc® Calprotectin Home Testing Solution, allowing the patient to test calprotectin levels at home using a smart phone. Not only does BÜHLMANN stand for calprotectin, but also for a selection of unique, high-quality assays for clinical routine use such as the BÜHLMANN GanglioCombi™ products, the only screening ELISAs for anti-Ganglioside testing.

---

## CHUGAI PHARMACEUTICAL CO., LTD.

1-1 Nihonbashi-Muromachi 2-Chome Chuo-ku  
Tokyo, 103-8324, Japan  
www.chugai-pharm.co.jp/english/



Chugai Pharmaceutical is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs. The consolidated revenue in 2014 of Chugai totaled 461.1 billion yen and the operating income was 77.3 billion yen (IFRS Core basis).



## CMSRI

1751 Pinnacle Drive Suite 600  
 McLean, VA 22102, USA  
[www.cmsri.org](http://www.cmsri.org)

The Children's Medical Safety Research Institute is a sponsor of the International Congress on Autoimmunity and a nonprofit organization dedicated to funding independent research into the causes of autoimmune diseases and to promoting awareness of scientifically validated and published findings.



## CSL BEHRING AG

Wankdorfstrasse 10  
 Bern 22, 3000, Switzerland  
[www.cslbehring.com](http://www.cslbehring.com)

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a global biopharmaceutical company and a member of the CSL Group of companies. The parent company, CSL Limited (ASX:CSL), is headquartered in Melbourne, Australia. For more information, visit [www.cslbehring.com](http://www.cslbehring.com).

## CSL Behring

Biotherapies for Life™

## CTL EUROPE GMBH

Hans-Boeckler-Strasse 19-29  
 Bonn, 53225, Germany  
 Booth #: 23  
[www.immunospot.eu](http://www.immunospot.eu)

CTL is the only company that specializes on GLP compliant high throughput ELISPOT analysis for monitoring T cell immunity in clinical trials (CRO). CTL is the leading manufacturer of ELISPOT analyzers, reagents required for ELISPOT standardization, including reference PBMCs, ImmunoSpot® ELISPOT T and B Cell Kits and Serum-Free-Media.



---

## CYREX LABORATORIES, LLC

2602 S. 24th Street  
Phoenix, AZ 85034, USA  
[www.joincyrex.com](http://www.joincyrex.com)



Cyrex is a clinical immunology laboratory specializing in functional immunology and autoimmunity. Cyrex offers multi-tissue antibody testing for the early detection and monitoring of today's complex autoimmune conditions. Cyrex develops innovative testing arrays through continuous collaboration with leading experts in medical research and clinical practice. Cyrex technology is built on four pillars of excellence, including the antigen purification system, optimized antigen concentration, antigen-specific validation and parallel testing technology. Cyrex is based in Phoenix, Arizona and is a CLIA Licensed laboratory.

---

## DEVEXI

3201 Jermantown Road  
Fairfax, 22030, USA  
Booth #: 36  
[www.devexi.com](http://www.devexi.com)



DEVEXI is a powerful, sophisticated yet intuitive health research data platform linking medical and dental data to enable researchers to connect the dots between diagnoses, treatments, prescribed drugs, exposures and short and long-term health outcomes – for groundbreaking, longitudinal studies never before possible. DEVEXI will help health and medical researchers, universities, teaching hospitals, insurance payers, government health agencies and pharmaceutical companies to improve quality of health care delivery, identify best practices and increase successful, cost-effective outcomes.

---

## DIASORIN S.P.A.

Via Crescentino, snc  
Saluggia (VC), 13040, Italy  
Booth #: 07  
[www.diasorin.com](http://www.diasorin.com)



DiaSorin - The Diagnostic Specialist DiaSorin is a global leader in the field of biotechnologies, developing, producing and marketing reagent kits for in vitro diagnostics worldwide for over 40 years. DiaSorin has recently introduced new molecular offer entering the markets of nucleic acid isolation and cell separation. Its line of products used by diagnostic laboratories can meet the needs of the following clinical areas: infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology. Today DiaSorin can offer an assay menu that is unique for its width and presence of specialty tests which identify DiaSorin as "the" in vitro diagnostics specialist.

## ELSEVIER B.V.

Radarweg 29  
 Amsterdam, 1043NX, The Netherlands  
 Booth #: 34  
[www.elsevier.com](http://www.elsevier.com)



Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals. We publish over 2,500 journals, including Autoimmunity Reviews, Journal of Autoimmunity and a prestigious collection of immunology journals, The Lancet and Cell, and more than 33,000 book titles. Visit [elsevier.com](http://elsevier.com) for more information.

## EURO DIAGNOSTICA

Lundavägen 151  
 Malmö, 202 11, Sweden  
 Booth #: 32  
[www.eurodiagnostica.com](http://www.eurodiagnostica.com)



Euro Diagnostica's goal is to constantly develop solutions to aid clinicians in diagnosis, prognosis, monitoring and treatment of autoimmune and related diseases. Due to our flexibility as a complete, cross-functional organization, we are an optimal assay partner throughout the drug development process, beginning from the exploratory phase to the clinical trial stage and beyond. Our offerings include: of-the-shelf kits, custom assay development and custom manufacturing of ELISA and RIA kits, bioanalytical and laboratory services by our in-house laboratory Wieslab, and iLite™ cell lines for assessment of drug potency, i.e. drug activity, and neutralizing antibodies (NAbs).

## EUROIMMUN AG

Seekamp 31  
 Luebeck, 23560, Germany  
 Booth #: 03  
[www.euroimmun.de](http://www.euroimmun.de)



EUROIMMUN is an international provider of medical laboratory products with a strong focus on autoimmune diagnostics. The company's portfolio includes indirect immunofluorescence, ELISA, immunoblot and radioimmunoassay test systems for the serological detection of hundreds of different autoantibody biomarkers. Specialised DNA microarrays allow determination of genetic risk factors, for example in coeliac disease or ankylosing spondylitis. State-of-the-art instruments and software provide efficient automation of analyses. The EUROPattern system, in particular, automates immunofluorescence microscopy including image interpretation, while the EUROBlotOne device allows complete walkaway processing of multiplex immunoblots. EUROIMMUN's autoimmune diagnostics range complements its products for infection diagnostics, allergology and molecular diagnostics.

---

## EUROSPITAL S.P.A.

Via Flavia 122  
Trieste, 34147, Italy  
Booth #: 30  
www.eurospital.com



Eurospital aims at being No. 1 in the specific markets where it operates in order to give its customers with the highest quality systems. Eurospital focuses its activities in specific sectors such as in vitro diagnosis of Autoimmune Diseases, Coeliac Disease and IBD. To succeed Eurospital has to be able to renew itself and progress continuously in time and to set for itself increasingly ambitious goals. At the congress "Autoimmunity 2016" in Leipzig, Eurospital will launch the "ERA Eurospital Random Access" chemiluminescence system which represents the most advanced and complete diagnostic system for autoimmune disorders.

---

## FONDAZIONE AREA

Via Tavoleria 28  
Pisa, 56100, Italy  
www.fondazionearea.it



Foundation Area purposes are: -Supporting research, particularly about systemic and thyroid autoimmune diseases and thyroid cancer (Prof. Antonelli A, Prof. Miccoli P), in concert with public and private Italian and foreign institutions. -Establish links between industries and those of research, particularly to promote the activities of young scientists and the inclusions in operating domestic and international economic environments. -Cultivating relationships with the European Union to enhance the role of science and technology studies, and knowledge of funding opportunities for research and training. -Encourage initiatives to promote cultural awareness of the mutual benefits of better relations between science and society.

---

## GFID E.V. (ASSOCIATION FOR THE ADVANCEMENT OF IMMUNOLOGIC DIAGNOSTICS)

Wasastraße 14  
Dresden, 01219, Germany  
www.gfid-ev.de



On behalf of the Organizing Committee we have the great pleasure to hereby announce the 13th Dresden Symposium on Autoantibodies taking place from September 27 to September 30, 2017. The aim of the Symposium is to bring together clinicians and scientists specializing in "autoimmunology" to exchange academic information and to present and discuss the results of basic and applied research on autoantigens, autoantibodies and autoimmunity. Main Subjects: Autoantibodies in systemic and organ specific autoimmune diseases (induction, pathology, clinical relevance), Novel Autoantibodies of pathogenic, diagnostic and predictive relevance, Autoimmune diagnostics: Methodical aspects and diagnostic strategies, Harmonization, Standardization Chairman: Karsten Conrad, Germany

**GRIFOLS**

Av. de la Generalitat 152-158  
Sant Cugat del Valles, 08174, Spain  
Booth #: 12  
[www.grifols.com](http://www.grifols.com)

Grifols is a global healthcare company whose mission is to improve the health and wellbeing of people around the world. We accomplish this mission by producing life-saving protein therapies for patients and by providing hospitals, pharmacies and healthcare professionals with the tools they need to deliver expert medical care. We have three primary divisions -- Bioscience, Diagnostic and Hospital – which develop, produce and market our innovative products and services to medical professionals in more than 90 countries around the world. The Diagnostic division supplies clinical analysis and laboratory testing tools to labs, hospitals and blood banks worldwide. Our Diagnostic division produces analyzers, reagents and instrumentation to provide accurate and reliable test results for specialists in the fields of immunohematology, hemostasis and specialty tests including autoimmunity tests, Therapeutic Drug Monitoring tests and Infectious Diseases assay.

**GRIFOLS****HUMAN GESELLSCHAFT FÜR  
BIOCHEMICA UND DIAGNOSTICA MBH**

Max-Planck-Ring 21  
Wiesbaden, 65205, Germany  
Booth #: 21  
[www.human.de](http://www.human.de)

HUMAN Diagnostics Worldwide Discover HUMAN! Today one of the few global players in the in vitro diagnostics industry, maintaining what is perhaps the broadest distribution and service & support network in the world. Here in Leipzig discover one of the broadest selections of innovative and aligned LIA solutions for differential diagnosis in autoimmune diagnostics. To Discover HUMAN online, please visit: [www.human.de](http://www.human.de)



**Human**  
Diagnostics Worldwide

**IBA GMBH**

Rudolf-Wissell-Str. 28  
Göttingen, 37079, Germany  
Booth #: 25  
[www.iba-lifesciences.com](http://www.iba-lifesciences.com)

IBA GmbH offers you a new way of cell selection from whole blood for analytical and diagnostic purposes! The T-CATCH- technology is based on an affinity chromatography using fab fragments to isolate specific target cells without magnetic beads. The automatic device FABian® can select CD3, CD4, CD8 (T-cells), CD81 (PBMCs), CD19 (B-cells) and CD14 (Monocytes) cells. Moreover, we continuously develop different fab fragments for specific selections and customized solutions.



**iba**  
Solutions  
For Life Sciences

---

## ILLUMINA

5200 Illumina Way,  
San Diego, 92122, USA  
Booth #: 29  
[www.illumina.com](http://www.illumina.com)



Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With rapid advances in technology taking place, it is mission-critical to offer solutions that are not only innovative, but flexible and scalable, with industry-leading support and service. We strive to meet this challenge by placing a high value on collaborative interactions, rapid delivery of solutions, and meeting the needs of our customers.

---

## IMMCO DIAGNOSTICS, A TRINITY BIOTECH COMPANY

60 Pineview Drive  
Buffalo, NY, 14228, USA  
Booth #: 19  
[www.trinitybiotech.com](http://www.trinitybiotech.com)



Since 1971, Immco Diagnostics has provided high quality diagnostic products and services for the detection and diagnosis of autoimmune diseases. Our Product division supplies leading in vitro diagnostic assays and reagents to laboratories worldwide. Immco Reference Laboratory offers biopsy, serology and other test services for diagnosis of autoimmune disorders and related immunological conditions. The Contract Research group supports clinical research trials for organizations, pharmaceutical and biotechnology industries. Immco Diagnostics incorporates innovative medical devices, diagnostic laboratory testing expertise and pioneering research for a comprehensive solution to autoimmune disease diagnostics.

---

## IMMUNODIAGNOSTIC SYSTEMS (IDS)

10 Didcot Way, Boldon Business Park  
Boldon, NE35 9PD, UK  
Booth #: 22A  
[www.idsplc.com](http://www.idsplc.com)



Immunodiagnostic Systems PLC (IDS) is a leading in-vitro diagnostic solution provider to the clinical laboratory market. We develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients. Our immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields. We now offer 24 fully automated Autoimmune assays and 16 fully automated Infectious Disease assays for use on the IDS-iSYS Multi Discipline Automated system. If you would like to learn more about our product portfolio, please come and visit us at stand 22A

---

## INOVA DIAGNOSTICS

9900 Old Grove Road  
 San Diego, 92131, USA  
 Booth #: 01  
[www.inovadx.com](http://www.inovadx.com)



Inova Diagnostics is redefining the boundaries of autoimmune testing. Inova integrates the autoimmune laboratory with systems and instruments, including NOVA View®, a digital approach to reading and archiving IFA images, BIO-FLASH®, a rapid-response chemiluminescent analyzer, QUANTA-Lyser®, a family of EIA/IFA processors for increased flexibility and efficiency, and QUANTA Link®, a centralized network to make workflow management easy. Inova also offers a comprehensive menu of high quality NOVA Lite® IFA, QUANTA Lite® ELISA, and QUANTA Flash® CIA test kits for autoimmune diseases. Laboratories, clinicians and patients benefit from the excellent technical expertise, support and service offered by Inova Diagnostics.

---

## JACKSON IMMUNORESEARCH EUROPE LTD.

Unit 7 Acorn Business Centre  
 Newmarket, CB8 7SY, UK  
[www.jireurope.com](http://www.jireurope.com)



At Jackson ImmunoResearch, we manufacture secondary antibodies and related reagents, earning an outstanding reputation for quality over the past 30 years. Our products are used in Western Blotting, IHC/ICC/IF, Flow Cytometry, ELISA, Electron Microscopy and many other immunological techniques. Our range includes a wide choice of species and specificity options, enabling reliable and precise detection. All antibodies are available conjugated to a comprehensive selection of fluorophores (including Alexa Fluors®), Enzymes (HRP and Alkaline Phosphatase), Colloidal Gold or Biotin. We serve customers directly from our European distribution centre, providing outstanding technical service, fast delivery and euro pricing.

---

## JANSSEN PHARMACEUTICAL RESEARCH & DEVELOPMENT, LLC

3210 Merryfield Row  
 San Diego, CA 92121, USA  
[www.janssen.com](http://www.janssen.com)



At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people with serious diseases throughout the world. Beyond its innovative medicines, Janssen is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates and healthcare professionals have access to the latest treatment information, support services and quality care.

---

## LFB BIOMEDICAMENTS

31 avenue des Tropiques, BP 40305 - LES ULIS  
91958, COURTABOEUF CEDEX, France  
Booth #: 11  
[www.lfb.fr](http://www.lfb.fr)



The LFB group is a biopharmaceutical company that develops, manufactures, and markets medicinal products for the treatment of serious and often rare diseases in the fields of Immunology, Haemostasis, Perinatal, and Intensive Care. The LFB group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies. The LFB group is pursuing a growth strategy that seeks to extend its international activities and develop innovative therapies. Today, the LFB group currently markets its products in more than 40 countries around the world.

---

## LILLY DEUTSCHLAND GMBH

Werner-Reimers-Strasse 2-4  
Bad Homburg, 61352, Germany  
[www.lilly-pharma.de](http://www.lilly-pharma.de)



About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating highquality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at [www.lilly.com](http://www.lilly.com) and [newsroom.lilly.com/social-channels](http://newsroom.lilly.com/social-channels).

---

## MEDICARE INTERNATIONAL TRADING LIMITED

Room 3, 3/F., Block B, Veristrong Industrial Centre,  
34-36 Au Pui Wan Street  
Fotan, N.T., 1000, Hong Kong S.A.R.  
[mcintl.en.alibaba.com](http://mcintl.en.alibaba.com)

Medicare International



Medicare International Trading Limited was established in June 2012. The main business field is about Assisted Reproduction Technology. We are selling reagent, consumables, equipments and also hospital management software systems. In addition to the Hong Kong market, we also have long term customers from Macau and Mainland China. Our customers cover all over the provinces and municipalities in Mainland China which includes universities and education institutions, research laboratories, laboratory inspection and testing services, government laboratories, hospitals and clinics. Our mission is to become your partner. We provide competitive price, superior quality products and also efficient service to satisfy customer's needs.



## MEDIPAN GMBH

Ludwig-Erhard-Ring 3  
Dahlewitz, 15827, Germany  
Booth #: 18  
[www.medipan.de](http://www.medipan.de)



MEDIPAN founded 1992, is a leading company in development, manufacturing and international distribution of in vitro diagnostic tests. The main fields are the diagnosis of thyroid disease, diabetes type 1, systemic rheumatic diseases and other autoimmune disorders. MEDIPAN invented the AKLIDES® system, a platform technology for digital immunofluorescence. This technology is used for automated evaluation of cell and bead based immunofluorescence tests. A new application here is the detection of DNA damage caused by radiation, oxidative stress or drugs. Our company is an accepted and innovative partner for laboratories and physicians worldwide.

## NOVO NORDISK A/S

Novo Alle  
Bagsvaerd, 2880, Denmark  
[www.novonordisk.com](http://www.novonordisk.com)



Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).

## OCTAPHARMA

62 bis Avenue A. Morizet  
Boulogne Billancourt, 92 100, France  
[www.octapharma.com](http://www.octapharma.com)



Headquartered in Lachen, Switzerland, Octapharma AG is one of the world's largest human protein products manufacturers and has been committed to patient care and medical innovation for 30 years. With a broad and expanding pipeline, Octapharma's core business is the development, production, and sale of high quality human protein therapies from both human plasma and human cell-lines, including intravenous immune globulin and von Willebrand Factor/Coagulation Factor VIII Complex. Octapharma employs over 6,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, New Jersey. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit [www.octapharma.com](http://www.octapharma.com).

---

## ORGENTEC DIAGNOSTIKA GMBH

Carl-Zeiss-Str. 49-51  
Mainz, 55129, Germany  
Booth #: 17  
[www.orgentec.com](http://www.orgentec.com)



ORGENTEC Diagnostika, Mainz, Germany, is a global leader in research, development, and production of test systems for laboratory diagnostics. ORGENTEC offers numerous highly specific ELISA assays, immunoblots and kits for immunofluorescence. The innovative Alegria® instrument allows for rapid automated analysis of serum, stool and CSF biomarkers for autoimmune and infection diseases. The point of care test rheumachec® has been the first rapid test for diagnosing rheumatoid arthritis. With distribution channels and subsidiaries in Germany, Austria, Hungary, France, USA and China, and an established global network of distribution partners, ORGENTEC's products are benefitting patients in over 100 countries around the world.

---

## PEPPERPRINT

Rischerstr. 12  
Heidelberg, 69123, Germany  
Booth #: 22  
[www.pepperprint.com](http://www.pepperprint.com)



PEPPERPRINT provides high-content peptide microarrays with custom and off-the-shelf contents. PEPPERCHIP®s are predominantly applied for antibody epitope mapping, antigen discovery and biomarker development. Our PEPPERCHIP® Autoimmune Epitope Microarray covers 3,359 linear autoimmune epitopes including 192 citrullinated peptides to e.g. disclose differential antibody responses of autoimmune patient groups. Additionally, the PEPPERCHIP® Cyclic Citrullinated Peptide Microarray covers 577 different cyclic peptides and the corresponding cyclic arginine controls for RA research. PEPPERCHIP® Peptide Microarray analysis is straightforward and can be done in your own lab or by PEPPERPRINT experts within a PEPPERMAP® Service Offer.

**ROCHE S.P.A.**

Viale G.B. Stucchi, 110  
 Monza, 20900, Italy  
 roche.it



About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit [www.roche.com](http://www.roche.com). All trademarks used or mentioned in this release are protected by law.

**SANOFI GENZYME**

Gooimeer 10  
 Naarden, 1411 DD, The Netherlands  
 www.genzyme.com

Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

---

## SENSOVATION AG

Markthallenstraße 5  
Radolfzell, 78315, Germany  
Booth #: 31  
[www.sensovation.com](http://www.sensovation.com)



Sensovation is focused on the development and manufacturing of unique smart imaging solutions for the Life Science and Diagnostics market, certified for medical use (EN ISO 9001 and EN ISO 13485). We offer optical detection solutions ranging from scientific cameras up to highly integrated instrumentation for multiplexed diagnostics and microscopy. Sensovation is primarily active in the OEM business and designs customer specific imaging products. The SensoSpot® Microarray Analyzers are dedicated for routine analysis of planar, low-density microarrays for multiplexed diagnostics. This open and flexible platform allows for read-out of colorimetric and fluorescent microarrays in a very robust and affordable manner.

---

## SHANGHAI CP GUOJIAN PHARMACEUTICAL CO., LTD.

No. 399, Libing Road, Zhangjiang Hi-Tech Park, Pudong New Area  
Shanghai, 201203, China  
[www.cpgj-pharm.com/EN/](http://www.cpgj-pharm.com/EN/)



Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a biopharmaceutical company invested and controlled by China International Trust and Investment Corporation (CITIC Limited). Since established in 2002, CPGJ has committed to the R&D, pilot scale development, industrialization and commercialization of antibody drugs. It has grown into a leading company in China's antibody sector that provides targeted drugs for cancer, autoimmune diseases and organ transplantation immunosuppression treatment. As an R&D-based biopharmaceutical company, CPGJ has successfully developed its core technologies to continuously develop and commercialize new biologics therapies. CPGJ's antibody manufacturing capacity is among the largest in the industry.

---

## TEVA PHARMACEUTICAL INDUSTRIES LTD.

16 Basel St.  
 Petach Tikva, 4951008, Israel  
[www.tevapharm.com](http://www.tevapharm.com)



Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to \$19.7 billion. For more information, visit [www.tevapharm.com](http://www.tevapharm.com)

---

## THERADIAG

14 rue Ambroise Croizat  
 Croissy Beaubourg, 77183, France  
 Booth #: 14  
[www.theradiag.com/en/](http://www.theradiag.com/en/)



With 30 years' experience in the development and commercialization of IVD tests, Theradiag keeps innovating with the development and commercialization of theranostics that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range, which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. Concerned of bringing new and up-to-date solutions for labs, Theradiag constantly develops its ranges of products and services. Today and thanks to its new solution, Theradiag positions more than ever as a key player of the specialized immunology diagnostic in Europe.

---

## THERMO FISHER SCIENTIFIC

Phadia GmbH Munzingerstr. 7  
 Freiburg, 79111, Germany  
 Booth #: 06  
[www.thermoscientific.com/phadia](http://www.thermoscientific.com/phadia)



As the ImmunoDiagnostics experts within Thermo Fisher Scientific, we work to significantly improve the management of allergy, asthma and autoimmune diseases. We do this by providing healthcare professionals with superior diagnostics technologies and clinical expertise. This results in better healthcare and quality of life for millions of patients and their families.

---

## UCB

Allée de la Recherche 60  
Brussels, 1070, Belgium  
[www.ucb.com](http://www.ucb.com)



UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.3 billion in 2014. UCB is listed on Euronext Brussels (symbol: UCB).

---

## UNOMEDICAL A/S

Aaholmvej 1-3. Osted  
Lejre, 4320, Denmark  
Booth #: 28  
[www.neria.com](http://www.neria.com)



Unomedical is a leading manufacturer of infusion sets. Since 1980s Unomedical has sold millions of infusion sets worldwide for use with continuous subcutaneous drug delivery. Our neria™ infusion sets have been drug compatibility tested with drugs for the following diseases; Primary Immune Deficiency, Parkinson Disease, Thalassemia, and Pain Management. Our success is based on a high degree of innovation supported by user-friendliness and superior quality. All over the world users benefit from the Unomedical infusion sets improving their quality of life and treatment options. Please visit [www.neria.com](http://www.neria.com) for more information on the neria™ infusion set product line.

---

## WISEPRESS LTD

25 High Path  
London, SW19 2JL, UK  
Booth #: 37  
[www.wisepress.com](http://www.wisepress.com)



Wisepress.com, Europe's leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.